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Tumour associated macrophages (TAMs) have been associated with prognosis in a 
wide variety of tumours with most studies showing a high number of macrophages 
equating with poor prognosis.  This is postulated to be due to TAMs providing 
support to the tumour through a wide variety of mechanisms including suppression 
of the immune response, promotion of angiogenesis and provision of growth 
supporting signals.  Previous work within the group has characterised some of the 
mechanisms by which Burkitt lymphoma cells attract macrophages to the tumour and 
some of the mechanisms by which these macrophages support tumour cell growth.  
This thesis extends some of the work carried out in Burkitt lymphoma to Diffuse 
Large B cell lymphoma (DLBCL) and examines TAMs in this tumour type. 
 
Diffuse Large B cell lymphoma is the commonest high grade lymphoma in the 
Western world.  Like Burkitt lymphoma it is characterised by diffuse sheets of 
lymphoid blasts.  In contrast to Burkitt lymphoma, it represents a less well-defined 
entity that encompasses tumours with variable morphology, genetic abnormalities 
and outcome.  Rates of proliferation and apoptosis vary between individual tumours, 
and unlike Burkitt lymphoma not all cases are characterised by a prominent 
macrophage infiltrate.  Previous work within the group has shown a relationship in 
Burkitt lymphoma between apoptosis, macrophage infiltration and proliferation 
suggesting that apoptosis recruits macrophages to provide support to the tumour 
cells.  This relationship was studied here in a large cohort of patients with DLBCL 
and the same relationship shown to exist in this tumour also.   
 
Following this observation, a bioinformatic approach was taken to define a gene 
expression signature of the TAM in DLBCL in situ in an unbiased way.  Using large 
publicly available human tumour gene expression datasets, a graph clustering 
approach using the tool Biolayout Express 3D was used to explore the transcriptome 
of DLCBL and other human tumours. Signatures of immune cells and stromal cells, 
functional pathways and tumour specific signatures were defined from individual 
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tumour type transcriptomes by study of clusters of co-expressed genes.  Further work 
used a novel graph clustering approach based on mean Pearson correlations to define 
a ‘core’ transcriptome signature shared across many unrelated tumour types and in 
which elements of the tumour stroma were prominent.  To validate the TAM 
signature derived from the DLBCL dataset, protein expression of selected elements 
of the signature were analysed at the protein level by immunohistochemistry in an 
unrelated cohort of DLBCL. 
 
Selected markers from the DLBCL TAM signature were then assessed for 
relationship to outcome in a cohort of patients treated with CHOP chemotherapy.  Of 
the proteins studied, a significant difference in outcome was demonstrated only for 
leukocyte associated immunoglobulin receptor 1 (LAIR1) expression by TAMs, 
where low intensity staining for LAIR1 in TAMs was associated with better overall 
survival.   
 
LAIR1 is a collagen-binding inhibitory receptor expressed only in cells of 
haemopoetic lineage whose role is little studied in macrophages.  The final results 
chapter presents some preliminary data from co-culture experiments in which the 
expression of LAIR-1 on the ‘macrophage-like’ cell line THP-1 is studied in various 
polarisation states and the ability of these cells to support or constrain tumour cell 







Diffuse Large B cell lymphoma is the commonest high grade lymphoma in the 
western world.  It affects a wide age range from children to the very elderly, although 
the disease is commonest in adults.  With current therapies the disease is curable in 
approximately 60% of case, leaving a significant burden of incurable disease. 
 
In this tumour, as in many others, there is a significant infiltrate of inflammatory 
cells in to the tumour, including macrophages, known in this context as TAMs.  
Macrophages are normally important in fighting infection and, in the aftermath of 
infection or inflammation, in helping tissues repair and wounds to heal.  Some of the 
functions that are used in healing and repair can be ‘borrowed’ by tumour cells to 
help the tumour grow.  If we can better understand the ways in which tumours 
interact with TAMs, then these macrophages may represent another facet of the 
tumour susceptible to attack by drugs or other therapies.   
 
Others within the group have looked at the ways in which apoptosis (a particular 
form of programmed cell death) of tumour cells can attract macrophages into the 
tumour in Burkitt lymphoma, another form of high grade lymphoma.  This thesis 
starts by looking at the relationship of apoptosis, macrophage infiltration and tumour 
cell proliferation in a large group of tumour samples from patients diagnosed with 
Diffuse Large B cell lymphoma, and shows that there is a relationship in this tumour 
type also between the number of tumour cells undergoing programmed cell death and 
the number of macrophages in the tumour, suggesting that the dying cells may be 
recruiting the macrophages to the tumour.   
 
To better understand the macrophages, a gene expression signature of the cells was 
then sought.  The gene expression signature is simply a list of genes being expressed 
by the macrophages and gives an idea of what functions the cells are undertaking 
rather than studying genes of interest one by one.  Macrophages are very changeable 
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cells and isolating them from the tissue in which they reside is likely to make them 
alter the genes they are expressing.  In an effort to overcome this, a signature was 
sought of the cells in the tissue.  To do this a computational method was used, 
whereby gene signatures of whole tumours were studied.  Diffuse Large B cell 
lymphoma was studied, as were several other malignancies including breast, 
colorectal, and ovarian carcinomas, testicular and primary brain tumours to ensure 
that the computational method was widely applicable.  The computational method 
relies on the fact that every tumour is different, so that tumour A might have more 
macrophages in it than tumour B, which would be different again from tumour C.  
Because the macrophage genes will alter with the number of macrophages present in 
the tumour they should all show the same or similar pattern of expression across the 
samples.  The computational method used allows genes with the same profiles to be 
identified as clusters.  This approach was applied across multiple datasets 
representing data from more than one thousand patients to generate signatures of 
macrophages, as well as many other cell types and cellular processes.   
 
Having identified a macrophage signature by this approach, this was verified by 
looking for the proteins encoded by a subset of genes using immunohistochemistry to 
ensure that the proteins were expressed in macrophages and not tumour cells.  Some 
of these selected genes were studied further to assess whether expression by the 
macrophages equated with a good or a poor outcome for the patient.  Only one of the 
markers studied (LAIR1) showed a relationship with outcome with patients with a 
low level of staining for the protein in their TAMs being associated with a better 
outcome.  LAIR1 is a receptor which binds collagen and sends an inhibitory signal 
into the cell, preventing it being activated.  This suggested that patients who had 
lower levels of staining for LAIR1 might have easier to activate macrophages, 
leading to a better outcome.  The final part of the thesis looked at expression of 
LAIR1 on macrophages, how it was altered in different settings and how these 
affected the way tumour cells grow in culture.  This very preliminary work hinted 
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1.1 Diffuse large B cell lymphoma 
 
Diffuse large B cell lymphoma (DLBCL) as currently defined by in the WHO in 
Classification of Tumours of Haemopoetic and Lymphoid tissues, 4
th
 edition is the 
commonest high grade lymphoma in the Western world (Swerdlow et al 2008).  As 
such it still represents a relatively rare malignancy, with all non-Hodgkin lymphoma 
combined ranking 6
th
 in the UK in terms of incidence and DLBCL accounting for 
about half of those cases giving a crude incidence rate of 8 or 9 per 100,000 of the 
population in the UK (data from Cancer Research UK).  Unlike many commoner 
malignancies however, diffuse large B cell lymphoma affects a very wide age range 
stretching from the paediatric age group, through all adult ages to the very elderly.  
There are currently many related subtypes of DLBCL which are separately classified 
due to unique clinical and pathological features such as EBV-positive diffuse large B 
cell lymphoma of the elderly, chronic infection related DLBCL, primary DLBCL of 
the central nervous system, primary cutaneous DLBCL, leg-type and lymphomatoid 
granulomatosis which appear to represent unique disease entities and will not be 
discussed further, this thesis focussing on the major disease classification of DLBCL, 
not otherwise specified.   
 
The WHO classification of lymphoma draws together histological, clinical and 
genetic features to create a classification system and it is clear that DLBCL actually 
represents a heterogeneous collection of diseases defined as a single entity in the 
absence of our ability to further subdivide these in a clinically meaningful way.  
Whilst intellectually unsatisfying such a pragmatic approach to classification groups 
together diseases predicted to behave in a broadly similar way, that are therefore 
treated in a broadly similar way.  The classification encompasses DLBCL arising de 
novo as well as high grade transformation of low grade lymphomas such as follicular 
lymphoma, marginal zone lymphoma and small lymphocytic lymphoma/chronic 
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lymphocytic leukaemia (Swerdlow et al 2008).  DLBCL may present as any age, 
though is commoner in the adult population.  It can present at any site in the body, 
either in a nodal or extranodal location and it tends to behave in an aggressive 
manner.  A variety of genetic abnormalities are described in the classification 
including mutations in MYC, PIMI, RHOH/TTF and PAX5 and translocations 
involving the BCL6 gene, BCL2 gene and the MYC gene but none are characteristic 
or necessary to reach the diagnosis (Pasqualucci et al 2001, Bastard et al 1994, Offit 
et al 1994, Ohno and Fukuhara 1997, Lipford et al 1987, Weiss et al 1987, Yunis et 
al 1989, Hummel et al 2006).  Histologically the disease shows wide morphological 
variation with three major morphological variants (immunoblastic, centroblastic or 
anaplastic) and other rare variants.  These morphological differences show poor 
inter- and intra-observer reproducibility and, perhaps because of this, do not predict 
tumour behaviour (Harris et al 1994).  The tumours also differ considerably in the 
content of other cells such as macrophages and small lymphocytes that are present or 
the degree of fibrosis present.   
 
Prognosis is predicted by various clinical features many of which are used to 
calculate the IPI (International Prognostic Index) including the patient age, stage of 
disease, performance status, presence of extranodal disease and serum levels of 
lactate dehydrogenase (LDH) (International Non-Hodgkin’s Lymphoma Prognostic 
Factors project, 1993).   There is considerable heterogeneity of clinical response 
within IPI grouping however, reflecting the heterogeneity of the underlying tumours.  
Poor outcome and particular patterns of tumour spread can also be predicted by 
features such as the presence of a MYC translocation in the tumour or involvement of 
‘sanctuary sites’ such as the testis and treatment tailored accordingly, but currently 
little information about the abnormalities driving the tumour is used in the planning 
of treatment, most patients being uniformly treated with CHOP (cyclophosphamide, 
doxorubicin, vincristine and prednisolone), or a CHOP-like regimen plus Rituximab, 
as dictated by patient fitness (Barrans et al 2010, Cheah et al 2014, Ferreri et al 2015, 
Ghose et al 2015).  Multiple individual features or combinations of features have 
been assessed over recent years in an effort to provide further information about 
prognosis but while many studies have shown associations with outcome, much of 
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the data have been contradictory and very little of this data has influenced individual 
patient treatment. (Adida et al 2000,  Barrans et al 2004, Berglund  et al 2005, 
Colomo et al 2003, De Paepe et al 2005, Gasgoyne et al 1997, Hans et al 2005, 
Hermine et al 1997, Iqbal et al  2006, Milleret al 1988, Muris et al 2006, Veelken  et 
al 2007, Yamguchi et al 2002)    
 
Whilst the disease has an aggressive behaviour it is frequently sensitive to 
chemotherapy and is potentially curable by this approach.  Prior to the introduction 
of the anti-CD20 monoclonal antibody Rituximab the cure rate was in the region of 
40-50%.   Since the widespread introduction of Rituximab to standard 
chemotherapeutic regimens in the last decade the cure rate has increased dramatically 
to about 60-70%, although clearly longer term data on this are limited and captured 
within this figure there are still differences in outcome between subtypes and 
prognostic groups (Alizadeh et al 2000, Lenz et al 2008, reviewed in Roschewski et 
al 2014 and Sehn and Gascoyne 2015).  There is clearly however still a large burden 
of incurable disease, and a greater understanding of the biology of this disease/these 
diseases is required if the percentage of patients who are cured is to be increased.  
Currently a significant proportion of the incurable disease cohort represents patients 
with primary refractory disease or those whose tumours recur very rapidly after 
cessation of the initial chemotherapy (Martelli et al 2013).   
 
Several large studies of DLBCL in recent years using high throughput gene 
expression and gene mutational analysis have furthered our understanding of the 
diversity of the diseases captured under the DLBCL umbrella.  A seminal paper by 
Alizadeh et al in 2000 showed that DLBCL could be subtyped on the basis of their 
gene expression profile, with two broad classes being described; those whose gene 
expression signature resembled that of normal germinal centre B cells (GCB-type) 
and those whose expression signature resembled that of peripheral blood B cells 
activated in vitro (activated B cell (ABC)-type) (Alizadeh et al 2000).  This gene 
expression signature as well as revealing aspects of the biology of the tumours 
appeared to provide prognostic information with patients whose tumours had an 
ABC-type pattern of gene expression having a considerably poorer prognosis when 
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treated with standard chemotherapy regimens, than those with a GCB-type pattern of 
gene expression.  Tumours with the ABC-profile were characterised by expression of 
genes such as IRF4, a gene transiently expressed in B cell activation, and anti-
apoptotic genes FLIP and BCL-2, while GCB-type tumours showed expression of 
genes characteristic of germinal centre B cells such as CD10 and BCL-6, as well as 
genes known to be mutated in other haematological malignancies BCL-7A and 
LMO2 (Alizadeh et al 2000).  Of importance was the observation that there was no 
single gene whose expression predicted which group the tumours would fall into.  
Instead it was the signature identified of many genes that allowed stratification of the 
tumours into the subtypes.  A further study from the same group using an array cGH 
based approach to a large number of tumours identified 272 recurrent chromosomal 
abnormalities, 30 of which were differentially present in the DLBCL subtypes, 
suggesting that these do truly represent different disease entities characterised by 
different oncogenic pathways (Lenz et al 2008).  ABC-type tumours were 
characterised by trisomy 3, deletion of chromosome arm 6q, gain or amplification of 
an area on 18q, deletion of the tumour suppressor locus INK4a on chromosome 9 and 
gains or amplications of an area of chromosome 19.   GCB tumours were 
characterised by amplifications on chromosomes 2, 12 and 13, as well as a deletion 
on chromosome 10. Identified targets of these mutations included loss of the PTEN 
tumour suppressor gene and amplification of REL (Lenz et al 2008).   
 
Gradually a picture has built up of the underlying genetic abnormalities in these 
subtypes of DLBCL.  The ABC-subtype appears to be characterised by signalling 
through NFκB pathways (Davis et al 2001).  ABC-tumours are characterised by IRF4 
expression, a target of NFκB.  In the normal setting this is expressed by B cells 
differentiating towards plasma cells (Shaffer et al 2009).   In the malignant B cells of 
the ABC-DLBCL tumours terminal differentiation to plasma cells is blocked by the 
inactivation of Blimp-1 by a variety of mutations included those affecting PRDP1 
(encoding Blimp-1), BCL6 and SPIB (Iqbal et al 2007, Lenz et al  2008a, 
Mandelbaum et al 2010, Pasqualucci et al 2006, Schmidlin 2008, Tam et al 2006).  
Thus ABC-type tumours appear stuck in a normally transient stage in the 
differentiation pathway as a plasmablast.    Multiple influences on the NFκB pathway 
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are represented in ABC-type tumours; mutations in CARD11 and CD79 lead to 
activation through the BCR signalling pathway; mutations in MYD88 seen in 39% of 
ABC-type tumours lead to signalling through the TLR pathway, as well as driving 
secretion of IL-6, IL-10 and IFN-β and downstream autocrine signalling (Davis et al 
2010, Lenz et al 2008b, Ngo et al 2011).   Signalling through the BCR-complex 
appears important in ABC-tumours which maintain expression of the IgM heavy 
chain (and hence its functional signalling qualities) in their functional BCR despite 
the non-productive allele undergoing class switch recombination (Pasqualucci et al 
2011a).  BCRs in ABC tumours are immobile and clustered on the cell surface, a 
property seen normally in antigen-stimulated B cells, and inhibition of BCR 
signalling components results in cell death in vitro (Davis et al 2010).  Intriguingly, 
recent data suggests the antigen recognised by the BCR in some ABC-DLBCL 
lymphoma cell lines may be a ‘self’ antigen derived from apoptotic tumour cells (L. 
Staudt, unpublished data).  The underlying mechanisms in GCB-DLBCL are less 
well characterised.  GCB-type tumours are often characterised by translocations 
involving BCL2, rendering the cells less responsive to apoptosis (Iqbal et al 2004).  
BCL6 activity is frequently dysregulated in DLBCL, either by translocation, or 
mutation (reviewed in Pasqualucci et al 2003).  BCL6 is a central transcriptional 
regulator in the normal germinal centre reaction with multiple downstream targets 
with three broad functions; blocking differentiation to plasma cells, repressing 
inhibitors of the cell cycle and blocking expression of many genes associated with 
inflammation (Shaffer et al 2000).  In tandem with mutations of BCL2, cells with 
dysregulation of BCL6 would be predicted to proliferate without differentiating and 
be protected from apoptosis (Ci et al 2009).  Epigenetic phenomena clearly also have 
a role to play, with mutations in histone modifying enzymes being relatively 
common.  These tend to be seen more in GCB than ABC subtype with 41% of GCB 
tumours having mutations in CREBBP compared to only 17% in ABC type 
(Pasqualucci et al 2011b).  These mutations impact on acetylation of BCL6, 
representing one of the mechanisms by which this dysregulated.   
 
Other approaches to subclassification of DLBCL by gene expression analysis have 
been undertaken by groups looking at genes involved in apoptosis, clustering of all 
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genes on the chip (as opposed to the approach used by Alizadeh which focused on 
lymphocyte genes only) or clustering based on good or poor prognosis and these 
approaches have also yielded insights into tumour behaviour (Alizadeh et al 2000,  
Lenz et al 2008c, Linderoth et al 2008, Monti et al 2005 and Muris et al 2007, 
Rosenwald et al 2002).   The study reported by Rosenwald et al expanded on the 
Alizadeh et al paper using a customised chip enriched in immune/lymphoid genes 
but in contrast to the previous study where only genes expressed in lymphocytes 
were used for clustering, used all genes and derived signatures that as well as 
representing the germinal centre, also represented the background lymph node, 
proliferation, and a signature they called MHC class II (Rosewald et al 2002).  Of 
these, the proliferation signature was correlated with poor outcome and the lymph 
node signature and MHC II signature with good outcome suggesting a role for the 
host response in determining outcome.  Monti et al analysed gene expression using 
Affymetrix chips and showed that when the whole gene expression pattern of the 
tumour is considered, DLBCL showed three main patterns that they characterised as 
‘oxidative phosphorylation’, ‘B cell receptor/proliferation’ and ‘host response’ 
(Monti et al 2005).  These clusters, unlike those described by Alizadeh et al, did not 
predict outcome, and was unsurprising given this, did not overlap with the ‘cell of 
origin’ signatures.   The approach taken in the Muris et al paper was to select genes 
involved in apoptosis that hence may represent a mechanism of resistance to 
chemotherapy and cluster based only on expression of these genes (Muris et al 
2007).  They identified three clusters, a ‘cellular cytotoxic response’, an ‘activated 
apoptosis cascade’ and ‘hyperplastic lymphoid tissue’ cluster, of which the first two 
were associated with poor prognosis and the ‘activated apoptosis cascade’ showed 
some overlap with the ABC type of DLBCL.     The Linderoth et al paper clustered 
genes on the basis of patient outcome and found a better prognosis associated with 
genes of the tumour microenvironment (Linderoth et al 2008).     Lenz et al clustered 
DLBCL on the basis of all genes on Affymetrix U133 Plus2 arrays and showed a 
germinal centre cluster similar to the GCB cluster, which was expressed in the 
malignant B cells and two stromal clusters, one of good and one of poor prognosis 
associated with the non-B cell component of the tumour (Lenz et al 2008c).  This 
analysis suggested that a vascular signature predicted poor response to chemotherapy 
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while a macrophage and extracellular matrix-rich signature predicted good response 
to chemotherapy.  It is of interest that there is very little overlap between signatures 
from different analyses strategies despite for example, multiple signatures predicting 
poor prognosis and contradictory findings as to the significance of these clusters.  
The ‘cell of origin’ analysis which can at least partly be predicted at the protein level 
by immunohistochemistry and thus used outwith the research setting where fresh 
frozen tissue is available, remains the subclassification most used (Choi et al 2009, 
Hans et al 2004, Muris et al 2006).   
 
Although Rituximab has made an enormous contribution to the treatment of DLBCL 
(and many other B cell lymphomas) its mechanisms of action have been poorly 
understood.  In vitro the molecule has multiple actions including induction of 
apoptosis and complement mediated cell death, but the situation in vivo is far less 
well characterised (Golay et al 2000, Maloney et al 2002).    There is limited in vivo 
data as to the mechanism of action of Rituximab, but what there is points to its 
activity being due to a combination of activation of complement, direct induction of 
programmed cell death of tumour cells and antibody dependent recruitment of 
effector cells, especially cells of monocytic origin with the recruitment of effector 
cells being believed to be the most important, hinting that the relationship of the 
TAM with the tumour is likely to be of importance not just in the development and 
survival of the tumour but also its response to therapy  (Illidge et al 2014, Minard-
Colin et al 2008).  Considerable work has been ongoing for many years to produce 
additional monoclonal antibodies against B cells that are more effective than 
Rituximab.  Many of these have been designed to have specific functions such as 
enhanced activation of complement, induction of cell death or delivery of a cytotoxic 
molecule in an effort to address ‘effector-cell exhaustion’, one proposed short-
coming of Rituximab  (Honeychurch et al 2012, Illidge et al 2014, Goede et al 2015, 
Palanca-Wessels et al 2015).   Several of these drugs are currently in clinical trial, 
but not yet in routine use.   
 




1.2 Tumour associated macrophages 
 
There is extensive data both from spontaneously developing human tumours and 
experimental models suggesting that macrophages play multiple important roles in 
tumour formation, survival and spread (Allavena and Mantovani 2012, Qian and 
Pollard 2010).  Tumour associated macrophages (TAMs) have been ascribed roles in 
the development of tumours, the angiogenic switch allowing tumour growth past a 
few millimetres in dimension, suppression/evasion of effective immune responses to 
the tumour, acquisition of the ability to breach basement membranes and invade into 
blood or lymphatic channels and the ability to extravasate from blood or lymph and 
proliferate in metastatic sites.  
 
The evidence for the role of macrophages in the development of tumours comes from 
a combination of epidemiological data from humans and experimental models.  The 
increased risk of malignancy in chronic inflammatory conditions is well recognised.  
In ulcerative colitis for example, a disease characterised by relapsing and remitting 
inflammation largely confined to the colonic mucosa, there is an increase in the risk 
of development of colorectal carcinoma compared to the general population (Burisch 
and Munkholm 2015).  This risk is influenced by the length of exposure to the 
inflammation, and the extent and severity of the inflammation.  Similar increased 
risk of malignancy is also seen in other chronic inflammatory conditions such as 
Helicobacter-associated inflammation in the stomach, which increases the risk of 
both extranodal marginal zone lymphoma and adenocarcinoma, chronic viral 
infections with Hepatitis B or C which increase the risk of hepatocellular carcinoma, 
and chronic inflammation related to Schistosome ova which increases the risk of 
bladder cancer in areas where Schistosomiasis haematobium is endemic (Fried et al 
2011, Oh and Weiderpass 2014).  This correlative human data is supported by data 
from animal models where it has been shown for example that ablation of Stat3 in 
myeloid cells leads to a chronic colitis and development of carcinoma (Deng et al 
2010).   Similarly mice deficient in GM-CSF and IFNγ demonstrated inflammatory 
lesions and an increased rate of spontaneously developing malignancy, both 




TAMs, as well as being implicated in the development of tumours, are also believed 
to play a role in supporting established tumours.  One of the key functions described 
here is in promoting angiogenesis (Qian and Pollard 2010).  Without the ability to 
develop new blood vessels to provide oxygen and nutrients and carry away waste 
products, tumours are severely constrained in their growth even if the tumour cells 
possess many of the other properties of malignancy such as independence from 
growth signals and resistance to death (Bergers and Benjamin, 2003).  Angiogenesis 
occurs to a limited extent in the adult normally being confined to specific settings 
such as the endometrium during the menstrual cycle and in wound healing and repair 
in response to injury and in these normal settings non-inflammatory/reparative 
macrophages play a role (Okada et al 2014, Novak et al 2013).  In order to develop a 
fully malignant phenotype, tumours appear to need to harness some of these 
functional abilities of macrophages to drive new vessel formation.   Correlative data 
from many human malignancies looking at microvessel density in established 
tumours shows a correlation between macrophage number and microvessel density 
as well as between microvessel density and poor outcome (Ch’ng et al, 2013, 
Espinonsa et al, 2010, Fujita et al, 2014, Hirayama et al, 2012, Koh et al, 2014, 
Kawahara et al, 2010, Kurahara et al, 2012, Murri et al, 2008, Romero et al, 2012, 
Shigeoka et al, 2013, Suyani et al, 2013, Wu et al, 2012).  Several drugs are currently 
in trials or routine use which target the tumour vasculature in malignancies including 
Bevacizumab, an anti-VEGF monoclonal antibody (Carmeliet and Jain, 2011).  The 
mechanisms by which TAMs promote angiogenesis have been partially elucidated in 
various animal models and in vitro systems.  Various molecules identified in TAMs 
have been shown to be involved in angiogenesis including semaphorin 4D, 
thymidine phosphorylase and VEGF (Lewis et al 2000, Mitselou et al 2012, Sierra et 
al 2008).   
 
Knockdown of macrophages either by genetic depletion of these cells or 
pharmaceutical depletion using liposomal clondronate results in reduced growth of 
tumours either arising in situ or transplanted (Lin et al 2006, Zeisberger et al 2006 ).  
Macrophages influence on angiogenesis is mediated partly via the expression of 
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hypoxia inducible factor (HIF), expressed by macrophages and responsive to hypoxia 
(Fang et al 2009, Rius et al 2008,).  This has multiple downstream targets including 
the canonical angiogenic factor VEGF.  VEGF expression has been demonstrated in 
TAMs in both mouse and human tumours (Ding et al, 2012, Gonzales et al, 2007, 
Kurahara et al, 2012, Lewis et al, 2000).  As well as direct secretion by macrophages, 
VEGF can also be released by macrophages from sequestration in the extracellular 
matrix by the action of macrophage-expressed molecules such as MMP-9 (Bergers et 
al 2000).   
 
A further function of macrophages believed to be subverted by tumours for their own 
means is that of invasion through tissues (Qian and Pollard 2010).  Normal epithelial 
cells are anchored in an organised and structured tissue and confined by the basement 
membrane.  To invade through tissues tumours need to be able to breach these 
physical barriers and migrate.  As cells which are migratory in the normal situation, 
and play a role in the degradation and remodelling of stroma in the wound healing 
and repair context, macrophages possess the ability to degrade extracellular matrix 
by a variety of mechanisms including secretion of proteolytic enzymes such as 
matrix metalloproteinases, cathepsins and urokinase plasminogen activator (uPA) 
(Kessenbrock et al 2010, Liguori et al 2011).  Recruitment of macrophages to 
tumours allows tumour cells to take advantage of these mechanisms (Hagemann et al 
2005, Kessenboeck et al 2010).   TAMs in human tumours can be demonstrated to 
express a wide variety of matrix proteases including MMPs 1,7,9,12,14 and 19, uPA, 
cathepsins B, C, D, L and Z, ADAMs and SPARC  (Liguori et al 2011, Meyer et al 
2011).     The role of these is far more complex than simply degradation/remodelling 
of the tumour stroma however with cleavage of ECM components releasing 
signalling molecules that affect other elements of the tumour microenvironment 
(Liguori et al 2011). 
 
 
Macrophages are also implicated in formation of metastatic foci with data indicating 
a direct role for macrophages in aiding malignant cells into the vasculature and into 
metastatic sites (Kaplan et al 2005, Wyckoff et al 2007).  There appears to be a very 
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close relationship between macrophages and invasion with Ojalvo et al 
demonstrating a specific sub-population of macrophages associated with invasive 
tumour cells.  (Oljalvo et al, 2010).  Recent work has highlighted the role played by 
CCL2 and CCL3 in recruitment and retention of these metastasis specific 
macrophages (Qian et al 2011, Kitamura et al 2015) 
 
A further role for tumour associated macrophage appears to be in alteration of the 
immune response for the benefit of the tumour.  At some point in tumour progression 
there appears to be a switch in the phenotype of the macrophage from the 
‘inflammatory’ type cells seen in the cancer promoting inflammatory conditions to a 
more reparative/immune suppressive phenotype seen in established tumours (Qian 
and Pollard 2010).    This later stage TAM has some features in common with the 
‘M2’ macrophage described as an in vitro phenomenon on polarisation with IL-4, but 
to simply view TAMs as ‘M2’ macrophages is to vastly oversimplify a complex cell 
type subject to multiple influences (Biswas and Mantovani 2010).   The 
immunosuppressive role of the TAM appears to be mediated in part by the cytokines 
it secretes with these tending to secrete IL-10 and TGFβ and lacking expression of 
IL-12 thus tending to recruit Th2 and regulatory T cells rather than Th1 T cells and 
cytotoxic T cells (Biswas et al 2006, Hagemann et al 2008, Torroella-Kouri et al 
2009).  In human ovarian tumours secretion of CCL22 by TAMs recruits regulatory 
T cells (Curiel et al 2004).  TAMS may also act directly on T cells to induce 
apoptosis through expression of B7-family members and via arginase to inhibit the 
availability of L-arginine (Biswas and Mantovani, 2010).   
 
The role that TAMs play in lymphoma is not yet entirely clear.  Some of the 
functions ascribed to TAMs in solid tumours such as the acquisition of the ability to 
invade the blood stream and migrate through tissue are likely to be of less relevance 
in tumours of lymphoid origin as normal lymphoid cells are much more mobile than 
epithelial cells and at some stages of their life possess the ability to circulate through 
the body as part of their normal function.  Some functions such as suppression of an 
effective immune response are clearly relevant however.  Much of the data in 
lymphoma comes from human studies looking at TAM numbers and outcome.  In 
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general these show that higher TAM numbers are associated with a poorer prognosis 
(Andjelic et al 2012, reviewed in Kridel et al 2015, Steidl et al 2010, Tan et al 2012).  
As these data are all derived from clinical samples, they necessarily capture outcome 
data in the light of chemotherapy rather than purely reflecting the relationship 
between TAMs and behaviour.  Of interest in this context is that the addition of 
rituximab to the chemotherapeutic regimen has altered this relationship, with patients 
who have large number of TAMs who are treated with CHOP chemotherapy plus 
rituximab having a better outcome (Alizadeh et al 2000, Lenz et al 2008, Kridel et al 
2015). This result suggests that the TAMs in these tumours are not ‘fixed’ in a pro-




Much of the mechanistic data as to the role macrophages play in tumours comes 
from mouse models and as yet, the extent to which the phenomena seen in inbred 
populations of mice map to real human disease is unclear.   Care is required in 
extrapolating directly from mice to humans as it is clear that there are major 
differences in macrophage activation profiles between these organisms (Martinez et 
al 2013).  There is a large body of data looking at classically (M1) or alternatively 
(M2) activated macrophages and drawing comparisons particularly between M2 
macrophages and TAMs which are often said to have an ‘M2-like’ profile (reviewed 
in Mantovani and Sica 2010, and Mantovani et al 2013).  When mouse and human 
macrophages are activated in an identical fashion (with IL-4 in this case), the well-
described markers of ‘M2’ activation in mice e.g. arg, Ym1, Fizz1, etc are not seen in 
human macrophages (Martinez et al 2013).  Indeed, many of the best characterised 
mouse markers of so-called M2 activation have no human homologues suggesting 
that human macrophages mount a different response to this stimulus (Raes et al 
2005, Martinez et al 2013).       
 
TAMs in human tumours are an appealing target however for novel therapies as, 
unlike the malignant cells they support, these cells do not possess the increased rate 
of mutagenesis that allows the malignant cells of the tumour to mutate away from the 
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selective pressure applied by treatment and as the data from lymphoma studies hints, 
these cells which are present in often large numbers in tumours, are reprogrammable 





1.3 The role of apoptosis in modulating macrophage function in 
tumours 
 
Apoptosis, a form of programmed cell death important in normal development, is 
considered to be a ‘quiet’ way for cells to die in contrast to necrotic cell death where 
the cellular contents are spilled from the disrupted cell and can act on cells in the 
microenvironment to induce an inflammatory response (Poon et al 2014).  Apoptosis 
is a tightly regulated programme of a cascade of effector molecules triggered either 
by an external signal to the cell (‘the death receptor’ pathway) or a signal derived 
from inside the cell in response to cellular damage (the intrinsic pathway).  The 
characteristic features of apoptosis with retained membrane integrity, nuclear 
condensation and formation of pyknotic nuclear fragments were described by Kerr, 
Wylie and Currie in 1972 (Kerr et al 1972).   Apoptotic cells are rapidly cleared from 
tissues, preventing them becoming secondarily necrotic and in many situations this 
appears to be a function of the neighbouring cells (Grimsley and Ravichandran 
2003).  In situations of high apoptosis such as that seen in resolving inflammation or 
within tumours, professional phagocytes are recruited to deal with these dying cells 
(Gregory and Pound 2011).   
 
Despite the ’quiet’ nature of apoptotic cell death, this is not a neutral event with 
apoptotic cells shown to influence the activation state of macrophages in a variety of 
inflammatory settings (Voll et al 1997, Fadok et al 1998, Huyn et al 2002, Duffield 
et al 2001).   Defects in apoptosis are associated in humans with autoimmune 
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conditions including systemic lupus erythematosus, where there is an uncommon but 
strong association with deficiencies in the complement component C1q (Savill et al 
2002).  Mouse models looking at genetic defects in phosphatidylserine-mediated 
apoptotic cell clearance have demonstrated autoimmune phenomena (Reviewed in 
Elliot and Ravichandran 2010).   
 
Cells dying by apoptosis appear to release ‘find me’ signals that recruit macrophages 
to the tumour including ATP/UTP, fracktalkine, lysophophatidylcholine and 
monocyte chemotactic protein (Elliot  et al 2009,  Kobara et al 2008,  Lauber et al 
2003, Truman et al 2008).  Once the macrophage is in the local environment of the 
apoptotic cell, a variety of molecules on the cell surface allow engulfment by 
macrophages either directly or via the action of a linker molecule.  The ‘eat me’ 
signals include phosphatidylserine ‘flipped’ from the inner to the outer cell 
membrane, and oxidized low density lipoproteins-like sites (Savill et al 2002).  
Characterised linker molecules include the complement component C1q, mannose 
binding lectin, Gas6, and milk fat globule epidermal growth factor 8 (MFGE8) 
amongst others (Elliott and Ravichandran 2010, Lauber et al 2004, Savill et al 2002).  
Cell surface receptors on the macrophage involved in apoptotic cell clearance include 
CD14, CD91, calreticulin, the scavenger receptors CD36, Scavenger receptor A, 
CD68 and LOX1, β2 integrins, the αvβ3 integrin, Mer, Bai1, Tim-2 and Stabilin-2 
(Elliott and Ravichandran 2010, Lauber et al 2004, Savill et al 2002) .  There appears 
to be a large amount of redundancy in the system as might be predicted by the ever 
growing list of molecules involved in phagocytosis of apoptotic cells and it is likely 
that different combinations of molecules are used in different settings.   
 
Apoptotic cells influence their neighbourhood.  They have been demonstrated to 
result in increased secretion by macrophages of anti-inflammatory molecules such as 
IL-10 and TGFβ and down-regulation of pro-inflammatory mediators including IL-6, 
IL-8, IL-12 and TNFα (Fadok et al 1998, Huynh et al 2002, Grimsley and 
Ravichandran 2003, Voll et al 1997).   This anti-inflammatory effect of apoptotic 
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cells was seen even in the face of previous activation by IFNγ and LPS (Reiter et al 
1999). This effect is mediated by contact with apoptotic cells and does not require 
phagocytosis by the macrophage (Gregory and Pound, 2011).   Ingestion of apoptotic 
cells can also lead directly to VEGF secretion, contributing to angiogenesis (Golpon 
2004). 
Tumours are microenvironments characterised by high rates of apoptosis, 
representing as they do a proliferative environment but one in which the cells 
proliferating have multiple mutations and hence are susceptible to apoptosis.  While 
the rate of proliferation in a tumour clearly outbalances cell loss or the tumour would 
not grow, and as a whole entity tumours are resistant to appropriate apoptosis, it is 
clear from histological examination of any tumour that apoptosis is a frequent event.  
This is therefore one mechanism by which tumours can influence the inflammatory 
microenvironment in which they exist.   
Recent work by our group has demonstrated the importance of apoptosis in tumour 
cell growth (Ford et al 2015).  Prevention of apoptosis by upregulation of anti-
apoptotic proteins constrained tumour cell growth in vivo in an animal model, 
suppressed angiogenesis and inhibited macrophage accumulation in the tumour.   
Improved tumour cell growth and macrophage accumulation was seen on inoculation 
of apoptotic tumour cells along with viable tumour cells in a transplant tumour 
model, and the effect of this was seen to be partly IL-4 dependent, being reduced in 
IL-4 knockout mice.  Previous work has demonstrated enhanced expression of IL-10 
and secretion of the B cell growth factor BAFF on phagocytosis of apoptotic cells 
suggesting mechanisms by which apoptotic cell death might influence tumour 
growth (Ogden et al 2005).   
Tumour supportive effects of macrophages exposed to apoptotic cells clearly have 
implications for therapy.  Many chemotherapeutic drugs act by inducing apoptosis in 
the target cells and an unintended consequence of this may be enhanced support of 
tumour cell growth, angiogenesis and immune evasion by the TAMs.  This effect 
clearly requires consideration in planning future chemotherapeutic 




1.4 The influence of the microenvironment in lymphoma 
 
In a recent review Scott and Gascoyne characterised three main patterns of 
interaction of lymphoma cells with their microenvironment which they called ‘re-
education, recruitment and effacement’ (Scott and Gascoyne, 2014).  Follicular 
lymphoma typifies the ‘re-education’ pattern being extremely reliant on the 
microenvironment for survival, with the tumour ‘re-educating’ the normal lymph 
node environment to provide trophic support for tumour cell survival and growth.  
The malignant follicles contain follicular dendritic cells and follicular T helper cells 
as in the normal lymph node, however there is an increase in number of TFH cells as 
well as a skew towards CD4 positive Tregs and away from TH17 cells (Ai et al 2009, 
Yang et al 2007, Yang et al 2009).  This appears to be driven by secretion of CCL22 
by the tumour cells and expression of co-stimulatory molecules CD70, CD80 and 
CD86 (Yang et al 2006).   Follicular lymphoma when it involves the bone marrow 
can induce the formation of follicular-like structures containing some of the same 
cellular elements seen in the lymph node.  The dependence on the microenvironment 
for follicular lymphoma growth and survival is demonstrated by its inability to grow 
in culture (Tweeddale et al 1987).  Intriguing work looking at the BCR expressed by 
follicular lymphoma has shown that many of these are mannosylated and can 
therefore interact with the mannose receptor and CD209 expressed by cells in the 
microenvironment (Coelho et al 2010, Zhu et al 2002)  This interaction appears to 
signal to the lymphoma cell and provide a survival signal.  CD40 expression by the 
TFH cells recruited to the microenvironment and expression of IL-4 have also been 
demonstrated to play a role (Calvo et al 2008, Johnson et al 1993, Pangault et al 
2010).   This appears to be a tumour very dependent on its microenvironment. 
 
Classical Hodgkin lymphoma shows what they called the ‘recruitment’ pattern, with 
a microenvironment characterised by a diffuse and variable mixture of cells 
including neutrophils, eosinophils, macrophages, plasma cells and T and B 
lymphocytes as well as stromal components recruited by the relatively sparse tumour 
cells (Scott and Gascoyne 2014).  This very prominent cellular and stromal infiltrate 
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appears to be driven by multiple chemokine and cytokines secreted by the Reed-
Sternberg cells which draw into the microenvironment of the involved lymph node 
elements that are not normally present.  These include CCL5, CCL17, CCL22, IL-5, 
CSF-1 and fracktalkine (reviewed in Steidl et al, 2011). The role played by these 
elements has yet to be unpicked in Hodgkin lymphoma, but given the enormous 
number of ‘recruited’ cells to the number of tumour cells, must play some role in the 
tumour growth and survival.  Like follicular lymphoma Hodgkin lymphoma cells are 
difficult to culture out of their normal microenvironment (Diehl et al 1981).  There is 
some suggestive data from gene expression profiling and immunohistochemical 
analysis that poor outcomes are predicted by large number of macrophages, NK cells 
and cytotoxic T cells in the tumour and low number of Tregs and B cells (Alvaro et al 
2005, Chetaille et al 2009, Kelley et al 2007, Steidl et al 2010).   
 
The ‘effacement’ pattern is that of Burkitt lymphoma where the microenvironmental 
component of the tumour is relatively inconspicuous suggesting the normal 
microenvironment of the lymph node has been effaced by the tumour cells which are 
associated with few other cell types with only macrophages being appreciable by 
normal light microscopy (Scott and Gascoyne 2014). However, as work from our 
group has shown, ‘effacement’ of the lymph node microenvironment does not equate 
to no role for the microenvironment in tumour cell growth (Ogden et al 2005, Ford et 
al 2015). 
 
Diffuse large B cell lymphoma according to this scheme, lies between ‘re-education’ 
and ‘effacement’ and appears closer to the situation in Burkitt lymphoma than that in 
follicular lymphoma being able in some cases to grow in culture but having a less 
completely effaced microenvironment than Burkitt lymphoma (Tweeddale et al 
1987).  The large gene expression studies discussed earlier have highlighted several 
facets of the microenviroment in DLBCL and triggered a wealth of studies, many of 
them somewhat contradictory in different patient cohorts.  The studies by Monti et al, 
Rosenwald et al, Lenz et al and Linderoth et al all identified signatures of the 
microenvironment in gene expression studies of whole tumour tissue from DLBCL 
(Lenz et al 2008c, Linderoth et al 2008, Monti et al 2005, Rosenwald et al 2002).  
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The possible influences these have on prognosis is relatively unclear with a ‘lymph 
node’ signature and a ‘microenvironment signature’ reported to correlate with good 
outcome, a ‘cellular cytotoxic signature’ to correlate with poor outcome and two 
stromal signatures indentified in the Lenz paper with different predictions of 
outcome.  The signatures identified in this paper are of particular interest suggesting 
a macrophage signature is associated with a good prognosis while a vascular 
signature, which might have been predicted to be quite closely aligned with the 
macrophage signature, predicts poor prognosis (Lenz et al 2008c).   Numerous 
studies have looked at the numbers of TAMS in DLBCL and the relationship this has 
with prognosis.  The majority of these studies have used either CD68 or CD163 or 
both as markers of TAMS.  As reviewed by Kridel et al recently, while there are 
contradictory findings in some of these studies, overall the pattern appears to be that 
large numbers of TAMs predict poor outcome in the pre-rituximab era and good 
outcome when rituximab is included in the treatment regimen (Kridel et al 2015).    
 
Like follicular lymphoma, there appears to be some role for signalling from the 
microenvironment for tumour cell growth and survival with secretion of APRIL 
reported by neutrophils (and very rarely by macrophages or other stromal cells) in 
DLBCL, (Schwaller et al 2007) despite neutrophils apparently not forming a large 
part of the tumour microenvironment on histological examination.    
 
Tumour cells avoid recognition by the immune cells normally present in their 
microenvironment by several mechanisms.  In some cases there is loss of expression 
of MHC II by the cells, a feature common to many subtypes of lymphoma 
(Riemersma et al 2000, Wilkinson et al 2011).  In DLBCL growing in immune 
privileged sites this is frequently due to chromosomal deletions affecting the MHC II 
genes, whilst the ABC-subtype downregulates expression as part of its abortive 
progression towards a plasma cell (Riemersma et al 2000, Wilkinson et al 2011).  
This downregulation of MHC II correlates with poorer outcome (Rimsza et al 2004).  
Frequent rates of loss of both MHC class I molecules (via mutations in β2-
microglobulin) and CD58 together in DLBCL  suggest  that these cells avoid the 
attention of both cytotoxic T cells and NK cells by downregulating the surface 
39 
 
molecules required for recognition by these cells (Challa-Malldi et al 2011).   Again 
similarly to follicular lymphoma, DLBCL cells express CD80 in a large percentage 
of cases, with some expression also seen in T cells providing another potential 
modulator of immune activation (Dakappagari et al 2002).  A recent intriguing study 
in a mouse model of lymphoma suggests a central role for T cells in the development 
of lymphoma (Afshar-Sterle et al 2014).   In this model mice carried B cells with 
either inactivation of Blimp-1 or overexpression of BCL6, both common mutations in 
DLBCL, but rarely developed spontaneous tumours.  These mice crossed onto a T 
cell deficient background developed overt lymphoma, and the T cell control of the 
lymphoma was seen to be mediated via Fas-Fas-ligand interactions (Afshar-Sterle et 
al 2014).   In established human tumours numbers of CD3-positive T cells, CD4-
positive T cells, FOXP3-positive Tregs  or numbers of cytotoxic T cells have all been 
shown to correlate with prognosis although the data within these studies is somewhat 
contradictory probably reflecting differences in the populations studied and methods 
used to define the cells of interest (Coutinho et al 2015, Hasselblom et al 2007, 
Keane et al 2013, Tzankov et al 2008).   
 
A study looking for genes assessable in routine diagnostic practice that predict 
prognosis identified two genes predictive of outcome, one of which, LMO2, is 
expressed by tumour cells and the other, TNFRSF9, expressed by cells of the 
microenvironment, in this case a small population of T cells of both CD4 and CD8 
subtypes (Alizadeh et al 2011).  The role played by these cells has not yet been 
elucidated but did not involve expression of the ligand on the tumour cells, 
suggesting an indirect effect of these activated T cells.   
 
Other components of the microenvironment have also been studied.  Mast cells in the 
tumour have been associated with increased microvessel density, with a relationship 
also demonstrated of mast cells with T cells (Marinaccio et al 2014, Marinaccio et al 
2015.  Mast cells have also been associated with an increase in fibrosis (Fukushima 
et al 2006).  In this study, the mast cells were also identified as a source of IL-4.  In 
lymphoplasmacytic lymphoma, a low grade B cell lymphoma, mostly confined to the 
bone marrow, there is an increase in mast cells associated with the tumour suggesting 
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active recruitment of these cells by the lymphoma cells (Swerdlow et al 2008).  
While not as obvious in DLBCL it is possible that these cells are recruited to perform 
a specific role.   
 
Huang et al demonstrated preferential expression of a molecule, Tim3, in 
endothelium in lymphomas that had a suppressive effect on T cells (Huang et al 
2010).  A study by Brandt et al looked at the expression of two of the extracellular 
matrix genes identified in the ‘stromal signature’ associated with good prognosis in 
the gene expression study by Lenz et al, fibronectin and SPARC.  (Brandt et al 2013, 
Lenz et al 2008c).  Expression of these in the extracellular matrix and endothelium at 
the protein level by immunohistochemistry confirmed the good prognosis seen in the 
earlier paper, but did not provide any insights into the role these molecules play.   
 
It has long been recognised that the tumour microenvironment in haematological 
malignancies contributes to resistance to drug therapies (reviewed in Shain et al 
2015) but much of the interaction of DLBCL with its microenvironment currently 
remains poorly understood.  Questions that are currently unanswered include; the 
mechanisms by which macrophages and T cells are recruited to the tumour, or re-
educated in the tumour; the role of the microenvironment in providing trophic 
support to the tumour; mechanisms by which macrophages and other immune cells 
are influenced by the lymphoma cells and influence the lymphoma cells; and the role 
of the extracellular matrix.  
 
This thesis examines some of the features of macrophages in DLBCL in tissue 
derived from human tumours in an effort to better understand the tumour associated 
macrophage in this tumour.  The underlying hypothesis is that the tumour associated 
macrophage in diffuse large B cell lymphoma, is not simply a bystander but plays a 
role in the pathogenesis of the tumour.  The relationship between apoptosis, 
proliferation and macrophage number is studied to assess the hypothesis that, as in 
Burkitt lymphoma, apoptosis of tumour cells represents a mechanism by which 
macrophages are recruited to tumours.  Generation of a gene expression signature of 
the tumour associated macrophage is then addressed using a bioinformatic approach 
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on a large number of human tumours and elements of that signature validated in a 
different cohort of patients.  Some of the markers of the tumour associated 
macrophage signature in human DLBCL are examined in relation to outcome in a 
standardly treated cohort of patients.  Finally, some in vitro experiments look at 
LAIR1, derived from the macrophage signature to assess possible mechanisms by 











Materials and Methods 
All work described here was carried out by the candidate unless otherwise stated. 
2.1  Studies on formalin-fixed paraffin embedded human tissue 
2.1.1  Tissue microarray used in chapter three. 
The DLBCL tissue microarray (TMA) used in chapter 3 was created by the Tayside 
tissue bank in Dundee containing 82 of cases of DLBCL diagnosed in Tayside and 
Highland region over an 8 year period (http://www.tissuebank.dundee.ac.uk). A 
minimum of two, but in most cases four, 0.6mm cores, were sampled from each 
tumour.  Areas of tissue for inclusion in the TMA were selected by two pathologists 
(not the candidate) to ensure cores contained tumour.   
 
The status of the cases with regard to the t(14:18)(q32;q21)translocation, which 
brings BCL2 and IGH together, was also made available.  Cases were classified as 
GCB or non-GCB-type using the immunohistochemical classification of Hans et al 
(Hans et al 2004).   
 All sections from the TMA were cut by Tayside tissue bank at 3 µm onto Superfrost 
slides (Thermo scientific, Loughborough, UK).  Sections were stained by Tayside 
tissue bank for markers of proliferation, apoptosis and macrophage infiltration using 
antibodies against ki67, active caspase-3 and CD68 respectively (Clones were; ki67 - 
MM1, Vector Labs (Peterborough, UK); active caspase-3 -  JHM62, Novocastra 
(Newcastle, UK) and CD68  - PG-M1, DAKO, (Cambridge, UK) with citrate buffer 
heat antigen retrieval by microwave pressure cooking.   These stained slides were 





2.1.2  Cell counting 
Cells were counted by a single observer using an eyepiece graticule.  A 
representative area to count was established by calculation of a cumulative mean of 
positive cells until the mean reached stability for each antibody and for cases 
representing ‘high’, ‘medium’ and ‘low’ levels of positive cells.  An area 0.25mm x 
0.125mm was counted for each core on the array.  To overcome variability in tumour 
cell size all values were expressed as percentage of total cells.  Mean values across 
cores were calculated for each case.   Cases were excluded for analysis if there were 
less than 2 cores available for analysis.   
 
2.1.3  Statistical analysis 
Associations were calculated by Pearson correlation.  Differences between groups 
were assessed by Kruskall-Wallis test.  
 
2.1.4  Creation of a CHOP treated DLBCL TMA used in chapters 5 and 6. 
A cohort of cases were identified by a search of the Scotland and Newcastle 
Lymphoma database to identify cases  of DLBCL diagnosed at Western General 
Hospital, Edinburgh, Edinburgh Royal Infirmary or St John’s Hospital, Livingston, 
who had received CHOP chemotherapy.  All cases were reviewed and seventy-three 
cases identified in which there was sufficient formalin-fixed paraffin embedded 
(FFPE) material available for inclusion in a tissue-microarray.  Cases were excluded 
if the FFPE-material was missing from the archive or if there was insufficient 
material to allow sampling for the tissue-microarray while preserving tissue for 
future use.   Representative areas of tumour were marked for sampling. 
 
The tissue microarray was built by the Edinburgh Experimental Cancer Medicine 
Centre (http://www.ecmcnetwork.org.uk/network-centres/edinburgh/edinburgh).  
Briefly, 2mm diameter cores of tissue were punched from the donor blocks of FFPE-
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material and placed into spaces created in a recipient paraffin block with the exact 
position of each donor core being recorded on a map of the tissue-microarray.  Up to 
three cores were sampled from each donor block.  Once completed, the recipient 
block was heated gently to fuse the donor paraffin wax with the recipient paraffin 
wax. 
Clinical outcome data and associated statistical analysis for cases examined in 
chapter 6 was provided from the Scotland and Newcastle Lymphoma database by 
Michel Sieniawski who manages the database. 
 
2.1.5  Creation of a reactive lymph node TMA used in chapters 5 and 6. 
Cases were identified from the archives of Edinburgh Royal Infirmary pathology 
department by a search using the SNOMed terms ‘lymph node’ and ‘hyperplasia’ 
over the period 1996-2005.  Cases were excluded if they were associated with a 
cancer resection specimen, even if not involved by cancer.  Cases were also excluded 
if there was insufficient material available in the FFPE-block for inclusion in a TMA 
while preserving material for future use.  Cases were also excluded where FFPE-
material was missing from the archive.  Sixty one cases were identified that were 
suitable for inclusion in a TMA.   
The tissue microarray was built by the Edinburgh Experimental Cancer Medicine 
Centre.  Briefly, 1.5mm diameter cores of tissue were punched from the donor blocks 
of FFPE-material and placed into spaces created in a recipient paraffin block with the 
exact position of each donor core being recorded on a map of the tissue-microarray.  
Up to three cores were sampled from each donor block.  Once completed, the 
recipient block was heated gently to fuse the donor paraffin wax with the recipient 
paraffin wax. 
 
2.1.6  Single colour immunohistochemistry. 
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Sequential three micron sections were cut from the TMA onto Superfrost coated 
slides (Thermo Scientific, Loughborough, UK).   Sections were dewaxed in xylene 
(Sigma, Poole, UK) and rehydrated through a series of dilutions of IMS (Sigma, 
Poole, UK) before antigen-retrieval and staining as listed in table 2.4 below.  All 
staining was performed using the Sequenza manual immunohistochemical staining 
system (Thermo Scientific, Loughborough, UK).  Endogenous peroxidise activity 
was blocked by incubating for 5 mins in 3% hydrogen peroxide (Sigma, Poole, UK) 
in PBS (Sigma, Poole, UK)  before washing and incubating with the primary 
antibody.   All antibodies were diluted in DAKO antibody diluent (DAKO, 
Cambridge, UK).  The wash buffer was TBS-Tween in all cases (Sigma, Poole, UK).   
DAB (DAKO, Cambridge, UK) was used as the chromogen in all cases.  
Counterstain was haematoxylin (Sigma, Poole, UK) for 30 seconds, then blued in 
sodium bicarbonate (Sigma, Poole, UK) for 1 minute before dehydration through a 
series of alcohols to Histoclear II (National diagnostics, USA) then mounting.  
Unless otherwise stated all reactions occurred at room temperature.  Negative 
controls used primary antibody species and isotype matched IgG at equivalent 
concentration to the primary antibody of interest, except for CD68 where primary 
antibody was omitted in the negative control.   Details of antigen retrieval, antibody 
concentrations and incubation periods are given in Table 2.3.   
 
2.1.7  Two colour immunohistochemistry 
Sequential three micron sections were cut from the TMA onto Superfrost coated 
slides (Thermo Scientific, Loughborough, UK).   Sections were dewaxed in xylene 
and rehydrated through a series of dilutions of IMS before antigen-retrieval and 
staining as listed in table 2.3 below.  Endogenous peroxidise activity was blocked by 
incubating for 5 mins in 3% hydrogen peroxide (Sigma, Poole, UK) in PBS (Sigma, 
Poole, UK)  before washing and incubating with the primary antibody. Both primary 
antibody incubations were performed simultaneously overnight at 4°C.  Secondary 
detection with a goat anti-rabbit-HRP conjugate was performed first with 
chromogenic detection using VIP peroxidise substrate (Vector, Peterborough, UK) 
then a sheep anti-mouse HRP-conjugate was used with chromogenic detection by 
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DAB (DAKO, Cambridge, UK).   All staining was performed using the Sequenza 
system.  All antibodies were diluted in DAKO antibody diluent (DAKO, Cambridge, 
UK).  The wash buffer was TBS-Tween in all cases.   There was no counterstain 
used.    Unless otherwise stated reactions occurred at room temperature.  Negative 
controls included rabbit IgG and Mouse IgG with anti-rabbit and anti-mouse HRP 
conjugates, anti-TYMP rabbit monoclonal antibody with anti-mouse HRP conjugate, 
anti-CD163 mouse monoclonal with anti-rabbit HRP conjugate, rabbit IgG with anti-
rabbit HRP conjugate and mouse IgG with anti-mouse HRP conjugate.  No staining 
was detected in any of the negative control conditions.  Appropriate positive controls 
were included which showed appropriate specific staining without background.  
Details of antigen retrieval, antibody concentrations and incubation periods are given 
in Table 2.4.   
 
2.2  Bioinformatic analysis 
2.2.1  Selection  of  Datasets 
The datasets used here were selected on the following criteria; analysis of primary 
human tumour, large study size, availability of data with provision of clinical 
annotation and genome-wide analysis using the Affymetrix U133 platforms (either 
U133A+B or U133Plus2.0). These datasets were identified from Gene Expression 
Omnibus (GEO) or caArray and CEL files downloaded. Details of the 7 datasets 
















194 (203) Affymetrix 
U133Plus2.0 




134 (159) Affymetrix U133A & 
B 





265 (285) Affymetrix 
U133Plus2.0 




86 (107) Affymetrix U133A & 
B 














253 (271) Affymetrix 
U133Plus2.0 
GSE7553 Riker et al.  
(18442402) 
Skin tumours 77(82) Affymetrix 
U133Plus2.0 
 
Table 2.1  Details of datasets used in bioinformatic analysis with database reference, original 
associated publication, tumour type  and platform given.  The total number of cases 
originally available for study and the number of cases passing the quality control step and 
therefore used in the analysis are given.   
 
The initial analysis used six individual datasets. The breast cancer dataset consisted 
of samples taken from 159 patients treated in Sweden. These were stratified on the 
basis of molecular tumour type (basal, HER2 positive, luminal A or B, or normal-
like), Ellis-Elston grade, survival outcome and recurrence outcome. The colorectal 
dataset contained 155 cases of colorectal carcinoma derived from an Australian 
population divided into microsatellite stable and unstable tumours. No information 
was available as to grade or stage. The lymphoma dataset consisted of 203 cases of 
diffuse large B cell lymphoma (DLBCL). These were stratified into germinal centre 
B cell-like (GCB), activated B cell-like (ABC), primary mediastinal B cell (PMBL) 
and unclassified, based on gene expression. The data was further organised on the 
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basis of sex and patient outcome. The glioma dataset, derived from caArray, 
contained samples of 271 tumours which were stratified on the basis of histological 
type (astrocytoma, oligodendroglioma, glioblastoma), WHO grade and sex. The 
ovarian dataset was from 285 cases from several hospitals in Australia and the 
Netherlands. These were stratified based on whether they were malignant or of low 
malignant potential, histological type (endometrioid or serous), grade, stage and 
primary site (ovary, peritoneum or fallopian tube). The testicular dataset was made 
up of 107 patient samples from the USA. This contained primary germ cell tumours 
and was stratified first on whether the tumours were pure or mixed histological types 
and then within each category on the constituent parts of the tumour using the WHO 
classification (seminoma, teratoma, embryonal carcinoma, yolk sac tumor, 
choriocarcinoma). A final dataset of 82 samples was derived from various types of 
skin cancer including basal cell carcinoma, squamous cell carcinoma, primary 
melanoma, including melanoma in-situ, and melanoma metastatic to subcutaneous 
tissue, lymph node, brain and adrenal gland. 
 
2.2.2  Quality control 
The quality of the raw data from each dataset was reanalysed by Fios genomics using 
the arrayQualityMetrics package in Bioconductor (http://www.bioconductor.org/) 
and scored on the basis of 5 metrics, namely maplot, spatial, boxplot, heatmap and 
rle. Any array failing on more than one metric was removed from the dataset (Table 
2.1) and in cases comprising A and B arrays, failure of one chip (A or B) resulted in 
removal of data from both arrays from the dataset. In cases where the data was 
derived from A and B arrays, these were merged to create a single file for each 
sample. Normalisation for each dataset was performed independently using the 
robust multi-array average (RMA) expression measure. Probesets were then 
annotated using latest annotation available in Bioconductor (26 June 2009) and 





2.2.3  Network Analysis 
Each dataset was saved as an ‘.expression’ file.  These contain a unique identifier for 
each row of data (Gene symbol concatenated to probeset ID), followed by columns 
of gene annotations which can be used as class-sets for the overlay and analysis of 
information with respect to the graph and finally natural scale normalised data values 
for each sample (each column of data being derived from a different sample). These 
files were then loaded into the network analysis tool BioLayout Express
3D
. Pairwise 
Pearson correlations were calculated for each probeset on the array(s). All Pearson 
correlations where r ≥ 0.6 were saved to a ‘.pearson’ file. Based on a user defined 
threshold designed to include approximately 40% of the data available, undirected 
network graphs of the data were generated. In this context nodes represent individual 
probesets (genes/transcripts) and the edges between them Pearson correlation 
coefficients above the selected threshold. The network was then clustered into groups 
of genes sharing similar profiles using the MCL algorithm with an MCL inflation 
value (which controls the granularity of clustering) set to 2.2. Graphs of each dataset 
were explored extensively in order to understand the significance of the gene 
clusterings and their relevance to the pathology of the tumours. 
 
2.2.4  Cluster annotation 
Gene set enrichment analysis was performed on clusters using DAVID and GSEA 
MSigDB web-based analysis tools (Huang et al 2009a, Huang et al 2009b, 
Subramanian et al 2005, Mootha et al 2003). Analysis through DAVID used the 
‘functional annotation clustering’ tool to identify clusters of related hits. This tool 
compares the submitted gene list with data from a variety of sources including gene 
ontology data, Swiss protein interaction data and curated pathway data such as is 
available in KEGG and Biocarta to see whether the submitted gene list is enriched in 
genes falling into any of these groupings beyond that which would be expected by 
chance.  In this analysis the background from which the tested gene list is derived is 
considered in analysis ie which genes could be present because of the chip used 
rather than all genes in the genome.  The functional clustering tool pulls together 
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groups of similar annotation from different sources to highlight functional annotation 
and reduce redundancy in the generated list of gene sets with significant overlap with 
the test set.  The GSEA MSigDB tool has a similar function allowing determination 
of whether there are overlaps beyond that expected by chance between entered gene 
sets and the gene sets that are present in the GSEA database.  The available genes 
sets for comparison include gene ontology sets, oncogenic signatures derived from 
microarray data deposited in GEO, immunological signatures generated by manual 
curation of published studies, positional gene sets reflecting individual gene position 
on chromosomes and curated gene sets from various sources including KEGG, 
Biocarta and Reactome.  Analysis using this tool mostly focussed on curated 
pathways, gene ontology terms, oncogenic and immune signatures although other 
gene sets were less frequently used.  Unlike DAVID this approach does not take into 
account the background from which the tested gene set was derived.   GSEA analysis 
generated multiple hits for most clusters and clusters were annotated if hits of high 
significance showed a common trend as to function. These analyses were 
supplemented by comparison of the clusters generated here with tissue- and cell-
specific clusters derived from network-based analyses of a human tissue atlas and an 
atlas of purified leukocyte populations, analysis of protein expression of selected 
targets using the Human Protein Atlas and review of the published literature (Ulhen 
et al 2010, Uhlen et al 2015).  
 
2.2.5  Comparison of Expression Patterns Across Six Cancers and Validation of 
Signatures 
To allow direct comparison of all datasets, probesets that were not represented in all 
datasets i.e. were only present on the U133Plus 2.0 array, were removed leaving 
44,754 probesets common to all U133 platforms. The Pearson correlation coefficient 
between data derived from each probe-set in each dataset was calculated using 
BioLayout Express
3D
 and all values written to file. A mean Pearson correlation was 
then calculated for each probe i.e. the average correlation between probesets across 
the six datasets. The mean Pearson correlations were then filtered to remove any 
mean correlation values below a user defined threshold and network graphs 
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constructed. The majority of the work described here is based on the use of graphs 
constructed using a mean Pearson threshold of r > 0.6 and clustered with an MCL 
inflation value of 2.2. 
 
2.2.6  Validation of ‘core’ signatures on independent dataset. 
 
A skin cancer dataset, not used in the 6 dataset merge analysis above was treated as 
described for the other individual datasets.  The gene clusters and annotations from 
the merged graph were mapped onto the dataset and  clusters in the skin dataset 
analysed for enrichment of genes from the ‘core’ signatures that were greater than 





2.3  In vitro cell culture studies 
2.3.1.  Cell line maintenance 
 
The EBV-negative Group 1 sporadic Burkitt lymphoma cell line BL2 was used in 
these studies (Rowe et al 1986).  These were cultured in suspension in RPMI 1640 
(Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum (PAA, USA), 





THP-1 cells, a human acute moncytic leukaemia cell line (European collection of 
authenticated cell cultures, Porton Down, Cat no. 88081201) were maintained in 
suspension in RPMI (Invitrogen, Paisley, UK), plus 10% foetal calf serum (PAA, 





2.3.2  THP-1 differentiation and polarisation 
 
THP-1 cells, were plated out a concentration of 0.2 x10
5 
cells/ml and PMA in DMSO 
added at a concentration of 200nM.  After three days, cells were washed in Dulbecco 
PBS (PAA, USA) and incubated in fresh culture medium, with the addition of 
cytokines and LPS as indicated.  Cytokine suppliers and final concentrations given 
below (Table 2.2).  The cells were incubated in the presence of the cytokines or LPS 
for five days and then washed with Dulbecco PBS before being used in experiments. 
 
Cytokine  Supplier Concentration  
Human IL-10   R&D  5ng/ml 
Human IFNγ   R&D  20ng/ml 
Human IL-4   R&D  20ng/ml 
LPS   Sigma  100ng/ml 
Table 2.2.  Cytokine concentrations used and suppliers.   
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2.3.3  Detachment of adherent cells from culture flasks 
Cells were washed with HBSS (Thermo-scientific, Loughborough, UK) to remove 
medium then cold detachment buffer added to the cell.  They were then shaken on an 
orbital shaker at 80rpm at 4°C for 30mins.  Cells were then gently lifted with a cell 
lifter and washed once in HBSS before use. 
 
2.3.4  Culturing THP-1 cells on collagen 
Collagen IV from human placenta (Sigma, Poole, UK) was dissolved in 0.25% sterile 
filtered acetic acid and was spread onto tissue culture dishes or chamber slides 
(Sigma, Poole, UK).   This was UV treated overnight to sterilise and cross-link the 
collagen.   These were stored at room temperature and before use were sprayed with 
70% alcohol them washed with sterile water and allowed to dry.   Control dishes 
with no collagen were treated in an identical manner but without collagen being 
present in the acetic acid diluent.   All THP-1 differentiation and polarisation steps as 
described above then took place on collagen, or control coated plates.   
 
2.3.5  Co-culture of THP-1 cells and BL2 cells 
THP-1 cells were grown on collagen-coated or dummy-coated slides as described 
above.  After three days of growth in the presence of PMA and a further 5 days 
growth in the presence of polarising cytokines, cells were washed and BL2 cells 
were added in fresh culture medium at concentrations of 0.1 or 0.2 x10
6
cells per ml.   
 
2.3.6  Cell counting 
Cells were counted on a Beckman-Coulter XL flow cytometer by adding 25 µl of a 
known concentration of fluorescent beads (Beckman-Coulter, High Wycombe, UK) 
to a fixed volume of BL2 cells from culture and capturing events until 2000 beads 
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have been counted.  BL2 viable and non-viable counts were obtained by gating on 
the basis of forward and side scatter.   
 
2.3.7  Assessment of LAIR-1 surface expression by flow cytometry 
For each FACS tube 0.5 x 10
6
 cells per ml was used.  Cells were first washed in 
HBSS then resuspended in 100µl of FACS buffer (Dulbecco PBS with 5% normal 
goat serum and 10% normal mouse serum) (PAA, USA).  Primary antibody or 
isotype control was added at the concentrations indicated in Table 2.3 and incubated 
at 4°C for 30mins.  Cells were then washed in FACS buffer and resuspended in 
FACS buffer containing matching F(ab’)
2 
 fragment conjugated to Alexa 488 
conjugate (Invitrogen, Paisley, UK).  Cells were incubated at 4°C for 30 minutes 
before washing in FACS buffer and resuspension in FACS buffer.  Samples were run 
on a Beckman-Coulter XL flow cytometer and post-measurement analysis performed 
using ‘Flow Jo’ (Tree Star).  Histograms of cells were drawn only from cells that fell 
into a ‘viable’ gate based on forward and side scatter.    
 
2.3.8  Assessment of LAIR1 intracellular expression by flow cytometry 
To assess LAIR-1 expression using an antibody directed against the intracellular 
component of the molecule cells were fixed and permiabilised prior to staining using 
a commercial kit ‘Fix and Perm’ (Caltag, Buckingham, UK).  For each FACS tube 
0.5 x 10
6
 cells per ml was used.  Cells were first washed in HBSS then resuspended 
in 100µl of FACS buffer (Dulbecco PBS with 5% normal goat serum and 10% 
normal mouse serum).  An equal volume of Reagent A (Fix) was added and 
incubated at room temperature for 15 minutes.  Cells were washed in FACS buffer 
and then resuspended in reagent B (Perm) and Primary antibody or isotype control 
was added at the concentrations indicated in Table 2.3. Cells were then vortexed to 
mix and then washed in FACS buffer and resuspended in FACS buffer containing 
matching F(ab’)
2 
 fragment conjugated to Alexa 488 conjugate.  Cells were kept in 
the dark at room temperature for 40 minutes before washing in FACS buffer and 
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resuspension in FACS buffer.  Samples were run on a Beckman-Coulter XL flow 
cytometer and post-measurement analysis performed using ‘Flow Jo’ (Tree Star).  
Histograms of cells were drawn only from cells that fell into a ‘viable’ gate based on 
forward and side scatter.    
 
 
2.3.9  Immunoblotting 
 
2.3.9.1  Preparation of whole cell lysates 
Cells were washed 3 times in Dulbeco PBS to remove culture medium and then 
scraped from the culture dishes with a cell scraper.   The cells were collected and 
lysed with freshly made lysis buffer, 12.5µl of lysis buffer per million cells, and then 
transferred to a fresh eppendorf. Protease inhibitors were added (P8340, Sigma, 
Poole, UK) (1µl of inhibitor per million cells), before vortexing for 20 seconds and 
then leaving on ice for at least 30 mins to lyse.  Lysed cells were then spun at 
18,000g for 10 mins at 4°C to remove cellular debris.  Supernatants were transferred 
to fresh eppendorfs and frozen at -20°C until used in analysis.  Protein concentrations 
in whole cell lysates were measured using the Bradford assay 
 
2.3.9.2  Bradford Assay 
 
Protein concentrations were measured using Bradford dye reagent (Bio-Rad, Hemel 
Hempstead, UK).  Dilutions of whole cell lysate and serial dilutions of IgG (Sigma, 
Poole, UK) of known concentration were mixed with the dye reagent and colour 
concentration measured on a plate reader at 595nm wavelength.  A standard curve 
was created from the measurements of known concentration and protein 
concentration of cell lysates calculated. 
 
2.3.9.3  Electrophoresis and Western blotting 
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Electrophoretic sample separation and transfer to nitrocellulose membranes were 
performed using the Invitrogen NuPage system and reagents according to the 
manufacturers’ instructions (Invitrogen, Paisley, UK).  Samples were prepared as 
follows to give a total volume of 10µl in each well. 
Reagent     Reduced sample 
Sample     x µl 
NuPAGE LDS sample buffer(x4)  2.5µl 
NuPAGE reducing agent(x10)  1µl 
Deionized water    to 6.5µl 
--------------------------------------------------------------------------------------- 
Total volume     10µl 
 
Samples were denatured at 70°C for 10 mins before being loaded into the wells of 
the precast NuPage 4-12% Bis-Tris gel.  SeeBlue Plus 2 prestained standard 
(Invitrogen, Paisley, UK) was loaded as a molecular weight indicator.  Protein 
separation was carried out in NuPage MOPS SDS running buffer at 150-200v for 30-
40 mins.  Proteins were transferred onto PVDF membranes in NuPaGE transfer 
buffer at 30V for 1 hour.    Membranes were blocked with 0.1% Tween-20/PBS with 
5% non-fat milk and incubated at room temperature for 1 hour.  Antibodies were 
diluted to the required concentration (see table 2.3) in 0.1% Tween-20/PBS with 5% 
non-fat milk and incubated at 4°C overnight.  Membranes were then washed 
thoroughly in 0.1% Tween-20/PBS and sheep anti-mouse HRP conjugated antibody 
(GE Healthcare, Amersham, UK) in 0.1% Tween-20/PBS with 5% non-fat milk 
added and incubated at room temperature for 90 minutes.  Membranes were again 
washed and bands were developed using ECL reagents (GE Healthcare, Amersham, 
UK).  Chemiluminescence was captured using photographic film (GE Healthcare, 
Amersham, UK).  
For staining blots with multiple antibodies, membranes were stripped by incubating 
twice in stripping buffer for 10 minutes then washing twice with PBS and twice with 





2.3.10 Quantative reverse transcription PCR 
 
2.3.10.1  RNA extraction from whole cells 
RNA extraction was performed using the RNeasy mini kit (Qiuagen, Manchester, 
UK) following the manufacturers’ instructions.  Cell lysis was performed on the cell 
culture plates using RLT buffer and RNA extraction performed as per the handbook 
including an on-column DNA digestion step.  RNA concentration was measured 
using the Nanodrop system (Thermo Scientific, Loughborough, UK).   
 
2.3.10.2  cDNA synthesis 
cDNA was generated using the Supersript III First strand synthesis Supermix for 
qPCR  (Invitrogen, Paisley, UK) following the manufacturer’s instructions.  Each 
reaction included 10µl of RT reaction mix, 2µl of RT enzyme mix and RNA and 
water (Invitrogen) to total volume of 20µl.  Samples were mixed and incubated at 
25°C for 10 minutes, followed by 50°C for 30 minutes.  The reaction was terminated 
at 85°c for 5 minutes then cooled to 4°C.  1µl of RNA-ase H (Invitrogen) was added 
to each reaction and incubated at 37°c for 20 minutes.  cDNA was then stored at -
20°C until use. 
 
2.3.10.3  Quantitative PCR 
Quantitative PCR was carried out using the SYBR Green system on the FAST 7500 
Real Time PCR system (Applied Biosystems, Thermoscientific, Loughborough, UK 




LAIR1 (from Jansen et al 2007) – (synthesised by eurofins genomics, Ebersberg, 
Germany)  
Forward  5’ – CCT GAC CTG GCT GTT GAT GTT CT – 3’ 
Reverse 5’ – GCC CGG GCT GTC CTC TGT – 3’ 
 
18S  - (synthesised by Sigma, Poole, UK) 
Forward 5’ – CGA AGA CGA TCA GAT ACC GT – 3’ 
Reverse 5’ – GGT CAT GGG AAT AAC GCCG – 3’ 
 
Each reaction was set up containing 10µl of SYBR green master mix (Qiagen, 
Manchester, UK), 2µl of cDNA, primers at a concentration of 0.3µM and Ultrapure 
water (Invitrogen, Paisley, UK) to 20µl.  The reaction was run on the 7500 Fast Real 
Time PCR system (Applied Biosystems) using the following parameters;  2 minutes  
at 50°C once, 15 minutes at 95°C once, then 40 cycles of 15 seconds at 95°C 
followed by 1 minute at 60°C.  Melting curve analysis was performed.  18S was used 
as the endogenous control.   Undifferentiated THP-1 cells were used as the calibrator 
in performing  ΔΔCT  analysis.   
 
2.3.11  Induction and evaluation of apoptosis in BL2 cells  
BL2 cells from confluent cultures were washed 3 x 5mins in serum-free RPMI 
(Invitrogen, Paisley, UK) with 2mM L-glutamine, 100 IU/ml penicillin and 100 
μg/ml streptomycin, counted and resuspended in the same medium at a concentration 
of 1x10
6
 cells/ml.  Apoptosis was induced by treatment with Stuarosporine 
(Calbiochem, Millipore, Watford, UK) at 1µM for five minutes.  Cells were them 
washed  3 times in Dulbecco’s PBS without Ca and Mg, once in Dulbecco’s PBS 
with added Ca and Mg and a final time in RPMI (Invitrogen, Paisley, UK), plus 10% 
foetal calf serum (PAA), 2mM L-glutamine, 100 IU/ml penicillin and 100 μg/ml 
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streptomycin.   Induction of apopotosis in the BL2 cells was assessed after 75 
minutes by staining for Annexin V (AxV)-FITC (Life technologies, Thermo 
scientific, Loughborough, UK) and propidium iodide (PI) (Life technologies), using 
Beckman-Coulter XL flow cytometer.  Briefly, 1 x 10
6 
cells were placed in a FACS 
tube, spun down and re-suspended in 100 μl of Annexin V binding buffer (10 mM 
HEPES/NaOH (pH 7.4); 140 mM NaCl; 2.5 mM CaCl2). 1 μl of Annexin V-FITC 
was added per tube and incubated for 10 min on ice. Cells were next washed and re-
suspended in 500 μl of binding buffer. 10 μl of propidium iodide was added to each 
tube prior to FACS measurement.     
 
2.3.12  Co-culture of apoptotic BL2 cells with THP-1 cells 
THP-1 cells were previously differentiated for 8 days as described above.  BL2 cells 
induced to undergo apoptosis were added at three concentrations of 10,000 cells/ml, 
100,000 cells per ml and 1 x10
6
cells per ml.   Control culture conditions included co-
culture with BL2 cells not induced to undergo apoptosis with staurosporine, and 
culture of THP-1 cells with supernatant derived from the last wash of the 
staurosporine treated cells to exclude any effect of residual struarosporine on the 
THP-1 expression of LAIR1.   Cells were cultured in 5% CO2 at 37°C.   To assess 
whether co-culture  with apoptotic cells altered expression of LAIR1 surface staining 
was assessed by flow cytometry using an antibody directed at the extracellular 




Table 2.3  Antibodies and dilutions used. 
Antibody Catalogue 
number 





Rabbit polyclonal anti-LAIR-1 (clone 
HAP011155) 
HPA011155 Sigma 1:300 1µg/ml 1:5000 
Mouse monoclonal anti-human LAIR-1 
(clone DX26) (IgG1) 
550810 BD Pharmingen - 10µg/ml 1:1000 
Mouse monoclonal anti-human LAIR-1 
(clone NKTA255) (IgG1) 
NB100-66540 Novus 
biologicals 
- 10µg/ml 1:1000 
Mouse monoclonal anti-CD68 (clone PG-
M1) (IgG3) 
Ab783 abcam 1:50 - - 
Rabbit polyclonal  anti-LGALS3BP HPA000554 Sigma 1:400 - - 
Rabbit polyclonal anti-ECGF1 (TYMP) HPA001072 Sigma 1:100 - - 
Goat polyclonal anti-lba1 (AIF1) Ab5076 abcam 1:100 - - 
Mouse monoclonal anti-CD163 (IgG1) NCL-CD163 Leica 1:100 - - 










Equivalent concentration to 
primary antibody 
Equivalent concentration to 
primary antibody 
 
Goat IgG I 9140 Sigma Equivalent concentration to 
primary antibody 
  









Goat anti-rabbit F(ab’)2 fragment,  Alexa 
488 conjugated. 
A-11077 Invitrogen - 1:100  
Rabbit anti-mouse F(ab’)2 fragment, Alexa 
488 conjugated. 
A-21204 Invitrogen - 1:100  
Goat polyclonal anti-rabbit 
immunoglobulin/HRP conjugated  
P0488 DAKO 1:100  1:2000 
Rabbit polyclonal anti-goat 
immunoglobulin/HRP conjugated 
P0449 DAKO 1:100   
Anti mouse immunoglobulin/HRP 
conjugated. 
 DAKO 1:100   
Sheep anti-mouse IgG peroxidise linked NA931 ECL  GE 
Healthcare 












Table 2.4  Methods of antigen retrieval, blocking and incubation times for immunohistochemistry.  All incubations are at room 
temperature unless otherwise stated. 










LGALS3BP None 3% H2O2 in PBS Anti-LGALS3BP 
(Sigma HPA 554)   
105 DAKO goat  anti-
rabbit – HRP 
60 
LAIR1 Sodium citrate buffer with 





120 DAKO goat anti-
rabbit  - HRP 
30 
TYMP – single 
colour IHC 
Vector antigen unmasking 
solution with microwave heat 
retrieval 
3% H2O2 in PBS Anti-ECGF1 
antibody (Sigma 
HPA 001072 
16 hours at 4°C DAKO goat anti-
rabbit  - HRP 
60 
TMYP  - two 
colour IHC 
Vector antigen unmasking 
solution with microwave heat 
retrieval 
3% H2O2 in PBS Anti-ECGF1 
antibody (Sigma 
HPA 001072 
16 hours at 4°C DAKO goat anti-
rabbit  - HRP 
60 
CD163 Vector antigen unmasking 
solution with microwave heat 
retrieval 
3% H2O2 in PBS Anti-CD163 (Leica 
Novocastra NCL-
CD163 
60 DAKO anti 
mouse HRP 
60 
CD163 – two 
colour IHC 
Vector antigen unmasking 
solution with microwave heat 
retrieval 
3% H2O2 in PBS Novocastra NCL-
CD163 




CD68 Tris-EDTA buffer with 
microwave heat retrieval 
3% H2O2 in PBS Mouse anti human 
CD68 (PGM1) – 
Abcam (ab783 
120 Sheep anti-





AIF1 Sodium citrate buffer with 
microwave heat retrieval 
DAKO 
peroxidise block 
Anti –lba1  Abcam  
ab5076 
60 Rabbit anti –






2. 4   Reagent list 
 
Acetic acid       Sigma-Aldrich 
Antibody diluent      DAKO 
Antigen unmasking solution (citrate)    Vector 
Annexin V-FITC      Life technologies 
BSA (low endotoxin)       PAA 
Bradford dye       Bio-Rad 
Collagen IV (human)      Sigma-Aldrich 
DAB (3, 3’-diaminoebenzidine)     Vector 
DAKO antibody diluent      DAKO 
Dulbecco’s PBS      PAA 
DMSO        Sigma-Aldrich 
dNTP mix       Sigma-Aldrich 
EDTA        Sigma-Aldrich 
ECL chemoluminescence reagents    GE Healthcare 
F(ab)
2
 Goat anti-mouse IgG (H+L)  TRI-COLOUR conjugated Invitrogen 
FCS        PAA 
Flow count fluorespheres     Beckman Coulter 
Fix and Perm  cell permiabilisation reagent.   Caltag Laboratories 
Harris haematoxylin      Sigma-Aldrich 
HEPES        Sigma-Aldrich 
HBSS        Thermo Scientific 
Histoclear II       National Diagnostics, USA 
Hydrogen peroxide   Sigma-Aldrich 
Hydrochloric acid   Sigma-Aldrich 
Industrial methlylated spirit (IMS)    Sigma 
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LPS        Sigma 
L-glutamine       PAA 
MicroAmp  Fast optical 96 well plate    Applied Biosciences 
MicroAmp Optical adhesive film    Applied Biosciences  
NuPAGE LDS sample buffer     Invitrogen 
NuPAGE reducing agent     Invitrogen 
NuPAGE 4-12% Bis –Tris precast gel   Invitrogen 
NuPAGE MPOS SDS running buffer   Invitrogen 
NuPAGE transfer buffer     Invitrogen 
PBS        Sigma-Aldrich 
Penicillin/streptomycin      Invitrogen 
Peroxidase block      DAKO 
PMA        Sigma 
Propidium iodide       Life technologies 
Protease inhibitor  (P8340)     Sigma   
QuantiTect SYBR green PCR kit    Quiagen 
RPMI 1640       Invitrogen 
RNeasy Mini kit      Quiagen 
RNase free DNAase set      Quiagen 
SDS        Sigma-Aldrich 
SeeBlue plus 2 prestained standard    Invitrogen 
Sodium bicarbonate      Sigma-Aldrich 
Staurosporine        Calbiochem 
Superscript III First strand synthesis mix for qPCR  Invitrogen 
SYBR green master mix     Quiagen 
Tris-base       Sigma-Aldrich 
Tri-sodium citrate      Sigma-Aldrich 
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Triton –x-100       Sigma-Aldrich 
Tween-20       Sigma -Aldrich 
UltraPure™ DNase/RNase-Free Distilled Water   Invitrogen 
VIP peroxidise substrate     Vector 




IgG1 (mouse) MCA928     Serotec 
IgG1 (mouse) NCG01     Abcam 
IgG (goat)       Sigma-Aldrich 
Immunoglobulin fraction (goat)    DAKO 
Anti -LAIR-1 (HPA011155)     Sigma 
Anti –LAIR-1 (DX26)      BD Bioscience 
Anti-LAIR1 (NKTA255)     Novus Biologicals 
Anti-CD68 (PG-M1)      abcam 
Anti-LGALS3BP (HPA000554)     Sigma 
Anti-ECGF1 (HPA001072)     Sigma  
Anti-lba1 (ab5076)      abcam 
Anti-CD163 (NCL-CD163)     Leica 
 
Cytokines 
Human IL-10        R&D   
Human IFNγ        R&D   








1mM EDTA  









Made up to 1L with distilled water. 











Dulbecco’s PBS (with no Mg+ or Ca+) 
5% normal goat serum 
10% normal mouse serum 
 
 





Adjust pH to 7.4 with NaOH 
 
 
Sodium citrate buffer 
 
10mM sodium citrate 
0.05% Tween -20 







10mM Tris base 
1mM EDTA 
0.05% Tween-20 












Relationship of proliferation, apoptosis and 




Previous work within the group (Ford et al 2015) has demonstrated a significant 
linear relationship between rates of proliferation, apoptosis and macrophage 
infiltration in Burkitt lymphoma.  Burkitt lymphoma as currently classified in the 
WHO Classification of Tumours of Haemopoetic and Lymphoid tissue, 2008 is a 
relatively tightly defined entity that must meet defined clinical, histological and 
genetic parameters to be diagnosed as such (Swerdlow et al 2008).  The tumour is 
defined in part by the characteristic (although not invariable) presence of a myc 
translocation resulting in high rates of proliferation (often approaching 100%), and 
consequent high rates of apoptosis.  Morphologically, the tumour is characterised by 
a dense macrophage infiltrate, these macrophages containing abundant apoptotic 
debris, reflecting the incredibly high rate of cell loss in these tumours.  In these 
tumours therefore, there is a constant presence of tumour-associated macrophages, 
which are visibly involved in clearance of apoptotic cells and as such are likely to be 
functionally modified by these apoptotic cells.  Much work within the group has 
focussed on how these apoptotic cells may modulate the tumour microenvironment 
to provide a growth advantage to the tumour.  Various mechanisms including release 
of lactoferrin and fractalkine from apoptotic cells and production of BAFF from 
TAMs have been demonstrated (Bournazou 2009, Truman et al 2008, Ogden et al 
2005).   
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This chapter seeks to explore whether a similar relationship exists between apoptosis, 
proliferation and macrophage infiltration in DLBCL, with the resultant influences by 
apoptotic cells on macrophage function, to confirm that the phenomenon is not 
unique to Burkitt lymphoma.  In contrast to Burkitt lymphoma, DLBCL as currently 
defined is a much more heterogeneous group of diseases than Burkitt lymphoma, 
lacking a common clinical presentation, or genetic abnormality and containing 
tumours from a wider morphological spectrum.  Like Burkitt lymphoma, these 
tumours tend to be characterised by aggressive behaviour.  They show a much wider 
distribution of rates of proliferation, from relatively low to close to 100%.  In some 
cases, and often in cases with very high proliferation, there is evidence of a myc 
translocation, but this is not a universal finding and many other genetic abnormalities 
are also described.  The relationship between proliferation and apoptosis would 
therefore be predicted to be somewhat more complex than in Burkitt lymphoma, but 
if apoptosis is important in recruitment of macrophages to the tumour site to help 
support tumour cell growth, then the same relationship would be predicted to occur. 
 
To address this question, a cohort of 82 cases of DLBCL, representing all cases 
suitable for inclusion in a tissue microarray from two regional pathology laboratories 
(Tayside and Highland) over a 10 year period were examined for expression of 
activated caspase-3 as a marker of apoptosis, CD68 as a marker of macrophages and 
ki67 as a marker of proliferation.  The cohort of cases was obtained from the Tayside 
tissue bank and built into a TMA in which each case was represented at least twice 
and up to 4 times.  Cases had been divided into either ‘germinal centre’ type or ‘non-
germinal centre’ type (roughly equating with the activated B cell type defined by 
gene expression analysis) using the immunohistochemical algorithm of Hans (Hans 
et al, 2004).  There was also information available for all cases as to whether there 
was a t(14:18) translocation in the tumour bringing bcl-2 under the control of the 
immunoglobulin heavy chain promoter, and predicted to render the tumour cells 
more resistant to apoptosis.  For each characteristic studied, an index was calculated 




3.2.1  Rates of proliferation but not apoptosis or macrophage recruitment differ 
between subtypes of DLBCL 
Rates of proliferation, apoptosis and macrophage infiltration were calculated for all 
tumours in the microarray.  There was a wide variation in the rates of all of these 
between individual tumours reflecting the heterogeneous nature of the individual 
tumours and their hosts (see figure 3.1).   
 
 
Figure 3.1.  Representative photomicrographs to show examples of rates of proliferation [a) 
low proliferative index, d) high proliferative index], macrophage infiltration [b) high 
macrophage infiltration, e) low macrophage infiltration] and apoptosis [c) low apoptotic 
index, f) high apoptotic index]. All images represent different tumours.  Magnification in 
images a-d = x40 and images e &f = x100.   
 
Analysis of medians across the groups demonstrated the germinal centre-type of 
DLBCL without bcl-2 translocation to show significantly higher rates of proliferation 
than germinal centre-type with the translocation or non-germinal centre type 
(Kruskall-Wallis test for differences in rates of proliferation.  p = 0.026), but there 
were no significant differences in rates of apoptosis or macrophage infiltration (see 
figure 3.2 and table 3.1 on page 68).  This is somewhat at variance from what might 
have been predicted based on the known genetic mutations of these tumours.  Whilst 
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high rates of proliferation in GC-type cases without the bcl-2 translocation is not 
unexpected, it would have been predicted that cases with the translocation would 
show a lower rate of apoptosis and this was not shown to be the case.  Rates of 
apoptosis varied much more markedly in GC tumours lacking the bcl-2 translocation 
than others, but there were no significant differences between groups.  In part, this 
may reflect the generally low rate of apoptotic cells seen, with a median of 1.4% of 
all cells being positive for activated caspase-3.  This does not necessarily imply a low 
rate of apoptosis as clearance of apoptotic cells occurs very rapidly and potentially 
differences in rates of apoptosis between tumour types may be masked by differences 
in efficiency in macrophage clearance (reviewed in Gregory and Pound, 2011).  An 
alternative explanation would be that despite the role of bcl-2 in protecting cells from 
apoptosis, expression of this by DLBCL does not alter the rate at which apoptosis 
occurs in vivo.  The results contrast with those of Bai et al who found higher rates of 
apoptosis in germinal-centre type tumours but no differences in proliferation between 
groups in study of 79 cases of nodal and extranodal DLBCL subdivided into GC and 
non-GC type (Bai et al,  2004).  In this study no information on translocations was 









Figure 3.2  a) Median proliferative index (plus interquartile range) for all cases of DLBCL and 
subtypes of DLBCL.  Proliferative indices varied significantly between groups on Kruskall Wallis test 
(p=0.026).  b) Median apoptotic index (plus interquartile range) for all cases of DLBCL and subtypes 
of DLBCL.  There were no significant differences between groups.  c)  Median macrophage index 
(plus interquartile range) for all cases of DLBCL and subtypes of DLBCL.  There were a wide range 
of values between tumours but the median for all groups was low.  There were no significant 
differences between groups).   GC-neg (n=25)  = germinal centre-type cases without the t(14;18) 
translocation, GC-pos (n=13) = germinal centre-type cases with the t(14:18) translocation, and ABC 


















































































































































































70   (52-80) 1.4   (0.5-2.7) 11   (8-15) 
Non-GCB 


















0.026 NS NS 
 
 Table 3.1:  Summary of variables measured across all tumours assessed.  All values 
are number of positive cells as a percentage of total cells.   Differences between 
groups was assessed by Kruskall-Wallis test.  p-values <0.05 were considered 
significant.  (GCB= Germinal Centre B-cell subtype.  NS = Not significant). 
 
 
3.2.2  There is a significant correlation between rates of apoptosis and 
proliferation, and apoptosis and macrophage infiltration in DLBCL 
 
The relationship between these variables was studied in the cohort of DLBCL cases.  
Scatter plots in Figure 3.3 show the distribution of variables between individual 
cases.  Associations between these variables were analysed using Pearson 
correlations.  When proliferation and apoptosis was analysed there was a significant 
correlation (Correlation coefficient r=0.408, p-value <0.001) between proliferation 
and apoptosis when studied as a whole cohort.  This association remained, when 
cases were subdivided into smaller cohorts of GC-type or non GC-type, but was lost 
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if the cases were further subdivided into the smaller groups of GC-type divided by 
presence or absence of bcl-2 translocation.  (Table 3.2).  Similarly a correlation 
existed between apoptosis and macrophage infiltration (Correlation coefficient 
r=0.238, p-value <0.05).  No such correlation existed between macrophage 







Figure 3.3: Scatterplots demonstrate relationships between apoptosis, 
proliferation and macrophage infiltration.  Each dot represents the mean of two or 
more cores per tumour present on the array.  a) All cases – Proliferative index vs 
Apoptotic index, b) All cases – Apoptotic index vs Macrophage index, c) GCB cases 
only – Proliferative index vs apoptotic index, d) Non-GCB cases only – Proliferative 
index vs Apoptotic index.   
 
This data would support a relationship between proliferation and apoptosis, 
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association would be predicted given the known propensity of cells in cell cycle to 
undergo apoptosis, and would argue that in DLBCL, the cell cycle is not deregulated 
to the extent that this property is lost (Evan et al, 1992).  Similarly, although the 
association is less strong, there is a clear relationship between apoptosis and 
macrophage recruitment/retention to the tumour.  Again, based on the well 
characterised role of macrophages as professional phagocytes, and their attraction to 
apoptotic cells, this relationship was predicted to occur.  The data in relation to the 
association of macrophage infiltration is more difficult to interpret.  If, as 
hypothesised, macrophages recruited and programmed by apoptotic cells support cell 
proliferation, then an association between these variables would be predicted.  The 
absence of such an association however, does not necessarily imply that this 
supportive relationship does not in fact exist, but any such support may be only one 
of multiple factors affecting proliferation in DLBCL.  The relative complexity and 
heterogeneity of the tumours that fall within the classification of DLBCL would 
argue that there are many influences at play in these tumours.  To detect any such 
association may require study of much larger cohort of cases, which would of 
necessity require a multi-centre study to collect sufficient cases of this relatively rare 





















Table 3.2: The relationship between proliferation, apoptosis and macrophage infiltration were assessed for the whole cohort and for 
sub-groups within the cohort by Pearson correlation coefficients (r).  Significant correlations were shown to exist between proliferation, 

























































0.408 <0.001 0.477 <0.01 0.351 <0.0
5 




0.087 NS 0.049 NS 0.148 NS -0.096 NS 0.315 NS 
Apoptotic Index vs  
Macrophage Index 




This chapter examined proliferation, apoptosis and macrophage infiltration in a large 
cohort of cases of human DLBCL.  It demonstrated variable rates of all factors in this 
heterogeneous collection of cases.   
 There were no significant differences between these variables in subtypes of 
tumours with the exception of proliferation which varied significantly 
between germinal centre-type tumours with the t(14;18) translocation, 
germinal centre-type tumours without the t(14;18) translocation and the non-
germinal centre cell type of tumour. 
 There was a significant correlation between rates of proliferation and 
apoptosis, and rates of apoptosis and macrophage infiltration in these tumours 
providing support for the hypothesis, that as in Burkitt lymphoma, one of the 
roles of apoptotic tumours cells is to recruit and potentially modulate tumour-

















A bioinformatic approach to deriving gene 
expression signatures from human tumour 
data. 
Aims of the chapter 
 
Having established that there was a relationship between proliferation, apoptosis and 
macrophage infiltration in DLBCL as in Burkitt lymphoma, this study then focussed 
on the role of the tumour associated macrophage in the tumour microenvironment.  
The role of the tumour associated macrophage is clearly an important one in many 
types of tumour, but it is a very difficult cell to study due to its inherent plasticity as 
any analysis in which the macrophage is removed from its microenvironment will 
inevitably alter the cell.  For this purpose, a gene expression signature of the TAM in 
situ in human tumours was sought.  Work by another member of the group focussed 
on microdissection of TAMs from a mouse model of lymphoma to generate 
unaltered TAMs (Ford et al 2015).  This approach was not suitable for use on human 
lymphoma tissue which could not be handled in the stringent way required to extract 
mRNA of sufficient quality to make the analysis possible, and would be derived 
from a genetically unrelated and heterogeneous population requiring large numbers 
of specimens to be available for meaningful analysis.  An alternative approach was 
sought and in an effort to generate a tumour associated macrophage signature in an 
unbiased way, without either disrupting the tissue to remove the tumour associated 
macrophage or creating an artificial microenvironment in vitro, a bioinformatic 
approach was used.  A novel tool, Biolayout Express 3D, being developed by 
Professor Tom Freeman’s group at the Roslin Institute, was utilised for this analysis 
and some additional functions created to allow the analysis of core signatures 
(Freeman et al 2007, Theocharidis et al 2009).   This approach, which defines 
clusters of genes based on their patterns of co-expression, was used to generate 
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signatures of co-expressed genes within cancer datasets including signatures of 
elements of the cancer microenvironment, including the tumour associated 
macrophage.  This chapter presents the bioinformatic analysis from a broad spectrum 
of human tumours as well as common ‘core signatures’ derived from this data.   The 
rationale behind the analysis strategy is presented and then individual analyses from 
individual tumour types presented. 
 
The biolayout graphs presented in this chapter are available in an interactive 
Biolayout-ready format at the website www.Oncograph.org and selected gene lists 
for all datasets analysed are included in Appendix 1 as a CD.  A paper arising from 
this work is included as Appendix 2 (Doig et al, 2013). 
 
4.1   Introduction 
 
There is an enormous wealth of gene expression data that has been made publically 
available covering a wide range of human tumours and including samples from huge 
numbers of patients, now running to many thousands.  The challenge has been to 
analyse this data which runs to many billions of individual datapoints, and is 
inherently complex and heterogeneous.  Multiple strategies have been derived, each 
with their individual strengths and weaknesses, and hence comparison of 
bioinformatic analyses of similar data by different methods often yields very few 
similarities (Iwomata and Psztai 2010).  One of the problems in analysis of the data 
is the seemingly simple task of visualisation of the data in the way that allows the 
human brain to see and make sense of patterns in an incredibly complex set of data.  
Increasingly graphical representation of the data is being pursued although this also 
presents challenges due to the sheer volume of the data.  Biolayout 3D is a 3-
dimensional graphing tool to allow visualisation of complex data that is being 
developed by Professor Tom Freeman’s group in which it is possible to create graphs 
large enough to explore an entire gene expression experiment.   
 
The primary human tumour datasets that are available, in contrast to published gene 
expression experiments from in vitro experiments, contain gene expression 
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signatures derived from fragments of real tumours and as such are not pure 
populations of tumour cells but contain all the elements of the tumour 
microenvironment such as extracellular matrix, blood vessels and lymphatics, 
stromal cells and inflammatory cells, and frequently also contain contamination from 
adjacent normal tissues.  Given the large numbers of gene expression studies of 
intact human tumour tissue that have been undertaken to date, it is clear that there 
must exist in these datasets a gene expression signature of the tumour-associated 
macrophage;  the challenge is to dissect it from the surrounding signatures.  Using 
the ability of Biolayout to visualise very large complex datasets, and cluster these 
into highly related cliques of genes, signatures with a high degree of co-expression 
were isolated from human tumour datasets.  These signatures were extensively 
explored using tools to assess gene set enrichment analysis, comparison with known 
signatures from isolated cell types and review of the literature.  Signatures unique to 
individual tissues and tumour types and common to all tumours were identified 
including signatures related to the immune response and extracellular matrix. 
 
4.1.1 Correlation as a measure of relatedness of gene expression 
 
In any given individual tissue or tumour there will be influences that drive the 
expression of various gene ‘signatures’ or collections of genes.  The driving 
influences behind these signatures are broad, ranging from collections of genes under 
the control of certain extracellular signals to genes stably expressed by a particular 
cell type.  Regardless of the driving nature of the signature, if these genes are 
expressed in a co-ordinated fashion, then they would be predicted to rise and fall in 
association with each other.  Thus a signature driven by a signalling molecule would 
be predicted to rise in the presence of that activating signal or a cell signature be 
predicted to reflect the relative abundance of that cell type (Figure 4.1).  This co-
ordinate expression of genes, if viewed across a large dataset would be expected to 
rise or fall in a coordinated pattern.    The degree of relatedness of the pattern of 
expression of individual genes can be calculated as a measure of their co-expression.  
A range of variables have been used as a measure of this relatedness including 
Spearman Rank Correlation, and Pearson correlation coefficient.  In the data 
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presented below co-expression is measured using the Pearson correlation coefficient, 
a measure that takes into account only the shape of the data considered and not the 
amplitude of the signal and should therefore capture low abundance signal that 
correlates with other gene expression as well as genes expressed at a high level in 
any given cell/pathway/signature.  To create the 3-D graph networks used in 
Biolayout, a Pearson correlation is created for every single probe on a gene 
expression array versus every other probe on the array so that there is a measure of 
relatedness for every single gene covered by the analysis with every single other 





    
 
 
Figure 4.1. Rationale behind the study.   The relative number of a specific cell type or 
activity of certain pathways will vary across a collection of individual tumours. For example, 
the macrophage content (Φ) will differ in every tumour and so therefore will the mRNA 
level of macrophage specific genes (in blue).  Similarly in every tumour at the point it is 
sampled the number of cells in mitosis (the mitotic index) will differ and this will be 
reflected in different levels of expression of cell cycle genes (in red).  As a result the 
expression level of genes specifically expressed by those cells or associated specifically with 
the pathways will vary accordingly.  By calculating the correlation coefficient between every 
gene on the array and every other gene on the array it is possible to calculate a correlation 
matrix that includes all these correlation coefficients.  Graphs are then used to visualise 
relationships above a given correlation threshold and clustering used identifying groups of 







4.1.2 Graphical representation of complex data 
 
Graphical representation of complex data is increasing used in an effort to render 
large and complex datasets in a form in which the human eye and brain are able to 
discern and interpret patterns (Barbaris et al 2011, Huber et al 2007, Pavlopoulos et 
al 2008).  Biolayout analysis uses a 3-dimension graphing approaching to 
visualisation and analysis of data by creating a 3-dimensional graph in which genes 
with similar patterns of expression will lie close to each other in space.  Briefly, it 
uses a modified Fruchterman-Rheingold algorithm in 3-dimensional space in which 
nodes representing genes/transcripts are connected by weighted, undirected edges 
representing correlations above the selected threshold.  Each node finds its place in 
the graph dependent on which other genes it is highly correlated with, these 
correlations forming the edges that connect the nodes.  The degree of correlation that 
is used as the threshold is dependent on the nature of the data and question posed.  
Setting a very low correlation threshold will ensure that no data is lost, but will 
increase the risk of spurious associations, increase the complexity of the graph and 
obscure the relationships within the graph as well as rendering the size of the graph 
unmanageable.  Use of a correlation threshold that is very high will result in a much 
smaller graph, with clearly co-expressed genes forming tight clusters but will result 
in the exclusion of much of the data.  Such a threshold would be appropriate in 
analysis of experimental data from a controlled experiment where there should be 
relatively little variation in gene expression, but would lose much of interest in the 
setting presented here where the data is derived from genetically diverse individuals 
with genetically diverse tumours.    The numbers of nodes and edges generated at 
each correlation threshold above 0.5 for the datasets used here is given in figure 4.2 
to demonstrate how these relationships vary in individual datasets.  The use of a 3-D 
graph network allows a global view of the data where all the relationships between 
genes/transcripts can be visualised and explored.  In addition, ‘noise’ in the data is 
excluded by the nature of the graph; random, non-biologically relevant associations 
between genes will be unlikely to form structures in the graph as it is implausible that 
if a spurious correlation exists between a non-relevant gene (x) and one which forms 
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part of the graph network (y) that the non-relevant gene will also be highly correlated 
with the genes that surround y and as such will form part of the graph network.  For 
this reason, it is not necessary, as it is in many other data analysis approaches to gene 
expression data, to apply a fluorescence amplitude threshold above which gene 
expression data is considered to be real rather than representing an artefact of the 
experiment, as low-signal ‘noise’ will be naturally excluded from the graph while 
true low amplitude gene expression should be retained.    
 
In all the graphs presented below the majority of the data is represented in one 
complex network that occupies one corner of the space available for the graph layout 
with multiple unconnected clusters mostly of small numbers of highly connected 
genes/probesets occupying the rest of the space.  These smaller clusters represent 
probesets/genes that show a high degree of correlation with the other probesets/genes 
in that cluster but little correlation with all the other probesets/genes in the analysis 
and hence do not form part of the main graph.  As such they mostly do not inform the 
analysis of the overall gene expression patterns in the tumour and most of the data 







Figure 4.2.   Effect of correlation co-efficient on graph size.  As the  correlation coefficient 
at which data is included in the graph is decreased (x-axis), the number of nodes and edges 
increases.  The effect differs in every individual dataset dependent on various factors 
inherent to each dataset.   The six datasets used in the main analysis in this chapter are 
presented here (see table 4.1 for dataset details).  It can be seen that for both the testicular 
and glioma datasets there is a sharp increase in the number of edges formed under a 
correlation coefficient cut-off of 0.65, while the ovarian tumour dataset adds smaller number 
of edges as the correlation coefficient is decreased.   
 
 
4.1.3 Markov clustering algorithm 
 
The Markov clustering algorithm is employed by Biolayout to divide the complex 3-
dimensional graphs into cliques or clusters of genes that have a high degree of 
interconnectivity, with all the elements within the cluster having a similar expression 
pattern and thus being correlated with many or all of the other elements within the 
cluster.  The algorithm simulates multiple iterations of random flow through the 
graph to define areas of high connectivity which make up the clusters.  There are no 
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clusters being determined by the interconnectivity of the data.  The only user defined 
feature of the clustering is the granularity which determines whether the data divides 
into many smaller clusters or fewer larger clusters.  In all the data presented below an 
MCL inflation value (which determines the granularity) of 2.2 was used, which has 
been empirically determined in previous analysis of large datasets to generate 
meaningful data.    Not all nodes within the graph network are assigned to a cluster.  
Those which lie outwith the areas of tight connectivity that define the clusters are not 
allocated to a cluster.  These nodes often lie within the complex graph network and 
adjacent to clusters implying that there is a high degree of correlation of expression 
pattern with the genes within the cluster, but insufficient relationship with the other 
genes within the cluster to form the multiple connections required to lie within the 
cluster.  There is still scope to analyse these genes and their relationship to the genes 
that lie close to them within the Biolayout programme where the ‘nearest 
neighbours’ of individual genes or groups of genes can be visualised.   
 
 
4.1.4 Use of Biolayout to extract cell specific signatures 
 
A hypothesis was made; that there must be a signature or signatures that define 
macrophages to make them the unique cell type they are; that this signature must 
represent a group of co-expressed genes and that is therefore extractable by 
clustering groups of genes that are co-expressed.  In this analysis of large human 
cancer datasets the variability and complexity of the data becomes an advantage 
rather than a problem as the variation in tissue composition, relative abundance of 
tumour cells to other cells etc, that confound gene expression analysis focussed on 
the tumour cells provides the patterns in the data that powers the analysis.  Large 
datasets were selected for analysis meaning the data presented in this chapter 
encompasses many genetically unique individuals totalling more than eleven hundred 
patients and also providing sufficient variability and complexity in each dataset to 
allow differentiation of patterns of co-expression.  The six large datasets used in the 
initial analysis were all analysed individually (Figure 4.3).  In each case the data was 
quality controlled, normalised and log-transformed before annotation using 
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Bioconductor.  The samples in each dataset were ordered using the clinical data 
provided to allow easier visualisation of the data and then loaded into Biolayout.  
Pearson correlations were calculated for all probes on the array and all correlations 
over 0.6 stored.  Depending on the size of the dataset and the inherent variation of 
samples, datasets produced graphs of varying sizes at a given correlation threshold 
value (see figure 4.2). Selected correlation thresholds for individual datasets were 
designed to include approximately 40% of the available data.   Graphs were then laid 
out and clustered using the Markov clustering algorithm.   Graphs of each dataset 
were then explored to understand the significance of the gene clusters and their 
relevance to the pathology of the tumours. 
 
 
Figure 4.3  Workflow scheme.  For each individual cancer dataset the left-hand pathway 
was followed.  All datasets were treated individually and following QC and normalisation 
steps were laid out in network graphs and clustered.  Clusters were explored using external 
sources of information inclusing GSEA, DAVID, literature review and the Human Protein 
Atlas.  Annotation was mapped from graph to graph in an iterative approach.  To create the 
merged ‘core’ graph, the right-hand pathway was followed.  All pairwise Pearson 
correlations from 6 datasets were stored and mean correlations calculated for each pairing.  




Clusters are identified by the known function of genes within them.  Indeed clusters 
can only be meaningfully identified if the function of some of the genes within them 
are already characterised.  Intriguingly one of the most stable and frequently present 
clusters identified in the data in this chapter and in many other datasets (Freeman, 
unpublished data) is formed of genes about which very little is known and about 
which therefore very little can be inferred.  It can be speculated however, that this 
represents a fundamental part of the cell machinery such that is does not alter 
significantly between cell types, be they normal or malignant and as such has never 
become the subject of study.  
 
 The requirement that to be identified, a cluster must contain genes of known 
function does not imply that the analysis contributes nothing new to the 
understanding of the signature of clusters so identified.  Rather the presence of 
known and well-characterised genes forming part of a biologically meaningful 
cluster allows  other genes within that cluster to be assigned the same biological 
function on a ‘guilt-by-association’ principle;  that is, if all the other genes that can 
be identified in a cluster are recognised as playing a role in the cell cycle, or 
belonging to a particular cell type then it can be inferred that other genes that share a 
similar expression profile share the same or a very closely related function.    
 
The significance of the clusters identified were analysed using several strategies;  
web-based tools GSEA MSigDB and DAVID were used to look for functionally 
enriched clusters of genes (Subramanian et al 2005, Huang et al 2009 a&b).  This 
approach proved useful in determining functional signatures, but due to the nature of 
the available genes sets in these tools proved less successful at identifying individual 
cell type signatures.  Signatures derived from isolated cell types were overlain on the 
data to help identify these.  Literature reviews were undertaken for genes from 
clusters of interest, and the Human Protein Atlas was used to help confirm the 
protein localisation of genes of interest (Uhlen et al 2010, Uhlen et al 2015).  
Clusters were annotated if hits of high significance in GSEA MSigDB and DAVID 
showed a common trend as to function and/or the genes appear cell specific either 
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due to comparison with known cell signatures, literature review or protein expression 
pattern in the Human Protein Atlas.  It was not possible to assign putative functions 
to all clusters based on current knowledge. 
 
Finally, in a novel approach to gene expression signature analysis, a ‘core’ signature 
of gene clusters common to a wide variety of tumours was calculated (Figure 4.3).  
All pair-wise Pearson correlations from six human cancer datasets were stored.  A 
mean value was calculated for each pair-wise correlation across those six datasets.  A 
biolayout graph was then created using these mean values to create a graph in which 
edges were formed only where mean correlations above a set threshold were used.  In 
this way signatures unique to each tissue type or tumour were excluded as while 
modules of co-expressed genes would show very high levels of correlation in an 
individual tumour, unless that module also existed in the other datasets then the mean 
level of correlation between those genes in that module would be low and hence 
below the threshold at which the graph was drawn.  Only those genes forming 
modules or clusters that existed in all datasets would be expected to be preserved 
across a wide range of tumour types.  The core signature derived from this data was 
then overlain on further independent datasets to ensure the signatures generated from 
the ‘core’ signature’ also existed in independent datasets.    
Analysis occurred in an iterative approach with identification of clusters from one 
dataset being used to inform analysis of other datasets and the ‘core’ annotation from 
the merged datasets mapped back to the original datasets to inform analysis.  As a 
consequence of this approach, datasets were repeatedly laid out and clustered to 
allow the new annotation to be visualised.  Thus although the stability of the clusters 
was not formally assessed, these were observed to be very stable varying very little 







4.2  Selection of data sets analysed 
 
Publically available datasets containing samples from large numbers of human 
tumours were used in the analysis.  Datasets were identified from Gene Expression 
Omnibus or caArray.    All datasets selected used the Affymetrix platform to allow 
direct mapping of probesets from one dataset to another in the subsequent analysis.  
This allowed for direct mapping of annotations from one analysis to the next, as all 
probe set identities remained the same between datasets  and the clusters and the 
genes within them were annotated with functional information as the analysis 
proceeded.   Use of the Affymetrix platform also provided absolute values for 
fluorescence for each probe set, rather than values relative to normal tissue or a 
different disease state.     Datasets were also selected on the basis of containing large 
numbers of cases to provide sufficient power to the analysis, ranging in size from 77 
cases to 265 cases.  The use of large datasets decreases the likelihood that observed 
correlations between genes across the dataset are random events, rather than 
reflecting a true co-expressed ‘module’ of genes with a common function.  Finally, 
only datasets where there was clinical information provided were considered for 
inclusion to allow the data to be ordered in an informative manner for the subsequent 

































GSE11318 Lenz  et al.  
(18765795) 
DLBCL 194 Plus 2.0 19,850 614,273 




 134 A & B 19,246 559,761 





 265 Plus 2.0 19,415 268,471 





 86 A & B 18,934 954,082 















 253 Plus 2.0 23,015 623,591 




 77 A & B 19,623 600,143 
 
Table 4.1.  The seven primary human tumour datasets used in the analysis.   All used the 
Affymetrix platform with a mixture of U133A and B and U133 plus 2.  To allow direct 
comparison between datasets only those probesets present on the U133A and U133B chips 
were used for analysis of data from U133plus 2 chips.   
 
Each dataset had a unique graph structure reflecting the individual gene expression 
patterns contained within that dataset.  All graphs were laid out at a correlation 
coefficient such that roughly 40% of the probesets were represented on the graph as 
nodes.  As seen in table 4.1 the number of edges contributing to these graphs at that 
size varied considerably between datasets ranging from only 268,471 edges in the 
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very large ovarian dataset to 954,082 edges in the much smaller testicular tumour 
dataset which also contained a much wider variety of individual tumours and hence 
showed a tendency to form very tight clusters with large numbers of edges relating to 
each individual tumour type.  Each dataset had its own idiosyncrasies owing to the 
high degree of inherent variation in gene expression data derived from cancer 
samples. This variation is due the samples’ derivation from an outbred population, 
heterogeneous cellular composition and the inherent variability associated with 
cancer. Further variation in the data is also down to the type of cancer from which it 
was derived, the number of subtypes of cancer included in the dataset and the 
number of samples analysed.  All of these factors ultimately determine the overall 
topology of the network derived from the data.    
 
4.3 Internal validation of the clustering approach 
 
Before presenting the analyses from individual datasets, it is worth discussing some 
of the types of clusters that were present in all datasets and some of which, while not 
necessarily informing the analysis with regards to the individual tumour types, 
provided some internal validation for the graph layout and clustering method.   
 
In all datasets there were biologically explicable clusters, many of which clearly 
correlated with clinical or histological features of the tumours from which they were 
derived and provided support to the data analysis being able to accurately graph and 
partition co-expressed genes into clusters.  Identification of tumour specific clusters 
and relationship to tumour type and outcome was not the focus of this analysis which 
aimed to identify mainly the common features of tumour datasets and such ‘cancer 
signatures’ are only discussed in as much as they provide support for the approach 
used.  Unknown clusters that appear from their expression profiles to provide 
information about tumour biology were not extensively explored, although there is 
clearly a wealth of untapped data in the network graphs presented below, far beyond 
the scope of this thesis to explore.    In addition to these more biologically relevant 
clusters, there were other less interesting clusters that none the less provided 
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evidence that probesets with similar expression patterns were being clustered 
together;  genes that were represented on the Affymetrix array by multiple probe sets 
tended to form clusters in which all the members were probes directed to that gene;  
internal Affymetrix controls formed a single cluster;  genes known to be co-regulated 
were seen to form clusters,  eg probe sets to Haemoglobin A and Haemoglobin B 
genes formed a cluster (Figure 4.4); genes expressed in males or females only were 
mutually exclusive (figure 4.5); and there were clusters present that represented a 
‘spike’ in the data formed by only a few tumours (Figure 4.6).  These ‘spikes’ 
frequently appeared to represent contamination of the sampled tumour by tissues that 
were otherwise absent in the dataset resulting in gene expression profile across the 
dataset that was very different from the profiles seen in genes that were more 
commonly expressed across the dataset.  As demonstrated in figure 4.6, these 
contaminants generate very distinctive gene expression profiles and demonstrate one 
of the weaknesses of the use of Pearson correlation co-efficients as the measure of 
relatedness of genes; i.e. the measure is very sensitive to outliers which will have 
very high correlation coefficients.  In these very large and complex datasets, this 
effect however appears not of great importance with the clusters formed of such 
spikes mostly consisting of only small numbers of genes.  Other ‘spikes’, such as 
those seen in the teratoma samples of the testicular cancer dataset, could be readily 
explained by the nature of the tumour with expression profiles of mature non-
testicular tissues (such as skin, gut, thyroid, pancreas etc.) representing the 
differentiated tissues present in these tumours.  However, other of these clusters with 
a ‘spiked’ expression pattern were more difficult to explain in terms of grouped 
functions of genes. They frequently however, included multiple transcripts of the 
same gene (which would argue against these observations being due to hybridisation 
artefacts where one might expect a truly random set of transcripts to be affected), 
various subunits of a multi-unit structure or multiple members of a gene family, all of 
which argue that these are real effects rather than due to technical error.  On analysis 
through GSEA using the ‘positional gene sets’ collection, it is apparent that at least 
some of these spikes are enriched in genes from a given area of a single 
chromosome, suggesting individual tumour-specific dysregulation of genes in that 
location either through localised chromosomal rearrangements or epigenetic factors.  
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The fact that these spikes are unique to a very small number of tumours argues that 
any such translocation or localised dysregulation of gene expression is not essential 
to development of the tumour or it would be expected to be present in a larger 







Figure 4.4.  Haemogloblin cluster.  The probeset directed against the genes for haemoglobin 
A and B frequently clustered together.  Shown above are these genes forming a cluster in the 
testicular tumours dataset.  The top panel of the figure shows the haemoglobin cluster 
expanded and the rest of the graph hidden to allow visualisation of the multiple connections 
between these probesets that result in cluster formation.  The two genes are represented in 
different colours with probesets to HBA1 in blue and HBB in red.  The bottom half of the 
figure shows the mean expression pattern of the probesets across the tumour dataset to show 
how closely the expression of these genes mirrors each other.  Again HBA1 is represented in 







Figure 4.5.   Male and female clusters.  The DLBCL graph laid out at p≥0.6 and MCL 
inflation value 2.2 contains mutually exclusive clusters that display contrasting patterns in 
males and females.  The top panel shows a ‘scanning power’ view of the DLBCL graph 
network.  The majority of the structure lies in the top left hand corner of the graph.  Small, 
highly separate clusters lie in the remainder of the space.  High-lighted by green squares are 
two clusters that represent genes expressed in only males or females.  The expression 
patterns of these genes are very different from much of the rest of the data and form widely 
separate clusters that do not join the main graph.  The lower half of the figure shows the 
average gene expression values for these clusters (male cluster in grey, female cluster in 
green).  The x-axis represents individual tumours.  The tumours have been stratified first by 
tumour type, then outcome, then sex so that the group  ‘male patients’  lies in multiple 
discrete areas along the X-axis and the female patients in the intervening areas.   See table 




probe ID Description Cluster annotation 
CYorf15A;232618_at chromosome Y open reading frame 15A Cluster0075*Y-chromosome-male 
CYorf15A;236694_at chromosome Y open reading frame 15A Cluster0075*Y-chromosome-male 
CYorf15B;214131_at chromosome Y open reading frame 15B Cluster0075*Y-chromosome-male 
CYorf15B;223645_s_at chromosome Y open reading frame 15B Cluster0075*Y-chromosome-male 
CYorf15B;223646_s_at chromosome Y open reading frame 15B Cluster0075*Y-chromosome-male 
DDX3Y;205000_at 
 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-
linked  Cluster0075*Y-chromosome-male 
DDX3Y;205001_s_at 
 DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-
linked  Cluster0075*Y-chromosome-male 
EIF1AY;204409_s_at 
 eukaryotic translation initiation factor 1A, Y-
linked  Cluster0075*Y-chromosome-male 
EIF1AY;204410_at 
 eukaryotic translation initiation factor 1A, Y-
linked  Cluster0075*Y-chromosome-male 
JARID1D;206700_s_at  jumonji, AT rich interactive domain 1D  Cluster0075*Y-chromosome-male 
NA;1560800_at NA Cluster0075*Y-chromosome-male 
NA;239677_at NA Cluster0075*Y-chromosome-male 
NA;244482_at NA Cluster0075*Y-chromosome-male 
NLGN4Y;207703_at  neuroligin 4, Y-linked  Cluster0075*Y-chromosome-male 
PRKY;206279_at  protein kinase, Y-linked  Cluster0075*Y-chromosome-male 
RPS4Y1;201909_at  ribosomal protein S4, Y-linked 1  Cluster0075*Y-chromosome-male 
TTTY15;214983_at  testis-specific transcript, Y-linked 15  Cluster0075*Y-chromosome-male 
USP9Y;206624_at 
 ubiquitin specific peptidase 9, Y-linked (fat 
facets-like, Drosophila)  Cluster0075*Y-chromosome-male 
USP9Y;228492_at hypothetical protein LOC100130216 Cluster0075*Y-chromosome-male 
UTY;208067_x_at 
 ubiquitously transcribed tetratricopeptide 
repeat gene, Y-linked  Cluster0075*Y-chromosome-male 
UTY;210322_x_at 
 ubiquitously transcribed tetratricopeptide 
repeat gene, Y-linked  Cluster0075*Y-chromosome-male 
UTY;211149_at 
 ubiquitously transcribed tetratricopeptide 
repeat gene, Y-linked  Cluster0075*Y-chromosome-male 
ZFY;230760_at  zinc finger protein, Y-linked  Cluster0075*Y-chromosome-male 
NA;229315_at NA Cluster0205*Female  
XIST;214218_s_at 
X (inactive)-specific transcript (non-protein 
coding) Cluster0205*Female  
XIST;221728_x_at 
X (inactive)-specific transcript (non-protein 
coding) Cluster0205*Female  
XIST;224588_at 
X (inactive)-specific transcript (non-protein 
coding) Cluster0205*Female  
XIST;224589_at 
X (inactive)-specific transcript (non-protein 
coding) Cluster0205*Female  
XIST;224590_at 
X (inactive)-specific transcript (non-protein 
coding) Cluster0205*Female  
XIST;227671_at 
X (inactive)-specific transcript (non-protein 
coding) Cluster0205*Female  
XIST;231592_at 
X (inactive)-specific transcript (non-protein 
coding) Cluster0205*Female  
ZFX;229022_at  zinc finger protein, X-linked  Cluster0205*Female  
 
Table 4.2.   Gene cluster lists from the DLBCL data in figure 4.4.  There are two mutually 




Selected genes from cluster  Selected functional annotation 
from DAVID with P values for 
modified Fisher exact test  
Actin , alpha 1, skeletal muscle  GO Term:  contractile fibre  - P 
value = 1.3 
e-72 
 
Creatine kinase, muscle  SP Keywords: muscle protein  -  
P value = 1.6
e-49 
 
Desmin  GO Term: Z disc  - P value =1.1
e-24
 
Myoglobin  GO Term: myofibril  - P value = 1.7 
e-70 
 









Figure 4.6  Skeletal muscle cluster.  The DLBCL graph contains a ‘spiked’ cluster formed of 
genes that are only expressed to an appreciable level in 7 cases out of 194 being absent in the 
remainder of the cases.  Analysis of this cluster indicates this represents ‘contamination’ of 
the tumour by skeletal muscle i.e. biopsies taken from where the tumour is infiltrating 
skeletal muscle.  The upper half of the figure represents the mean expression profile of the 
genes in this cluster across the entire dataset demonstrating the small number of cases where 
there is expression of these genes.  The lower part of the figure highlights selected genes 
from within the cluster typical of skeletal muscle and selected functional annotation from 
DAVID analysis.  The complete gene list forming the cluster is given in appendix 1.    
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4.4 Gene signatures from DLBCL 
 
The lymphoma dataset consisted of 203 cases of diffuse large B cell lymphoma, 194 
of which passed the QC step and were included in the analysis.  These were stratified 
into Germinal centre B cell-like (GCB), activated B cell-like (ABC), primary 
mediastinal B cell (PMBL) and unclassified, based on gene expression profiles as 
determined in the paper by Alizadeh et al (Alizadeh et al 2000).  The data was further 
organised on the basis of sex and patient outcome.  The DLBCL dataset (figure 4.7) 
when laid at out at Pearson correlations r≥ 0.65 gives a graph of 19,850 nodes joined 
by 614,273 edges.   
 
The graph breaks into three main areas, with immune related clusters and 
extracellular matrix lying in one area which appears to broadly represent the tumour 
stroma, cell cycle genes in another area, and a group of poorly characterised clusters 
lying in the third main area (Figures 4.7 and 4.8). These poorly characterised clusters 
tend to show little variation between samples and are often expressed at relatively 
low level.  For ease of discussion these are referred to as housekeeping or HK 
clusters.  Numerous small clusters not forming part of the main graph lie in the 
remainder of the space.  Many of these small clusters are formed of multiple probe 
sets to the same gene, while others are formed of small numbers of genes whose 
expression in very closely related to each other but have little relationship to the 
genes that make up the bulk of the graph.  The immune area contains clusters of 
macrophage, T-cell and interferon related genes and lies close to but distinct from the 
extracellular matrix clusters.  Within the cell cycle cluster there are several distinct 
but related clusters with genes that are expressed in the S/M phase forming a cluster 







Figure 4.7  Two views of the DLBCL graph.  In the upper panel the whole graph is 
visualised.  The main component of the graph lies in front and centre formed of the majority 
of the probes that correlate with other probes.  The genes of interest for the analysis lie 
mostly within this area.  Clusters as defined by the MCL clustering algorithm are represented 
by colours.  Due to the complexity of the graph little of the overall structure can be 
appreciated at this magnification.  Extending off into the distance are a series of small 
clusters which do not connect with another clusters.  These are of genes/probesets that have a 
high degree of internal correlation but which show very little correlation with the other 
probesets on the array.  In the lower panel the main part of the graph is represented just as 




Figure 4.8  Different areas of the overall graph contain different main clusters.  These 
relationships are best appreciated in 3-D within the Biolayout programme where the graph 
can be interacted with, but a simplified view of the DLBCL graph is presented here to 
illustrate some of the relationships.  a) Overall graph structure with nodes minimised, b) the 
cell cycle related clusters are superimposed on the graph network with the S/M phase cluster 
in green and other cell cycle related clusters in blue and brown, c) the ECM clusters occupy 
a different space in the graph, d) Immune clusters, here highlighting the macrophage cluster, 
occupy one pole of the large cluster 
 
 
4.4.1 Stromal signatures   
 
The macrophage cluster contains 769 probe sets representing  497 genes and contains 
well-characterised markers of macrophage/monocyte differentiation including CD14, 
CD68, CD163, colony stimulating factor receptors (CSF receptor 1, CFS receptor 2β 
and CSF receptor 3), and Fc receptors (Fc receptors for IgA, IgE and IgG; FCRG1A, 
FCRG1B, FCRG2A, FCRG3B).  In addition to these there are also multiple 
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chemokines and cytokines (CCL4, CCL5, CCL18, CXCL9, CXCL10, CXCL11, 
CXCL12, CXCL16, IL15, IFNG), chemokine and interleukin receptors (CCR1, 
CCR5, IL15RA, IL17RA, IL31RA), and toll-like receptors (TLR1, TLR2, TLR4, 
TLR5, TRL8).  There are multiple apolipoproteins (APOE, APOL1, APOL2, 
APOL3, APOL4, APOL6), metallothioneins (MT1E, TM1F, MT1G, MT1M, MT1X, 
MT2A) and genes encoding lysosomal proteins (CD63, CD68, GM2A, NPL, NPC1, 
NPC2, ACP2, ACP5, CTSA, CTSB, CTSD, CTSL1, CTS, CTSZ, DNASE2, 
GALNS, GLAC, GNS, HEXA, HEXB, IGF2R, IFI30, LIPA, LAMP1, LAMP2, 
M6PR, MANBA, PPT1, PSEN1, PRCP, PSAP, SCARB2, SCL11A2, SCL29A3).  
The macrophage scavenger receptors are represented (MARCO, SCARB2). A list of 
selected genes found in the macrophage cluster, omitting less informative genes 
characterised only as open reading frames and numbered loci without additional 
annotation is given in table 4.4.  Analysis of the gene signature through the DAVID 
functional annotation clustering software and GSEA MolSigDB software shows the 
signature to be significantly enriched in genes associated with defence response, 
myeloid cells, lysosomal genes, pattern recognition receptors and many others as 
would be expected reading the list of genes identified.  These analysis methods when 
applied to the cluster discussed pull out hundreds of points of annotation, many of 
which are similar (Table 4.3).  Only a few selected annotations are provided in each 
case for illustration. 
 
Looking at the expression profile of the macrophage signature across the dataset, 
there is obviously marked variability in expression between individual tumours 
(Figure 4.9).  There is no obvious pattern of expression separating the tumour types 
or outcomes.  This is in contrast to the paper by Lenz et al (Lenz et al 2008) who 
demonstrated differences in outcome dependent on stromal signatures.  Their 
approach differed from that used here in that they first isolated genes associated with 
poor outcome and then clustered those using a hierarchical clustering method.  Their 
stromal signatures are derived from these groups of genes that define outcome rather 





It is important to recognise that the “macrophage cluster” does not contain obvious 
markers of other stromal or tumour cell type or process (e.g. cell cycle), so there 





Figure 4.9   Mean expression intensity of the genes present in the ‘macrophage signature’ 
across the dataset.  There is considerable variation between individual tumours but no clear 
pattern between tumour types or with differences in outcome.   Coloured bars denote tumour 
subtypes.  For each tumour subtype patients with good outcome lie in the left part of the bar 
























Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Defense response 2.6 x10
-23
 







































Genes downregulated in 















Table 4.3  Functional annotation for the gene list from the ‘macrophage signature’. Selected 
annotation derived from DAVID and GSEA gene expression analysis tools.  The 
macrophage gene list was uploaded to DAVID and analysed through the functional 
annotation clustering and in GSEA using the molecular signatures database.  Only selected 
annotation is shown here.  Annotation derived from DAVID gives modified Fisher Exact p-















Table 4.4   Macrophage signature from DLBCL dataset laid out at Pearson correlation  ≥ 0.6 
with MCL inflation values of 2.2.  Only probesets that represent genes with official gene 
symbols are listed, with open reading frames, hypothetical proteins and unannotated 
probesets excluded.  A complete list is given in appendix 1 . 
Symbol Description 
AADACL1 arylacetamide deacetylase-like 1 
ABCA1  ATP-binding cassette, sub-family A (ABC1), member 1  
ABCD2  ATP-binding cassette, sub-family D (ALD), member 2  
ABHD12 abhydrolase domain containing 12 
ABHD2 abhydrolase domain containing 2 
ABHD2 abhydrolase domain containing 2 
ACO1  aconitase 1, soluble  
ACP2  acid phosphatase 2, lysosomal  
ACP5  acid phosphatase 5, tartrate resistant  
ACSL1 acyl-CoA synthetase long-chain family member 1 
ACSS2 acyl-CoA synthetase short-chain family member 2 
ACVR1B  activin A receptor, type IB  
ADAMDEC1  ADAM-like, decysin 1  
AGTRAP angiotensin II receptor-associated protein 
AIF1 allograft inflammatory factor 1 
ALAS1  aminolevulinate, delta-, synthase 1  
ALDH1A1  aldehyde dehydrogenase 1 family, member A1  
ALDH3B1  aldehyde dehydrogenase 3 family, member B1  
ANKRD22 ankyrin repeat domain 22 
AOAH acyloxyacyl hydrolase (neutrophil) 
APOC1 apolipoprotein C-I 
APOE apolipoprotein E 
APOE apolipoprotein E 
APOL1  apolipoprotein L, 1  
APOL2  apolipoprotein L, 2  
APOL3  apolipoprotein L, 3  
APOL4  apolipoprotein L, 4  
APOL6  apolipoprotein L, 6  
AQP9 aquaporin 9 
ARHGEF10L Rho guanine nucleotide exchange factor (GEF) 10-like 
ARHGEF11 Rho guanine nucleotide exchange factor (GEF) 11 
ARRB1  arrestin, beta 1  
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 
ASCL2 achaete-scute complex homolog 2 (Drosophila) 
ASGR1 asialoglycoprotein receptor 1 
ATG7 ATG7 autophagy related 7 homolog (S. cerevisiae) 
ATP13A2 ATPase type 13A2 
ATP6AP1  ATPase, H+ transporting, lysosomal accessory protein 1  
ATP6V0C  ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c  
ATP6V1A  ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A  
ATP6V1B2  ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2  
B2M beta-2-microglobulin 
BATF2  basic leucine zipper transcription factor, ATF-like 2  
BLVRB biliverdin reductase B (flavin reductase (NADPH)) 
BLZF1 basic leucine zipper nuclear factor 1 
BRI3 brain protein I3 
BST1 bone marrow stromal cell antigen 1 
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BTBD14A BTB (POZ) domain containing 14A 
C1QA  complement component 1, q subcomponent, A chain  
C1QB  complement component 1, q subcomponent, B chain  
C1QC  complement component 1, q subcomponent, C chain  
C1RL  complement component 1, r subcomponent-like  
C2 complement component 2 
C3AR1 complement component 3a receptor 1 
CA11 carbonic anhydrase XI 
CALCOCO2 calcium binding and coiled-coil domain 2 
CAPG  capping protein (actin filament), gelsolin-like  
CARD9  caspase recruitment domain family, member 9  
CASP5  caspase 5, apoptosis-related cysteine peptidase  
CCL18 chemokine (C-C motif) ligand 18 (pulmonary and activation-
regulated) 
CCL4 chemokine (C-C motif) ligand 4 
CCL5 chemokine (C-C motif) ligand 5 
CCL8 chemokine (C-C motif) ligand 8 
CCR1 chemokine (C-C motif) receptor 1 
CCR5 chemokine (C-C motif) receptor 5 
CCRL2 chemokine (C-C motif) receptor-like 2 
CD14 CD14 molecule 
CD163 CD163 molecule 
CD244  CD244 molecule, natural killer cell receptor 2B4  
CD300LF CD300 molecule-like family member f 
CD302 CD302 molecule 
CD33 CD33 molecule 
CD4 CD4 molecule 
CD63 CD63 molecule 
CD68 CD68 molecule 
CD81 CD81 molecule 
CD97 CD97 molecule 
CDA cytidine deaminase 
CDS2 CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 2 
CEBPB  CCAAT/enhancer binding protein (C/EBP), beta  
CEBPD  CCAAT/enhancer binding protein (C/EBP), delta  
CECR1  cat eye syndrome chromosome region, candidate 1  
CENTG2  centaurin, gamma 2  
CENTG3  centaurin, gamma 3  
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 
CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 
CLEC10A  C-type lectin domain family 10, member A  
CLEC12A  C-type lectin domain family 12, member A  
CLEC2B  C-type lectin domain family 2, member B  
CLEC4D  C-type lectin domain family 4, member D  
CLEC4E  C-type lectin domain family 4, member E  
CLEC7A  C-type lectin domain family 7, member A  
CMKLR1 chemokine-like receptor 1 
CNIH4 cornichon homolog 4 (Drosophila) 
CPD carboxypeptidase D 
CPVL  carboxypeptidase, vitellogenic-like  
CRAT carnitine acetyltransferase 
CREBL2 cAMP responsive element binding protein-like 2 
CREG1 cellular repressor of E1A-stimulated genes 1 
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CRIM1 cysteine rich transmembrane BMP regulator 1 (chordin-like) 
CSF1 colony stimulating factor 1 (macrophage) 
CSF1R colony stimulating factor 1 receptor 
CSF2RB  colony stimulating factor 2 receptor, beta, low-affinity 
(granulocyte-macrophage)  
CSF3R colony stimulating factor 3 receptor (granulocyte) 
CST3 cystatin C 
CTNND2  catenin (cadherin-associated protein), delta 2 (neural 
plakophilin-related arm-repeat protein)  
CTSA cathepsin A 
CTSB cathepsin B 
CTSD cathepsin D 
CTSL1 cathepsin L1 
CTSS cathepsin S 
CTSZ cathepsin Z 
CXCL10 chemokine (C-X-C motif) ligand 10 
CXCL11 chemokine (C-X-C motif) ligand 11 
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 
1) 
CXCL16 chemokine (C-X-C motif) ligand 16 
CXCL9 chemokine (C-X-C motif) ligand 9 
CYBB  cytochrome b-245, beta polypeptide  
CYFIP1 cytoplasmic FMR1 interacting protein 1 
CYP1B1  cytochrome P450, family 1, subfamily B, polypeptide 1  
DAB2  disabled homolog 2, mitogen-responsive phosphoprotein 
(Drosophila)  
DAPK1 death-associated protein kinase 1 
DENND5A DENN/MADD domain containing 5A 
DIRC2 disrupted in renal carcinoma 2 
DLL1 delta-like 1 (Drosophila) 
DMXL2 Dmx-like 2 
DNASE2  deoxyribonuclease II, lysosomal  
DOCK4 dedicator of cytokinesis 4 
DOCK5 dedicator of cytokinesis 5 
DOK2  docking protein 2, 56kDa  
DPYD dihydropyrimidine dehydrogenase 
DRAM damage-regulated autophagy modulator 
DUSP3 dual specificity phosphatase 3 
DYNLT1  dynein, light chain, Tctex-type 1  
DYSF  dysferlin, limb girdle muscular dystrophy 2B (autosomal 
recessive)  
EIF4E3 eukaryotic translation initiation factor 4E family member 3 
EMR2  egf-like module containing, mucin-like, hormone receptor-like 
2  
EPB41L3 erythrocyte membrane protein band 4.1-like 3 
EPHX1  epoxide hydrolase 1, microsomal (xenobiotic)  
ERLIN1 ER lipid raft associated 1 
F2R coagulation factor II (thrombin) receptor 
FAIM2 Fas apoptotic inhibitory molecule 2 
FAM105A  family with sequence similarity 105, member A  
FAM125B  family with sequence similarity 125, member B  
FAM20A  family with sequence similarity 20, member A  
FAM26F  family with sequence similarity 26, member F  
FASLG  Fas ligand (TNF superfamily, member 6)  
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FCAR  Fc fragment of IgA, receptor for  
FCER1G  Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide  
FCGR1A  Fc fragment of IgG, high affinity Ia, receptor (CD64)  
FCGR1B  Fc fragment of IgG, high affinity Ib, receptor (CD64)  
FCGR2A  Fc fragment of IgG, low affinity IIa, receptor (CD32)  
FCGR3B  Fc fragment of IgG, low affinity IIIb, receptor (CD16b)  
FCGRT  Fc fragment of IgG, receptor, transporter, alpha  
FCHO2 FCH domain only 2 
FER1L3  fer-1-like 3, myoferlin (C. elegans)  
FFAR2 free fatty acid receptor 2 
FGL2 fibrinogen-like 2 
FNIP2 folliculin interacting protein 2 
FPR1 formyl peptide receptor 1 
FPR2 formyl peptide receptor 2 
FRMD4B FERM domain containing 4B 
FTH1  ferritin, heavy polypeptide 1  
FTHP1  ferritin, heavy polypeptide pseudogene 1  
FTL  ferritin, light polypeptide  
FUT4  fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-
specific)  
FZD2 frizzled homolog 2 (Drosophila) 
FZD5 frizzled homolog 5 (Drosophila) 
GAB3 GRB2-associated binding protein 3 
GADD45G  growth arrest and DNA-damage-inducible, gamma  
GALC galactosylceramidase 
GALM galactose mutarotase (aldose 1-epimerase) 
GALNS galactosamine (N-acetyl)-6-sulfate sulfatase 
GALNT11 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 11 (GalNAc-T11) 
GBP1  guanylate binding protein 1, interferon-inducible, 67kDa  
GBP2  guanylate binding protein 2, interferon-inducible  
GBP3 guanylate binding protein 3 
GBP4 guanylate binding protein 4 
GBP5 guanylate binding protein 5 
GCH1 GTP cyclohydrolase 1 
GGTA1  glycoprotein, alpha-galactosyltransferase 1  
GJD3  gap junction protein, delta 3, 31.9kDa  
GK glycerol kinase 
GK3P glycerol kinase 3 pseudogene 
GLIPR2 GLI pathogenesis-related 2 
GLUL glutamate-ammonia ligase (glutamine synthetase) 
GM2A GM2 ganglioside activator 
GMPR guanosine monophosphate reductase 
GNA15  guanine nucleotide binding protein (G protein), alpha 15 (Gq 
class)  
GNPTG  N-acetylglucosamine-1-phosphate transferase, gamma 
subunit  
GNS glucosamine (N-acetyl)-6-sulfatase 
GPNMB glycoprotein (transmembrane) nmb 
GPR171 G protein-coupled receptor 171 
GPR56 G protein-coupled receptor 56 
GPR65 G protein-coupled receptor 65 
GPR84 G protein-coupled receptor 84 
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GPX1 glutathione peroxidase 1 
GRIN3A  glutamate receptor, ionotropic, N-methyl-D-aspartate 3A  
GRINA  glutamate receptor, ionotropic, N-methyl D-aspartate-
associated protein 1 (glutamate binding)  
GRN granulin 
GZMA  granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated 
serine esterase 3)  
GZMH  granzyme H (cathepsin G-like 2, protein h-CCPX)  
HAPLN3 hyaluronan and proteoglycan link protein 3 
HAVCR2 hepatitis A virus cellular receptor 2 
HEXA hexosaminidase A (alpha polypeptide) 
HEXB hexosaminidase B (beta polypeptide) 
HK3 hexokinase 3 (white cell) 
HNMT histamine N-methyltransferase 
HS3ST2 heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 
HSD17B14 hydroxysteroid (17-beta) dehydrogenase 14 
HSD3B7  hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 7  
HTRA4 HtrA serine peptidase 4 
IDH1  isocitrate dehydrogenase 1 (NADP+), soluble  
IFI30  interferon, gamma-inducible protein 30  
IFNAR1  interferon (alpha, beta and omega) receptor 1  
IFNG  interferon, gamma  
IGF2R insulin-like growth factor 2 receptor 
IGSF22  immunoglobulin superfamily, member 22  
IGSF6  immunoglobulin superfamily, member 6  
IL15 interleukin 15 
IL15RA  interleukin 15 receptor, alpha  
IL17RA interleukin 17 receptor A 
IL18BP interleukin 18 binding protein 
IL31RA interleukin 31 receptor A 
INDO  indoleamine-pyrrole 2,3 dioxygenase  
INDOL1  indoleamine-pyrrole 2,3 dioxygenase-like 1  
IRAK3 interleukin-1 receptor-associated kinase 3 
IRF1 interferon regulatory factor 1 
IRG1 immunoresponsive 1 homolog (mouse) 
ITFG1 integrin alpha FG-GAP repeat containing 1 
ITGB2  integrin, beta 2 (complement component 3 receptor 3 and 4 
subunit)  
ITM2B integral membrane protein 2B 
JAKMIP1 janus kinase and microtubule interacting protein 1 
KAL1 Kallmann syndrome 1 sequence 
KCNE1  potassium voltage-gated channel, Isk-related family, member 
1  
KCNE3  potassium voltage-gated channel, Isk-related family, member 
3  
KCNJ10  potassium inwardly-rectifying channel, subfamily J, member 
10  
KCNJ2  potassium inwardly-rectifying channel, subfamily J, member 2  
KCTD12 potassium channel tetramerisation domain containing 12 
KLF3 Kruppel-like factor 3 (basic) 
KLHDC8B kelch domain containing 8B 
LACTB  lactamase, beta  
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LAIR1 leukocyte-associated immunoglobulin-like receptor 1 
LAMP1 lysosomal-associated membrane protein 1 
LAMP2 lysosomal-associated membrane protein 2 
LAP3 leucine aminopeptidase 3 
LASS6  LAG1 homolog, ceramide synthase 6  
LCP2 lymphocyte cytosolic protein 2 (SH2 domain containing 
leukocyte protein of 76kDa) 
LGALS2  lectin, galactoside-binding, soluble, 2  
LGALS3  lectin, galactoside-binding, soluble, 3  
LGALS3BP  lectin, galactoside-binding, soluble, 3 binding protein  
LGALS8  lectin, galactoside-binding, soluble, 8  
LILRB1  leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 1  
LILRB2  leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 2  
LILRB3  leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 3  
LILRB4  leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 4  
LIMK2 LIM domain kinase 2 
LIPA  lipase A, lysosomal acid, cholesterol esterase  
LPCAT2 lysophosphatidylcholine acyltransferase 2 
LRP1 low density lipoprotein-related protein 1 (alpha-2-
macroglobulin receptor) 
LST1 leukocyte specific transcript 1 
LTA4H leukotriene A4 hydrolase 
LTBR  lymphotoxin beta receptor (TNFR superfamily, member 3)  
LY96 lymphocyte antigen 96 
M6PR mannose-6-phosphate receptor (cation dependent) 
MADD MAP-kinase activating death domain 
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(avian) 
MANBA  mannosidase, beta A, lysosomal  
MAP3K3 mitogen-activated protein kinase kinase kinase 3 
MARCO macrophage receptor with collagenous structure 
MCTP1  multiple C2 domains, transmembrane 1  
ME1  malic enzyme 1, NADP(+)-dependent, cytosolic  
MFSD1 major facilitator superfamily domain containing 1 
MFSD7 major facilitator superfamily domain containing 7 
MGAT4A  mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A  
MITF microphthalmia-associated transcription factor 
MPND MPN domain containing 
MPP1  membrane protein, palmitoylated 1, 55kDa  
MRAS muscle RAS oncogene homolog 
MT1E metallothionein 1E 
MT1F metallothionein 1F 
MT1G metallothionein 1G 
MT1H metallothionein 1H 
MT1M metallothionein 1M 
MT1P2 metallothionein 1 pseudogene 2 
MT1X metallothionein 1X 
MT2A metallothionein 2A 
MVP major vault protein 
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MYO1F myosin IF 
NAGK N-acetylglucosamine kinase 
NAIP  NLR family, apoptosis inhibitory protein  
NDRG1 N-myc downstream regulated gene 1 
NFE2L2 nuclear factor (erythroid-derived 2)-like 2 
NINJ1 ninjurin 1 
NKG7 natural killer cell group 7 sequence 
NLRC4  NLR family, CARD domain containing 4  
NPC1  Niemann-Pick disease, type C1  
NPC2  Niemann-Pick disease, type C2  
NPL N-acetylneuraminate pyruvate lyase (dihydrodipicolinate 
synthase) 
NR1H3  nuclear receptor subfamily 1, group H, member 3  
NRP2 neuropilin 2 
NUB1 negative regulator of ubiquitin-like proteins 1 
NUPR1 nuclear protein 1 
OLFML2B olfactomedin-like 2B 
OSCAR  osteoclast associated, immunoglobulin-like receptor  
OSTM1 osteopetrosis associated transmembrane protein 1 
P2RX7  purinergic receptor P2X, ligand-gated ion channel, 7  
P2RY13  purinergic receptor P2Y, G-protein coupled, 13  
P2RY6  pyrimidinergic receptor P2Y, G-protein coupled, 6  
P76 mannose-6-phosphate protein p76 
PADI2  peptidyl arginine deiminase, type II  
PECAM1 platelet/endothelial cell adhesion molecule 
PECAM1 platelet/endothelial cell adhesion molecule 
PILRA paired immunoglobin-like type 2 receptor alpha 
PLA1A phospholipase A1 member A 
PLA2G7  phospholipase A2, group VII (platelet-activating factor 
acetylhydrolase, plasma)  
PLAUR  plasminogen activator, urokinase receptor  
PLCL1 phospholipase C-like 1 
PLD1  phospholipase D1, phosphatidylcholine-specific  
PLD3  phospholipase D family, member 3  
PLEKHB2  pleckstrin homology domain containing, family B (evectins) 
member 2  
PLEKHG3  pleckstrin homology domain containing, family G (with 
RhoGef domain) member 3  
PLEKHO2  pleckstrin homology domain containing, family O member 2  
PLOD3  procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3  
PLSCR1 phospholipid scramblase 1 
PLXDC2 plexin domain containing 2 
PLXNC1 plexin C1 
PPP2R2B  protein phosphatase 2 (formerly 2A), regulatory subunit B, 
beta isoform  
PPT1 palmitoyl-protein thioesterase 1 
PQLC3 PQ loop repeat containing 3 
PRAM1 PML-RARA regulated adaptor molecule 1 
PRCP prolylcarboxypeptidase (angiotensinase C) 
PRF1 perforin 1 (pore forming protein) 
PSAP prosaposin 
PSEN1 presenilin 1 
PSTPIP2 proline-serine-threonine phosphatase interacting protein 2 
PTAFR platelet-activating factor receptor 
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PTGER2  prostaglandin E receptor 2 (subtype EP2), 53kDa  
PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator B) 
PYCARD PYD and CARD domain containing 
RAB20  RAB20, member RAS oncogene family  
RAB32  RAB32, member RAS oncogene family  
RALB v-ral simian leukemia viral oncogene homolog B (ras related; 
GTP binding protein) 
RALGDS ral guanine nucleotide dissociation stimulator 
RAP2B  RAP2B, member of RAS oncogene family  
RARRES1 retinoic acid receptor responder (tazarotene induced) 1 
RARRES3 retinoic acid receptor responder (tazarotene induced) 3 
RASSF4 Ras association (RalGDS/AF-6) domain family member 4 
RBM47 RNA binding motif protein 47 
RENBP renin binding protein 
RGL1 ral guanine nucleotide dissociation stimulator-like 1 
RNF13 ring finger protein 13 
RNF130 ring finger protein 130 
RNF149 ring finger protein 149 
RNF213 ring finger protein 213 
RRAS related RAS viral (r-ras) oncogene homolog 
S100A11 S100 calcium binding protein A11 
S100A11P S100 calcium binding protein A11 pseudogene 
S100A8 S100 calcium binding protein A8 
S100A9 S100 calcium binding protein A9 
SAMHD1 SAM domain and HD domain 1 
SASH1 SAM and SH3 domain containing 1 
SAT1 spermidine/spermine N1-acetyltransferase 1 
SCARB2  scavenger receptor class B, member 2  
SCO2 SCO cytochrome oxidase deficient homolog 2 (yeast) 
SCPEP1 serine carboxypeptidase 1 
SDC3 syndecan 3 
SDCBP syndecan binding protein (syntenin) 
SDSL serine dehydratase-like 
SECTM1 secreted and transmembrane 1 
SERPINA1  serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1  
SERPING1  serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  
SFXN3 sideroflexin 3 
SGK3  serum/glucocorticoid regulated kinase family, member 3  
SH3PXD2B SH3 and PX domains 2B 
SIGLEC1  sialic acid binding Ig-like lectin 1, sialoadhesin  
SIGLEC11 sialic acid binding Ig-like lectin 11 
SIGLEC16 sialic acid binding Ig-like lectin 16 (gene/pseudogene) 
SIGLEC7 sialic acid binding Ig-like lectin 7 
SIGLEC9 sialic acid binding Ig-like lectin 9 
SIRPB1 signal-regulatory protein beta 1 
SIRPB2 signal-regulatory protein beta 2 
SLAMF7 SLAM family member 7 
SLAMF8 SLAM family member 8 
SLC11A2  solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 2  
SLC16A3  solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4)  
SLC22A18  solute carrier family 22, member 18  
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SLC24A6  solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 6  
SLC27A1  solute carrier family 27 (fatty acid transporter), member 1  
SLC27A2  solute carrier family 27 (fatty acid transporter), member 2  
SLC29A3  solute carrier family 29 (nucleoside transporters), member 3  
SLC2A9  solute carrier family 2 (facilitated glucose transporter), 
member 9  
SLC30A1  solute carrier family 30 (zinc transporter), member 1  
SLC31A1  solute carrier family 31 (copper transporters), member 1  
SLC31A2  solute carrier family 31 (copper transporters), member 2  
SLC38A6  solute carrier family 38, member 6  
SLC39A8  solute carrier family 39 (zinc transporter), member 8  
SLC46A1  solute carrier family 46 (folate transporter), member 1  
SLC46A3  solute carrier family 46, member 3  
SLC6A12  solute carrier family 6 (neurotransmitter transporter, 
betaine/GABA), member 12  
SLC8A1  solute carrier family 8 (sodium/calcium exchanger), member 
1  
SLC8A1  solute carrier family 8 (sodium/calcium exchanger), member 
1  
SLCO2B1  solute carrier organic anion transporter family, member 2B1  
SMPDL3A  sphingomyelin phosphodiesterase, acid-like 3A  
SNX10 sorting nexin 10 
SNX6 sorting nexin 6 
SOAT1 sterol O-acyltransferase 1 
SOD2  superoxide dismutase 2, mitochondrial  
SPECC1 sperm antigen with calponin homology and coiled-coil 
domains 1 
SPG20 spastic paraplegia 20 (Troyer syndrome) 
SPNS1 spinster homolog 1 (Drosophila) 
SPPL2A signal peptide peptidase-like 2A 
SPRY2 sprouty homolog 2 (Drosophila) 
SQSTM1 sequestosome 1 
STARD8 StAR-related lipid transfer (START) domain containing 8 
STAT1  signal transducer and activator of transcription 1, 91kDa  
STEAP3 STEAP family member 3 
STOM stomatin 
STX4 syntaxin 4 
TBC1D2  TBC1 domain family, member 2  
TBC1D2B  TBC1 domain family, member 2B  
TBXAS1 thromboxane A synthase 1 (platelet) 
TCF7L1  transcription factor 7-like 1 (T-cell specific, HMG-box)  
TCN2 transcobalamin II; macrocytic anemia 
TEX2 testis expressed 2 
TGM2  transglutaminase 2 (C polypeptide, protein-glutamine-
gamma-glutamyltransferase)  
TIFAB  TRAF-interacting protein with forkhead-associated domain, 
family member B  
TIMP2 TIMP metallopeptidase inhibitor 2 
TLR1 toll-like receptor 1 
TLR2 toll-like receptor 2 
TLR4 toll-like receptor 4 
TLR5 toll-like receptor 5 
TLR8 toll-like receptor 8 
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TMBIM1 transmembrane BAX inhibitor motif containing 1 
TMEM127 transmembrane protein 127 
TMEM140 transmembrane protein 140 
TMEM144 transmembrane protein 144 
TMEM176A transmembrane protein 176A 
TMEM176B transmembrane protein 176B 
TMEM50A transmembrane protein 50A 
TMEM51 transmembrane protein 51 
TMEM86A transmembrane protein 86A 
TMSB10 thymosin beta 10 
TNFAIP2  tumor necrosis factor, alpha-induced protein 2  
TNFRSF1A  tumor necrosis factor receptor superfamily, member 1A  
TNFSF10  tumor necrosis factor (ligand) superfamily, member 10  
TNFSF12  tumor necrosis factor (ligand) superfamily, member 12  
TNFSF13  tumor necrosis factor (ligand) superfamily, member 13  
TNFSF13B  tumor necrosis factor (ligand) superfamily, member 13b  
TNS1 tensin 1 
TNS3 tensin 3 
TSPAN14 tetraspanin 14 
TSPAN4 tetraspanin 4 
TSPO translocator protein (18kDa) 
TYMP thymidine phosphorylase 
TYROBP TYRO protein tyrosine kinase binding protein 
UBD ubiquitin D 
UBE2F ubiquitin-conjugating enzyme E2F (putative) 
VAC14 Vac14 homolog (S. cerevisiae) 
VAMP3 vesicle-associated membrane protein 3 (cellubrevin) 
VAMP5 vesicle-associated membrane protein 5 (myobrevin) 
VAT1 vesicle amine transport protein 1 homolog (T. californica) 
VPS37C vacuolar protein sorting 37 homolog C (S. cerevisiae) 
VSIG4 V-set and immunoglobulin domain containing 4 
VWA5A von Willebrand factor A domain containing 5A 
WARS tryptophanyl-tRNA synthetase 
WDFY3 WD repeat and FYVE domain containing 3 
ZDHHC7  zinc finger, DHHC-type containing 7  
ZFYVE16  zinc finger, FYVE domain containing 16  
ZMYND15  zinc finger, MYND-type containing 15  
ZNF438 zinc finger protein 438 






Lying close to the macrophage cluster is a cluster enriched in genes associated with 
T cells.  This is formed of 255 probesets representing 152 genes.  It includes many T-
cell surface markers including the pan-T cell antigens CD2, CD3 (the delta, epsilon 
and gamma components of the CD3 molecule), CD5 and CD7 as well as multiple 
components of the T cell receptor.  Various elements of T cell receptor signalling are 
represented (FYN, ITK, LAT, LCP2, PRKCQ and ZAP70), as are cytotoxic 
molecules granzyme K and granzyme M.  
 
Examination of the T cell expression profile across the dataset shows a pattern 
similar to that seen with the macrophage signature in that there is considerable 
variation in expression across the dataset but no obvious pattern to the expression 
(Figure 4.10).  Again selected functional annotation is provided (Table 4.5).   
 
 
Figure 4.10  Mean intensity of the T cell cluster across the DLBCL dataset. There is 
considerable variation across the dataset but no obvious trend associated with tumour 
subtype or outcome.  Individual tumours across x-axis with coloured bars indicating tumour 








Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA GSE10325 
Genes upregulated in 
comparison of healthy 



































Table 4.5   Functional annotation for the gene list from the ‘T cell signature’.  Selected 
annotation derived from DAVID and GSEA gene expression analysis tools.  The T cell gene 
list was uploaded to DAVID and analysed through the functional annotation clustering tool 
and in GSEA using the molecular signatures database.  Only selected annotation is shown 
here.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values.  
 
There is a cluster lying adjacent to and between the macrophage cluster and T cell 
cluster that appears to represent the interferon response consisting of 83 probesets 
representing 58 genes (Figure 4.11, Table 4.6).  These include the interferon 
regulatory factors IRF7 and IRF9 as well as multiple interferon inducible genes 
(IFI27, IFI35, IFI44, IFI44L, IFI6, IFIH1, IFIT2, IFIT3, IFIT5, IFITM1, IFITM2, 
IFITM3).  Figure 4.12 demonstrates the relationships between the T cell, 
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Table 4.6  Functional annotation for the gene list from the ‘IFN signature’. Selected 
annotation derived from DAVID and GSEA gene expression analysis tools.  The IFN gene 
list was uploaded to DAVID and analysed through the functional annotation clustering tool 
and in GSEA using the molecular signatures database.  Only selected annotation is shown 




Figure 4.11  Mean expression intensity of the IFN cluster across the dataset.  Individual 
tumours along the x-axis.  Coloured bars demote tumour subtypes. 
 
As well as these clearly immune clusters there are other clusters that lie in the 
‘stromal’ area of the graph that appear to represent components of the extracellular 
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matrix and vasculature.   The main ECM cluster forms a relatively large cluster close 
to but separate from the immune clusters.  Expression levels of the genes in this 
cluster are higher in cases classified as PMBL compared to the other subtypes of 
DLBCL (Figure 4.12).  This is in keeping with the recognised histological 
characteristics of PMBL, a tumour frequently characterised by a dense fibrotic 
stroma in which the tumour cells reside (Swerdlow et al 2008).  The main ECM 
cluster contains 437 probesets representing 288 genes.  This cluster contain genes for 
many structural proteins  (collagens I, III,IV, V, VI, XI, XIII,XV and XVI, 
fibronectin 1, laminin alpha 4, beta 1 and 2 and gamma 1, caldesmon 1 and heparan 
sulphate proteoglycan 2).  In addition to these, there are many modulators of the 
extracellular matrix including ADAM metallopeptidases (AMAM12, AMADTS12, 
ADAMTS5), matrix metallopeptidase 2 and several TIMPS (TIMP1, 2 and 3).  
Elements of the vascular signature are also included in this cluster including VEGFC, 
WT1, endothelial cell adhesion molecule and podoplanin.  See table 4.7 for selected 
functional annotation.  The relationships between the T cell, macrophage, interferon 





Figure 4.12  Mean expression intensity across the ECM cluster. Expression is higher in the 
tumours of PMBL subtype reflecting the histological appearances.  There is no association 
with outcome.  Individual tumours lie along the x-axis, with coloured bars representing 
tumour subtypes.  Within each subtypes good outcome tumours lies to the left and poor 






Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA GO term Extracellular matrix 1.8 x10
-40
 













Table 4.7 Functional annotation for the gene list from the ‘ECM signature’. Selected 
annotation derived from DAVID and GSEA gene expression analysis tools.  The ECM gene 
list was uploaded to DAVID and analysed through the functional annotation clustering tool 
and in GSEA using the molecular signatures database.  Only selected annotation is shown 
here.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
 
Figure 4.13  Further view of the graph network to show the relationships within the stromal 
cluster. The main graph is represented as edges only with no visible nodes.  Selected nodes 
are made visible and enlarged.  The right hand panel indicates mean gene expression in each 
cluster illustrated.   A) The skeletal muscle cluster which lies separate from the main graph 
but connected to it.  B) The ECM cluster lying close to but separate from the immune 
clusters.  C) T-cell, D) Interferon response and E) Macrophage all lie very close together. 
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As well as elements of the endothelial signature that lie within the main ECM cluster 
there are is also a separate small cluster of endothelial genes.  This lies closely 
associated with the ECM cluster and contains genes such as CD34, cadherin 5 
(vascular endothelial cadherin), von Willibrand factor, endomucin and TEK, tyrosine 
kinase endothelial.  A further cluster of ECM genes lies immediately adjacent to the 
main cluster and a cluster of adipocyte genes near but not abutting the main ECM 
cluster (Figure 4.14). 
 
 
Figure 4.14  The clusters identified as ECM or endothelial genes cluster together within the 
graph network.  The selected cluster are made visible while the rest of the graph is hidden to 
demonstrate cluster relationships.   
 
 
4.4.2 Cell cycle related clusters 
 
The other major area of the graph where it is possible to assign function to the 
clusters is in the area broadly represented by the cell cycle.  There are several 
separate but closely related clusters in this area which group together. The main cell 
cluster contains 652 probesets representing 539 genes.  This contains genes in which 
RNA binding activity and transcriptional regulators are prominent and include 
multiple RNA binding proteins (RBM14, RBM17, RBM22, RBM26, RBM33), 
splicing factors (SF1, SFRS1, SFRS2, SFRS4, SFRS7, SFRS8), nuclear riboproteins 
(HNRNPC, HNRNPF, HNRNPR, HNRNPU), and transcription factors (E2F1, E2F4, 
124 
 
SP1, YY1, ATF1, ATF2, HSF1, HSF2, NFYC) (see table 4.8 for selected functional 
annotation).  A further cluster contains 184 probesets representing 143 genes. This 
appears to relate to the mitotic phase of the cell cycle (Table 4.9).   The cluster 
includes the aurora kinases (AURKA and AURKB), centromere proteins (CENPA, 
CENPE, CENPF, CENPK), lymphoid specific helicase (HELLS), kinesin family 
members (KIF11,KIF14, KIF18A, KIF18B, KIF20A, KIF20B, KIF2C, KIFC1), 
DNA polymerases (POLA2, POLE3A) topoisomerase (TOP2A) and tubulins 
(TUBB2C, TUBB3) among many others.   A complete list of genes in this cluster is 
provided in appendix 1.  Several small related clusters that lie adjacent to these main 
clusters contain cell cycle related genes such as TATA box binding protein 
associated factor (TAF1B), RNA polymerase (POLR3H), splicing factor (SFRS7) 
and ribonuclease (RPP14).   Analysis of the expression profile of the cell cycle genes 
shows variation across the dataset but no particular relationship with tumour type or 
outcome (Figure 4.15).  This may in part reflect the treatment approach used in 
lymphoma where with current therapeutic regimens tumours with higher rates of 
proliferation including DLBCL are potentially curable in response to aggressive 
chemotherapy thus subtle differences in cell cycle in the tumour expression profile 




Figure 4.15 Cell cycle genes across DLBCL dataset.  Mean expression of the genes forming 
the cell cycle clusters.  Coloured bars represent tumour subtypes.  Cell cycle activity shows 







Analysis tool Source of annotation Annotation Significance 
(p-value)  
















Table 4.8 Functional annotation for the gene list from the largest cell cycle cluster. Selected 
annotation derived from DAVID and GSEA gene expression analysis tools.  Only selected 
annotation is shown here.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Cell cycle 7.1 x10
-46
 













Table 4.9  Functional annotation for the gene list from the cell cycle S/M phase cluster. 
Selected annotation derived from DAVID and GSEA gene expression analysis tools.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
 
4.4.3  Other non-stromal, non-cell cycle clusters 
In addition, in this dataset, as in the others studied there were clusters of genes which 
could be assigned a function, but which were not of great interest in terms of insight 
into either stromal or malignant components of the dataset.  These included clusters 
of ribosomal genes, genes involved in glycolysis, histone clusters, and haemoglobin 
clusters, among others.  
 
The focus of this analysis was not on determining groups of genes that could 
subdivide types of tumour, but rather on looking for non-cancerous signatures, in 
particular those relating to the stroma, but analysis of the dataset did provide some 
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insights into the cancer related elements of each dataset.  In this dataset, as in the 
others discussed here there are very few clusters that demonstrate clear difference in 
expression between subtypes of tumour or between clinical outcome, illustrating the 
difficulties in gene expression analysis directed to these questions i.e. that most of 
the data in a cancer gene expression study does not relate to factors specific to the 
tumour or to outcome.  Where such clusters can be found however, they can be 
informative.  In the DLBCL dataset, IRF4, one of the markers by 
immunohistochemistry of the ABC-subtype, does not lie in a cluster, but searching 
for the nearest neighbours of this draws in genes from the periphery of several small 
adjacent clusters which include FOXP1, PIM2 and CARD11, all described to be up-
regulated in ABC-subtype of DLBCL, with amplifications or mutation affecting 
FOXP1 and CARD11 identified in 38% and 10% respectively of tumours studied 





Figure 4.16  Tumour networks in DLBCL.  IFR4 shows variation in expression between 
tumour subtypes being higher in ABC subtype than others.  Searching for the nearest 
neighbours of this gene captures a small group of genes, many of which have been 
demonstrated to be mutated in tumours of ABC subtype.  The other genes within this 
grouping are therefore also worthy of further study.   
 
Having demonstrated that cell type and function signatures could be demonstrated by 
clustering analysis in the DLBCL dataset, this analysis was expanded to multiple 
further datasets to ensure the approach could be applies more universally and to 
provide signatures of TAMs in more than one tumour type to allow the final ‘merge’ 
analysis to be performed.   
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4.5  Gene signatures from Breast cancer 
 
The breast cancer dataset consisted of 159 samples from patients treated in Sweden, 
of which 134 passed the QC step.  These were stratified on the basis of molecular 
tumour type (Basal, HER2 positive, Luminal A or B, or normal-like), Ellis-Elston 
grade, survival outcome and recurrence outcome. The breast cancer network when 
laid out at r ≥ 0.65 contains 19,246 nodes and 559,761 edges and has a polarised 
shape, with a large central core and clusters arising from opposite poles of this 
(Figure 4.17).  The clusters at opposite ends of the graph are poorly characterised and 
designated housekeeping clusters, but within the main central area there are immune 
and cell cycle clusters.  The immune clusters do not form a tight group, but rather 
separate into two main areas on opposite sides of the main cluster.  There is 
considerable overlap of immune cell type signatures in these clusters with some B 
and T cell genes falling in a single cluster and T cell and macrophage genes in a 
single cluster.  Cell cycle genes form multiple clusters related to expression pattern 
across tumour subsets with a large cluster formed of genes that go up with increasing 
aggressiveness of tumour and tumour grade, and others clusters with a different 
pattern of expression.   This dataset seems particularly rich in tumours with ‘spiked’ 
profiles with many clusters formed of genes that are essentially expressed in only a 





Figure 4.17  The breast cancer network laid out at r≥0.65 with nodes hidden and only edges 
visible.  The stromal and cell cycle related clusters lie at sides of the main  graph while less 
well characterised clusters make up the central part and extreme poles.  
 
4.5.1 Stromal signatures 
There are several distinct immune related signatures present in the dataset.  These 
tend to fall within the central part of the graph.  These break up into two main areas 
with several closely related clusters that appear to represent a lymphocyte signature 
and a macrophage signature falling closely together, and several other clusters which 
lie apart from these that represent T cells and macrophages (Figure 4.18).  The 
interferon cluster breaks into three parts which joins these two main immune areas.  
Unlike in the DLBCL dataset, there is a distinct B cell/plasma cell signature which 
lies adjacent to the lymphocyte signature.  These signatures all show considerable 
variation across the dataset, but no clear pattern of expression related to tumour type 
other than a suggestion of higher expression of all in the basal and EBB2 types, and 




Figure 4.18.  The immune clusters in the Breast dataset.  The rest of the graph is hidden and 
only the selected immune clusters remain visible showing the division of the immune 
signatures into two broad areas.  Side panels show the mean expression patterns in each of 
these clusters.  Each cluster and the corresponding expression profile is in the same colour.  
Individual tumours represented on x-axis of these panels.  Coloured bars indicate tumour 
subtype.   
 
The macrophage only signature consists of 116 probesets representing 93 genes and 
contains markers of myeloid differentiation CD14, CD163, CD33 and CD4.  The 
MCH class II genes fall within this cluster as do multiple Fc receptors (FCER1G, 
FCGR1A and FCGR1B).  Allograft inflammatory factor, legumain, and mannose 
receptor C, type 1 also lie in this cluster.  Analysis through DAVID identifies the 
cluster as being enriched in genes involved in defence response, antigen processing 





Analysis tool Source of annotation Annotation Significance 
(p-value)  























Table 4.10 Functional annotation for the macrophage signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The cluster with overlapping signatures of macrophages and T cells is slightly larger 
consisting of 147 probesets and 99 genes.  This contains less obviously lineage 
specific genes and is identified largely from overlaps with T cell and macrophage  
clusters from other datasets.  It does however contain CD5, CTLA4 and FYB as 
markers of T cell lineage as well as TLR8, IL-6 and IL-7 receptors and macrophage 
specific genes such as macrophage expressed 1 (MPEG1).  Annotation from 
databases is less clear as to the nature of this cluster but does identify T cell 
activation and genes involved in the immune system (Table 4.11).   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT 













Table 4.11 Functional annotation for the macrophage/T cell signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
132 
 
The largest immune cluster (232 probesets representing 187 genes) contains elements 
common to both B and T lymphocytes.  This shared lymphocyte signature appeared 
largely lost in the DLBCL signature where the only normal lymphocyte population 
identifiable was the T cell signature.  This contains surface markers of both T and B 
cell lineage (CD2, CD3, CD7, CD52,  CD19, CD22, CD79B) as well as elements of 
the T cell receptor and B cell receptor molecules (TRA, TRAC, IGMH).  There are 
cytotoxic molecules granzymes A, H, K and M (GZMA, GZMH, GZMK, GZMM) 
and perforin 1 (PRF1).  Multiple  intracellular signalling molecule specific to each 
cell type or shared between them are present (BTK, FYN, FYB, ITK, ZAP70), as are 
numerous chemokines, cytokines and their receptors (CCL19, CCL5, CCR2, CCR5, 
CCR7, CXCL9, CXCR3, CXCR5, CXCR6, IL10RA, IL16, IL21R, IL23A, IL2RB, 
IL2RG, 1L32, IL7R).  Selected functional annotation given in Table 4.12.   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  










DAVID KEGG PATHWAY 






Table 4.12 Functional annotation for the lymphocyte signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values.  
 
 
A small cluster (105 probesets of 53 genes) represents B cells or plasma cells, most 
likely plasma cells given the cluster contains CD38, a surface marker of plasma cells 
and IRF4, a transcription factor expressed in the late B cell/plasma cell stage of 
differentiation.  This cluster is formed mostly of immunoglobulin genes.  A further 
much small cluster of only 24 probesets formed also of B cell genes lies separately.   




Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDDS Immunoglobulin 1.5 x10
-19
 




Upregulated in B cells 





Table 4.13 Functional annotation for the B cell/plasma cell signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The interferon response splits into three clusters that bridge the space between the 
two main immune grouping.  In total these clusters represent 96 probesets and 68 
genes.  These show some variation with a subset of genes showing lower expression 
in normal-like breast cancer samples than others.  Analysis through DAVID and 
GSEA support the categorisation as being associated with the interferon response but 
do not provide any insight into the nature of the differential expression between 
tumour types.  This interferon cluster contains genes for multiple interferon induced 
proteins (IFI27, IFI35, IFI44, IFI44L, IFIH1, IFI6, IFIT1, IFIT2, IFIT3, IFIT5), 
interferon regulatory factors (IRF7, IRF9) and interferon stimulated exonuclease 
gene (ISG20). 
 
The non-immune stromal signatures fall into two distinct and unattached areas, each 
of which contains areas representing extracellular matrix, endothelium and fat. 
(Figure 4.19)  Those forming the tighter cluster of fat, endothelium and ECM tend to 




Figure 4.19.  The stromal clusters in the Breast dataset.  The rest of the graph is hidden  and 
only the non-immune stromal signatures left visible.  The stromal signatures divide into two 
broad, unconnected areas.  The side panels around the network graph show the mean 
expression patterns in each of these clusters.  Each cluster and the associated expression 
profile uses the same colour.  Individual tumours represented on x-axis of these panels.  
Coloured bars indicate tumour subtype.   
 
The ECM cluster in this area (red in figure 4.19)  contains 273 probesets representing 
195 genes and contains numerous collagens (COL1A1, COL1A2, COL3A1, 
COL5A1, COL5A2, COL6A1, COL6A2, COL6A3, COL8A2, COL10A1, 
COL11A1, COL16A1, COL18A1), caldesmon 1 (CALD1),  laminins (LAMA4, 
LAMB1, LAMC1), vimentin (VIM) and versican (VCAN).  Modifiers of the ECM 
are also present including ADAM metallopeptidases (ADAM12, ADAMTS2), 
matrix metallopeptidases (MMP11, MMP2), TIMP 3 and growth factors (TGFB3).  
There are elements of a vascular signature mixed into this cluster including 
angiopoetin-like 2 (ANGPTL2) and podoplanin arguing that expression of these 
molecules is regulated along with or closely influenced by factors also influencing 
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the extracellular matrix.  Analysis of this cluster clearly identifies the enrichment for 
extracellular matrix genes (Table 4.14). 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Extracellular matrix 2.9 x10
-42
 









GSEA Stanford tumour modules ECM and collagen 9.9x10
-110 
 
Table 4.14 Functional annotation for the ECM signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The main endothelial cluster in this area consists of 188 probesets representing 162 
genes.  It contains well-characterised endothelial associated genes such as PECAM1 
encoding for CD31, CD248 (endosialin), cadherin 5 type 2 (vascular endothelium) 
(CDH5), caveolin 1, (CAV1), endomucin (EMCN), ERG, TEK endothelial tyrosine 
kinase and von Willebrand Factor (VWF).  Analysis highlights this cluster to be 
enriched in genes expressed in the extracellular region and involved in angiogenesis 
(Table 4.15). 
 








DAVID GOTERM_CC_FAT Extracellular region 1.9x10
-11
 




Table 4.15 Functional annotation for the endothelial signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 




The adipocyte cluster consists of 123 probesets to 92 genes.  It contains genes 
including lipoprotein lipase (LPL), hormone sensitive lipase (LIPE), CD36, 
adipocyte fatty acid binding protein (FABP4), growth hormone receptor, adiponectin 
(ADIPOQ) and elements of the PPAR receptor (PPARG).  Annotation from GSEA in 
particular supports an adipocyte signature (Table 4.16). 
 





























Table 4.16 Functional annotation for the adipocyte signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The smaller ECM cluster lying at the opposite side of the graph consists of 132 
probesets representing 87 genes.  This contains smaller numbers of collagen genes 
(COL12A1, COL1A2, COL3A1), fibrillin 1 (FBN1) and several integrins (ITGA11, 
ITGBL1).  Modifiers of the ECM are included in this cluster also (ADMATS12, 
ADMATS16, TIMP2).  Analysis again confirms the enrichment of ECM genes in 







Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Extracellular matrix 9.6 x10
-7
 
DAVID GOTERM_BP_FAT Cell adhesion 1.9x10
-4
 




Table 4.17 Functional annotation for the ECM signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
There is a further cluster containing overlaps between endothelial and adipocyte 
signatures.  This is of 115 probesets and 77 genes and contains genes involved in 
angiogenesis such as SOX17, endomucin (EMCN), endothelial cell-specific 
chemotaxis regulator (ECSCR) and ROBO4 and genes involved in lipid binding such 
as CD36, annexin A1 (ANXA1), and adipocyte fatty acid binding protein (FABP4) 
and genes involved in triglyceride biosynthesis (AGAT9, DGAT2, GPAM).  This 
cluster does not demonstrate the highly significant enrichment of genes seen in other 
clusters but DAVID analysis does still draw some functional annotation (Table 4.18). 
 








DAVID GOTERM_BP_FAT Angiogenesis 1.5x10
-2
 




Table 4.18 Functional annotation for the adipocyte/endothelial signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 






4.5.2 Cell cycle related signatures 
The main cell cycle cluster contains 154 probesets representing 133 genes and 
appears to represent the mitotic phase of the cell cycle (see table 4.19).  Expression 
of these genes is highest in the more aggressive tumour types basal-like and ERBB2 
(Her2 positive).  Of note the expression of these rises with increasing grade across 
tumour types where a spectrum of grades are represented in the dataset (luminal A 
and normal like) (Top panel figure 4.20).  This correlates with the histological 
features of these tumours, the Ellis-Elston grade being calculated on mitotic count in 
a set area, nuclear pleomorphism and tubule formation.   This cluster contains aurora 
kinase A (AURKA), cyclins A2 and B1, (CCNA2, CCNB1), cell division cycle 
associated genes 3,4 and 8 (CDCA3, CDCA4, CDCA8), various centromere proteins 
A, E, F, M (CENPA, CENPE, CENPF, CENPM), E2F transcription factors 1 and 8 
(E2F1, E2F8), numerous kinesins (KIF11, KIF14, KIF15, KIF18B, KIF20A, KIF23, 
KIF2C, KIF4A, KIFC1), MKI67 and PCNA, (the proteins of which are both used 
immunohistochemically to quantify proliferation), topoisomerase 2 alpha (TOP2A) 
and DNA polymerase (POLA2).   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_keywords Cell division 8.2 x10
-35
 










Table 4.19 Functional annotation for the main cell cycle signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 





Figure 4.20.  Top panel: The mean expression pattern of the main cell cycle cluster viewed 
across the dataset.  The aggressive tumour subtypes basal-like and ERBB2 (Her-2 positive) 
lie to the left of the figure.  Within each individual tumour type the cases are ordered from 
lowest grade at left to highest grade at right.  The effect is most marked in the luminal A 
cases where all tumour grades from 1 (left) to 3 (right) are represented, although a similar 
pattern in seen in the normal-like cases as well.  Bottom panel:  The small cell cycle related 
cluster containing TP53.  Individual tumours represented on x-axis of these panels.  
Coloured bars indicate tumour subtype.   
 
There are several cell cycle associated clusters present.  One of these, a much smaller 
cell cycle related cluster containing 39 probesets mapping to 35 genes has a pattern 
quite different from the main cell cycle cluster (lower panel figure 4.20). The genes 
within this cluster lie within cell cycle clusters in the merged dataset implying that in 
the other tumour types these genes show similar expression to cell cycle genes but on 
applying functional annotation using DAVID and GSEA little useful annotation is 
found.  These genes show an expression pattern at variance with the mitotic phase 
cluster discussed above.   Of interest, represented within this cluster is TP53 





4.5.3 Other signatures 
 
As in other datasets, aside from cell cycle and stromal signatures there were other 
clusters, often small, where functional annotation could be assigned.  These included 
clusters of ribosomal genes, genes involved in glycolysis, etc much as in the DLBCL 
dataset.  These are not discussed further.  Much of the graph in this as in other 
datasets cannot be interpreted as representing specific functions or cell types.  In part 
this is due to the large number of genes about which little is known and which often 
cluster together providing no handle to approach the gene list from.  In this dataset 
however, there is a relatively diverse group of tumours represented and there are 
clusters that provide information about these. 
 
In the breast cancer dataset, searching for genes that differ between subsets, these 
tend to form small clusters in separate areas of the graph.  One of these areas 
contains a sparse network of genes, separate from the main graph and containing a 
number of small clusters. These clusters represent genes whose profile is lower in 
expression in basal-like and ERBB2-positive tumours, tumours which normally lack 
expression of oestrogen receptor histologically and do not respond to anti-
oestrogenic drugs.  These clusters include ESR1 (the oestrogen receptor alpha), 
GATA3, FOXA1, and XBP1, and this cluster grouping appears to capture part of the 
oestrogen signalling transcriptional network, including modulators and downstream 
targets (Figure 4.21).  GATA3 is involved in luminal differentiation in normal breast 
tissue  and ESR1 and GATA3 have been demonstrated to reciprocally regulate each 
other (Asselin-Labat et al 2007, Eeckhoute et al 2007).  GATA3 is an inducer of 
FOXA1, which in turn can induce XBP1, while ESR1 acts both upstream and 
alongside FOXA1 (reviewed in Nakshatri and Badve 2009).    This small group of 







Figure 4.21.  The oestrogen receptor (ESR1) lies in a small cluster outwith the main graph.  
Selecting the ‘nearest neighbours’ of this cluster pulls in other small clusters of interest.  The 
expression pattern of the ERS1 cluster is shown in the bottom panel.  Individual tumours 







4.6  Gene signatures from ovarian cancer 
The ovarian data set was of 285 cases from several hospitals in Australia and the 
Netherlands of which 265 passed the QC step and were used in the analysis.  These 
were stratified based on whether they were malignant or of low malignant potential, 
histological type (endometrioid or serous), grade, stage and primary site (ovary, 
peritoneum or fallopian tube).  The ovarian network laid out at r = 0. 65 has a rather 
‘hairy’ appearance being formed of a large central area with numerous smaller 
clusters round the periphery (Figure 4.22).  This is reflected in the relatively low 
number of edges as compared to nodes, with 19,415 nodes being joined by only 
268,471 edges.  Lying within the central area are clusters of immune genes, 
extracellular matrix genes and cell cycle genes.  There are several clusters that 
represent immune related cells.  These lie within the same area of the central part of 
the graph and lie near but not abutting the non-immune stromal elements.  The cell 
cycle and cell cycle related clusters lie close together and separate from the stromal 
elements. The clusters of cell cycle genes show a clear difference in expression 
between the tumours of low malignant potential which show low expression and the 






Figure 4.22.   Ovarian carcinoma dataset laid out at r≥0.65 with nodes hidden and only 
edges visible.   
 
4.6.1 Stromal signatures 
 
The immune clusters fall together in one area of the graph (Figure 4.23).  The largest 
cluster, which is enriched for macrophage and T cell genes, consists of 619 probesets 
representing 378 genes.  There is lower expression in tumours of LMP and higher 
expression in tumours not arising in the ovary.  This contains myeloid lineage 
markers such as CD14, CD163, CD68, CSF1R and T cell markers CD2, CD3 (delta, 
epsilon and gamma subunits), CD5, and CD52.  There are multiple chemokines, 
cytokines, interleukins and their receptors (CCL3, CCL4, CCL5, CCR1, CCRL2, 
CXCL13, CXCL9, CXCR3, CXCR6, IL10RA, 1L12RB1, IL16, IL18RAP, IL21R, 
IL23R, IL2RB, IL2RG, IL7R and IFNG).  Toll-like receptors are represented (TLR1, 
TLR2, TLR4, TLR7, TLR8, TLR10) as are some MHC class II molecules (HLA-
DMA, HLA-DMB, HLA-DOA, HLA-DPA1, HLA-DPB1, HLA-DRA, HLA-DRB1, 
HLA-DRB4, HLA-DRB4, HLA-DRB6)  and associated genes such as the class II, 
MHC, transactivator (CIITA) and CD74, the invariant chain of MHC II .  There are 
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multiple elements of the T cell receptor signalling pathway (FYB, LAT2, TRA@, 
TRAC, TRAT1. TRAV20, TRGC2, TCRGV9, ZAP70).  Cytotoxic granules are 
represented with multiple granzymes (GZMA, GZMB, GZMH,GZMK) and perforin 
1 present.   Analysis of the cluster confirms the enrichment for macrophage and T 
cell genes (Table 4.20). 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Defence response 94.5 x10
-36
 




Antigen processing and 




















Table 4.20 Functional annotation for the macrophage/T cell signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 





Figure 4.23.    The immune cluster from the ovarian dataset with the rest of the graph hidden 
(central panel).  Mean expression profiles for each cluster are shown with the colours of the 
clusters corresponding to the colours of the expression plots.  Individual tumours are 
represented along the x-axis with the coloured bar indicating tumour types (red = LMP, 
green = endometrioid, blue  = serous). 
 
 
The interferon response (103 probesets representing 61 genes) and MHC class I 
signatures which fall next to the macrophage signature, show similar expression 
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patterns (Figure 4.23).   The interferon response cluster contains numerous interferon 
induced proteins (IFI27, IFI35, IFI44, IFI44L, IFI6, IFIH1, IFIT1, IFIT2, IFIT3, 
IFIT5, MX1) and the interferon regulatory factors IRF7 and IRF9.   The MHC class I 
cluster contains 57 probesets representing 29 genes.  This contains the HLA 
molecules HLA-A, HLA-B, HLA-D, HLA-E, HLF-F, and HLA-G.  Two 
components of the TAP transporter TAP1 and TAP2 are present as is the TAP 
binding protein (tapasin), two subunits of the proteasome (PSMB8, PSMB9) and 
beta-2-microglobulin (B2M).  See tables 4.21 and 4.22 for selected functional 
annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA HECKER_IFNB_TARGETS 
Genes modulated in 
MS patients treated 






in HT1080 cells by 








Table 4.21 Functional annotation for the interferon response signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
   
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT 
Antigen processing and 














Table 4.22 Functional annotation for the MHC class I signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 




The plasma cell signature is largely absent from the LMP tumours (Figure 4.23).  It 
consists of 162 probesets representing only 81 genes.  It contains some markers of 
B/plasma cell differentiation such as CD79A, CD38 and IRF4 but consists mostly of 
immunoglobulin genes for both heavy and light chains.  See Table 4.23 for 
functional annotation.  
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Immunoglobulin 6.5 x10
-17
 
DAVID GOTERM_MF_FAT Antigen binding 2.8 x10
-14
 
GSEA GSE10325_B CELL_VS_MYELOID 
Genes upregulated in B 






Table 4.23 Functional annotation for the plasma cell signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The B cell signature consisting only of 50 probesets to 27 genes is seen in only a 
small number of tumours (Figure 4.23).  This contains the B cell marker CD79B, the 
BLK B lymphoid tyrosine kinase and several Fc-receptor like genes (FCRL1, 
FCRL2, FCRL3, FCRLA) as well as the immunoglobulin heavy chain, mu.  See 
table 4.24 for functional annotation. 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA GSE10325_B CELL_VS_MYELOID 
Genes upregulated in B 









Table 4.24 Functional annotation for the B cell signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
148 
 
The relative absence of an immune signature in the tumours of low malignant 
potential likely reflects the behaviour of these tumours.  Tending to remain confined 
to the ovary and not invading in a tissue destructive way, one could envisage that 




Figure 4.24.   The non-immune stromal clusters shown with the rest of the network graph 
hidden. (Central panel)  The mean expression pattern of the clusters are given in the 
surrounding panel with colours of the expression plots corresponding to the cluster colours.  





The non-immune stromal signatures consist of extracellular matrix which breaks into 
two closely related clusters, two endothelial clusters and an adipocyte signature 
(Figure 4.24).  The main ECM signature consisting of 323 probesets to 180 genes 
shows lower expression in LMP tumours and higher but more variable expression in 
serous tumour with more consistently high expression in those serous tumours of 
primary peritoneal origin (right side of serous group in figure 4.24).  This would be 
predicted given the increased likelihood of sampling of subperitoneal fibrous 
tissue/abdominal wall in these tumours.   The cluster contains multiple collagens 
(COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, COL6A2, COL6A3, COL8A1, 
COL10A1, COL11A1, COL16A1), and other structural proteins caldesom1, 
calponin2, fibrillin 1, laminin alpha 4, and tropomyosin.  There are modifiers of the 
extracellular matrix (ADAM12, ADMATS12, AMADTSL1, MMP2, MMP11, 
TIMP2, TIMP3) as well as some growth factors and growth factor receptors (FGF1, 
TGFBR2, PDGFRB).  Elements of the vascular signature are included in this cluster 
implying that expression of these genes is related to expression of the ECM genes.  
These include cerebral endothelial cell adhesion molecule (CERCAM), podoplanin, 
(PDPN) and vascular cell adhesion molecule 1 (VCAM1). See table 4.25 for selected 
functional annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Extracellular matrix 9.3 x10
-28
 










Ensemble of genes 





Table 4.25 Functional annotation for the extracellular matrix signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The smaller ECM signature (bright green in figure 4.24) (22 probesets and 16 genes) 
shows low expression in most cases but slightly higher expression in those serous 
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tumours not of primary ovarian origin.  This contains mostly collagen 6 components 
(COL6A1, COL6A2, COL6A6 AND COL29A1) and some modifiers of the ECM 
(AMADTS14, ADAMTS2, MMP13). See table 4.26 for selected functional 
annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  










Table 4.26 Functional annotation for the smaller ECM signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The larger of the two small endothelial clusters (green in figure 4.24) (8 probesets 
and 7 genes) shows consistently lower expression in LMP tumours but is variable 
across the remaining dataset.  This contains markers of endothelium such as CD248 
(endosialin), CDH5, endothelial cell adhesion molecule (ESAM), and von 
Willebrand factor (VWF).  See table 4.27 for selected functional annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA GOTERM Angiogenesis 1.4 x10
-6
 










Table 4.27 Functional annotation for the endothelial signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 




The smaller endothelial cluster (black in figure 4.24) (8 probesets and 4 genes) has a 
much spikier pattern, being expressed only in subsets of tumours and includes 
angiopoetin 2 (ANGPT2), endothelial cell-specific molecule (ESM1), and vascular 
endothelial growth factor receptor (FLT1).  The cluster is too small to derive 
meaningful annotation from using GSEA and DAVID but from the known function 
of the genes is clearly involved in angiogenesis. 
 
 
The adipocyte signature (22 probesets and 14 genes) has a spikey profile with many 
tumours essentially lacking this signature (Figure 4.24).  Those of primary peritoneal 
origin are more consistently positive likely reflecting sampling of normal adipose 
tissue underlying the peritoneum.    These genes present include CD36, adiponectin 
(ADIPOQ), adipocyte fatty acid binding protein (FABP4) and TIMP4.  See table 
4.28 for selected functional annotation.   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  




















Table 4.28 Functional annotation for the adipocyte signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 









4.6.2 Cell cycle signatures 
The cell cycle signatures lie within the main part of the graph, but separate from the 
stromal signatures.  As in other tumours there are clusters that represent the mitotic 
phase of the cell cycle and other related clusters (Figure 4.25).  The cluster 
representing the mitotic phase is the largest cell cycle cluster formed of 162 
probesets representing 108 genes (represented in black in figure 4.25).  As would be 
expected, expression of this signature is low in the tumours of low malignant 
potential, characterised as they are histological by little visible mitotic activity.  The 
frankly malignant tumours of any subtype show high expression of this signature.  
The cell cycle and related clusters separate into two main areas, the largest cluster 
forming the first area and a second area containing several smaller clusters.  As 
illustrated in figure 4.25 these clusters also show a lower expression in the LMP 
tumours but to a much lesser degree.  
The main cell cycle cluster contains aurora kinases A and B (AURKA, AURKB), 
cyclins A2, B1 and B2, (CCNA2, CCNB1, CCNB2), the cell cycle division genes 
CDC2, CDC25C, CDC6, CDCA2, CDCA3, CDCA5 and multiple genes for 
centromeric proteins (CENPQ, CENPE, CENPF, CENPI, CENPL, CENPM).  There 
are multiple kinesin family members (KIF11, KIF14, KIF15, KIF18A, KIF18B, 
KIF20A, KIF23, KIF2C, KIF4A) and genes involved in DNA replication and repair 
including  DNA polymerase (POLQ), DNA topoisomerase (TOP2A), exonuclease 
(EXO1) and an excision repair associated gene (ERCC6L).   Analysis using DAVID 
and GSEA confirms the enrichment of this cluster for genes involved in the M phase 
of the cell cycle (Table 4.29). 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT M phase 1.1 x10
-58
 




Genes showing cell 





Table 4.29 Functional annotation for the cell cycle signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 




Figure 4.25.  The cell cycle-related area of the graph consists of two main groups of clusters.  
Only selected expression profiles are illustrated for clarity.  In the larger cluster area (top of 
central panel) there are clusters in which expression in markedly lower in LMP tumours (top 
panel).  The second set of clusters also show lower expression in LMP tumours but the 
difference between subtypes is less marked (bottom panel). 
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The next largest cluster (blue in figure 4.25) containing  25  probesets and 19 genes 
lies in the second cell cycle area of the graph and contains several transcription 
factors (AHCTF1, SP1) and  other  genes  that may be involved in transcription and 
RNA binding (AFF4, EWSR1, DHX, HNRNPU, ZFR).   No highly significant 
annotation is associated with this cluster but that identified suggests a role in 
transcription (Table 4.30). 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS RNA binding 1.3 x10
-3
 




Table 4.30 Functional annotation for the cell cycle/transcription signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The rest of the cell cycle related clusters break into multiple small clusters none 
larger than 11 probesets and which contain such genes as CHEK1, DNA polymerase 
(POLE2),  and cyclin E2.  
 
4.6.3 Other signatures 
 
As well as the cell cycle clusters there were many others clusters that separated 
tumours of low malignant potential from those of frank malignancy.  As this was not 
the focus of the analysis these were not explored further.  In addition, in this dataset 
as in all the others clusters representing histones, ribosomes, haemogloblin, 





4.7  Gene signatures from colorectal cancer 
The colorectal dataset contained 155 cases of colorectal carcinoma derived from an 
Australian population, divided into microsatellite stable and unstable tumours. One 
hundred and fifty of these passed the QC stage and were used in subsequent analysis.  
This was the dataset with the least clinical annotation with no information available 
as to grade or stage.  The colorectal dataset when laid out at r ≥ 0.65 gives a graph of 
22,687 nodes joined by 725,467 edges (Figure 4.26).  One pole of the graph contains 
cell cycle genes, while immune genes lie within the main area of the graph.  As 
would be predicted from histological appearances, the immune associated genes are 
present at higher level in microsatellite instable tumours, which are characterised 
histologically by a greater number of tumour infiltrating lymphocytes.  In this dataset 
unlike many of the others the immune/inflammatory signatures contained a 
neutrophil signature reflecting the frequently high number of neutrophils seen in 
colorectal cancer in contrast to most other tumour types.    An extracellular matrix 
cluster and endothelial cluster lie fairly centrally within the graph.  Also present 
within this graph are “spiked” clusters where expression of the genes in the cluster is 
seen in only a few cases.  These include a cluster of adipocyte related genes.  In this 
dataset, as in other non-sex specific tumours, there are clusters of genes expressed 





Figure 4.26.  The colorectal cancer dataset when laid out at r≥0.65 with nodes hidden  and 
only edges visible.  The separate large cluster at 11 o’clock is of house-keeping genes.  The 




4.7.1 Stromal  signatures 
There is an area of graph lying centrally in which both immune and non-immune 
stromal elements lie.  The immune clusters lie close together and the non-immune 
stromal elements form a separate group of clusters.  The immune signatures consist 
of one large cluster which contains macrophage and T cell signatures with small 
clusters surrounding this representing plasma cells, IFN response, MHC I and other 
clearly immune signatures that are none the less difficult to characterise further 
(Figure 4.27).  As would be predicted based on the histology, these immune 
signatures tended to be higher is MSI tumours.  In the absence of other annotation no 
comment can be made on the clinical features of much of the graph.   
 
The large macrophage and T cell cluster consists of 699 probesets to 458 genes.    
This contains markers of monocytic differentiation such as CD14, CD163, and 
CSF1R as well as markers of T cell differentiation such as CD3, and elements of the 
T cell receptor complex.  Both CD4 and CD8 are represented suggesting that the 
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cluster represents all subsets of T cells.   The cluster contains multiple toll-like 
receptors (TLR1, TLR7, TLR8), cathepsins (CTSC, CTSO, CTSW), and granzymes 
(GZMA, GZMH, GZMK, GZMM).   There are multiple MHC class II molecules 
(HLA-DMB, HLA-DOA, HLA-DPA1, HLA-DPB2, HLA-DQA1, HLA-DQB1, 
HLA-DRA, HLA-DRB1, HLA-DRB5) as well as CD74, the MHC class II invariant 
chain.   Chemokines, cytokines, interleukins and their receptors are represented 
(CCL18, CCL4, CCL5, CCR1, CCR2, CCR5, CXCL13, CXCL9, CXCR6, IL16, 
IL10RA, IL18RAP, IL21R, IL23A, IL2RA, IL2RB, IL7R).  Macrophage scavenger 
receptors are represented (MARCO, MRC1), as are apoliproteins (APOC1, APOE).   
Analysis using DAVID and GSEA confirms the enrichment for macrophage and T 
cell genes (Table 4.31).   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Defense response 2.0 x10
-31
 
DAVID GOTERM_BP_FAT Leukocyte activation 2.5x10
-24
 
DAVID GOTERM_BP_FAT Chemotaxis 6.2x10
-11
 
DAVID GOTERM_BP_FAT Phagocytosis 3.1x10
-6
 










Table 4.31 Functional annotation for the macrophage/T cell signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 





Figure 4.27.    The immune clusters with the rest of the graph hidden.  Top and bottom panel 
show mean expression profile of each cluster.    The colours of the cluster correspond to the 
colours given in the expression plots.   IFN response and macrophage/T cell in top panels, 
MHC class I in bottom left and other less well characterised immune cluster, bottom right.  
 
 
The IFN response breaks into several clusters the largest of which (seen in figure 4 
25 in green) is of 176 probesets and 121 genes (Figure 4.27).  This cluster contains 
many interferon regulatory factors and interferon induced genes (IFI16, IFI35, IFI44, 
IFI44L, IFI6, IFIT1, IFIT2, IFIT3, IFIT5, IRF1, IRF7).  Multiple components of the 
proteasome are present as well as elements of the antigen presentation machinery 
(CD74, MICB, TAPBP, TAP1, TAP2, PSMB9, PSMB10, PSME1, PSME2, HLA-E, 
HLA-DMA, HLA-DPA1, HLA-DRB1, HLA-DRB4).  Selected functional annotation 





Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT 








Genes upregulated in 
fibroblasts after culture 





Genes modulated in 
the blood of patients 






Table 4.32 Functional annotation for the interferon response signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
There is a plasma cell cluster containing 131 probesets and 67 genes.  This contains 
mainly immunoglobulin genes which make up 17 of the 67 genes as well as markers 
of B cell/plasma cell differentiation CD79A, IRF4 and TNFRSF17.  See table 4.33 
for selected functional annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Immunoglobulin 4.5 x10
-17
 




in comparison of 
healthy T cell with 





Table 4.33 Functional annotation for the plasma cell signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
 
A small cluster of 85 probesets and 61 genes appears to represent a neutrophil 
signature.  This signature is absent in the other datasets representing the paucity of 
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neutrophils in the inflammatory infiltrate associated with most established tumours.   
This contains the granulocyte CSF receptor (CSF3R) as well as the low affinity 
granulocyte-macrophage receptor (CSF2RB).  There are the Fc receptors CD32 and 
CD16 (FCGR2A, FCGR2C, FCGR3B) as well as the chemotactic receptors C5AR1, 
FPR1, FPR2, and FPR3.  See table 4.34 for selected functional annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Defense response 1.5 x10
-10
 




in comparison of naive 







Table 4.34 Functional annotation for the neutrophil signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
   
A small B cell cluster of 62 probesets to 41 genes is also present.  This contains the B 
cell markers CD19, CD79A and MS4A1 (CD20) as well as B cell signalling 
molecules such as B lymphoid tyrosine kinase (BLK), and  B cell scaffold protein 
with ankyrin repeats 1 (BANK1).  Selected functional annotation given in table 4.35. 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS B cell activation 2.0 x10
-4
 




in comparison of 
healthy B cells with 





Table 4.35 Functional annotation for the B cell signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 






Figure 4.28.  The non-immune stromal signature clusters with the rest of the graph hidden.  
Mean expression plots for each cluster in the surrounding panels.  Colours of clusters 
correspond to colours of the expression plots.  The x-axis of the plots represent individual 
tumours.  Tumour subtypes are denoted by the coloured bars.   
 
The non-immune clusters are formed of a large cluster that encompasses most of the 
ECM and endothelial signature, plus two smaller rather ‘spiked’ clusters in which 
there has clearly been sampling of muscle and fat (Figure 4.28).  The large ECM 
cluster is of 481 probesets to 308 genes.  This contains elements of the extracellular 
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matrix, part of the smooth muscle signature and elements of the endothelial signature 
and is seen in all cases.  There is higher expression in subsets of MSI and MSS 
tumours but without further annotation the significance of this is lost.   The cluster 
contains numerous structural proteins including collagens, fibulins, laminins and 
integrins, (COL10A1, COL11A1, COL12A1, COL15A1, COL18A1, COL1A1, 
COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COL6A1, COL6A2, 
COL6A3, FBLN1, FBLN2, FBLN5, LAMA4, LAMC1, ITGA11, ITGA5).  There 
are modifiers of the extracellular matrix including ADAM metallopeptidases, matrix 
metallopeptidases and TIMP metallopeptidase inhibitors (ADAM12, ADAMTS12, 
ADAMST2, ADAMTS5, MMP2, MMP16, TIMP2, TIMP3).  Growth factors and 
receptors are represented including connective tissue growth factor and platelet 
derived growth factor receptor (CTGF, PDGRFA, PDGFRB).  There is a vascular 
signature contained within this cluster also implying tight association between the 
vasculature and the extracellular matrix.  This includes the endothelial markers CD34 
and CD31 (PECAM1), as well as angiopoetin 2 and similar molecules (ANGPT2, 
ANGPTL2, AMOTLO1), vascular endothelial cadherin (CDH5), endomucin, 
endothelial cell-specific molecule, and podoplanin (EMCN, ESM1, PDPN).  
Enrichment analysis confirms the cluster to be enriched in ECM and endothelial 
genes (Table 4.36).  
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_CC_FAT Extracellular matrix 1.7 x10
-43
 









Table 4.36 Functional annotation for the ECM signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
The adipocyte cluster is of 388 probesets representing 262 genes.  This has a spiked 
profile with expression being seen only in a subset of cases and presumed to 
represent sampling of the tumour where it has breached muscularis propria and is 
invading into fat outwith the bowel wall (Figure 4.28).  The cluster contains 
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adipocyte expressed genes CD36, leptin, hormone sensitive lipase, lipoprotein lipase, 
and insulin-like growth factor 1 (CD36, LEP, LIPE, LPL, IGF1).  There are 
numerous genes involved in lipid transport and metabolism (GM2A, GULP1, 
AKR1C1, CIDEA, CLU, GPIHBP1, DGAT2, GPAM).    Enrichment analysis 
confirms the enrichment for adipocytic genes (Table 4.37). 
 














Genes upregulated in 
cultured stem cells 
from adipose tissue vs 
freshly isolated cells 
2.5x10
-31 




Table 4.37 Functional annotation for the adipocyte signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
 
The muscle cluster is 194 probesets to 137 genes.  This also has a rather spiky profile 
but is present in a higher number of cases than the adipocyte genes, again most likely 
reflecting the method of sampling the tumour, in this case presumably including 
muscularis propria (Figure 4.28).  This contains myosin light and heavy chains, 
actins and desmin (MYH11, MYL9ACTC1, ACTG2, DES) as well as many other 
muscle associated genes such as calponin 1, leiomodulin, myocardin, nicotinic 
cholinergic receptor, tropomyosin, vinculin (CNN1, LMOD1, MYOCD, CHRNA3, 
TPM2, VCL). Analysis demonstrates enrichment for genes associated with 
contractile fibres and the sarcomere (Table 4.38).     
Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA REACTOME Muscle contraction 1.9 x10
-14 
DAVID GOTERM_CC_FAT Contractile fibre 5.2x10
-12 






Table 4.38 Functional annotation for the muscle signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
4.7.2 Cell cycle signatures 
The cell cycle clusters were dominated by one large cluster of 822 probesets 
containing 648 genes.  This showed a distinctive expression pattern (top panel figure 
4.29) but in the absence of clinical annotation this is difficult to interpret, although it 
is tempting to speculate that the higher peaks represent the higher grade tumours.  
There are several smaller associated clusters with less distinctive patterns of gene 
expression (one cluster for illustration (cluster 26), bottom panel figure 4.29).  The 
remaining clusters are all small, containing less than 20 probesets per cluster and are 







Figure 4.29.  The cell cycle related clusters with the rest of the graph hidden.  Expression 
plots for two selected clusters shown.  Colours in clusters correspond to colours of 
expression plots. Individual tumours are represented along the x-axis in the expression plots 
with the coloured bars representing tumour subtype.   
 
The largest cluster (pale blue in figure 4.29)  appears to represent transcriptional and 
translational activity with multiple RNA binding proteins represented in the gene list 
including RNA binding motif proteins, eukaryotic translation initiation factors, 
heterogenous nuclear riboproteins, splicing factors and poly(A) polymerases 
(RBM14, RBM15, RBM17, RBM33, RBM34, RBM47, RBM9, EIF3J, EIF4E, 
EIF4EBP2, EIF4G1, EIF5, HNRNPC, HNRNPM, HNRNPU, HNRNPUL2, 
HNRNPDL, SFRS1, SFRS2, SFRS5, PAPOLA, PAPOLG) as well as genes 
involved in protein transport (ARF1, ARF6, RAB14, RAB18, RAB1A, AP1G1, 
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AP1S3, AP3B1, AP3D1, EXO5, EXO6, GOPC, GGA2, IPO11, IPO8, NUP133, 
TNPO2).  See table 4.39 for selected functional annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Protein transport 7.6 x10
-13 
DAVID SP_PIR_KEYWORDS RNA binding 3.0x10
-13 




Table 4.39 Functional annotation for the cell cycle transcription/translation signature using 
the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
Cluster 26 (red in figure 4.29) contains 76 probesets to 67 genes.  This, along with 
several of the smaller clusters appears to represent the mitotic phase of the cell cycle 
containing several cyclins, kinesin family members, helicase, and centrosomal and 
centromere proteins (CCNA2, CCNB1, CCNB2, KIF18A, KIF23, KIF2C, HELLS, 
CENPE, CEP55).  Enrichment analysis confirms this enrichment for mitotic phase 
genes (Table 4.40).   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT M phase 3.3 x10
-25 
DAVID SP_PIR_KEYWORDS Cell division 1.4x10
-26 
 
Table 4.40 Functional annotation for the cell cycle mitotic phase signature (cluster 26) using 
the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 






4.8  Gene signatures from glioma 
The glioma data set contained 271 tumours of which 253 passed the QC step, and 
which were stratified on the basis of histological type (astrocytoma, 
oligodendroglioma, glioblastoma), WHO grade and sex.   The glioma dataset when 
laid out at r = 0.7 forms a network of 23,015 nodes joined by 623,591 edges in which 
the immune genes lie together (Figure 4.30).  These tend to be higher in glioblastoma 
and lower in oligodendrogliomas.  There are also multiple clusters formed of brain-
specific genes, not seen in any other datasets and identified as brains specific from 
comparison with tissue atlases.  As would be expected from the higher mitotic rate 
which forms part of the classification of glioblastoma, the cluster of cell cycle genes 
are expressed at the highest levels in this tumour, and as in other tumours the cell 
cycle and cell cycle related cluster fall in one area of the graph.    
 
Figure 4.30.  Glioma graph laid out at r≥0.7 with nodes hidden and only edges illustrated.   
 
 
4.8.1 Stromal signatures 
The immune clusters group together in one area of the graph.  The largest cluster is 
enriched in macrophage genes and lies close to but separate from a cluster enriched 
in IFN associated genes (Fgiure 4.31).  There is a small B cell signature with a rather 
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spiked profile in astrocytomas and glioblastomas but absent from 
oligodendrogliomas.  Several other small clusters with spiked profiles are enriched in 
genes of broadly immune function but which cannot be further characterised.   
 
 
Figure 4.31.  The immune clusters with the rest of the graph hidden. Mean expression plots 
for the clusters are given in the surrounding panels. Colours of clusters correspond to the 
colours of expression plots.    Individual tumours are represented along the x-axis of the 
expression plots with coloured bars representing tumour types.   
 
 
The largest cluster contains macrophage and T cell genes and consists of 513 
probesets to 346 genes.  It contains macrophage markers such as CD14, CD68, 
CD163 and CSF1R.  There are multiple components of the class II antigen 
processing and presentation pathway with CD74, the class II invariant chain being 
present as well as multiple MCH class II genes and the class II transactivator (HLA-
DMA, HLA-DMB, HLA-DOA, HLA-DPA,1 HLA-DPB1, HLA-DRA, HLA-DRB1, 
HLA-DRB4, HLA-DRB5, HLA-DRB6, CIITA).  There are multiple toll-like 
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receptors (TLR1, TLR2, TLR5, TLR7, TLR8) as well as some macrophage 
scavenger receptor and apolipoprotein receptor (MSR1, APOB48R).  Multiple Fc 
receptors are included in the cluster (FCER1G, FCGR1A, FCGR1C, FCGR2A, 
FCGR2B, FCGR2C, FCGRB3).  Cytokines, and their receptors are represented 
(CCR1, IL10RA, IL12RB1, IL12RA1, IL17RA, IL18, IL21R, IL4R).  There are 
complement receptors (C3A1, C5A1) as well as three chains of the C1q molecule 
(C1QA, C1QB, C1QC).  There are several genes associated with the lysosome 
present (CTSB, CTSC, CTSD, CTSS, CTSZ, NAGA, IFI30, LGMN, LAPTM5, 
MAN2B1, MANBA, PLA2G15, SRGN, SLC15A3, STXBP2, ZNRF2).  The 
enrichment for genes associated with immune response is confirmed on enrichment 
analysis (Table 4.41).   
Analysis tool Source of annotation Annotation Significance 
(p-value)  

















Table 4.41 Functional annotation for the macrophage signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values.   
 
A rather spiked cluster (purple in fig 4.31) is enriched in genes for T cells as well as 
containing some vascular genes.  This contains 190 probesets representing 136 genes 
and appears to represent a cytotoxic T cell signature containing CD8, the cytotoxic 
granules granzymes A, B, H and K.  ZAP70 is present but the other elements of the 
TCR signalling pathway are not seen.  There is a vascular signature including CD34, 
PECAM1 (CD31), vascular endothelial cadherin,  endomucin, endothelial cell-
specific chemotaxis regulator,  selectin P and thrombospondin 1 ( CD34, PECAM1, 
CDH5, EMCN, ECSCR, SELP, THBS1).  This close association between elements 
of the vascular signature and the T cell signature is not seen in other datasets and 
may represent an association unique to primary CNS tumours, but is more likely to 
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represent the skewing effect seen due to this expression pattern being seen in only a 
few tumours and therefore showing a distinctive gene expression profile.  See table 
4.42 for selected functional annotation.   
  







DAVID SP_PIR_KEYWORDS T cell  3.2x10
-8 




Table 4.42 Functional annotation for the T cell/vasculature signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values.   
 
The interferon response cluster as in other datasets is closely associated with the 
macrophage cluster.  This contains 123 probesets to 75 genes and is enriched in 
interferon induced proteins and regulatory factors (IFI27, IFI35, IFI44, IFI44L, IFI6, 
IFIH1, IFIT1, IFIT2, IFIT3, IRF1, IRF7, IRF9).   The class I MHC molecules are 
represented as well as components of the proteasome and TAP transporters (B2M, 
HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, PSMB8, PSMB9, PSME1, 
PSME2, TAP1, TAPBP).  Enrichment analysis confirms the cluster to be enriched 













Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Immune response 1.1 x10
-14 
DAVID GOTERM_BP_FAT 





Genes modulated in 
the blood of patients 








Genes upregulated in 
primary fibroblast 
culture after treatment 





Table 4.43 Functional annotation for the interferon response signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
 
The small B cell cluster consists of 80 probesets to 39 genes.  In this cluster, most of 
the genes with identified function encode immunoglobulin genes, with other 
elements of the B cell signature seen in other tumours largely absent.  The 
informative genes that are present however include POU2AF1, which encodes the B 
cell transcription factor BOB-1 and TNFRSF17 encoding CD269, a marker of 
mature B cells.   
 
There are several clusters representing the extracellular matrix.  With the exception 
of the one ‘spiked’ cluster, these tend to show higher levels of expression in 






Figure 4.32.  The non-immune stromal clusters with the rest of the graph hidden.  Mean 
expression plots for selected clusters given in the surrounding panels.  Colours of clusters 
correspond to colours of expression plots.   Individual tumours represented along x-axis of 
expression plots with tumour types denoted by coloured bars.    
 
 
The largest ECM cluster (blue in figure 4.32) is driven by expression in only a very 
small number of tumours.  This contains 221 probesets representing 136 genes.   The 
genes making up this cluster contain fewer collagens than seen in the ECM signature 
in most tumours reflecting the unique structure of the brain but contains extracellular 
proteins such as bone morphogenic protein 5, type 1 cadherin, cortexin 3, democollin 
3, desmoglein 2, elastin, fibrillin 1 and 2, matrilin 3, and proteoglycan 4 (BMP5, 
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CHD1, DSC3, DSG2, ELN, FBN1, FBN2, MATN3, PRG4).    See table 4.44 for 
selected functional annotation. 
Analysis tool Source of annotation Annotation Significance 
(p-value)  















Table 4.44 Functional annotation for the ECM signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA (Blue cluster in figure).  Selected 




The next largest ECM cluster shows expression in the majority of tumours (purple in 
figure 4.32).  Expression is lowest in the oligodendrogliomas, a pattern seen with 
several of the ECM clusters.    This cluster is of 168 probesets to 124 genes.   This 
again shows a less obvious ECM signature than that seen in other tumours and 
indeed it is only recognisable as such by comparison with ECM signatures derived 
from other analyses.   This cluster contains among others caldesmon 1, chondroitin 
sulphate synthase, fibronectin 1, myosin light and heavy chains, myoferlin, transgelin 
and vimentin (CALD1, CHSY1, FN1, MYH9, MYL12A, MYL12B, MYOF, 
TAGLN2, VIM).   
 
 
The next largest cluster is of 75 genes represented by 112 probesets.  This is also 
shows higher expression in GBM than other tumours.  There is more obvious 
enrichment for extracellular proteins in this cluster with multiple collagens 
represented as well as caldesmon1, fibrillin1, several laminins, and tropomyosins 
(COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, COL18A1, CALD1, FBN1, 
LAMA3, LAMC1, TPM1, TPM2).  There are modifiers of the extracellular matrix 
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including ADAM metallopeptidases (ADAM12, ADAMTS12, ADAMTS2) and 
MMP14.    Enrichment of this cluster for ECM genes is confirmed on analysis with 
DAVID and GSEA (Table 4.45).   
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Extracellular matrix 9.5 x10
-19 









Table 4.45 Functional annotation for the smaller ECM signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
Lying adjacent to this is a small cluster of 28 probesets and 16 genes that appears to 
represent a vascular signature.  This includes collagen 4, notch 3, angiopoetin 2 and 
the endothelial specific molecule (COL4A1, COL4A2, NOTCH3, ANGPT2,  
ESM1).  This signature is higher in GBM than the other tumours, as would be 
predicted based on histology, these tumours being characterised by abundant neo-
vascularisation.   Despite the small number of genes present, analysis for enrichment 
demonstrates enrichment for genes associated with angiogenesis (Table 4.46).   
 







GSEA ROY_WOUND_BLOOD VESSEL 
Genes upregulated in 





Table 4.46 Functional annotation for the vascular signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 




4.8.2 Cell cycle signatures 
 
The cell cycle signatures fall in one area of the graph although individual clusters are 
not particularly tightly related (Figure 4.33).  Most of the cell cycle and cell cycle 
related signatures show higher expression in GBM reflecting the aggressive nature of 
that tumour. 
 
The largest cluster (green on the left side of figure 4.32) appears to represent the 
mitotic phase of the cell cycle.  This consists of 379 probesets to 260 genes.  The 
cluster contains both A and B aurora kinases, multiple units of DNA polymerases 
and topoisomerases (AURKA, AURKB, POLA2, POLD3, POLE, POLE2, POLQ, 
TPO2A, TOPB1).  There are multiple cyclins and kinesins (CCNA2, CCNB1, 
CCNB2, CCNF, KIF11, KIF14, KIF15, KIF18A, KIF18B, KIF20A, KIF22, KIF23, 
KIF2C, KIF4A, KIFC1).  There are also many cell cycle division associated genes 
and centromere proteins (CDC6, CDC7, CDCA2, CDCA3, CDCA4, CDCA5, 
CDCA7, CDCA8, CENPA, CENPE, CENPF, CENPH, CENPI, CENPK, CENPL, 
CENPM, CENPN, CENPO).  Enrichment analysis confirms the enrichment for genes 
associated with the mitotic phase of the cell cycle (Table 4.47).  
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Cell cycle 1.6 x10
-84 
DAVID GOTERM_BP_FAT M phase 5.4x10
-78 




Genes showing cell 





Table 4.47 Functional annotation for the cell cycle mitotic phase signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 




The next largest clusters all contain cell cycle related genes with the next 3 largest 
illustrated in figure 4.33.  One of these (illustrated in purple, bottom left of figure 
4.33) containing 45 probesets to 36 genes appears to represent 
transcription/translation being rich in RNA binding proteins, RNA polymerase, 
heterologous nuclear riboproteins and splicing factors (RBM12, RBM8A, PLOR2D, 
HNRNPA2B1, HNRNPA3P1, HNRNPAB, HNRNPR, HNRNPU, HNRPLL, 
SFRS1, SFRS2, SFRS7, SFRS9). 
 
There is a small cluster associated with these others with a rather spread out pattern 
within the graph (green cluster right hand side figure 4.33).  This consists of 24 
probesets and 20 genes.  These show no clear functional annotation when considered 
as a cluster but frequently cluster with cell cycle related genes in other datasets 
suggesting a common function.  This small cluster contains multiple units of the 





Figure 4.33.  The cell cycle-related clusters with the rest of the graph hidden.  Surrounding 
panels show mean expression profile in each cluster.  Colours of clusters correspond to 
colours in expression plots.  Individual tumours are represented along the x-axis of 
expression plots.  Coloured bars denote tumour types.   
 
 
4.8.3 Other signatures 
As in other datasets there are clusters representing ribosomes, glycolysis, oxidative 
phosphorylation, histones, haemoglobin and similar.  There are also clusters that 
appear from comparison with tissue libraries to be only expressed in the brain, as 
well as very many clusters that separate the tumour types from each other.  These are 




4.9 Gene signatures from testicular tumours 
The testicular dataset was formed of 107 samples from patients from the USA.  
Eighty six of these passed the QC step and were used in subsequent analysis.   The 
dataset was of primary germ cell tumours and was stratified first on whether the 
tumours were pure or mixed histological types and then within each category on the 
constituent parts of the tumour using the WHO classification (seminoma, teratoma, 
embyronal carcinoma, yolk sac tumor, choriocarcinoma). 
The testicular network has a very large number of edges in relation to nodes (945,082 
and 18,934 respectively) (Figure 4.34).  This reflects the complex mix of tumours in 
the dataset and specifically the inclusion of teratomas.  These tend to form tight 
structure that shows very high internal connectivity but does not show high 
connectivity to the rest of the graph and on analysis often represent signatures of 
mature (non-testicular) tissue types in keeping with the histological appearances of 
teratoma.    Because the signatures seen particularly in the teratomas are often unique 
to a single tumour, the graph structure is in part driven by ‘spiked’ signatures that 
form very tight clusters within the graph.  The graph is laid out to include a smaller 
number of nodes than other graphs, as the high number of edges and complexity of 






Figure 4.34.  The testicular tumour graph laid out at r≥0.75.  Left hand figure; only edges 
are shown to demonstrate the structure of the graph.  Right hand figure; selected clusters are 
superimposed on the underlying structure.  The immune clusters lie together at one edge of 
the graph.  Other stromal signatures are dispersed dependent on whether they are common to 
all tumours (ECM signature here) or present only in individual teratomas (smooth muscle 
cluster). 
 
4.8.4 Stromal signatures 
The immune clusters, with the exception of the mast cell signature, lie together at 
one pole of the graph and cluster tightly together (Figure 4.34).  All clusters show a 
relatively ‘spiky’ architecture reflecting the small number of tumours in the dataset.  
The macrophage signature tends to have a uniformly high expression in teratomas, 
and immune signatures all tend to be lower in yolk sac tumours but there is otherwise 
no close relationship with tumour type (Figure 4.35).  The exception to this, and the 
cluster that lies entirely separate within the main graph, is the small mast cell cluster, 
which is more frequently seen in teratomas than other tumour types and bears no 
relation to the other immune signatures.    The non-immune stromal signatures exist 
in two distinct patterns; there are those that are expressed in all tumour types and 
represent broadly the tumour stroma and vasculature and there are those that are 
discrete clusters of genes expressed in teratomas.   The generic ECM signature is 
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expressed at higher levels in teratoma-containing tumours than others, in keeping 
with the histological appearances, most types of testicular tumour having an 
inconspicuous extracellular matrix histologically.   
The largest immune cluster appears to represent a lymphocyte signature and is 
formed of 629 probesets to 428 genes (Figure 4.35).  This contains markers of T cells 
including CD2, CD3 (delta, epsilon and gamma components), CD5, CD7, CD8 (A 
and B), CD52, and markers of B cells including CD19, CD22, CD79A and CD79B 
and CD20 (MS4A1).  There are genes involved in lymphocyte activation, antigen 
recognition and immune function including the chemokines and receptors CCL21, 
CCR6, CCR7, CXCR4, CXCR5, MHC molecules including HLA-DOA, HLA-DOB, 
HLA-DQA1, HLA-DQB1, HLA-E, HLAF, CIITA, and interleukins IL15, IL16, 
IL23A along with interleukin receptors IL21R, IL2RB, IL2RG, IL4R, IL7R.  
Analysis via DAVID and GSEA confirms significant enrichment for lymphoid genes 
(Table 4.48).   
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Lymphocyte activation 7.3 x10
-35 
DAVID GOTERM_BP_FAT T cell differentiation 4.8x10
-16 
DAVID KEGG_PATHWAY 





Genes upregulated in 





Table 4.48 Functional annotation for the lymphocyte signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 






Figure 4.35.  The immune clusters with the rest of the graph hidden.  Surrounding panels 
show mean expression profile for each cluster.  Colours of clusters correspond to colours of 
expression plots.  Individual tumours are represented along the x-axis with coloured bars 
representing tumour groupings.    Mixed tumours lie to the left and pure histological types to 
the right.  (Key;  Chorio = Choriocarcinoma, EC = Embryonal carcinoma, Sem = Seminoma, 
Ter = Teratoma, YST = Yolk Sac Tumour). 
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Adjacent to this is a large macrophage cluster of 376 probesets to 256 genes (Figure 
4.35).  This contains known macrophage markers CD14, CD68, CD163, CSF1R as 
well as multiple Fc receptors (FER1G, FCGR1A, FCGR1B, FCGR2A, FCGR2C), 
and toll-like receptors 2, 4 and 8.  There are also multiple subcomponents of the C1q 
complement molecule, and the chemotaxis receptors C3AR1 and C5AR1.  There are 
the cytokines CCL3, CCL4, CXCL16 and receptors CCR1, CCR5, CXCR3.  Other 
macrophage associated genes such as allograft inflammatory factors 1 (AIF1), 
legumain (LGMN), and mannose receptor (MRC1) are also present.  Analysis 
confirms enrichment for macrophage genes (Table 4.49).   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Defense response 6.0 x10
-30 

















Table 4.49 Functional annotation for the macrophage signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The interferon response breaks into three clusters, the largest 155 probesets to 135 
genes, the second 30 probesets to 20 genes and the third 19 probesets to 17 genes.   
As in other datasets, this cluster is closely related to both the T cell and macrophage 
signatures.  The largest cluster contains genes such as interferon induced proteins 35, 
44, interferon-induced protein with tetratricopeptide repeats 2 and 3, and interferon 
regulatory factor 7.  Analysis confirms enrichment for interferon induced genes 




Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA HECKER_IFNB_TARGETS 
Genes modulated in 
the blood of patients 







Genes upregulated in 
primary fibroblasts 




GSEA REACTOME Immune system 4.6 x10
-29 
 
Table 4.50 Functional annotation for the largest cluster of interferon response signature 
using the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from GSEA gives hypergeometric distribution p-
values. 
 
There is are 3 plasma cell clusters, one of 59 probesets and 32 genes and further 
smaller clusters of 17 probesets and 10 genes and 15 probesets and 7 genes (Figure 
4.34).  These consist largely of immunoglobulin genes with 24 genes representing 
immunoglobulin loci and many others hypothetical proteins.   
 A further difficult to characterise immune cluster contains 31 probesets and 25 genes 
including the macrophage scavenger receptor MARCO, RANKL (TNFSF11), DC-
SIGN (CD209), CCL23 and CCR1.  It is difficult to identify a clear functional 
enrichment in this cluster although the signature is clearly broadly an ‘immune’ one. 
 
A mast cell cluster consists of 16 probesets to 11 genes and contains an Fc receptor 
for IgE, KIT ligand, tryptase alpha and beta components, mast cell carboxypeptidase, 
and CXCL14 (MS4A2, KITLG, TPSAB1, TPSB2, CPA3, CXCL14).  This has a 
markedly different pattern of expression than the other immune clusters and appears 
to represent part of a teratoma-associated signature rather than forming part of the 
immune response to the tumour (Figure 4.35).  Enrichment analysis, despite the 




Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA NAKAJIMA_MAST CELL 





Table 4.51 Functional annotation for the mast cell signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.   
DAVID analysis provides no informative functional annotation.  Annotation derived from  
GSEA gives hypergeometric distribution p-values. 
 
Present in this dataset but not seen in others is a small cluster representing a gamma-
delta T cell signature.  This consists of 14 probesets and 11 genes and contains the 
TCR gamma and delta chains, the cytotoxic granule components perforin 1 and 
granzymes A and H (TARP, TRD@, TRGC2, TRGV9, PRF1, GZMA, GZMH).  
This cluster also contains interferon gamma (IFNG) and CCL5.  
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Figure 4.36.  The non-immune stromal clusters with the rest of the graph hidden.  The 
surrounding panels show mean expression profiles for each cluster.  Cluster colours 
correspond to the colours of the expression plots.  Individual tumours are represented on the 
x-axis of the expression plots.  The coloured bars indicate tumour groupings.    Mixed 
tumours lie to the left and pure histological types to the right.  (Key;  Chorio = 
Choriocarcinoma, EC = Embryonal carcinoma, Sem = Seminoma, Ter = Teratoma, YST = 
Yolk Sac Tumour). 
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 The largest ECM clusters not associated with a specific teratoma, is of 77 probesets 
to 54 genes (Figure 4.36).  This contains collagens I, III, V, VI and XII as well as 
biglycan, bone morphogenic protein, laminin alpha 4, and microfibrillar-associated 
protein 4 (COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, COL6A1, COL6A2, 
COL6A3, COL12A1, BGN, BMP1, LAM4A, MFAP4).  See table 4.53 for selected 
functional annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Extracellular matrix 4.4 x10
-18 
GSEA STANFORD_TUMOUR _MODULES ECM and collagens 1.7x10
-46 
GSEA NABA_CORE_MATRISOME 





Table 4.53 Functional annotation for the ECM signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
There are two further small ECM clusters one of 29 probesets and 23 genes and one 
of 16 probesets to 14 genes (Figure 4.36).   These contain genes such as fibulin 1, 
layilin, matrix remodelling associated 7, and TIMP2  (FBLN1, LAYN, MXRA7, 
TIMP2).  These 3 ECM clusters show closely associated patterns of expression 
tending to be higher in tumours containing teratomatous elements.   
There is a small endothelial cluster of 31 probesets to 25 genes.   This has a similar 
profile to the generic ECM signature also tending to be higher in tumours with a 
teratomatous element (Figure 4.36).  The cluster contains endosialin (CD248), 
endothelial cell specific chemotaxis regulator (ECSCR), endomucin (EMCN),  CD31 




4.8.5 Cell cycle related signatures 
In comparison with other datasets, the cell cycle cluster is smaller and rather more 
diffuse with much less obvious patterns between tumour types than in other datasets 
(Figure 4.37).  In part this is likely to reflect the makeup of the dataset with the 
unique profiles in teratoma providing much highly correlated data forming complex 
structure within the graph and requiring a higher correlation threshold to be set to 
generate a visualisable graph than in other tumour types.  Less highly correlated data, 
as much of this might be being driven by a variety of influences, has likely been lost 
from this dataset due to the limitation of the software.  
 
The largest cell cycle signature (96 probesets, 87 genes) contains genes such as 
several general transcription factors (GTF2I, GTF3C2), mitogen activated protein 
kinases (MAPK1, MAP3K2, MAPK1IP1L), DNA polymerase interacting protein 
(POLDIP3) and retinoblastoma binding protein (RBBP9).  Enrichment analysis 
identifies the cluster as being enriched in nuclear genes, genes involved in RNA 
binding and the cell cycle, but these enrichments are not highly significant (Table 
4.53).   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_CC_FAT Nuclear lumen 5.0 x10
-7 
DAVID GOTERM_MF_FAT RNA binding 2.5x10
-4 
DAVID GOTERM_BP_FAT M phase 5.4 x10
-3 
 
Table 4.53 Functional annotation for the largest cell cycle cluster using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 




Figure 4.37.  The cell cycle-related clusters with the rest of the graph hidden.  Surrounding 
panel show mean expression profile for each cluster.  The cluster colours correspond to the 
colours in the expression plots.  Individual tumours are represented along the x-axis.  
Coloured bar denotes tumour groupings.    Mixed tumours lie to the left and pure histological 
types to the right.  (Key;  Chorio = Choriocarcinoma, EC = Embryonal carcinoma, Sem = 




The next cell cycle signature (45 probesets, 42 genes) appears from enrichment 
analysis to be translation related containing genes associated with protein transport, 
mRNA processing and the endoplasmic reticulum (RAB5A, SEC23B, COPA, 
EXOC5, EXOC6, NUP133, STX16, XRN2, DHX35, CPSF2, PAPOLA, LASS6, 
PSEN1, SPTLC1, TMX1).  Again these enrichments are not highly significant 
(Table 4.54).   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Protein transport 4.0 x10
-5 








Table 4.54 Functional annotation for the cell cycle translation related signature using the 
DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
Another small cluster of 31 genes appears to relate to DNA damage response 
pathways containing tumour protein p53 plus BRAC1 interacting protein, RAD21 
homolog, and structural maintenance of chromosomes 3  (TP53, BRIP1, RAD21, 
SMC3). 
There are only two small clusters that appear to represent the mitotic phase of the cell 
cycle (one of 17 and the other of 16 genes).  These show a distinctive pattern of 
expression being much lower in teratomas compared to all other types of tumours as 
would be predicted from the histological appearances and clinical behaviour of the 






4.8.6 Other signatures 
The inherent complexity and variability of the graph demonstrates many signatures 
not seen in other datasets.  Many of these, which appear to represent differentiated 
tissues are contributed by teratomas and include a skin signature, a neural tissue 
signature, a pancreas signature, a cartilage signature and a skeletal muscle signature.  
A liver signature is present in yolk sac tumours and there are three distinct but 
similar signatures of placenta, one of which represents chorionic somatotrophin, 
which are seen in choriocarcinoma-containing tumours.   Many of the other 
signatures seen repeatedly in the datasets such as the housekeeping clusters, 
ribosomes, haemoglobin etc are also present.     
 
The largest cluster in the graph (1349 probesets to 1051 genes), a position normally 
represented by a house-keeping cluster, represents testis specific genes, possibly 
reflecting the fact that the normal underlying gene expression profiles of testicular 
tissue has little in common with somatic tissues.   Much of the cluster appears to 
related to spermatogenesis and contains such genes as the spermatogenesis 
associated genes 1, 3, 4, 6, 8, 9, 12, 16, 18, 20 and 22, sperm associated antigens 3, 6, 
16 and 17, gametogenin, primary ciliary dyskinesia protein 1, outer dense fibre of 
sperm tails 1, 2 and 3-like, testis specific serine kinases 2, 4 and 6, and zona pellucid 
binding proteins (SPATA1, SPATA3, SPATA4, SPATA6, SPATA8, SPATA9, 
SPATA12, SPATA16, SPATA18, SPATA20, SPATA22, SPACA3, 
SPACA6,SPACA16, SPACA17, GGN, hCG_17324, ODF1, ODF2, ODF3L1, 
TSSK2, TSSK4, TSSK6, ZNBP, ZNBP2).  Enrichment analysis confirms the 
enrichment for testis specific genes and genes involved in spermatogenesis (Table 







Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Sexual reproduction 1.9 x10
-58 
DAVID GOTERM_BP_FAT Spermatogenesis 1.4x10
-56 
DAVID GOTERM_CC_FAT Cilium 1.6 x10
-11
 










Table 4.55 Functional annotation for the testis specific signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The skeletal muscle cluster is of 519 probesets to 370 genes and contains genes 
including skeletal muscle actin, muscle creatine kinase, desmin, myoglobin, myocyte 
enhancer factor 2C, myosin binding protein C fast and slow types, multiple myosin 
light and heavy chains, myomesin family members, myotilin, myozenin 1 and 2, 
myopalladin, troponins and tropomyosins (ACTA1, CKM, DES, MB, MEF2C, 
MYBPC1, MYBPC2, MYH1, MYH2, MYH3, MYH4, MYH7, MYH8, MYL1, 
MYL2, MYL3, MYL5, MYL10, MYOD1, MYOD2, MYOD3, MYOT, MYOZ1, 
MYOZ2, MYPN, TNNC1, TNNC2, TNNI1, TNNI2, TNNT1, TNNT3, TPM1, 









Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Muscle contraction 2.9 x10
-45 
DAVID GOTERM_CC_FAT Sarcomere 2.5x10
-60 




Table 4.56 Functional annotation for the skeletal muscle signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
 
The neural tissue cluster (363 probesets, 281 genes) contains genes such as multiple 
glutamate receptors, and GABA receptors, synapsin 1 and 2, synaptic vesicle 
glycoproteins, neurotrophic tyrosine kinases, neurofilament, oligodendrocyte 
transcription factor 1 and glial fibrillary acidic protein (GRIA1, GRIA2, GRIA3, 
GRIA4, GRIK1, GRIN2A, GRM1, GRM3, GRM5, GRM7, GABBR2, GABRA1, 
GABRA2, GABRB1, GABRG1, SYN1, SYN2, SV2A, SV2C, NTRK2, NTRK3, 
NEFL, OLIG1, GFAP).  The enrichment for neural genes is confirmed on analysis. 
(Table 4.57)   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Synaptic transmission 3.7 x10
-27 
DAVID GOTERM_BP_FAT Neuron differentiation 1.1x10
-12 
 
Table 4.57 Functional annotation for the neural signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  




The skin cluster (265 probesets, 206 genes) contains multiple keratins, keratinocyte 
differentiation associated protein, dermokine, democollin 1 and 3, desmoglein 1 and 
3, epiregulin, late cornified envelope 2B and 3D and involucrin (KRT1, KRT2, 
KRT5, KRT6A, KRT6B, KRT10, KRT14, KRT15, KRT16, KRT17, KRT31, 
KRT77, KRT80, KRTDAP, DMKN, DSC1, DSC3, DSG1, DSG3, EREG, LCE2B, 
LCE3C, IVL).  The enrichment for skin associated genes is confirmed on enrichment 
analysis (Table 4.58). 











in metastases from 
malignant melanoma 






Table 4.58 Functional annotation for the skin signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
A smooth muscle signature (54 probesets, 31 genes) contains smooth muscle actin, 
smooth muscle calponin, leiomodulin, myosin light and heavy chains, myosin light 
chain kinase and tropomyosin (ACTA2, ACTG2, CNN1, LMOD1, MYH11, MYH6, 
MYL4, MHL9, MYLK, TPM1).  See table 4.59 for selected functional annotation. 
Analysis tool Source of annotation Annotation Significance 
(p-value)  











Table 4.59 Functional annotation for the smooth muscle signature using the DAVID 
functional annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given 
only.  Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
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A cartilage signature (52 probesets, 34 genes) is seen in several tumours containing a 
teratomatous component consistent with the frequent occurrence of areas of 
cartilaginous differentiation in teratomas (Figure 4.38).  This signature includes 
collagens II, IX, XI and XXIV, chondroitin sulphate proteoglycan, aggrecan, and 
matrilin 1 cartilage matrix protein (VOL2A1, COL9A1, COL11A2, COL24A1, 
CSPG4, ACAN, MATN1).  Enrichment for cartilaginous genes is confirmed on 
analysis via DAVID (Table 4.60). 







DAVID GOTERM_BP_FAT Cartilage development 3.7x10
-6 
 
Table 4.60 Functional annotation for the cartilage signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values. 
 
Figure 4.38.  The genes in the cartilage cluster are expressed in only a few tumours all with 
a teratomatous component.  Mean expression profile of genes forming cartilage cluster.  
Individual tumours are represented on the x-axis with the coloured bars denoting tumour 
groupings.   Mixed tumours lie to the left and pure histological types to the right.  (Key;  
Chorio = Choriocarcinoma, EC = Embryonal carcinoma, Sem = Seminoma, Ter = Teratoma, 
YST = Yolk Sac Tumour). 
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There is a ‘liver’ signature (140 probesets, 103 genes) which is expressed in tumours 
with a yolk sac component (Figure 4.39).  This includes many of the synthetic 
products of hepatocytes including alpha-fetoprotein, albumin, multiple 
apolipoproteins, coagulation factors II and VII, fibrinogen and plasminogen (AFP, 
ALB, APOA1, APOA2, APOA4, APOB, APOC3, APOM, F2, F7, FGA, FGG, 
PLG).  This enrichment for liver specific genes is confirmed on enrichment analysis 
(Table 4.61). 
 
Figure 4.39.  The ‘liver’ signature is expressed only in tumour with a yolk sac component.  
Mean expression profile of all genes in the signature.  Individual tumours are represented on 
the x-axis with the coloured bar denoting tumour groupings.   Mixed tumours lie to the left 
and pure histological types to the right.  (Key;  Chorio = Choriocarcinoma, EC = Embryonal 
carcinoma, Sem = Seminoma, Ter = Teratoma, YST = Yolk Sac Tumour) 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
GSEA HSIAO_LIVER SPECIFIC GENES Liver selective genes 2.9 x10
-50 










Table 4.61 Functional annotation for the ‘liver’ signature using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 
hypergeometric distribution p-values. 
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There are three placental clusters (155 probesets and 103 genes, 86 probesets and 63 
genes and 55 probesets to 31 genes) (Figure 4.40).  These are show expression only 
in a small number of mixed tumours that contained elements of choriocarcinoma, 
cases of pure choriocarcinoma and one case labelled pure embryonal carcinoma that 
presumably contains a component of choriocarcinoma not identified in the tissue 
selected for histological examination and classification and hence mis-classified.  
The first cluster contains genes such as ABP1 (amiloride binding protein 1, which is 
expressed at the feto-maternal interface in humans), and placental growth factor 
(PGF) and is not obviously enriched in placental specific genes simply by reading the 
gene list.  Comparison with a tissue atlas and DAVID and GSEA analysis confirms 







Figure 4.40.  Three closely related placental signatures seen in tumours with a 
choriocarcinamatous component.   These form a group three closely related clusters.  Top 
panel:  Network graph with all other clusters hidden.  Bottom panel:   Mean expression 
profile of all genes in each signature. Colours of clusters correspond to colours of expression 
plots.   Individual tumours are represented on the x-axis with the coloured bar denoting 
tumour groupings.   Mixed tumours lie to the left and pure histological types to the right.  
(Key;  Chorio = Choriocarcinoma, EC = Embryonal carcinoma, Sem = Seminoma, Ter = 
Teratoma, YST = Yolk Sac Tumour). 
 
The second placental cluster much more obviously contains placental specific genes, 
including pregnancy specific beta-1 glycoproteins 1,2,3,4,5,6,7 and 9, prolactin 
receptor, chorionic gonadotrophin beta polypeptide, placental insulin-like 4 
luteinizing hormone beta polypeptide and placenta specific 4 genes (PSG1, PSG2, 
PSG3, PSG4, PSG5, PSG7, PSG9, PRLR, CGB, INSL4, LHB, PLAC4).   The third 
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placental cluster consists of chorionic somatomammotrophin hormones and the 
closely related growth hormones (CSH1, CSH2, CSHL1, GH1, GH2). 
 













Placental cluster 2 
DAVID GOTERM_BP_FAT Female pregnancy 5.6 x10
-9 
GSEA STANFORD_TUMOUR_MODULES Placental genes 3.3 x10
-14
 








Table 4.62 Functional annotation for the placental signatures using the DAVID functional 
annotation clustering tool and MSigDB tool in GSEA.  Selected annotation given only.  
Annotation derived from DAVID gives modified Fisher Exact p-values and GSEA 











4.9 Features common to all datasets 
 
In all six primary datasets studied, the analysis method generated biologically 
believable clusters in which functional enrichment of genes could be demonstrated.  
Having validated the approach in terms of its ability to identify genes expressed in 
specific cell types and functional processes within a given dataset, further work was 
performed to assess how these signatures were preserved across the different tumour 
types studied here with the assumption being that the elements which should be in 
common between tumours of different histogenesis should either be elements 
essential to tumour growth regardless of cell of origin, i.e. genes fundamental to 
replicating cells, or representative of the less variable elements of the tumour i.e. the 
non-malignant cells within the tumour. For instance is the immune signature in 
DLBCL the same as the signature in gliomas, or is the profile of the immune 
infiltrate in different environments highly heterogeneous, such that there is little 
overlap between these signatures? Or do all tumours have conserved signatures of 
cells or functions that exist regardless of the tissue from which they arise i.e. is there 
a core common cancer transcriptome?   
 
Analysis of each tumour type’s transcriptome demonstrated the clusters generated to 
fall into two broad groups; those which contain signatures which are specific to 
origin of the tumour and those with signatures that are conserved across all or most 
datasets.  The common or conserved signatures tended to fall into the broad 
categories of stromal cell signatures, proliferation related signatures and ‘house-
keeping’ signatures.  There were clusters in every dataset which represented 
signatures of various immune cells and the interferon response.  The extracellular 
matrix and other stromal signatures including the vasculature were represented in 
every dataset and many contained other stromal signatures dependent on the make-up 
of the individual tissue sampled.  Cell-cycle and cell cycle related clusters were 
present in every dataset as were less biologically interesting clusters such as clusters 
representing ribosomes, histones, haemoglobin etc.  In all datasets there were 
preserved clusters that were designated as ‘house-keeping’ clusters in the absence of 
informative annotation of the genes involved in those clusters.  This suggested that 
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there were common ‘core’ signatures present that defined for example, the tumour 
associated macrophage, regardless of the histogenesis of the tumour.   Comparison of 
clusters between datasets to identify conserved signatures proved difficult; genes 
present in all datasets were readily identifiable but for those only in a proportion of 
datasets there was the possibility they lay immediately adjacent in the network graph 
but did not fall within the cluster, thus they may appear falsely ‘absent’ from the 
cluster when they were in effect ‘almost present’.  Individual genes could be 
analysed by this method where the exact position (or absence of the gene from the 
network graph) could be established but it was not suitable for analysis of the whole 
dataset.   To overcome these difficulties a different approach was developed which is 
presented in the next section.  
 
4.10 Gene signatures from merged datasets 
To determine to what extent the signatures seen in all tumour types were conserved, 
a method was developed that allowed merging of the data from the six datasets 
discussed above.  Normally data from different labs, run under different conditions, 
even as in this case data on the same platform, cannot be directly compared as 
technical differences affecting measured fluorescence and the effect of normalisation 
will make direct comparison of expression values impossible.   To overcome this 
problem Pearson correlations generated for analysis of individual datasets were used 
to construct a network based on mean probeset to probeset correlations.  This 
preserves the co-expression associations, which are what drive the construction of 
the transcriptome network, while overcoming the difficulties involved in attempting 
to merge values.  The inference was made that signatures which persisted when 
treated in this way represented conserved signatures as weaker correlations or tumour 
specific correlations would tend to fall below the selected correlation threshold.    
Layout of a graph derived from the mean Pearson values (r = >0.6) across the six 
different tumour types resulted in a network of 9,882 nodes connected by 134,563 
edges (Figure 4.41), a much smaller graph than those derived from individual 
tumours at this threshold. Clustering of the graph using the MCL algorithm resulted 
in 639 clusters ranging in size from 1008 to 4 nodes (minimum cluster size set to 4). 
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When analysed in this way a number of clusters were again shown to be highly 
enriched with genes associated with expression in individual cell types and/or 
associated with specific cellular functions and were annotated as such .  A full list of 





Figure 4.41 Network graph of conserved transcription signatures in cancer.  a) 3D graph 
layout with labelling of main features in the network’s topology.  A graph of 9,882 nodes 
and 184,563 edges was created at Pearson threshold r0.6.  Clustering of the graph using the 
MCL algorithm resulted in 639 clusters ranging in size from 1,008 nodes to 4 nodes.  A 
number of large clusters were shown to be highly enriched in genes associated with 
expression in individual cell types and/or associated with specific cellular functions. See 
appendix 1 for details.  b) Collapsed cluster diagram where single nodes represent a gene 
cluster and are sized according to the number of transcripts within the cluster, edges 
represent connections between members of each cluster.  Nodes representing the main 
clusters have been coloured according to functional groupings.  Blue - clusters represent 
those associated with housekeeping functions; green - clusters of genes which are directly 
involved in cell cycle progression or whose expression is in way some linked to it; pink - 
genes associated with the immune component of the tumour and yellow - other 
stromal elements.  Smaller clusters enriched with genes of known function are also shown.   
 
As predicted, the signatures identified by this approach were those that were 
observed in all or most datasets, with loss of those that were tumour-type or tumour-
tissue type-specific.  The conserved signatures consisted predominantly of the three 
categories discussed briefly above; housekeeping clusters, pathways of common 
cellular activity (i.e. cell cycle, ribosome etc), and stromal signatures.  This approach 
allows analysis of the ‘core’ of the cancer transcriptome; those signatures that are 
conserved regardless of the histogenesis of the tumour. 
 
The overall structure of the graph could be broken down into three main groupings 
which draw together clusters enriched in genes representing broadly similar 
functions. The largest grouping of genes within the graph contained four of the five 
largest clusters being comprised of between 1,101 and 254 nodes/transcripts as well 
as many other smaller clusters. Many of the genes in this area of the graph are poorly 
characterised and GO enrichment and pathway analysis was of little use in better 
defining the functional significance of the clusters. However, the majority of the 
genes in these clusters were relatively uniformly expressed across all samples in all 
datasets and were therefore designated “house-keeping” (HK) clusters.  (Cluster 3, 
containing genes that clustered together tightly in all datasets  and which appears to 
be a very well-conserved signature fell apart from the other HK clusters, but was also 




A second portion of the graph was highly enriched with genes encoding cell-cycle or 
cell-cycle related proteins. Cluster 6 (229 transcripts) of this grouping being highly 
enriched in genes associated with mitosis and are commonly found to be highly 
expressed in proliferating cells. This cluster contains multiple cyclins (CCNA2, 
CCNB1, CCNB2, CCNE2, CCNF), kinesins (KIF2C, KIF4A, KIF11, KIF14, KIF15, 
KIF18A, KIF18B, KIF20A, KIF20B, KIF22, KIF23, KIFC1) and minichromosome 
maintenance complex components (MCM2, MCM3, MCM4, MCM5, MCM6, 
MCM7, MCM10). There is also expression of members of the E2F transcription 
factor family (E2F1, E2F8), DNA polymerases (DNA2, POLA2, POLE, POLE2, 
POLQ) and topoisomerase (TOP2A). The Aurora kinases (AURKA, AURKB), 
BUB1 and both CHEK1 and 2 checkpoint proteins are also present along with many 
others. (See appendix 1 for full list).   Selected functional annotation confirming the 
enrichment for cell cycle genes is given in table 4.63. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Cell cycle 2.3 x10
-74 
DAVID GOTERM_BP_FAT M-phase 1.2x10
-66 
DAVID GOTERM_BP_FAT DNA replication 3.4 x10
-44
 
GSEA BENPORATH_CYCLING GENES 
Genes showing cell 









Table 4.63 Functional annotation for the cell cycle signature from the merged datasets using 
the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-




The cell cycle cluster is also associated with clusters of genes whose expression 
would appear to be tied to it (clusters 10, 16 & 26) and involved in mRNA/protein 
processing.   Associated with the cell cycle cluster are further smaller clusters 
enriched in mitochondrial, ribosomal and glycolysis-related genes which were 
designated cell-cycle related gene clusters due to their close proximity to cluster 6. It 
is perhaps unsurprising that signatures relating to replication are shared across 
multiple tumours, given the proliferative nature of tumour cells. The presence of 
such a well-preserved set of cell cycle genes argues for the fundamental importance 
of the cell cycle in malignant cells, such that although elements of regulation may be 
missing in individual tumours, taken as an average across multiple tumour types the 
signature is well preserved. Due to the method of analysis used, which will tend to 
preserve the signatures contributed by normal cells, it is reasonable to assume that 
part of this signature is contributed by replicating non-malignant cells within the 
tumour, but when this signature is examined in individual tumour type, there is a 
relationship with more aggressive tumours, arguing that this signature is derived 
mostly from the tumour cells.   
 
 
Finally, a third area of the graph was enriched with genes whose expression is 
associated with different elements of the tumour stroma. Within this component the 
clusters associated with tumour-associated immune activity are in close proximity 
with each other, those representing other stromal components being somewhat more 
distant.  
 
The macrophage signature (cluster 7, 220 transcripts) contains many genes 
considered to be specific to the myeloid lineage including CD68, CD14, CD163 and 
CSF1R. There is enrichment for lysosomal genes (CD68, LAPTM5, SCL15A3, 
ACP2, CTSB, CTSC, CTSD, CTSL1, CTSS), multiple genes involved in chemotaxis 
are also present (CMKLR1, PTAFR, FCER1G, C5AR1, C3AR1, CCR1, CCRL2, 
ITGAM, ITGB2, FPR1), as are multiple toll-like receptors (TLR1, TLR2, TLR7, 
TLR8). The signature also contains scavenger receptors CD163, MARCO, MSR1, as 
has previously been described by many groups for tumour-associated macrophages 
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(reviewed in Allavena et al, 2010). Finally, within the macrophage cluster are 
multiple components of the MHC class II antigen processing machinery (HLA-
DMA, HLA-DMB, HLA-DOA, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-
DQB1, HLA-DRA, HLA-DRB1, HLA-DRB4, HLA-DRB5, HLA-DRB6, CD74, 
LGMN). Interestingly among the genes also expressed is CD86, the co-stimulatory 
molecule suggesting that these cells may be able to efficiently present antigen to T 
cells.   The presence of genes involved in phagocytosis, MHC class II antigen 
processing and T cell co-stimulation all suggest a macrophage able to act as an 
antigen-presenting cell. The presence of scavenger receptors and genes involved in 
lipid metabolism hint at a role in apoptotic cell clearance by TAMS.   
 
A full list of genes from the macrophage signature and selected enrichment analysis 
is provided below (Tables 4.64 and 4.65).  Other signatures are provided in appendix 
1 
Analysis tool Source of annotation Annotation Significance 
(p-value)  








DAVID SP_PIR_KEYWORDS Lysosome 2.5 x10
-12
 
GSEA GSE 10325 
Genes downregulated 
in comparison of 
healthy B cells  with 












Table 4.64 Functional annotation for the macrophage signature from the merged datasets 
using the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-





Table 4.65   Macrophage signature from merged dataset laid out at Pearson correlation  ≥ 
0.6 with MCL inflation values of 2.2.   
Gene 
Symbol  Description 
ACP2 acid phosphatase 2, lysosomal 
ADAMDEC1 ADAM-like, decysin 1 
ADAP2 ArfGAP with dual PH domains 2 
ADAP2 ArfGAP with dual PH domains 2 
ADORA3 adenosine A3 receptor 
AIF1 allograft inflammatory factor 1 
AOAH acyloxyacyl hydrolase (neutrophil) 
APOL1 apolipoprotein L, 1 
APOL2 apolipoprotein L, 2 
APOL3 apolipoprotein L, 3 
ARRB2 arrestin, beta 2 
ATP8B4 ATPase, class I, type 8B, member 4 
BCL2A1 BCL2-related protein A1 
C1orf38 chromosome 1 open reading frame 38 
C1orf54 chromosome 1 open reading frame 54 
C1QA complement component 1, q subcomponent, A chain 
C1QB complement component 1, q subcomponent, B chain 
C2 complement component 2 
C3AR1 complement component 3a receptor 1 
C5AR1 complement component 5a receptor 1 
CAPG capping protein (actin filament), gelsolin-like 
CCR1 chemokine (C-C motif) receptor 1 
CCRL2 chemokine (C-C motif) receptor-like 2 
CD14 CD14 molecule 
CD163 CD163 molecule 
CD300A CD300a molecule 
CD4 CD4 molecule 
CD68 CD68 molecule 
CD74 CD74 molecule, major histocompatibility complex, class II invariant chain 
CD84 CD84 molecule 
CD86 CD86 molecule 
CD97 CD97 molecule 
CECR1 cat eye syndrome chromosome region, candidate 1 
CHIT1 chitinase 1 (chitotriosidase) 
CIITA class II, major histocompatibility complex, transactivator 
CLEC10A C-type lectin domain family 10, member A 
CLEC2B C-type lectin domain family 2, member B 
CLEC7A C-type lectin domain family 7, member A 
CMKLR1 chemokine-like receptor 1 
CSF1R colony stimulating factor 1 receptor 
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CSF2RB colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 
CTSB cathepsin B 
CTSC cathepsin C 
CTSD cathepsin D 
CTSL1 cathepsin L1 
CTSS cathepsin S 
CYBB cytochrome b-245, beta polypeptide 
CYTH4 cytohesin 4 
DPYD dihydropyrimidine dehydrogenase 
DRAM damage-regulated autophagy modulator 
DSE dermatan sulfate epimerase 
EMR2 egf-like module containing, mucin-like, hormone receptor-like 2 
FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 
FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) 
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor (CD16b) 
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor (CD16b) 
FGL2 fibrinogen-like 2 
FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog 
FPR1 formyl peptide receptor 1 
FPR3 formyl peptide receptor 3 
GBP2 guanylate binding protein 2, interferon-inducible 
GCH1 GTP cyclohydrolase 1 
GPNMB glycoprotein (transmembrane) nmb 
GPR65 G protein-coupled receptor 65 
GPX1 glutathione peroxidase 1 
HCK hemopoietic cell kinase 
HK3 hexokinase 3 (white cell) 
HLA-DMA major histocompatibility complex, class II, DM alpha 
HLA-DMB major histocompatibility complex, class II, DM beta 
HLA-DOA major histocompatibility complex, class II, DO alpha 
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 
HLA-DRA major histocompatibility complex, class II, DR alpha 
HLA-DRA major histocompatibility complex, class II, DR alpha 
HLA-DRB1 major histocompatibility complex, class II, DR beta 1 
HLA-DRB4 major histocompatibility complex, class II, DR beta 4 
HLA-DRB5 major histocompatibility complex, class II, DR beta 5 
HLA-DRB6 major histocompatibility complex, class II, DR beta 6 (pseudogene) 
HS3ST2 heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
IFI30 interferon, gamma-inducible protein 30 
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IGSF6 immunoglobulin superfamily, member 6 
IL15RA interleukin 15 receptor, alpha 
IL18BP interleukin 18 binding protein 
ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) 
ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) 
LACTB lactamase, beta 
LAIR1 leukocyte-associated immunoglobulin-like receptor 1 
LAIR1 leukocyte-associated immunoglobulin-like receptor 1 
LAPTM5 lysosomal multispanning membrane protein 5 
LCP2 lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa) 
LGALS9 lectin, galactoside-binding, soluble, 9 
LGMN legumain 
LHFPL2 lipoma HMGIC fusion partner-like 2 
LILRB1 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), 
member 1 
LILRB2 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), 
member 2 
LILRB4 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), 
member 4 
LIPA lipase A, lysosomal acid, cholesterol esterase 
LST1 leukocyte specific transcript 1 
LY86 lymphocyte antigen 86 
LY96 lymphocyte antigen 96 
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 
MAN2B1 mannosidase, alpha, class 2B, member 1 
MARCO macrophage receptor with collagenous structure 
MFSD1 major facilitator superfamily domain containing 1 
MGAT1 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase 
MNDA myeloid cell nuclear differentiation antigen 
MPP1 membrane protein, palmitoylated 1, 55kDa 
MS4A4A membrane-spanning 4-domains, subfamily A, member 4 
MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 
MS4A7 membrane-spanning 4-domains, subfamily A, member 7 
MSR1 macrophage scavenger receptor 1 
MYO1F myosin IF 
NAGK N-acetylglucosamine kinase 
NCF2 neutrophil cytosolic factor 2 
NCKAP1L NCK-associated protein 1-like 
NPL N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) 
NR1H3 nuclear receptor subfamily 1, group H, member 3 
P2RY13 purinergic receptor P2Y, G-protein coupled, 13 
PILRA paired immunoglobin-like type 2 receptor alpha 
PLA2G7 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) 




PLEKHO2 pleckstrin homology domain containing, family O member 2 
PTAFR platelet-activating factor receptor 
RHOG ras homolog gene family, member G (rho G) 
RNASE6 ribonuclease, RNase A family, k6 
RNF130 ring finger protein 130 
SCO2 SCO cytochrome oxidase deficient homolog 2 (yeast) 
SCPEP1 serine carboxypeptidase 1 
SECTM1 secreted and transmembrane 1 
SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin 
SIGLEC7 sialic acid binding Ig-like lectin 7 
SLAMF8 SLAM family member 8 
SLC15A3 solute carrier family 15, member 3 
SLC31A2 solute carrier family 31 (copper transporters), member 2 
SLC7A7 solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 
SLCO2B1 solute carrier organic anion transporter family, member 2B1 
SNX10 sorting nexin 10 
SPI1 spleen focus forming virus (SFFV) proviral integration oncogene spi1 
SRGN serglycin 
TBXAS1 thromboxane A synthase 1 (platelet) 
TCIRG1 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 
TFEC transcription factor EC 
TLR1 toll-like receptor 1 
TLR2 toll-like receptor 2 
TLR7 toll-like receptor 7 
TLR8 toll-like receptor 8 
TM6SF1 transmembrane 6 superfamily member 1 
TMEM140 transmembrane protein 140 
TNFAIP2 tumor necrosis factor, alpha-induced protein 2 
TNFRSF14 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) 
TNFRSF1B tumor necrosis factor receptor superfamily, member 1B 
TNFSF13B tumor necrosis factor (ligand) superfamily, member 13b 
TREM2 triggering receptor expressed on myeloid cells 2 
TRPV2 transient receptor potential cation channel, subfamily V, member 2 
TYMP thymidine phosphorylase 
TYROBP TYRO protein tyrosine kinase binding protein 
VAMP5 vesicle-associated membrane protein 5 (myobrevin) 






The T cell signature (cluster 8, 181 transcripts) contains pan-T cell markers (CD3, 
CD2, CD7) and elements of the T cell receptor signalling cascade (ZAP70, LCK, 
VAV, ITK). There are many chemokines, cytokines and their receptors in the cluster 
(CXCL9, CCL19, CCL5, LTB, CXCR3, CXCR6, CCR7, CCR2, CCR5, IL2RB, 
IL2RG, IL17R, IL10RA). Interferon gamma, the prototypical ‘classical’ macrophage 
activator is also expressed in this cluster. The T-cell signature is suggestive of an 
active state with expression of cytotoxic molecules granzymes and perforin (GZMA, 
GZMH, GZMK, GZMM, PRF1) as well as markers of activation (CD69).   Selected 
enrichment analysis given in table 4.66 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT T cell activation 1.7 x10
-22 
DAVID KEGG PATHWAY 




GSEA GSE 22886 
Genes upregulated in 






Table 4.66 Functional annotation for the T cell signature from the merged datasets using the 
DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
 
Lying adjacent to the T cell and macrophage clusters there is the signature of an 
interferon response (cluster 12, 115 transcripts) containing elements of the 
proteasome and multiple interferon regulatory factors (IRF1, IRF2, IRF7 & IRF9) 
and interferon inducible proteins (IFI6, IFI27, IFI35, IFI44). See table 4.67 for 








Analysis tool Source of annotation Annotation Significance 
(p-value)  





modulated in the 
blood of MS patients 







Genes upregulated in 
primary fibroblast 
culture after 






Table 4.67 Functional annotation for the interferon response signature from the merged 
datasets using the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  
Selected annotation given only.  Annotation derived from DAVID gives modified Fisher 
Exact p-values and GSEA hypergeometric distribution p-values. 
 
 
The preservation across all tumour types of a cluster of genes associated with an 
interferon response and the presence of IFNG in the T cell signature suggests that 
activation of this pathway forms a consistent part of the response to a tumour. This is 
also in keeping with data derived from murine models in which it was shown that 
TAMs express many interferon inducible genes (Biswas et al., 2006).  Taken 
together, these data do not entirely support the view that TAMs have a so-called M2 
(or alternative activation) (Mantovani et al 2009) phenotype characterised by 
dominant actions of interleukin 4; there is clear evidence of M1-type activation 
involving type I and type II interferons.  Nor does the analysis support the view that 
recognition of tumour-associated antigens is compromised by a lack of antigen-
presenting cells. Though it should be noted, that as with any study based on gene 
expression signatures, the signatures derived represent an average cell within the 







The largest non-immune-related element of the stromal signature is a cluster of genes 
that are associated with extracellular matrix (cluster 9, 163 transcripts). As such the 
cluster appears to represent the fibroblast/myofibroblast component of the tumours 
and contains many structural proteins including collagens (COL1A1, COL1A2, 
COL3A1, COL5A1, COL5A2, COL6A1, COL6A2, COL6A3, COL11A1, 
COL12A1) as well as cadherins (CDH11),  laminins (LAMA4, LAMB1), fibrillin 
(FBN1) and integrins (ITGA5, ITGAV, ITGB1). The signature also contains 
modifiers of the extracellular matrix such as MMP2, LOXL1, ADAMTS12, 
ADAMTS2 and receptors for growth factors (PDGFRB).  See table  4.68 for selected 
functional annotation. 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Extracellular matrix 3.2 x10
-41 
DAVID GOTERM_BP_FAT Cell adhesion 2.2x10
-20 
GSEA NABA_CORE_MATRISOME 






Table 4.68 Functional annotation for the extracellular matrix signature from the merged 
datasets using the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  
Selected annotation given only.  Annotation derived from DAVID gives modified Fisher 
Exact p-values and GSEA hypergeometric distribution p-values. 
 
 
Histologically, the presence of a desmoplastic tumour stroma is a well recognised 
phenomenon occurring in many tumour types. However, like many other elements of 
the microenvironment the precise role played by this reactive stroma has been 
difficult to assess: is the role of the stroma to contain the tumour or is it yet another 
factor recruited to promote the survival of the malignant cells? Recent data from 
studies of DLBCL suggest that in this tumour at least the answer may be that 
different elements of the stroma contribute to both a good and a poor prognosis 
(Lenz et al., 2008a) whereas work in small cell carcinoma has established the role of 
interactions between the ECM and tumour cells in resisting chemotherapy-induced 
death (Hodkinson et al., 2006). More recently work by Kim et al. (2009) in a lung 
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carcinoma model highlighted the role that ECM components, in this case versican, 
can play in activating other elements of the microenvironment suggesting that as for 
other elements of the tumour microenvironment, cross talk between elements is 
likely to be of great importance.  
 
The vascular signature fragments into four closely aligned clusters, three of which 
(clusters 29, 38, and 49, 50 transcripts in total) appear to represent endothelium and 
the fourth (cluster 59) associated with the basement membrane/extracellular matrix 
component (Table 4.69). These clusters contain classical and well characterised 
markers of vascular differentiation such as CD34, PECAM1 (CD31), VWF, KDR 
and CDH5. In addition it contains many genes that have been identified as 
endothelial specific genes by alternative bioinformatic analysis approaches (ECSCR, 
EMCN, ROBO4, TEK, EPAS1, GPR116), components of the Notch signalling 
pathway (NOTCH3, NOTCH4) and other endothelial genes which have been 
demonstrated in normal and tumour associated endothelium such as PLVAP 
(plasmalemmal vesicle associated protein) (Ghilardi et al 2008, Herbert et al 2008, 
Huminieki and Bicknell 2000, Wallgard et al 2008, Strickland et al 2005).  It is 
worth noting that these alternative bioinformatic approaches to determining 
endothelial signatures used either purified cell populations for gene expression data 
or characterised profiles based on similarity to known markers in contrast to the 
approach presented here which uses unpurified tumour material and an unsupervised 
clustering approach.  This analysis also identifies genes not previously identified by a 
bioinformatic approach, such as PLVAP (plasmalemmal vesicle associated protein), 
which has been well characterised as an endothelial gene expressed in certain normal 
tissues and in some tumours (Strickland et al 2005). Expression of this protein is 
associated with diaphragm formation in fenestrated endothelium and has been 
reported in tumour endothelium in a wide spectrum of tumours. In our data, Notch 4, 
which is implicated in endothelial sprouting, lies in one of the endothelial clusters, 
while Notch 3, the causative gene for CADASIL (cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy) and which is 
expressed in vascular smooth muscle lies in the related cluster enriched in ECM and 
basement membrane proteins. A recent study has investigated the crosstalk between 
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endothelial and mural cells via Notch 3 signalling and shown a reduction in 
angiogenesis in an in vitro co-culture system when Notch 3 is knocked out in mural 
cells (Liu et al 2009).  
 







DAVID SP_PIR_KEYWORDS Angiogenesis 1.1x10
-10 
 
Table 4.69 Functional annotation for the endothelial signatures from the merged datasets 
using the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
 
Finally there is a small cluster that contains many adipocyte specific genes (cluster 
27, 22 transcripts) including ADH1B, ADIPOQ, FABP4 and LPL.  
 
Other small clusters or groupings of small clusters of note are comprised of the 
Affymetrix control probes (cluster 23 contains all hybridization controls and cluster 
28 all ‘spike-in’ control probes); histone complexes (cluster 20 contains 24 histone 
genes); AP1 transcription factors/early response genes (clusters 48, 89 and 336) 
containing the genes JUN, JUNB, FOS, EGR1, EGR3, IER2, NR4A1, NR4A2, 
ATF3, CTGF and DUSP1; and growth-related hormones GH1, CSH1, CSH2, 
CSHL2 (clusters 92 and 187). 
 
It is of interest to consider how the different signatures relate to each other.  The fact 
that macrophage, T cell, ECM and endothelial-specific genes cluster independently 
of itself indicates that there is not a tight causal relationship between them. However 
it is clear that the functions of these cells may be closely related, with the T cell 
signature and macrophage signature in particular, demonstrating a similar expression 
pattern and close spatial relationship in the network graph. The exact nature of the 
relationship between these elements of the stroma may differ between individual 
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tumours with the vascular signature lying in the same cluster as the T cell signature 
in some tumours, arguing a very close pattern of co-expression of these genes. While 
the expression pattern is correlated is not possible to be sure of the exact nature of 
the relationship; do factors secreted by lymphocytes drive angiogenesis?, or does the 
presence of the vasculature allow lymphocytes to reach and infiltrate the tissue?, or 
are both of these signatures driven by a separate, closely associated signatures such 
as that contributed by the tumour associated macrophage.  This analysis, providing a 
single ‘snapshot’ view of the individual tumours, does not allow this question to be 
answered.  The absence of a conserved pattern of tight association between 
signatures however argues that these relationships are not absolute and are influenced 
by many factors which are likely to be of variable strength in different tumour types.   
 Despite the frequent association of macrophage number with microvessel density in 
solid tumours (Sickert et al  2007,  Lissbrant et al  2000,  Eerola et al 1999, Orre and 
Rogers 1999), these signatures are clearly separate in the tumours studied here 
suggesting that there are other factors involved in the recruitment of neovasculature 





4.11 Conservation of ‘core’ signatures in independent dataset  of 
skin cancers 
In order to confirm that the ‘core’ signatures generated from the 6 datasets are 
generally applicable to cancer datasets rather than specific to the tumours studied, an 
independent tumour dataset, not used in derivation of the core signatures was 
analysed and the signatures generated from our merged analysis mapped to this.  
This final dataset of 82 samples was derived from various types of skin cancer 
including basal cell carcinoma, squamous cell carcinoma, primary melanoma, 
including melanoma in-situ, and melanoma metastatic to subcutaneous tissue, lymph 
node, brain and adrenal gland (Riker et al 2008).   
This graph was laid out at Pearson correlation threshold ≥0.8 giving a graph of 
21,293 nodes and 601,710 edges (Figure 4.42).  As with each of the previous 
datasets, this dataset had its own peculiarities relating to the individual tumour types, 
with many of the clusters representing genes with marked differences in expression 
between the three different tumour types and clusters with a tissue specific 
expression, in this case skin, adrenal gland and other sites of metastasis.  The data 
tended to show a spiked pattern, reflecting the relatively small number of tumours, a 
large number of which were metastatic melanoma.   In addition however, there was 
preservation of many of the signatures seen in the ‘core’ dataset, with clusters 
present in this new dataset which were highly significantly enriched for genes of the 
‘core’ signatures.  As in other datasets the spatial relationship between clusters was 
preserved with immune signatures falling in one part of the graph, non-immune 
stromal clusters lying together and cell cycle and related genes clustering together. 
On analysis of some of the individual expression patterns seen in the skin cancer data 
set, clusters of genes representing macrophages and lymphocytes showed increased 
expression in melanoma compared to BCC and SCC in keeping with the 





Figure 4.42.  Clusters present in the merged signature were conserved in the skin dataset.  
Left panel:  The skin dataset laid out at p≥0.8 with nodes hidden and only edges visible.  
Right:  The same network graph but with only those probesets that formed part of a cluster in 
the merged signature shown.   
 
4.11.1 Stromal signatures 
 
As in other datasets, there was a cluster representing the tumour associated 
macrophage (Figure 4.43).  This was of only 110 probesets to 62 genes and 
contained markers of macrophages including CD14 and CD163.  There are toll-like 
receptors 2 and 4, macrophage scavenger receptor 1 and single Fc receptor (CD64).  
Multiple genes involved in chemotaxis are present (C3AR1, CCL13, CCR1, 
CMKLR1, FPR3, ITGAM) as well as genes frequently seen in the macrophage 
signature in other datasets including AIF1, HCK, LAIR1, and TNFSF13.  
Enrichment analysis via DAVID and GSEA confirms this to represent a macrophage 







Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Defense reponse 1.0 x10
-12 
DAVID GOTERM_BP_FAT Chemotaxis 2.6x10
-4 
GSEA GSE 10325 
Genes downregulated 





GSEA GSE 29618 
Genes upregulated in 
monocytes vs myeloid 
DCs 




Table 4.70 Functional annotation for the macrophage signature from the skin dataset using 
the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
A further large cluster of 368 probesets representing 245 genes contains lymphocyte 
genes (Figure 4.43).  This contains surface markers of both B and T cells including 
CD22, CD79a and CD79b, MS4A1 (CD20), CD3, CD5, CD7, and TCR alpha.  
There are chemokines, cytokines and receptors including CCL21, CCR6, CCR7, 
IL2RG, IL21R and IL7R.  Elements of the T cell receptor signalling pathway are 
present including CD28, Ikaros family zinc finger (IKZF1), ZAP70, lymphocyte 
specific protein tyrosine kinase (LCK) and Wiskott-Aldrich syndrome gene (WAS).   
Enrichment analysis confirms the signature to be enriched in T and B cell associated 
genes (Table 4.71).  
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Lymphocyte activation 1.1 x10
-23 
DAVID GOTERM_BP_FAT T cell activation 2.5x10
-15 
DAVID GOTERM_BP_FAT 




GSEA GSE 10325 
Genes upregulated in 





GSEA GSE 29618 
Genes upregulated in 






Table 4.71 Functional annotation for the lymphocyte signature from the skin dataset using 
the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
There is a cluster representing plasma cells of 86 probesets to 24 genes.  This 
contains multiple immunoglobulin heavy and light chain genes, PIM2, expressed in 
B cells and TNFRSF17, which is expressed only in mature B cells.  Enrichment 
analysis does not provide much useful annotation for this cluster, with enrichment for 
‘antigen binding’ and immunoglobulins (Table 4.72).   
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_MF_FAT Antigen binding 6.4 x10
-12 
DAVID SP_PIR _KEYWORDS Immunoglobulin 1.1x10
-12 
GSEA GSE 29618 
Genes upregulated in 




Table 4.72 Functional annotation for the plasma cell signature from the skin dataset using 
the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
As in all datsetsets analysed, there is an interferon response here represented as 28 
probesets and 21 genes (Figure 4.42).  This contains all 3 components of the 2,5-
oligoadenylate synthetase (OAS1, OAS2, OAS3), and many interferon induced 
proteins (IFI44, IFI44L, IFIH1, IFIT1, IFIT2, IFIT3, IFI27, IFI6, IFIT2).  






Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID GOTERM_BP_FAT Immune reponse 1.9 x10
-6 
DAVID GOTERM_MF_FAT RNA binding 3.6x10
-4 
DAVID GOTERM_BP_FAT Response to virus 4.1x10
-6 
GSEA HECKER_IFNB_TARGETS 
Genes modulated in 
the blood of patients 
with MS treated with 




Table 4.73 Functional annotation for the interferon response signature from the skin dataset 
using the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
A small cluster of mast cell genes of only 11 probesets to 7 genes is also present.  
This contains mast cell carboxypeptidase, and tryptase alpha and beta as well as 
TWIST2 and OSR2 which do not appear to be particularly associated with Mast cells 
from the literature.  Enrichment analysis confirms only enrichment for protease 
activity reflecting the small number of genes in the cluster (Table 4.74). 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Protease 3.8 x10
-3 
 
Table 4.74 Functional annotation for the mast cell signature from the skin dataset using the 
DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
The non-immune components of the stromal signature include extracellular matrix, 
endothelial and skeletal muscle signatures. 
The largest ECM signature is of 57 probesets to 39 genes.  This contains no collagen 
molecules in contrast to ECM signatures seen in every other dataset.  There are 
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structural protein genes fibulin 1 and 2, fibrillin 1, elastin and laminin, alpha 2.  
(FBLN1, FBLN2, FNB1, ELN, LAMA2).  There are growth factor receptors 
including insulin like growth factor 1 (IGF1) and platelet-derived growth factor 
receptor like (PDGFRL).   Enrichment analysis confirms this to represent an ECM 
signature (Table 4.75).   
Analysis tool Source of annotation Annotation Significance 
(p-value)  








Table 4.75 Functional annotation for the ECM signature from the skin dataset using the 
DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
The endothelial signature contains 24 genes including CD31 (PECAM1), von 
willibrand factor (VWF), vascular endothelial cadherin (CDH5), ERG and 
endothelial tyrosine kinase (TEK).  Enrichment analysis confirms enrichment for 
genes associated with angiogenesis (Table 4.76). 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  








Table 4.76 Functional annotation for the endothelial signature from the skin dataset using 
the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values. 
 
The skeletal muscle signature is of 68 probesets to 61 genes and includes multiple 
myosins and their binding proteins (MYH1, MYH2, MYH7, MYL1, MYL2, MYL3, 
MYLPF, MYBPC1, MYBPC2), actins (ACTA1, ACTC1), muscle creatine kinase 
(CKM), troponins and tropomyosins (TNNC1, TNNC2, TNNI1, TNNI3, TPM1, 
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TPM2, TPM3).  Enrichment for skeletal muscle genes is confirmed on analysis 
(Table 4.77). 
 
Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Muscle protein 1.6 x10
-41 
DAVID SP_PIR_KEYWORDS Skeletal muscle 3.1x10
-22 
GSEA REACTOME 






Table 4.77 Functional annotation for the skeletal muscle signature from the skin dataset 
using the DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
4.11.2 Cell cycle signatures 
The cell cycle signature is difficult to discern in the this dataset, tending to fragment 
into small clusters, presumably reflecting the marked differences in proliferation 
between tumour types compounded by the tendency of normal proliferation in the 
epidermis to pull these genes into skin specific clusters.  The largest of the cell cycle 
clusters containing only 19 probesets and 16 genes appears to represent the mitotic 
phase of the cell cycle.  It contains cyclin B2, centrosomal protein 152kDa, 
centromere protein F, and the minichromosome maintenance complex components 6 
and 10 (CCNB2, CEP152, CENPF, MCM6, MCM10).  Despite the small number of 
genes, enrichment analysis demonstrates enrichment for genes associated with 






Analysis tool Source of annotation Annotation Significance 
(p-value)  
DAVID SP_PIR_KEYWORDS Cell division 4.2 x10
-8 
DAVID SP_PIR_KEYWORDS Mitosis 2.9x10
-7 
GSEA REACTOME 





Table 4.78 Functional annotation for the cell cycle signature from the skin dataset using the 
DAVID functional annotation clustering tool and MSigDB tool in GSEA.  Selected 
annotation given only.  Annotation derived from DAVID gives modified Fisher Exact p-
values and GSEA hypergeometric distribution p-values. 
 
4.11.3 Conservation of signatures 
 
To establish whether the signatures seen in this independent dataset showed 
conservation of the signatures seen in the ‘merged’ data, clusters derived in this 
analysis were tested for enrichment of the genes in the conserved signatures using 
Fisher’s test adjusted for multiplicity of testing.   The main macrophage cluster in the 
skin cancer dataset (cluster 16) was significantly enriched for genes in the merged 
macrophage cluster (cluster 7) with an adjusted p-value of 9.0
E-120 
by Fisher’s test 
with correction for multiplicity of testing.   Similarly other of the signatures from the 











Cluster name Gene 
number  in 
merged 
cluster(s) 
Genes in skin 
cluster 
Significance of enrichment in skin 
clusters 
(Adjusted Fisher’s test) 
Macrophage 163 62 9.0
E-120 
T cell 145 245 4.9
E-90 
IFN response 73 21 6.9
E-53 
MHC class I 16 27 6.8
E-65 
Plasma cell 36 24 3.9
E-175 






Endothelium 17, 13, 11 24 1.7
E-11, 2.9E-16, 7.5E-13 
Skeletal muscle 15 61 8.9
E-32 
Cell cycle 182 16 8.3
E-21 
Ribosomes 12 16 1.6
E-36 
Histones 26 10 9.1
E-32 
Glycolysis 5 5 2.9
E-30 
 
Table 4.79.  Signatures from the merged dataset were conserved in an independent dataset.  
Clusters from the skin dataset were tested for enrichment of genes in clusters in the merged 






Figure 4.43.  Conservation of the ‘core’ immune signatures in the skin cancer dataset.  The 
left-hand graph shows only the immune clusters in the skin cancer dataset with the rest of the 
graph hidden.  In the right hand graph, the same area of the graph is illustrated but with the 
cluster annotation from the merged graph applied, and nodes which represent genes not seen 
or not forming clusters in the merged graph absent.  The colours represent the individual 
cluster colours from on the left, the MCL clustering of the skin dataset and on the right, the 
imported cluster annotation from the merged clusters.  The clusters get smaller when only 
the conserved signatures are seen, but there is good preservation of most immune clusters.  
Some, such as the neutrophil cluster which is not seen in the merged graph, are lost when 
applying the merged annotation.   
 
Analysis of tumour type-specific clusters (i.e. unconserved clusters) also provided 
insight into tumour biology in this dataset; for example if we chose to look at the 
nearest neighbours of SILV, a gene whose product (gp100) is detected by the 
antibody HMB45 which is used clinically in the diagnosis of melanoma, being 
expressed only in junctional melanocytes and melanoma, we pull out the genes TYR 
(tyrosinase) the key enzyme in melanin biosynthesis, MLPH (melanophilin), which 
plays a role in melanosome transport, GPR 143 expressed on the melanosome 
membrane, and MLANA (melan-a),  as well as MITF, a melanocytic transcription 
factor and transcriptional regulator of many of these genes (Figure 4.44)(reviewed in 
Steingrımsson et al 2004).  SNCA (alpha-synuclein) also lies within this grouping, 
and while there is no literature regarding the expression of this in melanoma, it does 
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play a role in dopamine metabolism in the CNS, and therefore may also function in 
melanin metabolism.  In addition, CDK2, a gene downstream of and regulated by 
MITF and known to be required for melanoma growth and proliferation  (Du et al 
2004) lies within these ‘near neighbours’,  as does  BIRC7 , another target of MITF 
(Dynek et al 2008), and anti-apoptotic protein contributing to melanoma survival and 






Figure 4.44.  Nearest neighbours of SILV.  Selecting the nodes closest to SILV, the gene 
encoding the protein recognised by the antibody HMB45 generates a group of genes defining 
elements of melanocyte biology.  The mean expression of these genes is seen in the 
expression plot.  Individual tumours are represented on the x-axis.  The coloured bar 




Additional analysis by Freeman of further datasets confirmed conservation of the 
‘core’ signatures in other unrelated tumour types including Hodgkin lymphoma and 




This chapter presents a novel approach to isolating functional signatures, including 
cell-specific signatures, from large human datasets.  This was made possible by 
recent advances in graphical presentation and analysis of data that allow much larger 
datasets to be analysed than would previously have been possible as well as the 
public provision of these large datasets.  Signatures are defined on the basis of 
patterns of co-expression of genes within the dataset.  The analysis presented here 
applys no preconceived notions of what data is important in creation of the network 
graph allowing only the correlation threshold to decide what is included in the graph.  
The approach differs fundamentally from much of the gene expression clustering 
analysis presented in the literature which is often focussed on defining differences 
between groups.   
The data presented above demonstrates that it is possible to determine process and 
cell specific signatures from complex datasets, and thus define features of the cancer 
transcriptome in situ in genuine human tumours.   Clearly the data derived from this 
analysis cannot capture all the elements of an individual signature.  Features that are 
common to many cell types and processes such as intracellular signalling pathways 
will be represented in many cell types/processes and, unless there is a dominant 
driver in the dataset such that all other influences are insignificant, then the signature 
seen will be a sum of all the influences on the signature and will therefore not readily 
correlate with any one cell type or process.  Discrete processes that are identified 
such as stromal signatures or cell cycle pathways will also represent a sum of all the 
influences on them and thus the overall signature of, for example, the tumour 
associated macrophage.  As in any analysis method that looks at homogenized 
tissue/data it is impossible to localise the signal and know where in the complex 
229 
 
three-dimension structure of the tumour the signature resides.  Some of the 
limitations in spatial descriptions of the signatures will be addressed in a limited way 
in the next chapter where elements of the TAM signature are characterised in human 
DLBCL tissue samples.    What the analysis presented here does tend to isolate are 
those items of a signature that are unique to a cell type or process such that the only 
or dominant signature comes from that cell type or process.  Thus, while the analysis 
cannot capture all the elements of an individual cell type signature or process, it will 
capture the elements that make the signature unique from other cell types or 
processes. 
As with all approaches that analyse cells or signatures by levels of mRNA, any genes 
whose expression is regulated at a different point, be that rapid mRNA degradation, 
high protein turnover or sequestration of protein in intracellular compartment, will 
not be accurately represented in this data.    
Having identified signatures, among others, that relate to TAMs, the following 
chapter seeks to validate elements of this signature in an independent cohort of 
human diffuse large B cell lymphoma cases with emphasis on genes that formed part 










Validation of TAM gene signature  
Having identified a signature of the tumour associated macrophage in DLBCL using 
a bioinformatic approach, further work was undertaken to validate the signature by 
analysis of expression of selected elements of that signature.  As the studies in the 
previous chapter were performed using publically available datasets, it was not 
possible to validate any of the signatures by independent analysis of genes expressed 
in the macrophage signature on a gene by gene basis.  Instead, immunohistochemical 
studies were undertaken on an unrelated set of diffuse large B cell lymphomas as 
well as benign reactive lymphoid tissue to assess protein expression of elements of 
the signature. This moved the work from an in silico analysis of human tumour tissue 
back into human tumour tissue sections.  Initially nine genes from the signature were 
selected for further study.   
 
5.1 Creation of tissue microarrays for benign lymph nodes and 
DLBCL. 
To allow a large number of cases to be studied tissue microarrays were created using 
benign and malignant lymph nodes.  Benign lymph nodes were identified by 
searching the pathology archive over a 10 year period using the SNOMED codes 
‘lymph node’ and ‘hyperplasia’.  All cases so identified were reviewed and only 
those cases not associated with a malignancy selected, i.e. cases of isolated 
lymphadenopathy where there was no evidence of lymphoma.  Histological review 
of these cases confirmed the reactive nature of the lymph nodes in all cases selected 
for inclusion.   Malignant lymph nodes containing DLBCL were identified through 
the records of the Scotland and Newcastle Lymphoma Group database.  Again all 
cases were reviewed to confirm the diagnosis.  Selected representative areas of nodes 




Creation of tissue microarrays allows large numbers of specimens to be examined on 
a limited number of slides which provides several advantages; archival human tissue 
can be used without compromising the requirement to leave tissue in the block for 
future diagnostic use; removal of individual variation in staining between slides as 
well as savings in reagents required to examine the tissue and savings in time to 
analyse the cases without the need to move from slide to slide.  Large numbers of 
cases can be stained simultaneously without the requirement for access to large 
automated stainers capable of dealing with hundreds of slides simultaneously, an 
approach which removes some of the variability inherent in staining slides in 
batches, but may still show slide-to-slide variation.   The use of TMAs in the study of 
lymphoma is well established and has been validated in several studies (Hedvat et al 
2002, Rassidakis et al 2002, Tzankov et al 2003).  In the cases reported below, some 
whole sections were also stained to ensure uniformity of expression across the tissue.  
The use of 2mm cores also provided sufficient tissue to study so that localisation to 
anatomical compartments within the node was possible in the reactive lymph nodes.  
Sixty-one cases were included in the benign/reactive TMA and seventy-four in the 
DLBCL TMA.   
 
5.2  Immunohistochemistry for selected markers from TAM profile 
Initially nine genes from the signature were selected for validation at the protein 
level (Figure 5.1).  All showed marked variation in gene expression across the 
tumour dataset.   These were selected from genes present in both the DLBCL TAM 
signature and the ‘core’ TAM signature and cases that were only in the DLBCL 
TAM signature and not the ‘core’ signature.  These included well characterised 
markers of macrophages CD68 and CD163 as well as less-well characterised genes 
PLAUR, IL-18BP, LGALS3BP, TYMP, AIF1, LAIR1 and SIGLEC1 (CD169).   
Aside from CD163 and CD68, which were selected as being known macrophage 
markers, the selection was based on there being some knowledge of the function of 
the genes suggesting that their role in tumours may be of interest, and availability of 
reagents.   Antibodies which claimed to work on FFPE tissue were available for all 
targets selected.   After extensive preliminary work assessing different methods of 
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antigen retrieval and staining protocols PLAUR, IL-18BP and SIGLEC1 
wererejected as specific staining in control tissue was not achieved.   The remaining 
six targets were assessed by immunohistochemical expression in benign and 
malignant lymph node tissue (See tables 2.2 and 2.3 for details of clones, suppliers 
and antigen retrieval methods).  In the reactive lymph nodes, three major 
compartments containing macrophages could be recognised; tingible body 
macrophages in reactive germinal centres, sinus histiocytes and ‘stromal’ 
macrophages which lay in the nodal parenchyma but not in reactive germinal centres 
or sinuses.  To allow comparison of expression patterns of TAM markers within 







Figure 5.1 Expression pattern of the nine selected genes in the DLBCL cohort from chapter 
4.  Individual tumours are represented on the x-axis, with the coloured bars denoting tumour 
subtype.  Mean fluorescence values for each gene are given on the y-axis.  
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5.2.1  CD68 expression in lymphoid tissue. 
CD68 showed granular cytoplasmic staining and was seen in all compartments of the 
reactive lymph node (Figure 5.2).  Staining tended to be strong with little variation 
from case to case.   
Expression was seen in all tumour cases, showing a similar granular cytoplasmic 
staining to that seen in the reactive nodes (Figure 5.2). 
 
 
Figure 5.2.  Expression of CD68 was seen in all compartments of the reactive lymph node.  
a) in sinus histiocytes x200 magnification,  b)expression in tingible body macrophages in the 
germinal centre and stromal macrophages x100 magnification.  All tumour cases contained 
CD68 positive cells. c) and d)representative cases of DLBCL x100 magnification. 






5.2.2  CD163 expression in lymphoid tissue 
CD163, a macrophage scavenger receptor, showed membranous staining and was 
expressed by sinus histiocytes with a uniformly strong expression in reactive lymph 
nodes (Figure 5.3).  It was negative or occasionally weakly positive in tingible body 
macrophages and almost entirely absent in ‘stromal’ macrophages.   
Expression was seen in macrophages in most tumours, although there was 
considerable variation between tumours with some containing large numbers of 
positive cells and others very occasional weakly staining cells.  Some tumours were 
entirely negative (Figure 5.4). 
 
Figure 5.3   Expression of CD163 in reactive lymph nodes.  Strong staining was seen in 
sinus histiocytes a) x40 magnification and c) x200 magnification.  There was weak or absent 
staining in tingible body macrophages.  b) x100 magnification .  Arrows indicate tingible 
body macrophages and arrow head sinus histiocytes.  d)  x200 magnification.  Arrow 
indicates weak membranous expression in tingible body macrophage and arrow head absent 




Figure 5.4 Expression of CD163 in lymphoma.  Cases of DLBCL were stained with anti-
CD163.  There were positive macrophages in almost all cases, but with marked variation 
from case to case as to the number of positive cells.  Macrophages of varying morphology 
were positive including those containing abundant apoptotic bodies as in d).  All images at 
x200 magnification. 
 
5.2.3 AIF1 expression in lymphoid tissue 
Allograft inflammatory factor – 1 (AIF1), a calcium binding protein whose 
expression is upregulated in response to interferon gamma, showed membranous and 
cytoplasmic staining in reactive lymph nodes with macrophages in all compartments 
being positive (Utans et al 1995) (Figure 5.5).  Staining tended to be more intense in 
sinus histiocytes than other macrophage types, but all cell types were positive.   
 
In DLBCL, AIF1 was expressed in macrophages in all cases (Figure 5.5).  There was 
a mixture of patterns of staining, the majority of cases showing membranous and 
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cytoplasmic staining, some cases showing membranous staining only, and a small 
number of cases showing membranous, cytoplasmic and nuclear staining.    
 
Figure 5.5  AIF1 expression is seen in all compartments of reactive lymph nodes.  a) x40 
magnification to show staining in sinus histiocytes and tingible body macrophages in 
germinal centres.  b) x40 magnification to show ‘stromal’ macrophages and tingible body 
macrophages. c) x200 magnification.  Staining in germinal centre and ‘stromal’ macrophages 
with less positive cells in mantle zone.  d) x200 magnification.  Sinus histiocytes show 




5.2.4 LAIR1 expression in lymphoid tissue 
Leukocyte associated immunoglobulin-like receptor–1 (LAIR1) (CD305) expression 
was seen in all compartments of the reactive lymph node (Figure 5.6).  Staining 
showed a membranous pattern with some occasional weak granular cytoplasmic 
staining.   
Staining was seen in TAMs in all cases of DLBCL analysed.  Staining showed a 
similar pattern to that observed in the reactive lymph nodes with membranous and 
occasional cytoplasmic staining (Figure 5.6). 
 
Figure 5.6  a) x100 magnification.  LAIR 1 expression was seen in tingible body 
macrophages, sinus histiocytes and stromal macrophages.  b) x400 magnification.  LAIR1 
expression in tingible body macrophages shows membranous staining and some weak 
cytoplasmic staining.  C) x200 magnification.  Staining in sinus histiocytes.  d) x200 
magnification.  Representative case of DLBCL, in this case showing macrophages full of 




5.2.5 LGALS3BP expression in lymphoid tissue 
Lectin galactoside-binding, soluble, 3 binding protein (LGALS3BP, Mac2 binding 
protein, 90K) was expressed in a large proportion (70%) of reactive lymph nodes 
studied, but not all.  The pattern of expression was relatively restricted with 
expression in all positive cases in sinus histiocytes, expression in stromal 
macrophages in only 4% of cases and complete absence in tingible body 
macrophages.  Where expression was seen it was mostly weak and showed a 
granular cytoplasmic pattern (Figure 5.7). 
In lymphoma, the majority of cases were negative.  Only 30% of cases showed 
expression in TAMs and this expression tended to be very weak and focal.   
 
Figure 5.7  LGALS3BP expression was seen in the majority of cases of benign lymph nodes 
but almost always only in sinus histiocytes and with weak expression.  a) x400 
magnification.  Granular cytoplasmic expression in sinus histiocytes in reactive lymph node.  
b) x100 magnification.  Weak expression in sinus histiocytes in reactive lymph node (arrow).  
Adjacent reactive germinal centre is negative.  c). X200 magnification.  Absence of staining 
in DLBCL.   d).  X 400 magnification.  Occasional TAMs show weak granular cytoplasmic 




The expression pattern of LGALS3BP was of particular interest.  The known 
functions of the molecule will be discussed further in the next chapter, but much of 
the literature reflects its role as a secreted protein, measurable in serum or forming a 
linking molecule in the  ECM which connects cells and the structural matrix.  Thus 
the position in the macrophage signature was intriguing.  However, work on the role 
of the molecule in HIV has demonstrated expression at the mRNA level in both T 
cells and macrophages, but protein expression only in macrophages (Lodermeyer 
2013).   It is entirely conceivable therefore that it may form part of the macrophage 
signature and its presence in subsets of macrophages in the non-malignant lymph 
node would tend to confirm this to be a macrophage expressed protein.  The 
possibility that what the antibody used for immunohistochemistry is binding to is 
LGALS3BP secreted protein bound to galectin-3 on the surface of macrophages 
cannot be excluded however.  It is notable that not all TAMs, and in fact only small 
proportion, showed positive staining.  There are several possible explanations for 
this; the protein may be expressed by macrophages but secreted and hence not 
localised to the macrophage; there may be a disconnect between mRNA and protein 
in macrophages in this situation as has been described  in T cells in culture; 
expression may be mostly by non-TAM macrophages which are poorly represented 
in the TMA from lymphomas but are likely to represent part of the mean macrophage 
profile in the gene expression studies; protein expression may be below the level of 
detection of the assay or the inclusion of LGALS3BP in the signature may be wrong.  
The absence of ‘stromal’ staining on immunohistochemistry would not support a 
secreted, ECM-binding role for the molecule.  The presence of positive staining in 
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some macrophages would argue that this does not lie in the macrophage signature by 
error.  The level of protein expression in absolute terms or relative to the mRNA 
level may account for the expression patterns seen but this was not explored further.   
 
 
5.2.6 TYMP expression in lymphoid tissue 
Thymidine phosphorylase (TYMP, also known as platelet derived endothelial cell 
growth factor) was seen in all macrophage compartments in the reactive node as well 
as in high endothelial venules (Figure 5.8).  Staining was nuclear and cytoplasmic in 
pattern.   
There was expression in TAMS in all tumours which showed considerable variation 
from tumour to tumour.  Nuclear staining appeared to be a constant finding in TAMs 







Figure 5.8  a) x 100 magnification.  TYMP expression was seen in macrophages in the 
germinal centre (right hand side of image) as well stromal and sinus macrophages (left hand 
side of image).  TYMP expression also seen in high endothelial venules (arrow).  b)x 400 
magnification.  Tingible body macrophages in the germinal centre showing nuclear and 
occasional cytoplasmic staining.  c) x200 magnification.  Expression was also seen in sinus 
histiocytes.  d) x200 magnification.  Representative case of DLBCL showing TYMP 
expression in TAMs.  
 
5.2.7  Expression patterns in individual cases 
To examine distribution of staining of individual markers composite images were 
examined of serial sections in individual cases.  These demonstrated differences in 
staining patterns between antigens, although all stained in macrophage-like cells 
morphologically.  Not all macrophages expressed all antigens.  Some examples are 











Figure 5.10.  Representative reactive lymph node showing peripheral sinus, reactive 





















5.2.8  Double labelling of macrophage markers 
To determine whether the macrophages markers selected for study in this chapter 
were being expressed by the same cells, a limited panel of double staining was 
undertaken.  As the archival human tissue available to study was all formalin fixed 
and paraffin embedded, fluorescence staining was not possible due to high auto-
fluorescence of the tissue, so chromogenic labelling was undertaken using two 
different chromogens.  This approach was limited as many of the antigens were 
expressed in the same intracellular compartments, but staining with CD163, a purely 
membranous antigen, and TYMP, which showed a cytoplasmic and nuclear 
expression pattern was possible.   
In both the reactive lymph node and in TAMS in DLBCL, some cells with the 
morphology of macrophages showed double labelling with TYMP and CD163, but 
there were also cells that expressed one without the other.  Given the differences in 
observed expression pattern described above, this was to be expected with CD163 
appearing on sequential sections to have a much more limited pattern of expression 





Figure 5.13   Double labelling with TYMP (purple) and CD163 (brown).  a) and b) x 200 
magnification.  Reactive lymph nodes showing more widespread expression of TYMP than 
CD163 but a proportion of cells showing expression of both.  c) and d) x 400 magnification.  
TAMs in DLBCL, with some dual expression of TYMP and CD163.   
 
Conclusions 
All markers of macrophages selected from the ‘macrophage’ signature generated in 
the previous chapter, and in which immunohistochemistry was successfully 
performed were shown to be expressed in macrophages in both benign and malignant 
conditions, although in the case of LGALS3BP, expression was seen in only in 
lymph nodes from some individuals.  Not all markers were expressed by all 
macrophages with clear differences in expression patterns in benign lymph nodes 
between macrophages in different anatomical compartments of the node and 
therefore presumably with different functions.  This same pattern was observed, 
though with less obvious spatial distribution, in the macrophages in DLBCL.  In 
sequential sections, there appeared to be differing patterns of expression, although all 
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markers were expressed in cells with macrophage-like morphology.  The double 
immunolabelling highlighted this also, with a proportion of cells being positive for 
one of other of the proteins and a proportion being double-positive.   
This would imply that the signature derived from the data analysis is a ‘global’ 
signature of the macrophages within the tumour, with sufficient similarities between 
cells for them to cluster together, regardless of whether all the markers in the 
signature are expressed by individual cells.  It is to be expected the 
microenvironment of the tumour is not a uniform space, but reflects minute 
differences in the cellular composition, blood supply, and extracellular matrix of the 
tumour as well as local differences in availability of oxygen and nutrients.  
Macrophages as cells of marked plasticity would be expected to reflect these 
environmental changes.  It also implies that these elements of the signature are not 
simply genes that are expressed at all times in all macrophages, but rather are 
modulated in response to stimuli and therefore, of potential interest for further study.  
Given the complexity of the tumour microenvironment and the plasticity of the 
macrophage,  there is unlikely to be a single tumour associated macrophage signature 
in DLBCL or any other malignancy, but rather a collection of signatures that add up 
to the TAM signature and reflect the balance of activation and suppressive influences 











Relationship of expression of selected TAM 
markers with clinical outcome in DLBCL 
 
Aims of the chapter. 
Having established that selected markers from the macrophage RNA expression 
profile were indeed present in human macrophages at the protein level, both in 
macrophages in reactive lymphoid conditions and in macrophages in DLBCL, this 
chapter will focus on whether differences in the pattern and intensity of staining in 
TAMs and differences in absolute numbers of those macrophages correlates with 
outcome in a cohort of patients treated with a standard chemotherapeutic regimen.  
This is an independent cohort of patients from those discussed in chapter 3.  The 
clinical characteristics and demographic details of the patient cohort will be 
presented, then each of a panel of markers whose known functions suggest they may 
play a role in tumour response and their relationship to clinical outcome will be 
discussed.  For each protein studied, the pattern of antibody staining was assessed by 
eye to determine whether there appeared to be differences in intensity, expression 
pattern or number of positive cells between tumours and variables selected for 
scoring on this basis.  Four molecules were studied in relation to clinical outcome; 
Thymidine phosphorylase (TYMP), leukocyte associated Ig-like receptor-1 (LAIR1), 
allograft inflammatory factor 1 (AIF1) and soluble galectin-3 binding protein 
(LGALS3BP). 
 
6.1 Clinical features of DLBCL – CHOP treated cohort 
A cohort of patients were identified from the Scotland and Newcastle Lymphoma 
database.  The initial selection criteria to identify patients from the database were 
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that they had a diagnosis of Diffuse Large B-cell lymphoma, and that they were 
treated at one of the three hospitals in Lothian to which there was access to the stored 
formalin-fixed paraffin embedded tissue on which the diagnosis was based.  This 
identified 276 cases spanning a period from 1991 to 2002.  From this initial cohort 
only those patients treated with CHOP chemotherapy (cyclophosphamide, 
doxorubicin, vincristine and prednisolone), which was the standard treatment at this 
time, were included to create a cohort of patients in which any differences in 
outcome were not due to differences in chemotherapeutic regimen. 
One hundred and sixty five patients were identified who had received CHOP 
chemotherapy.  Diagnostic material from these patients was reviewed and cases 
excluded on any of the following grounds; formalin-fixed paraffin embedded 
material was missing from the pathology archives or there was insufficient diagnostic 
material present to allow sampling for inclusion in a TMA and preservation of 
material for future clinical use.   
Seventy four cases were identified suitable for inclusion in a TMA.  Clinical 
outcome data was available for 71 of these.  The clinical features and survival data 
for these cases is given in Table 6.1.    The patients ranged in age from 25 to 79 
years.  There were similar numbers of males and females (37 males, 34 females).  
The majority of patients (52 of 71) fell into ECOG performance status 1 or 2, 
indicating that they were ambulatory and self-caring , with only 12 patients falling in 
ECOG groups 3-5, a bias reflecting the fact that this is a cohort of patients selected 
on the basis that they are fit enough to undergo chemotherapy.  Treatment success 
was defined as ongoing complete or partial remission with treatment failure defined 
as relapsed disease or death.    Forty-one of seventy one patients relapsed or died in 
the period of follow up.   For the patients in the treatment failure group, the period of 
follow up lasted from 1.7 to 86 months with a median of 24 months.  In the treatment 
success group follow-up was from 10 to 141 months with a median of 47 months. 
For patients who relapsed or died, the mean time to treatment failure was 11.8 
months, with a median of 0 months.  The mean time to death in this group was 26.5 




































34 (48) 19 (46) 15 (50) 
 







61.7 [34  - 79] 
 
53.6 [25 – 77] 
Median [IQR] 
 
61 [50.5-69.5] 63 [56 - 71] 57 [41 – 66] 
 
Clinical stage 









2 15 (21) 8 (20) 7 (23) 
3 22 (31) 17 (41) 5 (17) 
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2 20 (28) 14 (34) 6 (20) 
3 7 (10) 3 (7) 4 (13) 
4 4 (6) 3 (7) 1 (3) 
5 1 (1) 1 (2) 0 (0) 
Not known 
 










No 44 (62) 26 (63) 18 (60) 
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No 59 (83) 33 (80) 26 (87) 
Not known 
 











2 14 (20) 12 (29) 2 (7) 
3 8 (11) 6 (14) 2 (7) 
4 1 (1) 0 (0) 1 (3) 
Not known 
 























Table 6.1.  Demographic data for group as a whole, then subdivided by the basis of 




 Mean (Range) Median (Interquartile 
range) 
Time to treatment failure  
in months 
11.8 (0 - 72) 0 (0 - 14.3) 
Time to death in months 26.5 (1.7 – 86) 21 (6.2 – 42.4) 
 
Table 6.2.  Outcome data for patients in whom treatment failed (defined as relapse of disease 







6.2.1 Introduction to TYMP 
Thymidine phosphorylase (TYMP) is an evolutionarily conserved molecule, 
originally isolated from bacteria, that plays a vital role in pyrimidine salvage, 
converting thymidine and phosphate to thymine and 2-D-deoxyribose- 1- phosphate 
(reviewed in Bronckaers et al 2009).  It was independently identified by several 
groups in different settings and was also given the alternative names of platelet-
derived endothelial cell growth factor and gliostatin (Friedkin and Roberts, 1954, 
Miyazono et al, 1987, Asai et al, 1992)    The name platelet derived endothelial cell 
growth factor hints at its role in angiogenesis, although the name is a misnomer, 
based on initial experiments carried out before the molecule was recognised as 
thymidine phosphorylase in which endothelial cell proliferation was measured using 
incorporation of radioactive thymidine.  Subsequent work has show TYMP to be a 
chemotactic factor for endothelial cells rather than a growth factor (Moghaddam and 
Bicknell 1992, Ishikawa et al 1989).   
Angiogenesis is a relatively uncommon phenomenon in the adult being confined to 
certain physiological and pathological processes including the endometrial growth 
cycle, inflammation, wound healing and neoplasia.  While TYMP has been shown to 
be an important angiogenic molecule in endometrial proliferation much of the work 
on TYMP has been in relation to tumorogenesis (Zhang et al 1997, Fujimoto et al 
1998, Moghaaddam et al 1995, Arima et al 2000, O’Brien et al 1996, Yoshikawa et 
al 1999, Takebayashi et al 1996a, Takebayashi 1996b, O’Byrne et al 2000, 
Takebayashi et al 1999, Fujimoto et al 1999, Yamamoto et al 1998, Mainou-Fowler 
et al 2006).  Tumours as rapidly growing tissues require to lay down new blood 
vessels to progress beyond a very small size.  In the absence of effective 
angiogenesis, tumours will fail to progress or infarct when they outgrow their blood 
supply.    TYMP appears to be regulated by a variety of factors including hypoxia, 
radiation damage and inflammation (Griffiths et al 1997, Blanquicett et al 2002, 
Sawada et al 1998, Sawada et al 1999).  Interferon gamma induces TYMP expression 
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and indeed, there is an interferon response element in the TYMP promoter (Schwartz 
et al 1998).    
In human tumours TYMP has been postulated to have a dual role in promoting 
angiogenesis and inhibiting apoptosis.    Much of the work on TYMP in human 
tumours has been correlative, looking at the association between TYMP expression 
and prognosis, with the majority of studies in the majority of types of tumour 
showing an association between high levels of TYMP and poor outcome (reviewed 
in Bronckaers et al 2009).  Some studies have also addressed the putative angiogenic 
role of TYMP in tumours by demonstrating an association between high levels of 
TYMP and microvessel density (Relf et al 1997, Kawahara et al 2010, Morita et al 
2001).    TYMP expression can be seen to correlate with expression of other 
angiogenic factors, notably VEGF, but data from HIF1 and HIF2 knockout mice, 
suggest that these may be under different regulation, although both are responsive to 
hypoxia (Toi et al 1996, Brown et al  1995, O’Byrne et al  2000, Sivridis et al 2002).  
In many of the earlier studies of TYMP in human tumours, expression of TYMP was 
analysed by RT-PCR or enzyme activity.  More recent studies have shown that in 
many of these tumours, the expression of TYMP is not by the tumour itself, but by 
TAMs implying a role for the microenvironment of the tumour in driving 
angiogenesis (Kim et al 2009, Kawahara et al 2010).    Data from a variety of sources 
have shown that the enzymatic activity of TYMP is essential for its role in 
angiogenesis, implicating a product of this enzymatic activity as the key signalling 
molecule, although the exact nature of the signal remains unclear, as the putative 
active molecule 2-deoxy-d-ribose does not appear to bind to a surface receptor 
(Moghaddam et al 1995, Miyadera et al 1995, Brown and Bicknell 1998, Hotchkiss 
et al 2003). 
TYMP however, also seems to have functions unrelated to angiogenesis showing the 
ability to inhibit apoptosis in various malignant cell lines.  There appears to be 
several facets to this, with different data suggesting the TYMP enzymatic activity is 
required or not required dependent on the mechanism driving the apoptosis 
(reviewed in Akiyama et al 2004).  It seems though that in certain settings in vitro, 
TYMP can exerting a direct anti-apoptotic effect via its metabolite 2DDR on tumour 
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cells, in an autocrine fashion (Ikeda et al 2006).  The significance, if any, of this role 
in vivo in unclear, but given that in most tumours, the majority of TYMP expression 
is in the TAMs, it could be hypothesised that a similar paracrine effect could be seen 
with TAMs suppressing apoptosis of tumour cells.    
In treated tumours TYMP has an additional role to that which it may play in 
tumorogenesis; TYMP may be induced by treatment with radiotherapy and various 
chemotherapeutic compounds causing upregulation of expression (Kim et al 2009, 
Liekens et al 2007) .  In addition there are a class of chemotherapeutic agents whose 
action relies on conversion of the pro-drug to the active form by the action of TYMP 
(reviewed in Leikens et al 2007).  Thus in cancer TYMP may be a double-edged 
sword helping promote cancer growth, but providing an avenue for chemotherapeutic 
attack.  This potential weakness is being targeted by current clinical approaches, with 
strategies designed to upregulate TYMP expression prior to commencement of 
chemotherapies reliant on TYMP activity.  Several of the drugs used in the treatment 
of DLBCL rely on the activity of TYMP, but there is currently no data as to whether 
TYMP expression is a good or adverse prognostic factor in DLBCL.   
TYMP was present in the TAM profile on gene expression analysis.  It can be 
hypothesised that in TAMs TYMP plays a dual role in supporting tumour cell growth 
by both promoting angiogenesis and protecting tumour cells from apoptosis.  In this 
hypothesis, expression of TYMP by TAMS should be a marker of poor prognosis.   
 
 
6.2.2 Scoring of TYMP expression 
 
Using the TMA of DLBCL cases, expression of TYMP by TAMs was assessed by a 
single observer blinded to the clinical outcome.  The total number of TYMP-positive 
macrophages in a set area of 3HPF was counted.  Of the seventy four cases present in 
the array, data was obtained for 55 cases.   Cases were excluded if all replicates of 
the case were lost during the staining protocol, or if too little tumour was represented 
to allow counting of 3 HPF.  Based on distribution of cases on a dot plot, the cases 
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were divided into high or low numbers of TAMs with a cut off value of 300 positive 
cells (Figure 6.1).   
  Time to treatment failure 
in months 
 
Mean (± SE) 









Number of positive cells 
 
High   
(n=31) 
 
63 (± 12) 
34 (± 13) 
 
 
81 (± 11) 
86 (± 25) 
 
 
Low   
(n=24) 
 
49 (± 11) 
36 (± 6) 
 
 
61 (± 10) 
56 (± 7) 
  
Table 6.3  TYMP  expression by macrophages in DLBCL and outcome in a CHOP-treated 
cohort of patients.  A TMA containing 74 cases was stained with anti-TYMP antibody 
(HPA001072) and the number of positive TAMs stained in 3 HPFs was counted and divided 
into high or low numbers of TYMP-positive TAMs with a cut-off value of 300 cells/3hpf.   
 
 
Figure 6.1   Sections of TMA were stained with anti-TYMP antibody (HPA001072) and 
number of positive cells counted in a set area (3HPF).  There was variation in staining 
patterns between tumours with differential staining in nucleus and cytoplasm.  No difference 
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in outcome was detected between tumours based on expression pattern, or staining intensity 







Figure 6.2    The number of TYMP expressing macrophages was counted in a set area 
(3HPF) in a cohort of DLBCL treated with CHOP chemotherapy.  Cases were divided into 
those with high or low numbers of TYMP positive cells and Kaplan-Meier survival curves 



















TYMP high  
Mantel-Cox log rank test.   



















TYMP high  
Mantel-Cox log rank test.   








6.2.3 Relationship to clinical outcome 
 
Outcome,  assessed both in terms of time to treatment failure and overall survival, 
was calculated using the data of the SNLG database dividing cases into those with 
high or low numbers of TYMP-expressing TAMs.  There was no difference between 
the two groups on Kaplan-Meier survival curves for either disease-free survival or 
overall survival with a mean time to treatment failure of 63 months in the TYMP-
high group and a mean time to treatment failure of 49 months in the TYMP-low 
group (Figure 6.2, Table 6.3). Mean overall survivals were 81 and 61 months 
respectively. 
  
In this cohort of tumours, there was no observed difference in outcome between 
tumours with high or low numbers of TYMP positive TAMs, or differences related 
to expression pattern or staining intensity implying that in DLBCL the presence of 
increased numbers of TYMP-expressing TAMs does not predict aggressive 
behaviour.    In considering the effect that TYMP expression has on tumour outcome, 
the role of chemotherapy also needs to be considered, the pyrimidine salvage 
pathway being important in the action of several chemotherapeutic drugs, including 
those used in CHOP chemotherapy.  Given that all the patients in this cohort were 
treated with CHOP chemotherapy following the biopsy, the possibility cannot be 
entirely excluded that there were differences in behaviours of the tumours, which 
were masked by differences in response to chemotherapy.    Given that all patients 
who are fit enough are treated with CHOP chemotherapy and that this has been the 
standard therapy for many years, this possibility is currently unassessable on the 




6.3  AIF1 
 
6.3.1 Introduction to AIF1 
 
Allograft inflammatory factor (AIF) 1 is a 17kD  cytoplasmic calcium binding 
protein which was originally identified in the context of organ transplantation as a 
factor expressed in both human and rat cardiac allografts in the context of rejection 
(Utans et al 1995, Utans et al 1996).  It lies in the MHC class III region of the 
genome in humans along with other important molecules in the immune response, 
such as TNF Alpha, NFκB and complement components (Iris et al 1993, Deininger et 
al 2002).   An evolutionarily conserved molecule, with extensive homology between 
species, increased expression is seen in sponges when they are allografted (Zhao et al 
2013, Muller et al 2002).   In humans it appears to be a marker of organ rejection, 
with differential expression separating patients into those with and without rejection 
of renal allografts (McDaniel et al 2013).   The distribution of the molecule in the 
normal situation has been studied in the mouse, in which, outwith the testis, it 
appears in the normal state to be expressed only by cells of the 
macrophage/monocyte lineage, but is not expressed by all macrophages being absent 
in alveolar macrophages (Kohler 2007).  It appears therefore to be a molecule which 
is relatively specific to the macrophage lineage, expressed only in certain situations 
and involved in mounting an immune response in allografts.   
The exact mechanism of action of AIF1 is not yet well understood.  Expression of 
AIF1 appears to lead to expression of pro-inflammatory cytokines, and may play a 
role in endothelial cell activation.   Broadly, AIF1 appears to be a marker of a ‘pro-
inflammatory’ state.  Studies in different setting yield different outcomes, but 
expression of AIF1 appears to be upregulated by various pro-inflammatory 
molecules such as IFNγ, IL-1, TNFα and oxidised lipoproteins  and upregulation of 
the molecule leads to increased expression of iNOS, IL-6, IL-12 and other such pro-
inflammatory mediators (Watano et al 2001, Yang et al 2005, Tian et al 2006, Utans 
et al 1995, Yan and Chen 2010, Nagawaka et al 2004).    Expression of AIF1 by 
macrophages decreased levels of macrophage apoptosis and increased the migratory 
capacity of the cells (Yang et al 2005).  Conversely knockdown of AIF1 expression 
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decreased macrophage migration, inflammatory mediator expression and survival 
(Yang et al 2005).  Such a tight relationship of expression with the function of the 
activated macrophage argues that AIF1 expression represents a fundamental 
component of macrophage activation rather than a molecule expressed simply as a 
non-essential bystander.  
Outwith the transplant situation, there is some further data as to the significance of 
the molecule in the immune response.  It appears to play a role in autoimmune 
disease with polymorphisms in the molecule associated with systemic sclerosis and a 
variant form of the molecule associated with Type 1 diabetes mellitus in Norwegian 
families (DelGaldo et al 2006, Alkassab et al 2007, Eike et al 2009).  It has also been 
detected in the synovium of patients with rheumatoid arthritis, but not those with 
osteoarthritis (Kimura et al 2007).  AIF1 expressing macrophages have been 
identified in other diseases as well, with AIF1 expression seen in macrophages in the 
atherosclerotic plaque, where activation appears to be secondary to the phagocytosis 
of oxidised LDL and where there is evidence for a role in promoting the proliferation 
of vascular smooth muscle cells (Tian et al 2005, Mishima et al 2008, Somerville et 
al 2012).    
Very little is known of its role, if any, in cancer.  It is expressed by a subset of 
microglial cells and macrophages in glioma, suggesting that in this setting either 
expression is regulated, or a specific subset of cells is recruited to the tumour site 
(Deininger et al 2000).  Higher numbers of AIF1 positive cells are seen in higher 
grade tumours, but given the propensity for higher grade tumours of any histological 
subtype to contain larger numbers of macrophages it is unclear how specific this 
effect is (Deininger et al 2000).   Outwith the setting of the tumour associated 
macrophage, it has been shown to be expressed by malignant epithelium in breast 
cancer and expression correlated with higher grade and stage (Liu et al 2008).  In 
vitro expression in breast cancer cells has been shown to increase proliferation of 
those cells by an undetermined mechanism (Liu et al 2008).   In contrast, recent data 
from gastric carcinoma indicates that lower levels of expression in epithelium 
correlates with poorer outcome (Ye et al 2014).   In giant cell tumour of bone, an 
unusual but usually benign tumour possibly derived from cells of the 
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monocyte/macrophage lineage, higher levels of AIF1 correlate with more aggressive 
behaviour (Conti et al 2011).   
 
AIF1 appears to represent a macrophage-expressed molecule with features of 
‘classical’ activation, with a role in autoimmune disease and transplant rejection but 
little studied in other settings.   Whilst there is little mechanistic data as to control of 
expression and downstream effectors, it can be hypothesised that increased 
expression of AIF1 expression macrophages in tumours would represent evidence of 
a ‘classically ’ activated, rejecting macrophage and as such would be associated with 
better prognosis.   
 
 
6.3.2 Scoring of AIF1 expression 
 
Using the TMA of DLBCL cases, expression of AIF1 by TAMs was assessed by a 
single observer blinded to the clinical outcome.  Cases were excluded if all replicates 
in the TMA were lost on processing.  Staining was assessed on a 4 point visual scale 
by eye (0 for no staining, through to 3 for strong staining). Cases were then further 
grouped for mean staining intensity ≤2 or >2 and relationship to clinical outcome 
sought.  Cases were also assessed by staining pattern and were divided into those 
with and without nuclear expression of AIF1. 
 
 
6.3.2 Relationship to clinical outcome 
Intensity of AIF1 staining in TAMs was not associated with difference in outcome 
measured either as disease free survival or overall survival with cases with high 
intensity staining having a mean disease-free survival of 48 months compared to the 
62 months in the low intensity staining group.   Mean overall survivals were 68 and 
84 months respectively (Table 6.4).    There were no differences in the Kaplan-Meier 
survival curves between groups (Figures 6.3 and 6.4).  While there was a shorter 
disease free survival and overall survival in those patients’ whose TAMS showed 
higher expression of AIF1, a relationship at odds to that hypothesised,  this did not 
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reach statistical significance.  Overall, this data does not suggest that AIF1 plays a 
significant role in the support or suppression of DLBCL growth by TAMS.  An 
interesting relationship was also observed with the pattern of expression of the 
protein.  In those patients in whom the macrophages showed expression of AIF in the 
nucleus as well as the cytoplasm, there were no deaths due to disease.  This 
represented a very small group of patients (11 patients in total), and again was not 
statistically significant.  A review of the literature does not produce any data as to 
nuclear expression of AIF1.  It is possible that the antibody used also binds an 
unidentified nuclear protein, but it could also be hypothesised that an alternative 
variant of AIF1 exists that can translocate to the nucleus.  The nature of the molecule 
being detected in the nucleus in these tumours was not explored further.   
 
 
  Time to treatment 
failure in months 
 
Mean (± SE) 
Median (± SE) 








Intensity of staining 
 
High   
(n=32) 
 
48 (± 13) 
34 (± 13) 
 
 
68 (± 8) 
82 (± 18) 
 
 
Low   
(n=26) 
 
62 (± 9) 
36 (± 7) 
 
 
84 (± 13) 


















44 (± 7) 
30 (± 12) 
 
 
66 (± 16) 
69 (± 16) 
 
Table 6.4.  Intensity of staining for AIF1 in macrophages in DLBCL and outcome in a 
CHOP-treated cohort of patients.  A TMA containing 74 cases was stained with anti-AIF1 
antibody (Ab5076) and the scored by eye on a 4 point scoring system (0-4).  Cases were 
divided into two categories with cases with mean staining intensity >2 allocated to the high 








Figure  6.3   The intensity of staining of TAMs in a cohort of patients with DLBCL treated 
by CHOP chemotherapy was scored visually by a single observer and cases divided into 
those with high or low intensity staining regardless of the distribution of staining within the 
cell.  Kaplan-Meier survival curves were plotted for a) time to treatment failure and b) time 















TIME TO TREATMENT FAILURE (MONTHS) 
Mantel-Cox log rank test.   
Chi square 0.072    p = 0.789 
 
---- 
AIF1 low intensity 















OVERALL SURVIVAL (MONTHS) 
 
---- 
AIF1 low intensity 
AIF1  high intensity 
Mantel-Cox log rank test.  










Figure  6.4   The localisation of staining for AIF1 in TAMs was assessed in a cohort of cases 
of DLBCL treated by CHOP chemotherapy.  A small group of  cases demonstrated nuclear 
staining for AIF1, and within this group in those patients who did not have primary treatment 
refractory disease, there were no cases of treatment failure.  This difference did not meet 
statistical significance.   Kaplan-Meier survival curves plotted for a) time to treatment failure 





















AIF1  no nuclear 
expression 
Mantel-Cox log rank test.  















OVERALL SURVIVAL (MONTHS) 
Mantel-Cox log rank test.  













6.4.1 Introduction to LGALS3BP 
Galectin-3 binding protein (LGALS3BP), also known as Mac-2 binding protein or 
90K, was originally identified in the serum of patients with cancer and postulated to 
be a cancer secreted molecule (Iacobelli et al 1986, Scambia et al 1988, Ullrich et al 
1994).  It has been identified in the serum of patients with a wide variety of 
malignancies and is usually a marker of poor prognosis (Fornarini et al 2000, Fusco 
et al 1998, Iacovazzi et al 2001, Marchetti et al 2002, Strizzi et al 2002).  It was 
subsequently shown to also be detectable in the serum of patients with HIV 
progressing to AIDS in the absence of neoplastic complications of AIDS suggesting 
its role was wider than simply being a biomarker of malignancy (Iacobelli et al 1991, 
Natoli et al 1993).  The protein is of 567 amino acids, is subject to extensive post-
translational glycosylation and has a molecular weight of between 90 and 95 KDa 
dependent on glycosylation status (Koths et al 1993, Ullrich et al 1994).  The protein 
appears to exist in serum as a large oligomeric complex (Sasaki et al 1998).    It 
contains a scavenger receptor motif, but unlike many other molecules with this motif 
which are membrane based has the structural characteristics of a secreted protein.  
The protein has been identified in the malignant cells in many types of tumour, but is 
also expressed by cells of the immune system including macrophages (Becker et al 
2008, Ulmer et al 2006). 
The mechanisms of actions of the molecule are poorly understood and much of the 
data relates to the secreted form of the molecule.  As well as galectin-3, this appears 
to bind to multiple components of the extracellular matrix and to integrins expressed 
on cells and is postulated to play a role in tumour metastasis by providing anchorage 
for circulating tumour cells, protection from apoptosis of tumour cells by the direct 
action of binding of tumour cells to the molecule and promotion of angiogenesis by 
VEGF-dependent and independent pathways (Inohara et al 1996, Piccolo et al 2012, 
Sasaki et al 1998, Stampolidis et al 2015).  In HIV, expression of the molecule by 
cells of the monocytic lineage renders them less susceptible to infection by HIV-1 
and promotes expression of IL-1 and IL-6 by the cells (Lodermeyer et al 2013).  
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Expression in this context is upregulated by IFN gamma.  Expression of IL-6 has 
also been seen in bone marrow stromal cells on binding of LGALS3BP (Fukaya et al 
2008). 
 
The relatively limited, but suggestive data as to the function of this molecule, a poor 
prognostic indicator in many types of cancer in serum, but whose expression at a 
local level influences macrophage function made this an interesting molecule to 
study further. Is this an immune-related molecule whose normal function has been 
subverted by tumour cells to promote survival and metastasis?   Of interest also was 
the very little functional data relating to this molecule in lymphoma where binding 
by Jurkat T lymphoma cells to LGALS3BP protected the cells from chemotherapy 
induced apoptosis suggesting a possible role in response to therapy (Fornarini et al 
2000).   
 
6.4.2 Scoring of LGALS3BP expression 
 
Using the TMA of DLBCL cases, expression of LGALS3BP by TAMs was assessed 
by a single observer blinded to the clinical outcome.  Cases were excluded if all 
replicates in the TMA were lost on processing.    Fifty nine cases were available for 
assessment.  LGALS3BP was expressed in macrophages in only a small number of 
tumours, and where present often showed only weak staining (Table 6.5 and Figure 
6.5).  Cases were assessed only for presence or absence of staining in TAMs. 
 
6.4.3 Relationship to clinical outcome 
 
There was no relationship between expression of LGALS3BP by TAMS and 
outcome with the mean time to treatment failure being 54 months in the cohort with 
positive staining in TAMs and 57 months in the cohort with negative staining in the 
TMAs.  The overall mean survivals in these groups were 67 and 81 months 
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respectively.  The Kaplan-Meier survival curves demonstrated no differences in 
survival (Figure 6.6). 
 
  Time to treatment 
failure in months 
 
Mean (± SE) 
Median (± SE) 











Positive   
(n=19) 
 
54 (± 11) 
36 (± 20) 
 
 
67 (± 10) 






57 (± 10) 
30 (± 14) 
 
 
81 (± 11) 
86 (± 14) 
 
Table 6.5  Presence or absence of staining in TAMs in DLBCL and outcome in a CHOP-
treated cohort of patients.  A TMA containing 74 cases was stained with anti-LGALS3BP 
antibody (HPA000554) and then scored by eye for presence or absence of staining in 





Figure  6.5   Sections of DLBCL were stained with an antibody against LGALS3BP 
(HPA000554).   In many cases there was no expression in TAMs, while a proportion of 
cases showed staining which was mostly weak and focal (Shown here in macrophages with a 











Figure  6.6  The presence of absence of staining for LGALS3BP in TAMs was assessed in a 
cohort of cases of DLBCL treated by CHOP chemotherapy.  A small group of cases showed 
positive staining in TAM.   Kaplan-Meier survival curves plotted for a) time to treatment 
failure and b) time to death in patients with or without LGALS3BP staining in TMAs 




















Mantel-Cox log rank test.   
Chi square = 0.292   p = 0.59 
 




























Mantel-Cox log rank test.   
Chi square = 0.019   p = 0.89 
 






6.5.1 Introduction to LAIR1 
 
 
LAIR1 is a 32kDa transmembrane protein of the immunogloblulin superfamily.  It is 
a 278 amino acid-containing inhibitory receptor containing two intracytoplasmic 
ITIM motifs, and a single extracellular C2 immunoglobulin-like domain (Meyaard et 
al 1997).  Homologues have been identified both in mouse and rat (Lebbink et al 
2007, Lebbink et al 2005).   In humans, but not in rodents there is a closely related 
molecule LAIR 2, which has a high degree of homology to LAIR1 but which lacks 
the transmembrane and cytoplasmic domains (Lebbink et al 2008).  This gene lies 
close to LAIR1 but is transcribed in the opposite direction.  The LAIR1 protein was 
first cloned by Meyaard et al in 1997 and its distribution on all peripheral blood 
mononuclear cells described (Meyaard et al 1997).  The inhibitory nature of 
signalling through LAIR1 was recognised well in advance of the identification of its 
ligand, with early work focussing particularly on inhibition of tumour cytotoxity by 
NK cells (Meyaard et al 1997).  Recently however, the specific ligand for this 
receptor has been identified as a motif almost entirely specific to and present on all 
collagen molecules, a hydroxyproline motif in the form of Gly-Pro-Hyp repeats 
(Lebbink et al 2006).    This ligand, which binds to LAIR1 with high affinity, seems 
to be involved in the formation of the collagen triple-helix and is present on both 
extracellular and transmembrane collagen proteins (Lebbink et al 2006). 
 
Collagen binding receptors are widely expressed in human biology including 
integrins, DDR1 and 2 and the platelet receptor, and the functions encompassed by 
these receptors is very broad, perhaps reflecting the fundamental importance of 
collagen in mammalian biology, but to date LAIR1 is the first described inhibitory 
collagen receptor (reviewed in Leitinger at al 2007).  As such, it provides an 
intriguing insight into the ways in which the structural microenvironment can control 
immune cell activation in the context of both innate and adaptive immunity.  With 
the exception of while cells of haemopoetic origin are in circulation, almost any 
conceivable immune interaction is likely to place in the immediate vicinity of 




Initial work on LAIR1 was carried out prior to identification of the receptor, but can 
now be interpreted in the light of current knowledge.  Crosslinking of the LAIR1 
receptor by antibodies specific for the receptor has been shown to result in inhibition 
of NK- cell tumour cell lysis, inhibition of T cell activation by either CD3 cross-
linking or antigen presentation, and downregulation of BCR-signalling driven 
calcium mobilisation and immunoglobulin production (Meyaard et al 1997, Merlo et 
al 2005).   As well as signals mediated through ITAM-containing receptors, LAIR1 
also inhibits signalling via cytokines with inhibition of GM-CSF driven 
differentiation of peripheral blood monocytes to dendritic cells and GM-CSF driven 
proliferation in primary leukaemia cells (Poggi et al 1998, Poggi et al 2000).    
 
Given the ubiquity of the ligand, it would seem apparent that the downstream 
signalling from LAIR1 must be more complex than an on-off signal, and the 
available data supports this:  studies in B-cells have demonstrated that the inhibitory 
signal of LAIR1 can be overcome in the presence of a sufficient activation signal 
(Merlo et al 2005).  In addition, levels of expression of the receptor itself may also 
play a role.  In B-cells, LAIR1 expression is down-regulated as B cells are activated, 
such that naive B-cells express high levels of LAIR1 compared to memory B-cells or 
plasma cells, suggesting that the activation threshold of these cells will be lowered 
(Meyaard et al 2008).  Similarly in T cells, expression is high in naive cells but lower 
and more heterogeneous in subsets of memory cells suggesting active regulation of 
LAIR1 expression (Maasho et al 2005, Jansen et al 2007).  There is limited in vitro 
data about the effect of T cell activation on LAIR1 expression, but in T cells, CD3 
and CD28 activation have been shown to downregulate LAIR 1 expression (Jansen et 
al  2007), while CD3 and IL-2 stimulation have been shown to upregulate expression 
(Maasho et al 2005).  While the data is limited, it is tempting to speculate that in T 
cells activation in the absence of an appropriate second signal, leads to upregulation 
of LAIR1, increasing the threshold for activation.  The method by which LAIR1 is 
regulated in T cell activation has been studied.  Regulation in T cells does not appear 
to be at the mRNA level, or by shedding of the protein as a soluble form, but rather 




The mechanisms by which LAIR1 regulates T cell activation have been partially 
elucidated; Src-homology-2(SH2) domain-containing protein tyrosine phosphatise 
(SHP-1) is constitutively associated with the intracellular ITIM motifs of LAIR1 in 
Jurkat cells and in primary human T cells suggestive of a role for LAIR1 in setting 
the activation threshold of the cells (Sathish et al 2001).  On crosslinking of LAIR1 
both ITIM-motifs are phosphorylated and this phosphorylation of both motifs is 
required for optimal LAIR1 activation (Verbrugge et al 2003).  The inhibitory effects 
of LAIR1 signalling in T cells appear related to the surface density of the molecule 
(Saverino et al 2002).  In these studies, the specific cytokine responses of T cells was 
also analysed, showing not a blanket inhibition of T cell responses but rather 
different effects dependent on the individual cytokine, with IL-2 and IFNγ 
production being inhibited in the presence of LAIR1 activation and TGFβ being 
enhanced (Saverino et al 2002).   
 
In addition to the mechanism described above, there appears to be a role, albeit 
poorly understood for soluble forms of the receptor.  Human LAIR1 has been 
reported to be found in the supernatant of stimulated PBMC suggesting that the 
molecule may be shed on activation (Ouyang et al 2004).   It is worth noting in the 
report above where soluble LAIR 1 was measured, that measurement was made 
using an ELISA technique directed against an extracellular component of the LAIR1 
which is identical to the extracellular component of LAIR2.  LAIR2 (which lacks a 
transmembrane and intracytoplasmic domain) has been reported to have an 
antagonistic effect on LAIR1 signalling (Lebbink et al 2008).  Currently there is little 
evidence to establish whether LAIR 1 is shed during immune activation and whether 
LAIR2 is secreted on immune activation.  Of note though there is no mouse or rat 
homologue of LAIR2 suggesting that it arose more recently, and is not necessary for 
the role LAIR1 plays in other mammals.   In vivo LAIR 2 has been shown to 
interfere with LAIR1 binding to collagen (Lebbink et al 2008 ). The same group also 
demonstrated that in PMBC stimulated with PMA and ionomycin, CD4 positive T 
cells, though not other cell types, secreted LAIR2.  LAIR2 was also found in large 
quantities in the urine, though not the plasma of pregnant women, as well as being 
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found in synovial fluid of patients with rheumatoid though not osteoarthritis, all 
suggesting a possible role for LAIR2 in immune modulation (Lebbink  et al 2008).  
 
In the context of primary human monocytes and macrophages, there is almost no 
data as to the expression of LAIR1 and the effect of activation save for a single study 
in which CD14+  precursors were driven in the direction of dendritic cell 
differentiation, with a resultant downregulation of LAIR1 (Poggi et al 1998).   
 
There is limited data from acute myeloid leukaemia (AML) cell lines, suggesting a 
role of LAIR 1 in myeloid cell differentiation.  A study by Poggi et al (Poggi et al 
2000) suggested that signalling through LAIR1 in AML cell lines induced apoptosis.  
In primary myeloid leukaemia cells, LAIR1 crosslinking stops the AML cells from 
responding to the proliferative signal of GM-CSF and in AML cell lines LAIR 1 
cross-linking induces apoptosis (Zocchi et al 2001).  These data however, being 
derived from cells which are inherently abnormal in their proliferation and 
differentiation, while suggestive of a role for LAIR1 in monocyte/macrophage 
function cannot be regarded as conclusive.   A recent gene expression study of the 
effect of hypoxia on monocytes demonstrated that LAIR1 was one of the genes 
whose expression was downregulated on exposure to hypoxic conditions, implying 
that monocytes may be more readily activatable in hypoxic conditions (Bosco et al 
2006).  From a biological point of view, this would seem plausible, implying that the 
activation thresholds for monocytes/macrophages may be lower in hypoxic (and 
therefore) diseased tissue than when in circulation.   
 
There is very little data as to the role, if any, that LAIR1 plays in human disease, 
save for a single case report of a case of chronic active EBV in a boy whose NK cells 
lacked LAIR1 (Aoukaty et al 2003).  Presence or absence of LAIR1 expression on 
other cell types was not commented on in this case.    
 
Expression of LAIR1 by TAMs provides an intriguing potential mechanism for 
immune cell modulation by tumours.  Deposition of collagen by tumours (or the 
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induction of collagen expression by other non-tumour cells by the tumour) would 
provide a mechanism to downregulate immune cell activation.  In this context, the 
desmoplastic response seen in many tumours may represent a mechanism of immune 
escape.  Coupled with the hypoxic environment that exists in many if not all 
tumours, the tumour microenvironment may provide multiple elements to activate 
these inhibitory receptors.   It can be hypothesised that in tumours where there is 
strong expression of LAIR1 on TAMs, these cells will be less readily activatable and 
hence less able to support tumour growth.  
 
The expression pattern and intensity of staining for LAIR1 in human TAMS in 
DLBCL was examined to determine whether differences in LAIR1 expression by 
TAMs correlated to differences in clinical outcome. 
 
 
6.5.2 Scoring of LAIR1 expression 
Using the TMA of DLBCL cases, expression of LAIR1 was scored in macrophages, 
both in terms of intensity of expression and number of macrophages expressing the 
protein in a given area.  A histoscore, combining staining intensity and number of 
stained cells was calculated where possible.   Of the seventy four cases present in the 
array, data was obtained for 56 cases for staining intensity and in 34 cases it was 
possible to calculate a histoscore.   Cases were excluded if all replicates of the case 
were lost during the staining protocol, and in the case of the histoscores if counting 
of cells in 5HPFs was impossible.  This group included cases where there was too 
little tumour present to count a sufficient area of tumour, cases with tumour cell 
staining as well as macrophage staining and cases where the morphology of the 
macrophages did not allow an accurate count to be made. 
Cases were scored for intensity on 5 point grading scale, by a single observer blind to 
outcome, where 0 was no staining and 4 was very intense staining (Figure 6.7).  
Multiple scores for a single tumour were converted to a mean score.    Cases were 
divided into high or low intensity (low <3, high ≥3) and high or low histoscore  
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(<500, ≥500)  based on examination of dots plots of individual cases to determine 




   
Figure 6.7  Sections of TMA were stained with anti-LAIR1 antibody (HPA001155) and 
intensity of staining was quantified by eye using a 5 point scoring system (0-4).  Examples 
are given of intensity of staining scoring 1-4.  a) Weak staining =1.  b) Moderate staining = 










6.5.3 Relationship to clinical outcome 
 
Outcome was assessed both in terms of time to treatment failure, a disease specific 
measure of success of therapy, and time to death, with the data from the SNLG 
database not recording whether death was disease specific or unrelated.  Kaplan-
Meyer survival curves were plotted and the Mantel-Cox log rank test applied to 
determine whether the groups differed in their outcome (Figure 6.8 and 6.9).  For 
intensity of staining, there was better outcome in terms of time to treatment failure 
and time to death in those patients whose TAMs showed low intensity staining with 
LAIR1, though this difference reached significance only for overall survival.  There 
were no differences in outcome between groups with high and low histoscores.  This 
would support the hypothesis that in macrophages with a lower activation threshold, 
these cells are more readily activatable to support tumour growth.  Alternatively, it 
could be argued that these macrophages are more activatable in the face of therapy 
and hence relate to better outcome because of cytotoxic effects on the tumour cells in 
the face of therapy.  As all patients were uniformly treated, it is not possible to 
differentiate between these two possibilities.   
 
Of interest, was the lack of expression of LAIR1 by the tumour cells.  Data from 
PBMC indicates that circulating B cells express LAIR1 at variable levels dependent 
on the status of the cell, expression being higher in naive cells than memory cells 
(Meyaard et al 1997).  LAIR1 staining was not observed in B cells in reactive lymph 
nodes (Figure 5.6) and was only rarely seen in B cells in lymphoma.  This absence in 
reactive lymph nodes would argue against loss of expression being a tumour specific 
phenomenon.  Two major possible explanations exist; that there are differences in 
LAIR 1 expression intensity and/or sensitivity to antigen retrieval techniques 
between macrophages and other cell types, or that expression of LAIR1 by 
lymphocytes is altered by the microenvironment of the lymph node.  Of note is that 
previous studies of LAIR1 expression by lymphocytes have only analysed those in 
the peripheral blood where expression has been seen to be downregulated on B cell 










Time to treatment 
failure in months 
 
Mean (± SE) 
Median (± SE) 








Intensity of staining 
 
High   
(n=39) 
 
39 (± 8) 
14 (± 9) 
 
 
58 (± 8) 
50 (± 9) 
 
 
Low   
(n=17) 
 
76 (± 16) 
72 (± 26) 
 
 
96 (± 14) 









46 (± 9) 
34 (± 7) 
 
 
62 (± 8) 





45 (± 11) 
36 (± 1) 
 
 
62 (± 9) 
68 (± 0) 
 
Table 6.6 LAIR 1 expression by macrophages in DLBCL and outcome in a CHOP-treated 
cohort of patients.  A TMA containing 76 cases was stained with anti-LAIR 1 antibody 
(Atlas antibodies) and scored for intensity of staining in TAMs on a five point scale.  Cases 
were divided into high or low intensity staining (<3 or ≥3) and comparison made with 
outcome data.  A Histoscore combining intensity of staining with number of positive cells 
was also calculated and divided into high or low histoscore (<500, ≥500) and comparison 








Figure 6.8   Diffuse large B cell lymphoma from a cohort of CHOP-treated patients were 
stained with an anti-LAIR1 antibody and scored for intensity of staining in TAMs.  Kaplan-
Meier survival curves were plotted to show (a) time to treatment failure and (b) time to death 
in patients with high or low intensity staining.  
Mantel-Cox log rank test.   
Chi square 2.724    p = 0.99 

















LAIR1 low intensity 















OVERALL SURVIVAL  (MONTHS) 
Mantel-Cox log rank test.   
Chi square 4.142.    p = 0.042 
 
---- 
LAIR1 low intensity 











Figure 6.9   Diffuse large B cell lymphoma from a cohort of CHOP-treated patients were 
stained with an anti-LAIR1 antibody and histoscores calculated by multiplying number of 
positive cells by staining intensity.  Histoscores greater than 500 are grouped into the high 
histoscore category.    Kaplan-Meier survival curves were plotted to show (a) time to 
treatment failure and (b) time to death in patients with high or low histoscores. 
 
---- 
LAIR1 low histoscore 















TIME TO TREATMENT FAILURE (MONTHS) 
Mantel-Cox log rank test.   















OVERALL SURVIVAL  (MONTHS) 
 
---- 
LAIR1 low histoscore 
LAIR1 high histoscore 
Mantel-Cox log rank test.   







Four genes from the in silico gene expression signature of TAMs in diffuse large B 
cell lymphoma whose known function suggested they may have a role to play in the 
macrophage response to the tumour were examined in an independent cohort of cases 
of DLBCL treated with a CHOP regimen and relationship to outcome studied.  For 
AIF, TYMP and LGALS3BP there was no relationship of expression of these 
molecules at the protein level with outcome.  Only for LAIR1 was a significant 
relationship seen with expression pattern and outcome and while the trend was 
similar for disease free survival and overall survival, only in the overall survival data 
was the result significant.  The failure to reach significance in the more specific 
measure of outcome, i.e. disease free survival, raises the possibility that this 
represent a spurious association rather than a true effect on outcome, but it is notable 
that in the Kaplan-Meir curves for disease free survival, the two curves do not come 
together despite the absence of significant difference between them.  It is possible 
that examination of a large cohort of cases of DLBCL may answer the question as to 









In vitro studies of LAIR1 
 
Following the observation that differences in staining intensity of TAMs in DLBCL 
were associated with better or worse outcomes in a standardly treated cohort of 
patients, a series of in vitro experiments were carried out to investigate the effects of 
LAIR1 expression by TAMs on the ability of these to support or suppress tumour 
growth.  A co-culture system was developed using THP-1 cells and BL2 cells and the 
expression of LAIR-1 characterised in this system.  THP-1 cells were selected as a 
source of human macrophage-like cells to provide a pure population of cells of the 
monocyte/macrophage lineage.  The use of BL2 cells was well established within the 
group in a co-culture model of tumour growth and provided a well-characterised 
model of tumour growth.   The expression of LAIR1 in this model system was 
studied, as well as the effect of polarisation of macrophages by the addition of 
cytokines, the effect collagen had on the expression of LAIR-1 expression and 
tumour cell growth, as well as the influence of apoptotic tumour cells on LAIR-1 
expression.  Limitations of time allowed for completion of this thesis meant much of 
the data presented here represents preliminary experiments requiring to be repeated.   
 
7.1 Characterisation of LAIR1 expression in BL2 and THP-1 cell 
lines. 
7.1.1 LAIR 1 is expressed on the surface of THP-1 cells but not BL2 cells 
Surface expression of LAIR1 was studied first on undifferentiated THP-1 cells and 
BL2 cells using 2 different antibodies directed to the extracellular part of the 
molecule (clones DX26 and NKAT255) (Figure 7.1).  There was clear expression of 
LAIR1 on the surface of THP-1 cells by flow cytometry, but no expression on BL2 
cells.   This was in keeping with the findings from the reactive lymph node and 
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DLBCL immunohistochemical studies, which showed expression to be confined to 
the macrophage component of the tissue and not expressed in benign or malignant B 
cells.  This is in contrast to earlier work on the expression levels of the molecule 
which showed clear expression on naive B cells with lower levels being present on 
memory B cells or plasma cells (Merlo et al 2005.)  In most of the studies which 
have looked at LAIR1 expression in human leukocyte populations, peripheral blood 
has been used as a source of cells, and it is possible that the expression profile of 
leukocytes in circulation differs from that in solid tissues.  In the original description 
of LAIR1 by Meyaard et al in 1997, they also noted an absence of expression of 
LAIR1 in many malignant cell lines of haemopoetic origin, despite expression in 
primary human cells (Meyaard et al, 1997).   Whilst it is possible that loss of LAIR-1 
expression may be common to malignant cell lines as a consequence of growth in a 
collagen-free environment, the absence of expression in the solid tissues studied in 
Chapter 5 suggests that this not a purely in vitro phenomenon. 
 
7.1.2 Differentiation of THP-1 cells alters the expression level of LAIR -1 on 
THP-1 cells 
To create macrophage-like cells, THP-1 cells were differentiated by addition of PMA 
for three days, and then allowed to mature either in the absence of cytokines or in the 
face of IFNγ and LPS, IL-10 or IL-4 for 5 days to stimulate differentiation towards 
the polarised states of M1 or M2 macrophages .  Cell morphology was assessed by 
growing cells on sterile glass coverslips and THP-1 cells were assessed at day 0, day 
3 and day 6 (Figure 7.2).  Cells became larger, with more voluminous cytoplasm and 
more spread-out morphology typical of macrophages during the course of the 
differentiation process.  Immunocytochemistry on permiabilised intact cells showed 
a decrease in the intensity of the staining for LAIR1 as the differentiation process 
progressed as well as a slightly granular pattern to the staining in the more 
differentiated cells hinting at the possibility that there may be sequestration of the 




Figure 7.1  Surface expression of LAIR1 on undifferentiated THP-1 cells and BL2 cells. 
THP-1 cells and BL2 cells were stained with antibodies to the extracellular component of 
LAIR-1, and then labelled with a secondary F(ab’)2 fragment conjugated to Alexa-Fluor 488 
and fluorescence intensity analysed by FACS.  (Isotype control show in grey.  DX26 clone in 









Figure 7.2  LAIR-1 is expressed on differentiated THP-1 cells 
THP-1 cells were differentiated by the addition of PMA and plated down onto chambered 
slides.  These were incubated for 3 or 6 days and then stained directly on the slides with 
haematoxylin and eosin (H&E) or anti-LAIR1 antibody (HPA011155) directed against an 
intracellular component of the molecule.  The day 0 slides represent cytospins.   The cell 
became larger, with increased cytoplasm over the course of the differentiation and the 
expression of LAIR 1 appeared less intense.  LAIR-1 expression was assessed at day 0 and 
day 6 by flow cytometry on permiabilised cells stained with an antibody recognising an 
intracellular epitope (HPA011155) and intact cells with antibodies to a surface epitope (blue 
represents clone DX26 and green clone NKTA255).  Red represents the isotype control in all 






Expression of LAIR1 in differentiating cells was further assessed by flow cytometry 
using antibodies against both the extracellular and intracellular components of the 
molecule (Figure 7.2).   In undifferentiated cells all three antibodies showed a similar 
pattern with the histogram showing strong expression of LAIR1 by THP-1 cells with 
very little overlap of the histogram with the isotype controls.  In contrast, in the 
differentiated cells there was a much wider histogram with considerable overlap with 
the isotype control indicating that individual cells showed variable levels of 
expression of LAIR1.  This effect was seen with both the intracellular and 
extracellular component of the molecule, although the effect was more marked with 
the extracellular component regardless of the clone used.  In all the experiments 
using differentiated THP-1 cells, there is also a relatively wide peak in the histogram 
for the isotype control despite the use of a secondary F(ab’)2 fragment rather than a 
secondary whole immunoglobulin molecule to minimise non-specific binding of 
antibodies to surface receptors on macrophages.   
 
7.1.3 THP-1 expression of LAIR1 shows only minor differences regardless of 
the polarisation status of the cell. 
Expression of LAIR-1 expression was assessed by flow cytometry on differentiated 
and polarised THP-1 cells.  Cells were prepared as previously described by growth in 
tissue culture plates in the presence of PMA for three days, washed and fresh 
medium added with either no cytokines or IFNγ/LPS, IL-4 or IL-10.  Prior to 
staining with antibodies, cells were lifted from the culture plates by first adding cold 
detachment buffer and gently shaking the cells at 4°C, and then gently lifting with a 
cell scraper.  By day 8 in the differentiation process, the cells were firmly adherent 
and detachment of the cells resulted in considerable cell death both by assessment by 
trypan blue exclusion and by gating on the flow cytometer for viable and non-viable 
cells by forward and side scatter.  Assessment of LAIR1 expression was analysed 
only for those cells falling into the viable gate on flow cytometry.  As seen in figure 
7.3  THP-1 cells, regardless of their polarisation state showed a broad histogram 
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which overlapped with the isotype control for  expression of LAIR1 for both 
extracellular and intracellular staining.  There did not appear to be reproducible 
differences in expression between any polarisation state, although all these 
experiments were confounded by the large rates of cell death seen in preparation of 
the cells for flow cytometry. 
Expression of LAIR1 was also assessed by Western blotting (Figure 7.3).  Cells were 
differentiated and polarised as above and then protein extracted from whole cell 
lysates.  Equal quantities of protein from each experimental condition were loaded 
onto precast 4-12% Bis-Tris gels and western blotting performed.  All three 
antibodies against LAIR1 were used.  All three antibodies detected a protein band of 
about 40kDa of similar intensity in all polarisation states.  The predicted molecular 
weight of LAIR-1 being 32kDa based on the protein structure, this would be 
consistent with the weight of the protein plus post-translational modifications, 
presumably glycosylation (Meyaard et al, 1997).  Interestingly, the two antibodies 
directed at the extracellular component of the LAIR1 molecule DX26 and 
NKTA255, showed a single band on western blotting while the antibody directed 
against an intracellular component of the molecule also showed several bands of 
lower molecular weight, being smaller than 14kDa.  This suggested that there might 
perhaps be a cleavage product of the molecule present, containing the intracellular 
component of the molecule, raising the possibility of surface shedding of the 
molecule.  Possible surface shedding has been reported in a variety of inflammatory 
conditions in humans including rheumatoid arthritis and pregnancy although in these 
studies it is unclear if the molecule being measured was cleaved LAIR1 or secreted 
LAIR2 (Lebbink et al, 2008).  In T cells, where expression of LAIR1 has been better 
studied, there does not appear to be cleavage of LAIR1 from the surface of cells, but 
rather internalisation of the molecule (Jansen et al, 2007).  While internalisation of 
the molecule might also happen in THP-1 cells, the presence of a shorter form of the 
molecule detected by an antibody to the intracellular component of the molecule is 
suggestive of cleavage occurring.  It is of interest that this potential cleavage product 
band was of greater intensity in cells treated with IFNγ/LPS than other polarisation 
states, hinting at a possible positive feed-forward loop in ‘classically activated’ cells 
reducing inhibitory signalling and making cellular activation more easy.  This result 
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is however in contrast with the cell surface expression data from flow cytometry 
which did not detect a difference between the levels of expression of LAIR 1 on the 
surface regardless of polarisation state. 
Expression of LAIR1 was also assessed at the level of mRNA in differentiated and 
polarised THP-1 cells (Figure 7.3).   Very similar levels of expression of LAIR1 
mRNA was seen in undifferentiated THP-1 cells, differentiated  but unpolarised 
THP-1 cells, and polarised THP-1 cells.  This suggests that if there is regulation of 















Figure 7.3  Polarisation status of THP-1 cells does not influence LAIR-1 expression. 
THP-1 cells were differentiated by the addition of PMA for 3 days, then cytokines as 
indicated for 5 days.  a). Expression of LAIR-1 was assessed by flow cytometry  both by 
surface staining using clone DX26 directed to the extracellular component of the molecule 
and using clone HPA011155 directed to the intracellular component of the molecule in 
permiabilised cells.  b). Western blotting was performed on whole cell lysates using three 
antibodies (HPA011155, NKTA255, DX265) against LAIR1.  Equal quantities of protein 
were used in each case and an antibody against β-actin used as a loading control. c).  RNA 
was extracted from the THP-1 cells and quantitative  RT-PCR performed.  18S was used as 





7.1.4  Addition of collagen to THP-1 cells does not alter expression of LAIR-1 
To assess the effect of collagen on expression of LAIR1 by THP-1 cells, cells were 
cultured in the presence or absence of collagen.  Preliminary experiments in which 
collagen was added at a late time point failed as the diluent for the collagen proved 
toxic to the cells, and similarly differentiating the cells in the absence of collagen and 
lifting and replating on collagen resulted in loss of large numbers of THP-1 cells.  
Eventually, a method was arrived at in which all stages of the experiment were 
performed with or without collagen.  Tissue culture plates were coated with collagen 
or diluent and dried in tissue culture cabinets under UV light to cross-link and 
sterilise the collagen.  The plates were then washed to remove the diluent and THP-1 
cells added along with PMA, and cultured for 3 days, before the addition of fresh 
media with cytokines and culture for 5 days.  Cells were lifted as described 
previously and surface and intracellular expression of LAIR1 assessed by flow 
cytometry (Figure 7.4).  There did not appear to be any difference in expression of 
LAIR 1 in the presence or absence of collagen regardless of the polarisation state of 
the THP-1 cells implying that any action of the LAIR1 ligand on macrophages is not 





Figure 7.4  Addition of collagen to culture conditions does not alter LAIR-1 expression. 
THP-1 cells were differentiated and polarised by the addition of PMA for 3 days then 
cytokines for 5 days either on untreated tissue culture dishes or dishes that had first been 
coated with human collagen IV.  Cells were lifted and stained with antibodies against the 
extracellular component [left panel] (DX26 and NKTA255) or intracellular component of the 
LAIR1 molecule [right panel] and expression analysed by flow cytometry.  Only viable cells 





Work by Poggi et al using AML cell lines suggested that crosslinking of LAIR1 was 
fatal to THP-1 cells (Poggi et al, 2000).  Although on morphological assessment of 
cells grown in tissue culture plates, this did not appear to be the case, more detailed 
morphological assessment of THP- 1 cells grown on or off collagen was undertaken.  
Chambered slides were coated with collagen or diluent and treated as the tissue 
culture plates above.  THP-1 cells were differentiated by the addition of PMA then 
allowed to mature, before fixing and staining with H&E.  In both conditions, cells 
reached near confluent growth and showed similar morphology suggesting that the 
presence of collagen was not toxic to THP-1 cells (Figure 7.5). 
 
Preliminary work was also undertaken looking at LAIR1 expression in primary 
human macrophages.  Monocytes were derived from donor blood by Percol gradient 
and plated onto tissue culture plates previously coated with either collagen or 
diluents. These experiments had to be abandoned as the cells behaved very 
differently in the presence or absence of collagen; cells cultured on plastic rapidly 
became adherent; cells cultured on collagen formed colonies in suspension that 
appeared morphologically to be proliferating and remained in that form for several 
days before becoming adherent.  The planned experiments with these cells were 
abandoned as the populations were very clearly different, and contained very 
different numbers of cell despite addition of identical numbers initially.  Whilst this 
observation, suggesting that primary monocytes are far more sensitive to the effects 
of collagen in the microenvironment that the malignant cell line THP-1, was very 
interesting there was insufficient time to pursue it further.  Differences in behaviour 
of primary human monocytes cultured on collagen as opposed to glass were 
described by Kaplan and Gaudernack in 1982, with further work by Kaplan showing 
that monocytes cultured on glass are cytotoxic to tumour cells while those cultured 
on collagen are not (Kaplan and Gaudernack, 1982, Kaplan, 1983).   In these 
experiments monocytes cultured on glass showed spontaneous cytotoxic activity 
against several malignant cell lines suggesting that the glass was activating the 
monocytes/macrophages to a cytotoxic phenotype as such behaviour is not normally 
seen when cultured in plastic tissue culture dishes.  The effect on morphology and 
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behaviour however is on interest in the light of the changes seen here in human 




Figure 7.5  THP-1 cells morphology when grown on collagen. 
THP-1 cells were cultured on chambered slides in the presence (a) or absence (b) of collagen 
to establish whether collagen induced cell death in THP-1 cells.  After 8 days cells were 
fixed and stained with haematoxylin and eosin.  In both culture conditions cells grew well 
and reached near confluence.  Cells showed similar morphology with a proportion of cells 
remaining small with little cytoplasm but the majority becoming large, adherent and round or 
dendritic in morphology.  (Representative field at x200 magnification from area of low 
density growth to demonstrate morphology.  Photomicrographs from one of three 
experiments).   
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7.2  Assessment of tumour cell growth when co-cultured with THP-1 
cells grown on collagen. 
To assess whether the addition of collagen alters the way THP-1 cells interact with 
BL2 cells a co-culture system was used in which BL2 cells were cultured in the 
presence of THP-1 cells grown on collagen or on plastic.  Co-culture of tumour cells 
with macrophages is a well characterised model in the Gregory lab most frequently 
in the context of bone marrow derived macrophages, and these macrophages have 
been shown to support or suppress BL2 tumour growth dependent on the exact 
experimental conditions.  In these experiments, BL2 cells were allowed to grow in a 
favourable environment, i.e. seeded into serum rich medium at a low initial 
concentration.    Cell growth kinetics were calculated by counting cell numbers at 0, 
1, 2 and 3 days, after which point there tended to be exhaustion of the medium and 
consequent high rate of cell death 
 
7.2.1  Presence of collagen does not inhibit BL2 growth. 
BL2 cells were grown in tissue culture dishes previously coated with collagen to 
establish whether the presence of collagen was toxic to the cells or provided a growth 
stimulus.  Cells were counted at day 0, and for the next three days and growth curves 
plotted.   The rate of increase in BL2 cell number was not altered by the addition of 
collagen implying that collagen itself in the co-culture model does not influence BL2 
cell growth. (Figure 7.6)  Given the absence of surface expression of LAIR1 on BL2 
cells, collagen would not be expected to influence BL2 cell growth, however it was 





Figure 7.6.  BL2 growth kinetics grown on collagen.  BL2 cells were plated out at an initial 
concentration of 1 x10
5
 cells per ml in tissue culture plates which were treated with collagen 
or diluent and grown for 3 days.  Cells were counted in triplicate on each day to day 3.   
(Representative experiment of three). 
 
Figure 7.7  BL2 growth kinetics on THP-1 cells.  BL2 cells were grown in co-culture with 
THP-1 cells which were differentiated to macrophages but unpolarised, or cells polarised by 
the addition of IL-4, IL-10 or IFNγ/LPS following differentiation.  Cell counts were obtained 
at days 0-3.  Results calculated in triplicate for each time point.  The figure shows means of 




















































the absence of additional cytokines, or those cultured with IL-10 than those cultured with IL-
4 or IFNγ/LPS, but only the IFNγ/LPS culture conditions showed a significant difference at 
all time points compared to unpolarised macrophages. (p<0.05, paired 2-tailed student’s t-
test).   
 
 
7.2.2   Collagen influences the growth of BL2 cells where THP-1 ells have been 
treated with IFNγ/LPS 
BL2 cells grown on THP-1 macrophages showed different rates of cell growth 
dependent on the polarisation condition of the macrophages (Figure 7.7).  Those 
grown on either unpolarised THP-1 cells or cells polarised by the addition of IL-10 
grew better than those in which the THP-1 cells were polarised by the addition of 
IFNγ and LPS or IL-4 but the differences did not reach significance, except when 
comparing cells treated with IFNγ/LPS with untreated THP-1 cells where growth of 
BL2 cells was significantly reduced in the IFNγ/LPS conditions.    In all cases, BL2 
cells grown in the presence of macrophages grew less well than BL2 cells alone.  
This was supported by a body of work within the group where it was frequently 
observed in a variety of co-culture systems, that tumour cells in optimum growth 
conditions are constrained by the addition of macrophages, while those in suboptimal 
conditions are supported by the addition of macrophages. 
 
When looking at individual culture conditions, only where THP-1 cells were 
polarised by the addition of IFNγ and LPS did the presence of collagen in the culture 
conditions alter BL2 cell growth (Figure 7.8).  At all time points, BL2 cells grown 
with the THP-1 cells on collagen grew better than those where the THP-1 cells were 
on plastic.   It could be hypothesised that in the presence of collagen, full activation 
of the THP-1 macrophages to an M1 type phenotype is inhibited allowing a more 





Figure 7.8  BL2 growth kinetics with THP-1 cells grown on collagen 
BL2 cells were grown in co-culture with THP-1 cells which were differentiated to 
macrophage-like cells and then either left unpolarised or polarised by the addition of IL-4, 
IL-10 or IFNγ/LPS.  Cell counts were obtained at days 0-3 of co-culture.  Results are plotted 
relative to growth on THP-1 cells not treated with collagen for each polarisation condition.  
The results are the means of 4 experiments (±1sd).  Only for cells grown on THP-1 cells 
treated with IFNγ/LPS was there a significant difference in growth on or off collagen and 
this difference was significant at all time points.  (p<0.05, paired 2-tailed student’s t-test).   








7.3  Co-culture of THP-1 cells with apoptotic BL-2 cells does not 
alter expression of LAIR-1. 
Given the known ability of apoptotic cells to modulate macrophage function and 
activation, experiments were performed to assess whether the presence of apoptotic 
cells alters the surface expression of LAIR-1 in THP-1 cells.  The THP-1 cells were 
incubated with BL-2 cells that were induced to undergo apoptosis by the addition of 
staurosporine.  Induction  of apoptosis in BL2 cells was confirmed by assessment of 
Annexin-V and propidium iodide staining, confirming that of the BL2 cells added to 
the culture about 20% of these would be expected to be apoptotic an hour after 
addition to the THP-1 cells.  THP-1 cells were incubated with BL-2 cells over a 
range of times from 2 to 24 hours and expression of surface LAIR1  assessed by flow 
cytometry.  There was no alteration in the expression of LAIR-1 by flow cytometry 
for surface LAIR1 by co-culture with apoptotic cells at any of the time points 
assessed (Figure 7.9).  This very preliminary experiment was only performed once 






Figure 7.9 Co-culture with BL-2 cells induced to undergo apoptosis does not alter 
expression of LAIR1. 
BL2 cells were induced to undergo apoptosis by exposure to staurosporine at 1µM for five 
minutes, then thoroughly washed and returned to culture.  a) After 75 minutes in culture cells 
were stained with Annexin V and propidium iodide to assess the percentage of cells in 
apoptosis.  b).  Differentiated but unpolarised THP-1 cells were co-cultured with BL2 cells 
treated with staurosporine, or untreated cells for 2 hours and then BL2 cells washed off and 
cell surface expression of LAIR1 assessed by flow cytometry.  Similar results were obtained 
after 6 and 24hours of culture.  These were very preliminary experiments and only 






In this chapter LAIR 1 expression in a tumour associated macrophage model was 
assessed using THP-1 cells as a source of ‘macrophages’ and BL2 cells as tumour 
model.   While much of this work is preliminary and would benefit from being 
repeated and with many questions which have not been addressed, the following 
conclusions can be reached; 
 LAIR-1, an inhibitory receptor that binds collagen as its ligand, is present on 
naive THP-1 cells. 
 Differentiation of THP-1 cells into more mature macrophage-like cells results 
in a degree of downregulation of expression of LAIR-1 although surface 
expression remains. 
 Surface expression of LAIR-1 does not appear to be affected by the 
polarisation status of the cells, although intriguingly, there does appear to be 
a cleaved form of LAIR1 present in differentiated cells particularly those 
polarised by the addition of IFNγ/LPS. 
 LAIR-1 expression in not altered by the addition of collagen to cultured THP-
1 cells, and the presence of collagen does not affect THP-1 cell differentiation 
or BL2 cell growth. 
 The addition of collagen does appear to affect how THP-1 cells polarised by 
IFNγ/LPS support tumour cell growth of BL2 cells with enhanced cell growth 
in the face of collagen suggesting that while surface expression of LAIR-1 







Discussion of the results 
8.1 Introduction 
This thesis examines some aspects of tumour-associated macrophages in Diffuse 
Large B cell lymphoma.  While there is considerable interest in the 
microenvironment in this tumour following the large scale gene expression data 
published in recent years, there is still little data as to the exact role of the tumour 
associated macrophage in DLBCL and their function and phenotype.  The work 
presented here is based on tissue derived from human DLBCL, with the exception of 
the preliminary in vitro experiments in the final chapter.  While this of necessity 
means much of the data presented is observational rather than subject to 
experimental manipulation, the findings represent those of the genuine human 
disease rather than an animal model.    
 
8.2  Possible role for apoptosis in recruiting macrophages in DLBCL 
Initially the possibility that tumour cell apoptosis may be one of the factors involved 
in the recruitment of macrophages was addressed.  Work by others in the group 
looking at the relationship of proliferation, apoptosis and macrophage infiltration in 
Burkitt lymphoma has shown an association between these variables.  Mechanisms 
by which apoptotic cells recruit macrophages in these tumours have been described 
as have some of the ways in which macrophages influence tumour growth (Ford et al 
2015, Ogden et al 2005, Truman et al 2008).   Such an association between 
apoptosis, proliferation and macrophage infiltrate has not previously been 
demonstrated in DLBCL.   Presented here in chapter 3, looking at a cohort of 82 
cases of DLBCL, an association was demonstrated between apoptosis and 
proliferation and apoptosis and macrophage infiltration, but not macrophage 
infiltration and proliferation (Figure 3.3 and Table 3.2).  This argues that, as in 
Burkitt lymphoma, tumour apoptosis may be one of the mechanisms by which 
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macrophages are recruited into tumours, and influenced by tumour cells.  In DLBCL 
there is no clear association between proliferation and macrophage number to argue 
that macrophages support tumour growth.  These however are heterogeneous 
tumours with multiple dysregulated pathways and any effect of macrophages on 
proliferation may very well be too subtle in the face of multiple other influences to 
be detectable.   
Clearly, as in any study looking at human tumour tissue, this analysis represents only 
a single point in time for each tumour studied and cannot inform as to causal 
relationships.  It could equally be argued that the relationship between macrophages 
and apoptosis exists because macrophages induce apoptosis and hence large numbers 
of macrophages induce substantial apoptosis.  While this cannot be refuted on the 
data presented here, a relationship in which apoptotic cells attract macrophages fits 
better with the data from experimental models in which apoptotic cells release many 
factors that send ‘find me’and‘eat me’ signals to macrophages and provides a more 
biologically plausible explanation of the association (Grimsley and Ravichandran, 
2003, Truman et al 2008, Ford et al 2015).  It should also be noted that, despite some 
differences in some studies, the weight of data in DLBCL suggests that large 
numbers of macrophages are associated with poorer outcome which would be at 
variance with the hypothesis that macrophages in the tumour drive tumour cell 
apoptosis (Kridel et al, 2015).   
 Both DLBCL and BL show high rates of proliferation and apoptosis.  Although the 
median rate of apoptosis seen in the DLBCL tumours studies was only 1.4%, given 
the efficiency with which apoptotic cells are cleared, this is likely to equate to a very 
high rate of cell death (Figure 3.2) (Gregory and Pound 2011).  That there is a 
relationship between proliferation and apoptosis in lymphoma has been recognised 
for a long time, with a study in 1993 of a wide variety of lymphomas (classified 
using the Kiel classification and Working formulation) showing a relationship 
between these variables (Leoncini et al, 1993).  These results are not directly 
comparable to the data presented here being of a mixture of high and low grade 
lymphomas and using a now-outdated method of classification, but they support the 
observations made here that proliferation and apoptosis are related in DLBCL.   It 
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should be noted that apoptosis is much less frequently seen in low grade tumours, 
and may therefore not have a role to play in recruiting macrophages in these 
lymphomas.  In the example of follicular lymphoma for instance, the tumour appears 
to use the pre-existing microenvironment of the lymph node and may therefore have 
less requirement for recruited elements of the microenvironment (Scott and 
Gascoyne, 2014).   
 
 
8.3  Capturing the gene expression signature of the TAM by an in 
silico approach 
In an effort to gain an unbiased view of the TAM in DLBCL, a gene expression 
signature of macrophages in situ in human tumours was sought using a bioinformatic 
approach.  This formed part of a wider study looking at the cancer transcriptome in a 
broad spectrum of human tumours.  The analytical approach was based on measuring 
the correlation between all genes across multiple large datasets in order to provide a 
statistical measure of the relatedness between expression patterns. This measure was 
then used to create 3D network visualizations of the graphs using BioLayout 
Express
3D 
a visualization tool that allows exploration of complex networks of a size 
not previously possible (Freeman et al. 2007).  The MCL algorithm (van Dongen 
2000) was then used to group nodes (genes) into clusters in a completely 
unsupervised manner. This algorithm uses the innate structure of the graph together 
with the correlation values associated with edges to divide the network into groups of 
co-expressed genes. In this respect MCL has been shown to perform as well or better 
than other network clustering algorithms (Brohee and van Helden 2006).  This 
approach differs from conventional clustering methods in viewing the data globally 
i.e. all ‘connections’ between genes are considered in the placement of genes in the 
network rather than simply considering data connectivity in a pairwise, hierarchical 
fashion.   Others have also sought to identify gene signatures/modules in cancer data, 
but have used different analytical approaches, less data, grouped far fewer genes and 
generally failed to explain the biological significance of their findings (Mosca et al 
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2009, Rhodes et al 2004, Segal et al 2004, Shaffer et al 2006, Shi et al. 2010). Where 
correlation networks have been used previously to analyse modularity in gene 
expression data (Langfelder and Horvath 2008, Stuart et al 2003), available 
computing frameworks have not permitted the visualization or exploration of the 
resultant graphs and these studies have focused on only a single dataset.   Advances 
in the ability to generate large graphs allows all the data from a gene expression 
signature to be considered in a single graph rather than having to apply some 
supervision to the graph whether that be selection of genes thought to be of interest, 
selection of differentially expressed genes or correlation with outcome.  The 
approach used here in contrast to many of those discussed above makes no 
prejudgement about what is important in the data. 
 
The primary focus of this study was to learn more about the functional profile of 
tumour-associated immune cells. To this end six large datasets of unrelated human 
primary tumours derived from different populations were examined initially, 
followed by an unrelated dataset to validate some of the findings from the ‘core’ 
datasets. Network analysis of individual cancer datasets demonstrated the correlation 
graphs to possess a highly structured topology. Detailed examination of these graphs 
revealed that many of the clusters of genes observed at the micro and macro level of 
graph structure were highly enriched in functionally related genes.  It was clear from 
the examination of the clusters that this approach was very effective in identifying 
cohorts of genes expressed in a cell- or pathway- specific manners, as discussed 
below. Also observed were groups of genes associated with known disease modules 
(Barabasi et al  2011).   These tended not to form a major component of the graph 
lying mostly as smaller clusters separate from or loosely connected to the main 
graph. For example, the breast cancer dataset contained a small group of genes 
whose expression is lower in aggressive tumour subtypes. This included ESR1 
(oestrogen receptor alpha), GATA3, FOXA1, and XBP1, and therefore appears to 
capture a significant proportion of the oestrogen signalling transcriptional network, 
including modulators and downstream targets (Figure 4.19). Similarly, in the 
DLBCL dataset, associated with IRF4, one of the markers of the ABC-subtype 
(Alizadeh et al 2000) were FOXP1, PIM2 and CARD11, all described to be up-
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regulated in ABC-subtype of DLBCL (Figure 4.14) (Davis et al 2010). A further 
example of a disease-specific network comes from the analysis of the nearest 
neighbours of SILV in the skin cancer data (Figure 4.42) (Riker et al 2008). The 
immediate neighbours of SILV, a gene whose product pMel17 (recognised by the 
HMB-45 antibody) is used clinically in the diagnosis of melanoma (de Vries et al 
2001), include TYR (tyrosinase) the key enzyme in melanin biosynthesis, MLPH 
(melanophilin), which plays a role in melanosome transport, GPR 143 expressed on 
the melanosome membrane, MLANA (melan-a), MITF, a melanocytic transcription 
factor and transcriptional regulator of many of these genes (reviewed in 
(Steingrimsson et al 2004)) and SNCA (alpha-synuclein). Whilst there is no literature 
regarding the expression of SNCA in melanoma, given that it plays a role in 
dopamine metabolism in the CNS, it is not inconceivable that it also functions in 
melanin metabolism (Sidhu et al  2004), highlighting the potential of this approach to 
identify novel genes in functional networks. In addition, CDK2, a gene downstream 
of and regulated by MITF and known to be required for melanoma growth and 
proliferation (Du et al  2004) lies within these ‘near neighbours’, as does  BIRC7, an 
anti-apoptotic protein contributing to melanoma survival and resistance to therapy 
(Lazar et al 2010, Vucic et al 2000) which is also regulated by MITF (Dynek et al 
2008). In all cases it would appear that the graphs have accurately identified key 
modules associated with key disease genes and other genes lying in the immediate 
neighbourhood must surely merit further investigation.  The focus of the analysis was 
not on identifying dysregulated pathways in the individual tumours, but the presence 
of such networks capturing these pathways known to be of importance in the 
individual tumours provides some further validation of the method (Barabasi et al 
2011). 
 
Much of the recognisable structure of each of the graphs was formed of three major 
components; cell cycle related clusters, extracellular matrix clusters and immune cell 
clusters.  These were clearly demonstrated to be significantly enriched in genes 
associated with individual cells or functions and were annotated on that basis.  The 
exact composition of these elements varied, as might be predicted from tumour to 
tumour with for example a neutrophil signature only being identifiable in tumours in 
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which histologically neutrophils are prominent.  A lymphocyte signature and a 
macrophage signature were identified in all tumour types.  There tended in all 
tumours to be a relatively tight grouping of immune clusters in one area of the graph 
with the exact degree of relatedness of these varying between tumours, suggesting a 
degree of interaction between these elements, reflective of the known interactions 
between for example lymphocytes and cells of the innate immune system.  Similarly, 
with the exception of the teratoma signatures in the testicular tumour dataset, the 
extracellular matrix signatures tended to lie together in all graphs and often very 
closely related to vascular signatures, again suggesting a relationship between these.  
Similarly cell cycle signatures broke into somewhat different clusters in individual 
tumours but the cluster tended to group together in every case.   
 
Many of the clusters seen and the patterns of gene expression they showed clearly 
correlated with histological features of the tumour in question providing further 
validation for the approach as a method of analysing the cancer transcriptome.  For 
example, the extracellular matrix signature showed a higher level of expression in 
PMBL than other types of DLBCL, in keeping with the pattern of fibrosis commonly 
seen in this tumour (Figure 4.12); the cell cycle signature rises in breast cancers of 
increasing grade and ovarian cancers of increasing malignancy (Figures 4.19 and 
4.24); somatic tissue signatures are seen in teratomas in the testicular tumour dataset 
(Figure 4.35).   It was not possible to assign annotation to all clusters or to examine 
in detail many of the clusters not related to the stromal components identified in each 
of the individual tumours, although the expression pattern of many of these was very 
interesting and appeared worthy of further analysis.   
 
In an effort to further define what elements of the signatures were conserved across 
all tumours a ‘core’ signature was defined by using the mean Pearson correlations 
between six datasets.  This would tend to remove any tumour- or tissue-specific 
signatures leaving only those signatures common to all tumours (Fig 4.40).   To 
confirm the signatures were truly conserved and not simply present only in the 
original datasets, this conserved signature was mapped to an independent dataset of 
skin tumours showing good preservation of the signatures (Fig 4.41 and table 4.78).   
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As predicted, a number of the clusters generated by this approach were highly similar 
to those that we had observed in the individual datasets, but with the loss of those 
that were tumour/tissue-type specific. The conserved gene signatures consisted 
predominantly of three categories of functionally related genes. By far the largest 
grouping of genes contained genes whose expression profile over the individual 
datasets showed little variation and which were poorly characterised. For these 
reasons they were designated ‘house-keeping’ (HK) clusters and are not discussed 
further. A second major structural feature within the ‘core’ graph was clearly 
associated with the cell cycle. A central cluster within this area of the graph was 
highly enriched in genes associated with cell cycle progression when compared to 
previously derived cell cycle lists (Huang et al 2009, Subramanian et al 2005). It is 
perhaps unsurprising that a signature relating to proliferation is shared across 
multiple tumours and when this signature was examined in the individual datasets 
there was a clear up-regulation of these genes in more aggressive tumours, 
suggesting that this signature is contributed largely by the malignant cells rather than 
the stromal elements. This cell cycle cluster is also closely associated with clusters of 
genes involved in mRNA/protein processing. These presumably represent functional 
modules whose expression and activity are tied to cellular proliferation. The final 
class of conserved gene signatures were associated with the stromal components of a 
tumour i.e. tumour-associated macrophages, other leukocytes, vascular components 
and mesenchymal cells. 
  
The preservation of specific clusters associated with stromal cells across such a large 
number of genetically diverse individuals and multiple tumour types argues there is, 
at least in part, a common tumour microenvironment that controls, and is controlled 
by, interactions amongst elements of the stroma.   One of the larger conserved 
signatures observed is associated with the extracellular matrix.  This was enriched in 
structural proteins, proteoglycans, modifiers of the extracellular matrix and signalling 
molecules. Histologically, the presence of a desmoplastic tumour stroma is a well 
recognised phenomenon occurring in many tumour types. However, like many other 
elements of the microenvironment the precise role played by this tumour-associated 
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stroma has been difficult to assess: is the role of the stroma to contain the tumour or 
to promote the survival of the malignant cells? Recent data from studies of DLBCL 
suggest that in this tumour different elements of the stroma contribute to both a good 
and a poor prognosis with elements of a vascular signature particularly being 
associated with poor prognosis while other stromal elements were associated with a 
good prognosis (Lenz et al 2008a).  The elements they describe as being in the 
‘good’ stomal signature tend to fall into the ECM cluster and to a lesser extent the 
macrophage cluster in the clustering presented here, while much of the ‘bad’ stromal 
signature tends to fall in the endothelial cluster derived here.  Work in small cell lung 
carcinoma has established the role of interactions between the ECM and tumour cells 
in resisting chemotherapy-induced death highlighting one possible role for the 
tumour stroma (Hodkinson et al  2006). More recently work by Kim et al (Kim et al 
2009) in a lung carcinoma model highlighted the role that an ECM component, in 
this case versican, can play in activating other elements of the microenvironment 
suggesting that as for other elements of the tumour microenvironment, cross-talk 
between elements is likely to be of great importance.   Similarly, a role has been 
demonstrated for sequestration of angiogenic signalling molecules in the ECM with 
these being released by the actions of MMPs (Bergens et al 2000).   
 
The ‘core’ vasculature signature observed here contains many familiar and well-
characterised markers of endothelial cells as well as less well characterised 
endothelial genes. It contains receptors and co-receptors (KDR, NRP2) for VEGF, 
the major angiogenic factor but also contains elements associated with Notch 
signalling, another important system in angiogenesis (for a review see (Phng and 
Gerhardt 2009)). NOTCH3 usually expressed in vascular smooth muscle, lies in the 
endothelial-related cluster enriched in ECM and basement membrane proteins and 
thought to represent the structural component of the vascular signature. A recent 
study investigating the crosstalk between endothelial and mural cells via NOTCH3 
signalling showed a reduction in angiogenesis in an in-vitro co-culture system when 




The macrophage signature in the ‘core’ dataset is smaller than in other datasets, some 
elements clearly having been lost as having mean correlation coefficients below the 
selected threshold.  The preserved signature contains gene associated with 
phagocytosis, MHC class II antigen presentation and T-cell co-stimulation and is 
therefore suggestive of a macrophage able to act as an antigen-presenting cell. The 
TAM profile also contains scavenger receptors and genes involved in lipid 
metabolism suggesting a role in apoptotic cell clearance by TAMs. Notably, the 
signature does not contain many of the ‘classical’ markers of macrophage 
polarisation such as IL-10, IL-12, arginase, etc. While some of these activation 
markers, derived from mouse data, are not expressed in human macrophages and 
therefore of little relevance in studying human macrophages, the absence of clear 
evidence of polarisation is interesting (Martinez et al 2013). When analysed in 
individual datasets, genes such as IL-10 and IL-12 appear often to be expressed in a 
very variable manner and frequently do not appear in the network analysis at all, 
suggesting that these macrophage polarising signals do not represent a uniform 
response to tumour in any of the datasets we have studied. It must be noted though, 
that as with all gene expression data generated from more than a single cell, that 
signatures represent  an ‘average’ impression of  cell type within a tissue and cannot 
provide information about whether, and/or where different subtypes of cells exist in 
that tissue.   
  
Analysis of the T cell profile demonstrates the presence of an almost completely 
intact antigen recognition and signalling pathway containing elements of the TCR, 
co-receptors and downstream signalling molecules. Also in the signature are 
cytotoxic molecules and markers of activation suggesting these are, at least in part, 
activated cytotoxic T cells. There is not obviously a Treg signature, but this may 
reflect in part the relatively limited number of markers of that cell type making the 
signature difficult to identify if the key markers are not present in a cluster.  The 
preservation across all tumour types of a cluster of genes associated with an 
interferon response and the presence of IFNG in the T cell signature argues that 
activation of this pathway forms a consistent part of the response to a tumour. This is 
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in keeping with data derived from murine models in which it was shown that TAMs 
express many interferon inducible genes (Biswas et al 2006). Taken together, these 
data do not support the view that TAMs have a so-called M2 (Mantovani et al  2009) 
phenotype characterised by dominant actions of interleukin 4, rather they appear to 
represent a cell type with some features in common with alternatively activated 
macrophage, but areas of difference.  Given that the M2 macrophage is an extreme 
polarisation state derived from a single polarizing signal in vitro, it would be 
predicted that this signature would not be reproduced completely in the complex 
microenvironment of the tumour even if certain elements of the signature, of benefit 
to the tumour, are present.   
 
Of interest is how the different stromal signatures relate to each other. The fact that 
macrophage, T cell, ECM and endothelial-specific genes form independent clusters, 
indicate that there is not a tight causal relationship between them. However, it is 
clear that the functions of these cells may be closely related, with the T cell signature 
and macrophage signature in particular, demonstrating a similar expression pattern 
and close spatial relationship in all network graphs. Despite the frequent association 
of macrophage number with microvessel density in solid tumours (Eerola et al  1999, 
Lissbrant et al  2000, Orre and Rogers 1999, Sickert et al 2005), these signatures are 
clearly separate in the tumours studied here suggesting that there are other factors 
involved in the development of the neovasculature of the tumour in addition to the 
role played by TAMs. This viewpoint is supported by the fact that the macrophage 
cluster does not contain any of the known regulators of endothelial proliferation, 
such as the vascular endothelial growth factors (VEGFs).  
 
The TAM signature from the DLBCL dataset has many features in common with that 
from the core dataset but contains a larger number of genes.  Like the core signature 
there are genes involved in chemotaxis and phagocytosis, genes involved in the 
innate recognition of pathogens and defence response (Table 4.3).  Macrophage 
scavenger receptors including MARCO, SCARB2 and CD163 are expressed, a 
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finding reported from other studies of TAMs (Allavena et al 2010, Ford et al 2015). 
Complement component C1q, one of the linker molecules involved in clearance of 
apoptotic cells is expressed, as is LRP1,  hinting at the macrophage’s role in 
clearance of dead tumour cells.  CXCL12, reported to promote a proangiogenic 
phenotype in macrophages is in the cluster, as is the angiogenic molecule TYMP, 
suggestive of a role in tumour angiogenesis (van Overmeire et al 2014).  Recent 
work highlighted a role for NRP1 in recruitment of macrophages to the hypoxic areas 
of tumour (Casazza et al 2013).  This is not present in the DLBCL TAM signature, 
but the closely related gene NRP2 is included.   
 
To date there are few global gene expression profiles from TAMs and these are often 
derived from inbred mouse tumour models in which the cells have been separated 
from their microenvironment and therefore potentially had their gene expression 
altered by the process of isolation.  Previous work looking at a mouse fibrosarcoma 
model in which TAMS were released from the tissue by physical disruption and 
enzymatic digestions demonstrated many IFN-inducible genes, despite the presence 
of the immunosuppressive cytokine IL-10, suggesting that in mouse as in the data 
presented here the interferon induced signature is important (Biswas et al 2006).  
They demonstrated that TAMs isolated from tumours maintained an altered response 
to LPS, with reduced production of proinflammatory genes including IL-12, IL-6, 
TNF-α and CCL3 suggesting that regardless of whether or not the TAM can be 
defined as an ‘alternatively’ activated macrophage, it is resistant to classical 
inflammatory activation .  AIF1, a marker of organ rejection in humans (analysed 
further in chapters 5 and 6) was also demonstrated as an upregulated gene in TAMs 
in their analysis (Biswas et al 2006).  TAMs from a mouse model of breast cancer in 
which cells were isolated by tissue mincing, phagocytososis of labelled dextran and 
fluorescence activated cell sorting showed increased abundance of genes involved in 
‘immune response’, ‘tissue development’ and ‘angiogenesis’ among others (Oljavo 
et al 2010).  Similarly to Biswas et al, Oljavo et al found evidence of the pro-
inflammatory mediators, in this case the chemokine CCL3 suggesting the TAM 
profile is more complex than simply an ‘alternatively’ activated macrophage (Oljavo 
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et al 2010).  Work by Sofia Petrova in our group demonstrated using laser-capture 
microdissection of macrophages from intact tumours a gene expression profile in a 
xenograph mouse model in which anti-inflammatory and pro-angiogenic genes were 
expressed by TAMs  and in which the TAM signature was enriched for genes 
involved in phagocytosis, lipid metabolism and matrix remodelling (Ford et al 2015).  
There was overlap between the signature generated from mouse, and those generated 
from human tumours by a bioinformatic approach, but not all genes seen in either 
setting were seen in the other.  As well as differences in analysis this is likely to 
represent differences in host and tumour type.    Allavena et al in one of the few 
studies in humans and focussing on expression of C-type lectins showed in TAMs 
from human ovarian carcinoma that c-type lectin receptor expression was similar 
between TAMs in malignant ascites and macrophages from peritoneal washings, 
with the exception of a few differentially expressed genes including the mannose 
receptor (CD206) which showed higher expression in TAMs from malignant ascites 
than resident peritoneal macrophages (Allavena et al 2010).  In the TAM population 
they studied, on binding of the mannose receptor by tumour mucins there was 
production of IL-10, but even with IFNγ and LPS stimulation these cells cultured ex 
vivo could not be induced to express IL-12.   Similarly Ford et al showed 
upregulation of the mannose receptor on TAMs in a mouse xenograft model (Ford et 
al 2015).   The TAM profile from DLBCL generated here did not contain the 
mannose receptor, which may reflect either a genuine absence or intratumoural 
heterogeneity of TAMs such that the correlation pattern does not cluster with the rest 
of the macrophage signature.  One of the issues highlighted by the Allavena et al 
paper is that of comparison with a normal macrophage population (Allavena et al 
2010).  It is very difficult when comparing macrophage signatures with TAM 
signatures to know what to consider as a ‘normal’ macrophage.  Is it a resident tissue 
macrophage?  Or a tissue reparative macrophage, a tingible body macrophage?  
Macrophages represent such intrinsically variable and plastic cells that differences 
between the normal and tumour associated macrophage unless very carefully 
selected may simply be the differences between the environment in which they exist 




In the bioinformatic data presented here, no equivalent normal signature is present, 
the datasets consisting of tumour tissue only. However, the macrophages studied 
would be subject to the multiple influences of the tumour microenvironment and 
hence the genes that they express are likely to be those they express in the face of 
multiple apoptotic tumour cells, and/or a hypoxic microenvironment, and/or under 
the influence of factors secreted by the tumour cells and thus while the analysis 
cannot inform as to which genes are up- or down-regulated in the face of these 
multiple influences, it can inform as to which genes are expressed in this context. 
 
It is impossible to know the extent to which the gene expression signatures relate to 
protein level and localisation in the cells.   For example while there is expression at 
the mRNA level of CD86 in the DLBCL TAM suggesting expression of co-
stimulatory molecules, the cell surface expression and availability for signalling of 
the molecule can only be assumed.  Expression at the protein level of some genes of 
interest was performed in chapter 5, but it was not within the scope of the thesis to 
explore all possibilities from the signatures.  It is also clear that there is considerable 
intra-tumoral heterogeneity of TAMS (van Overmeire et al 2014).  This is 
unsurprising given the heterogeneity seen within tumours, with areas of differential 
oxygenation frequently seen histologically as viable areas surrounding blood vessels, 
sub-clonal evolution giving rise to areas of morphological variation, differences in 
abundance of stromal components etc.  For this reason it was important to study the 
spatial distribution of the molecules of interest in the tissue.  A signature derived 
from whole tissue can only ever supply an ‘average’ of all the components 
contributing to the signature which may mask considerable spatial variation in 
protein expression.    This was explored to a limited extent in chapter 5.   
 
8.4  Validation of the TAM signature on an independent cohort of 
DLBCL 
Markers of TAMs from the in silico analysis of DLBCL and other tumour types were 
examined in a large cohort of cases of reactive lymph nodes and DLBCL by 
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immunohistochemistry.  This carried the in silico analysis back to human tumour 
tissue and allowed assessment of the spatial expression of the studied proteins.  Gene 
expression analysis in any setting, as with many other techniques that look at 
homogenized tissue, represents an ‘average’ of the tissue studied with loss of any 
spatial heterogeneity.  Examination of the selected markers at the protein level by 
immunohistochemistry did not provide a direct validation of the gene expression 
signature, looking at protein rather than mRNA expression, but does provide 
additional information about where and by what cells the proteins are being 
expressed. 
All the selected markers identified in the signature and for which acceptable 
immunohistochemical staining could be identified were present in macrophages in 
tumour tissue and reactive lymph nodes (Figures 5.2 – 5.8), but several showed 
marked variation in expression patterns with LGALS3BP in particular showing only 
weak and focal expression in tumours.  
 
Defining an equivalent ‘normal’ tissue in which to look at expression outwith the 
tumour is difficult and a reactive lymph node population was used as a non-tumour 
tissue.  The normal lymph node is a very changeable environment and given the 
plasticity of the macrophage lineage, there are multiple possible interactions of the 
macrophage and its environment all likely to represent subtly different activation 
states.  The tissue that was used was from lymph nodes that did not contain 
lymphoma and crucially were not derived from the drainage field of epithelial 
malignancies (which numerically represent the vast majority of non-lymphomatous 
lymph nodes in the pathology archives), and therefore not susceptible to soluble 
influences from tumours.  The nodes used were lymph nodes removed in the 
investigation of lymphadenopathy, not containing lymphoma and representing a 
variety of patterns of reactive lymphadenopathy secondary probably to multiple 




Macrophages in the non-tumour lymph nodes were considered in three, broad, 
morphologically identifiable groups; sinus histiocytes, stromal macrophages and 
tingible body macrophages.  CD68 and CD163 were included in the panel for 
analysis as both are recognised markers of the monocyte/macrophage lineage and 
allowed comparison of the expression pattern of these to the other less ‘classical’ 
macrophage markers.  Limited double staining was undertaken where the markers 
were expressed in different cellular compartments.  Due to the high autofluorescence 
of formalin-fixed paraffin embedded tissue, only chromogenic labelling of cells was 
carried out which limited the combinations of antibodies studied.  CD68, AIF1, 
LAIR 1 and TYMP were seen in all compartments in the reactive lymph node 
although AIF1 showed some variability in intensity of staining with much more 
intense staining seen in sinus histiocytes than other macrophages (Figures 5.2 -5.8).  
Interestingly, CD163 staining was seen mostly in sinus histiocytes with only 
occasional weak staining in tingible body macrophages and absence in stromal 
macrophages.  There was variable staining in tumours ranging from very occasional 
entirely negative cases, through cases with occasional positive cells to cases with 
many positive cells.  This did not appear to relate to macrophage content as assessed 
by CD68 staining, as there were cases with abundant CD68 positive cells and sparse 
CD163 positive cells, neither did it relate to phagocytosis of apoptotic cells as 
despite the relative absence in tingible body macrophages, expression was seen in 
tumour with high rate of apoptosis where the macrophages contained abundant 
apoptotic debris.  CD163 is widely quoted in the literature as a marker of M2 
macrophages, as a direct extrapolation from mouse data.  A concensus statement 
however from a group of ‘macrophage scientists’ in an effort to bring clarity to the 
confused terminology of macrophage activation/polarisation highlights the fact that 
on activation by IL-4 i.e. the originally described M2 activation, CD163 is not 
expressed by human macrophages (Murray et al 2014).  CD163 is a member of the 
scavenger receptor cystine-rich family and expressed exclusively on cells of the 
monocyte lineage and used here as a marker of that lineage (Buechler et al 2000).   
Expression is regulated by cytokine expression, tending to be upregulated by IL-10 
and IL-6 and downregulated by IFNγ, LPS, TNFα and IL-4 (Buechler et al 2000).   It 
is clear from the non-tumour lymph node TMA that it is only expressed in certain 
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subpopulations of macrophages being seen more frequently in sinus histiocytes and 
being seen also in subpopulations of macrophages in tumours.  This is supported by 
the double-labelling immunohistochemistry (Figure 5.13) where expression of 
TYMP and CD163 are seen together in a proportion of cells but single positive 
populations are identified for each marker.   
The marker from the TAM signature which showed most variation in expression was 
LGALS3BP which showed expression almost exclusively in sinus histiocytes in the 
‘normal’ lymph node and limited expression in TAMs. 
The genes selected from the in silico signature of TAMs did all appear to be 
expressed by TAMs in DLBCL, but none of these appeared to be specific to TAMs 
all also being expressed by macrophages in the non-lymphomatous lymph node.  The 
absence of specificity for TAMs does not however exclude a role for any of these 
molecules in support of the tumour as functions seen in the reactive lymph node may 
also be functions that provide support to the tumour.  The germinal centre, in 
particular, showing high rates of proliferation and death and a rapid expansion in size 
could be argued to share many features seen in malignancy.   
 
8.5 Relationship of expression of AIF1, LAIR1, LGALS3BP and 
TYMP with outcome in a patient cohort treated with CHOP 
Four genes of interest from the macrophage signature were studied further.  These 
were all selected on the basis that their known function suggested that they may have 
a role to play in the macrophage/tumour interaction, and their expression in DLBCL 
had not previously been studied.  Of these, three of the genes, AIF1, TYMP and 
LGALS3BP did not show any association with outcome when their expression 
pattern was studied in a large cohort of DLBCL treated with CHOP.  This may 
reflect a genuine absence of function of these molecules in the tumour 
microenvironment, or perhaps more likely, a minor effect, not identifiable by the 
relatively crude measure of patient outcome.  It is likely that the tumour 
microenvironment represents a complex balance of multiple influences on tumour 
growth and survival and is likely to be subtly different in every tumour representing 
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both the individual genetic landscape of the patient and the mutational landscape of 
the tumour.  Unless any effect exerted by a single molecule has a profound effect on 
tumour cell growth then it will be difficult to detect on the basis of patient outcome 
alone.  It is of note from the large scale gene expression analyses that these have 
highlighted the importance of a signature made up of large numbers of genes in 
predicting prognosis and that examination of isolated genes/their protein products 
have proved far less successful in predicting prognosis emphasising the multiple 
elements that contribute to the prognostic signature (Alizadeh et al, 2000, Lenz et al 
2008c, Adida et al 2000, Barrans et al 2004, Gascoyne et al 1997, Iqbal et al 2006, 
Uherova et al 2001, Hsi 2001, Ohshima et al 2001) 
 
The only marker that showed some relationship with outcome was LAIR1 which 
showed a significantly better overall survival in cases where the TAMs showed a low 
intensity of staining than where there was high intensity of staining, but no 
significant difference was seen in disease free survival suggesting that this may 
represent a spurious association rather than a genuine effect of TAMs on outcome.  
Examination of a larger cohort of cases may help to address this question as despite 
the non-significant result, the Kaplan-Meier curves for disease free survival for this 
parameter remained separate.     LAIR1 contains two ITIM motifs and functions as 
an inhibitory receptor (Meyaard et al 1997).   The pattern of expression noted in this 
cohort of cases is suggestive that lower expression of LAIR1 results in more readily 
activatable macrophages and hence better outcome.  As such it suggests that if the 
association seen is genuine, then the role of LAIR1 may either be via activation to a 
tumouricidal role in the face of therapy or activation to a tumour supportive role in 
the developing tumour.  Again, as human archival tissue represents a single 
timepoint in the life of the lymphoma, this question is not answerable on the current 
data.   
 
The ligand for LAIR1 is part of the collagen molecule and hence it has a plausible 
role in the microenvironment of the tumour (Lebbink et al 2006).  Collagen is a 
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common component of almost every tissue, the aberrant tissue of tumours included.  
As such it is possible that binding of macrophages to collagen in almost any setting 
outwith the blood stream will increase the activation threshold of the cell.  While this 
has been studied in T cells and NK cells it has not been studied in macrophages and 
it is unclear if it plays a role in macrophage activation and whether the role it plays is 
affected by the nature of the activating signal, i.e. binding via Fc receptors, toll-like 
receptor signalling pathways, cytokine signalling or others (Meyaard et al 1997, 
Verbrugge et al 2003, Maasho et al 2005).   The final chapter of preliminary 
experiments looks at the effects of macrophage activation on expression of LAIR1 in 
an in vitro cell line model using THP-1 cells. 
 
 
8.6  Preliminary data on the effect signalling through LAIR1 has on 
macrophage activation 
Given the possibility that LAIR1 expression by TAMs in human DLBCL may 
impact on outcome, some further studies were undertaken looking at the expression 
of LAIR-1 in various activation states of macrophage-like cells differentiated from 
THP-1 cells and the effect the addition of collagen had on malignant cell growth.  
Whilst this is very preliminary work and requires repeated and expanded, certain 
points can be drawn from it.  In THP-1 cells, there appears to be a downregulation of 
LAIR1 surface expression as the cells differentiate towards macrophage-like cells 
(Figure 7.2).  A similar pattern of downregulated expression has been seen in human 
B cell and T cells as they mature from naive to memory cells (Jansen et al 2007, 
Maasho et al 2005, Merlo et al 2005).  This alters the activation threshold in naive as 
opposed to antigen-experienced lymphocytes and could be considered as one of the 
mechanisms contributing to appropriate lymphocyte activation.  The role of 
downregulation in cells of the innate immune system is less clear, but it could be 
argued that as monocytes are recruited out of circulation to become macrophages in 
inflammatory/regenerating/apoptotic sites there is a need for them to be more 
activatable than when in circulation.   Expression has not previously been studied in 




The data as to the role macrophage polarisation has on expression is somewhat 
unclear; the does not appear to be differences in expression levels on the cell surface 
by flow cytometry and there is no difference in levels of LAIR1 mRNA, but western 
blotting using an antibody against an intracellular component of the molecule 
suggests a cleavage product is differentially present, being seen more when cells are 
activated with IFNγ and LPS (Figure 7.3).  It is difficult to equate the cell surface 
expression and whole cell lysate data, but it must be noted that the flow cytometry 
data is confounded by the high levels of cell death induced by detaching the cells 
from the culture dishes, an effect not seen in the Western blotting where lysis was 
performed on the cell culture plates.  Secretion of either the extracellular component 
of LAIR1 or of LAIR2 molecule is reported in various conditions and it would be of 
interest to see if there was shedding of LAIR1 in the supernatants of the THP-1 cells 
(Ouyang et al 2004, Lebbink et al 2008).   These experiments should also be repeated 
with primary human monocytes as while THP-1 cells provide a convenient and 
reproducible source of macrophage-like cells, clearly they may not have a normal 
LAIR1 signalling pathway/response.   
 
Co-culture of THP-1 macrophage-like cells showed differences in cell growth where 
IFNγ/LPS activated cells were cultured with or without collagen, BL2 cells growing 
with collagen showing an enhanced growth compared to those without collagen 
(Figure 7.8).  No effect was seen in any of the other activation states.  This suggests 
that LAIR1 may function to downregulate ‘classical’ inflammatory activation of 
macrophages.  As such this could play a physiological role in dampening down the 
inflammatory response in wound healing situations but may also provide a growth 
advantage to tumour cells preventing activation of a cytotoxic phenotype in the 
presence of collagen.  Mechanistically, this would suggest that the desmoplastic 
stroma seen in many tumours represents another route of immune suppression in the 
tumour microenvironment.  Again these experiments require repetition in primary 
cells as well as in different culture situations.  They were performed here in optimum 
growth conditions for BL2 cells, and the relationship of cell growth with 
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macrophages has been seen to alter dependent on the conditions in which the cells 
are maintained (C Ford, unpublished observations).   
 
This thesis examines some aspects of the tumour associated macrophage in diffuse 
large B cell lymphoma.  Much further work could be done to expand this study;  in 
the macrophage signature derived from the bioinformatic analysis genes were 
selected for further study on the basis that their function was not entirely unknown, 
however the genes in the signature about which very little is known also provide 
intriguing subjects for further study.  Their presence within the TAM signature 
strongly argues that they are genuinely macrophage-expressed genes on a ‘guilt-by 
association’ principle and that they are probably relatively specifically expressed by 
macrophages or their signature would be ‘diluted out’ by expression in other cell 
types and they would not fall within the signature.  The presence of macrophage 
genes in TAMs about which little or nothing is known is an interesting gap in our 
current knowledge.   
Not directly related to the TAM signature, this analysis approach also highlighted 
genes of interest in the tumour signatures, beyond the scope of this thesis to explore.  
These suggest several interesting avenues to explore in relation to deregulated 
pathways in DLBCL.  Further work could also expand the data looking at outcome in 
relation to expression of additional selected molecules of interest.  Although all cases 
of DLBCL over a long time period were considered for analysis, given the relative 
rarity of the tumour the number of cases available for study is still relatively small 
and more subtle influences on outcome may be detectable with a larger cohort of 
cases.  The influence of the selected genes on outcome could also be studied in a 
CHOP-Rituximab treated cohort of patients as the available data suggests that the 
role of the TAM may be altered by the addition of Rituximab.  Finally the 
preliminary data presented in the final chapter needs repeated and expanded to a 
more physiological macrophage-like cell having been performed so far only in a 




8.7  Future directions 
 
Some further study of the molecules selected from the DLBCL TAM signature 
should be undertaken.  In the first instance, the work performed looking at LAIR 1 in 
a co-culture model should be extended from the use of a malignant macrophage-like 
cell line to primary human monocyte derived macrophages to give a better 
impression of whether LAIR1 signalling is likely to play a role in macrophage 
activation in a more physiological model of macrophages.  These experiments would 
look both at activation of macrophages in the presence and absence of collagen as 
well as by cross-linking of LAIR1 on the surface of macrophages by antibodies.  As 
well as looking at the growth of tumour cells, measurable outcomes would include 
levels of secreted cytokines, surface expression of markers of activation and 
migratory and phagocytic activity of macrophages.  Given the intriguing findings of 
a possible cleaved product of LAIR1 in the presence of ‘classical’ activation of the 
THP-1 cells, this finding also could be explored further.  The presence of secreted 
LAIR1 or LAIR 2 in supernatants could be sought in different activation states to 
establish whether this cleaved form represented a way of modulating LAIR1 
availability for signalling. 
Other molecules from the TAM profile should also be studied.  TYMP in particular, 
having a reported role in both protection of cells from apoptosis and promotion of 
angiogenesis, is a molecule of interest.  Initially there are relatively simple in vitro 
experiments that should be performed to establish whether this may play a role in 
protection of lymphoma cells from apoptosis.  Protection from apoptosis in many 
settings is shown to be due to the actions of the metabolite 2-deoxy-D-ribose, by a 
poorly understood mechanism (Brown and Bicknell, 1998, Ikeda et al 2006).  
Addition of this molecule to lymphoma cells grown in culture in a variety of 
conditions such as hypoxia and serum starvation may help establish whether this 
molecule by itself has a direct role to play in modulating rates of apoptosis.  
Similarly addition of the molecule in a co-culture setting could help establish 
whether any effect observed of 2-deoxy- D-ribose, is due only to action on tumour 
cells or whether it alters the way tumour cells interact with macrophages.  Clearly 
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any effect seen in vitro may not be reflected in an effect in vivo, as is seen in the 
modulation of apoptosis in an animal model of Burkitt lymphoma reported in Ford et 
al (Ford et al 2015).  The role, if any, of TYMP in modulating tumour growth in the 
in vivo situation is less straightforward but could be assessed by a variety of 
approaches;  firstly by looking in real human lymphomas for any relationship 
between TYMP-expressing tumour associated macrophages and the 
microvasculature by immunohistochemistry for these two elements of the tumour 
stroma.  Modulation of TYMP expression in an in vivo model of tumour 
development is less straightforward as, given the molecule is expressed in the 
‘normal’ cells of the tumour host, manipulation of this would require manipulation 
either in the whole animal with potentially widespread effects beyond that of the 
tumour/macrophage interaction or as a conditional knockout in macrophages only, 
were such a model to be used.  A TYMP knockout mouse does exist, which may 
represent a possible avenue to explore.  A further possibility to explore looking only 
at the action of the 2-deoxy-D-ribose metabolite of TYMP, is the use of the 
stereoisomer 2-deoxy-L-ribose which has been used in both the co-culture and 
xenograft settings to inhibit the action of the active metabolite (Liekens et al 2007). 
 
There are other markers in the TAM signature that are of interest for further study.  
These include several markers that were not assessed in this thesis at all in terms of 
protein expression and localisation and for these molecules that would represent the 
first step in further investigations of their role in TAMs with additional work 
dependent on the confirmation of the presence of these in TAMs and the relative 
patterns of expression between TAMs and tumours in benign reactive lymph nodes.  
Of particular interest, from the little that is known about them, are myoferlin and 
chitinase 3-like 1.  Myoferlin is a protein implicated in abnormalities of muscle 
function and which is described in endothelial cells, where it is implicated in VEGF 
signal transduction,  and  more recently in tumour cells where is seems to play a role 
in membrane repair (Davis et al 2000, Bernatchez et al 2007, Bernatchez et al 2009, 
Leung et al 2013).  It does appear however to be expressed by macrophages in the 
Human Protein Atlas (Uhlen et al 2010, Uhlen et al 2015) and is one of the genes 
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upregulated in M2-polarised macrophages in the gene expression study by Martinez 
et al (Martinez et al 2013).  The function of this gene in macrophages is currently 
unknown.   Chitinase 3-like 1 was present in the TAM signature in DLBCL but not 
the ‘core’ TAM signature.  It is a secreted protein, found in activated macrophages, 
neutrophils, chondrocytes and synovial cells (Coffman 2008).  It is said to be a 
marker of alternative macrophage activation (Lee et al 2009).  What little 
mechanistic data there is suggests a role for the molecule in promoting tumor 
angiogenesis  as well as roles in tissue remodelling and development of fibrosis, and 
given that it forms part of the DLBCL TAM signature but is not seen more widely in 
TAM signatures may inform as to remodelling of the microenvironment in DLBCL  
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